<SEC-DOCUMENT>0001193125-21-160519.txt : 20210513
<SEC-HEADER>0001193125-21-160519.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513162110
ACCESSION NUMBER:		0001193125-21-160519
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silverback Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		21919954

	BUSINESS ADDRESS:	
		STREET 1:		500 FAIRVIEW AVENUE NORTH, SUITE 600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-456-2900

	MAIL ADDRESS:	
		STREET 1:		500 FAIRVIEW AVENUE NORTH, SUITE 600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d155579d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:sbtx="http://silverback.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2021To03_31_2021">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2021To03_31_2021">0001671858</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2021To03_31_2021">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2021To03_31_2021">2021</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2021To03_31_2021">Q1</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sbtx-20210331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_10_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sbtx:WuxiBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sbtx:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >sbtx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >sbtx:UnvestedCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_EsppWithholdingsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >sbtx:EsppWithholdingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_LiquidityAndCapitalResourcesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >sbtx:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" >us-gaap:CashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" >us-gaap:CashMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sbtx:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >sbtx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >sbtx:UnvestedCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis" >us-gaap:SeriesBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_RedeemableStockExcersibleOnAgreedUponMilestonesMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sbtx:RedeemableStockExcersibleOnAgreedUponMilestonesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >sbtx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_31_2019To10_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sbtx:WuxiBioMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-10-31</xbrli:startDate> <xbrli:endDate>2019-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sbtx:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >sbtx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2016To11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sbtx:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >sbtx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-11-01</xbrli:startDate> <xbrli:endDate>2016-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_AmendedLoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sbtx:TermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >sbtx:SiliconValleyBankMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sbtx:AmendedLoanAndSecurityAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2020To12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-03</xbrli:startDate> <xbrli:endDate>2020-12-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_03_2020To12_03_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-03</xbrli:startDate> <xbrli:endDate>2020-12-03</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis" >us-gaap:SeriesBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"><div style="font-size: 13.28px; margin-top: 0em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2021To03_31_2021">10-Q</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Mark&#160;One) </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P01_01_2021To03_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">OF 1934 </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2021To03_31_2021" format="ixt:datemonthdayyearen">March 31, 2021</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2021To03_31_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT </div></div></div><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">OF 1934 </div></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Number&#160;<ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2021To03_31_2021">001-39756</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2021To03_31_2021">Silverback Therapeutics, Inc.</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its Charter) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2021To03_31_2021">81-1489190</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2021To03_31_2021">500 Fairview Ave N</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2021To03_31_2021">Suite 600</ix:nonNumeric></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2021To03_31_2021">Seattle</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:stateprovnameen">Washington</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2021To03_31_2021">98109</ix:nonNumeric></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2021To03_31_2021">206</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2021To03_31_2021">456-2900</ix:nonNumeric></div> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol(s)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on which registered</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2021To03_31_2021">Common Stock</ix:nonNumeric>, par value $0.0001 per share</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2021To03_31_2021">SBTX</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></div></div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2021To03_31_2021">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2021To03_31_2021">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act: </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 21%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 54%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 20%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; width: 21%;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 54%;">&#9744;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 20%;">Accelerated filer</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; width: 21%;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 54%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 20%;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 2%;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2021To03_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; width: 21%;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 54%;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2021To03_31_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 20%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2021To03_31_2021" format="ixt:booleanfalse">&#9744;</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2021To03_31_2021" format="ixt:booleanfalse">&#9746;</ix:nonNumeric> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of May&#160;10, 2021 there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn05_10_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,905,511</ix:nonFraction>&#160;shares of registrant&#8217;s common stock, $0.0001 par value per share, outstanding. </div></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Table of Contents </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_40">FINANCIAL INFORMATION </a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_1">Financial Statements (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_2">Condensed Balance Sheets</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_3">Condensed Statements of Operations and Comprehensive Loss</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_4">Condensed Statements of Cash Flows</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">10</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_5">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:right;">9</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_6">Notes to Unaudited Condensed Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_8">Quantitative and Qualitative Disclosures About Market Risk</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_9">Controls and Procedures</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART&#160;II</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_41">OTHER INFORMATION </a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_10">Legal Proceedings</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_11">Risk Factors</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_12">Unregistered Sales of Equity Securities and Use of Proceeds</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_13">Defaults Upon Senior Securities</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_14">Mine Safety Disclosures</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;5.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_15">Other Information</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6.</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx155579_16">Exhibits</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> (this &#8220;Quarterly Report&#8221;) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our plans to research, develop and commercialize SBT6050 and any future product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain regulatory approval of product candidates arising from our ImmunoTAC technology platform, including SBT6050, in any of the indications for which we plan to develop them; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain funding for our operations, including funding necessary to commence and complete the clinical trials, conduct additional manufacturing and conduct preclinical studies of any of our product candidates, including SBT6050; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the success, cost and timing of our research and development activities, including our ongoing and planned clinical trials and preclinical studies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the size of the markets for our product candidates, and our ability to serve those markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to successfully commercialize our product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the rate and degree of market acceptance of our product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory developments in the United States and foreign countries; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the performance of our third-party service providers, including our CROs, suppliers and manufacturers; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the safety, efficacy and market success of competing therapies that are or become available; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to attract and retain key scientific and management personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> on our business and operations; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other risks and uncertainties, including those described under Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part II, Item 1A, &#8220;Risk Factors&#8221; of this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless the context otherwise indicates, references in this Quarterly Report to the terms &#8220;Silverback&#8221;, &#8220;the Company&#8221;, &#8220;we,&#8221; &#8220;our, and &#8220;us&#8221; refer to Silverback Therapeutics, Inc., and references to our &#8220;common stock&#8221; refers to our voting common stock. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part I, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Some of the material risks associated with our business include the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical and clinical development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials, including SBT6050, may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are required by the U.S. Food and Drug Administration (FDA) to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain or face delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We contract with third parties for the manufacturing and supply of certain of our product candidates for use in preclinical testing and clinical trials and will rely on third parties for commercial supply, which supply may become limited or interrupted at any time or may not be of satisfactory quality and quantity. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may not realize the benefits of any acquisitions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license,</div> or strategic alliances that we enter into. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may rely on trade secret and proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The price of our common stock is subject to volatility related or unrelated to our operations. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could continue to adversely impact our business, including our ongoing and planned clinical trials, supply chain, and business development activities. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We are currently party to an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> agreement under which we were granted rights to manufacture certain components of our product candidates. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these technologies or both, which would adversely affect our business and prospects. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx155579_40" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART I &#8211; FINANCIAL INFORMATION </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_1" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements (Unaudited) </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div id="tx155579_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Balance Sheets </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and par value data) </div></div></div></div> </div> </div> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(unaudited)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">386,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,141</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">378,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">390,656</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,618</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> asset</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">382,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">394,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities&#160;and stockholders&#8217; equity</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term loan payable, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LoansPayableToBankCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">495</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LoansPayableToBankCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">844</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of lease liability</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,595</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,601</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liability, net of current portion</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,650</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div>)</div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; equity:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred Stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2021 and December&#160;31, 2020; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2021 and December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; padding: 0px; text-align: right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2021 and December&#160;31, 2020, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,903,497</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,801,537</ix:nonFraction> shares issued, and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,827,204</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,701,274</ix:nonFraction> shares outstanding at<div style="display:inline;">&#160;</div>March&#160;31, 2021 and December&#160;31, 2020, respectively</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">484,147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">479,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">115,601</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">96,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">368,549</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">382,877</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, and stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">382,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">394,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx155579_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Statements of Operations and Comprehensive Loss </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share data) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,646</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">828</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,885</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,885</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income (expense), net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss and comprehensive loss</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share applicable to common stockholders, basic and diluted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">7.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,773,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">669,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx155579_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share data) </div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable&#160;Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preferred Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left: 0.75pt solid rgb(0, 0, 0); padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left: 0.75pt solid rgb(0, 0, 0); padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,701,274</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">479,608</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">96,734</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">382,877</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of common stock options and vesting of early exercised common stock options</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">125,930</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">254</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">254</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,285</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,285</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss and comprehensive loss</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,867</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,867</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March&#160;31, 2021</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,827,204</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">484,147</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">115,601</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">368,549</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="8" style="height: 6pt;">&#160;</td>
<td colspan="8" style="height: 6pt; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable&#160;Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preferred Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left: 0.75pt solid rgb(0, 0, 0); padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity&#160;(Deficit)</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left: 0.75pt solid rgb(0, 0, 0); padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2019</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,714,283</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,174</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">664,431</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,010</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">63,787</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">58,777</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series B redeemable convertible preferred stock for cash, net of $<ix:nonFraction name="sbtx:StockIssuanceCosts" contextRef="P01_01_2020To03_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction> in issuance costs</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,027,666</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,458</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,673,388</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,095</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of common stock options and vesting of early exercised common stock options</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,350</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss and comprehensive loss</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,279</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,279</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March&#160;31, 2020</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">30,415,337</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,727</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">669,781</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,063</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,066</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,003</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-left-color: rgb(0, 0, 0); border-left-width: 0.75pt; border-left-style: solid;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td><div style="display:inline;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements </div></div></div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc"></a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx155579_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Statements of Cash Flows </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited) </div></div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div> Months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,285</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> lease expense</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,208</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liability</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sbtx:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">240</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sbtx:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal payments on term loan payable</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfBankDebt" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from exercise of common stock options</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) provided by financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in cash, cash equivalents, and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInContinuingOperations" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInContinuingOperations" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents, and restricted cash at beginning of period</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">386,919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,526</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents, and restricted cash at end of period</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash flow information:</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment included in accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:FairValueOfAssetsAcquired" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160; </div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in early exercise liability included in accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="sbtx:ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 86%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 1%;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sbtx:UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">201</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 86%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx155579_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Unaudited Condensed Financial Statements </div></div></div></div> </div> </div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of Business </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. (&#8220;Silverback&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The Company&#8217;s platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed at specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January&#160;4, 2016. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Initial Public Offering and Related Transaction </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;3, 2020, the Company&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-250009)</div> for its initial public offering of common stock (&#8220;IPO&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). On December&#160;8, 2020, the Company issued and sold <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">13,225,000</ix:nonFraction> shares of common stock in the IPO at a public offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">21.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P12_03_2020To12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">255.3</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses paid by the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the IPO, all <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">77,074,884</ix:nonFraction> shares of redeemable convertible preferred stock outstanding at the time of the IPO converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P12_03_2020To12_03_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">20,758,098</ix:nonFraction> shares of the Company&#8217;s common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the Company&#8217;s existing products under development. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">115.6</ix:nonFraction>&#160;million as of March&#160;31, 2021. The Company had cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021_LiquidityAndCapitalResourcesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">374.2</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million as of March 31, 2021 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily through the issuance of redeemable convertible preferred stock, convertible notes, and the sale of common stock in connection with the IPO. The Company&#8217;s currently available cash and cash equivalents as of March 31, 2021 are sufficient to meet its anticipated cash requirements for the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern for a period of at least 12 months from the date the financial statements are issued.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management expects operating losses to continue for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical development activities as well as the commercialization of the Company&#8217;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21282777"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283410"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div></ix:nonNumeric> <ix:continuation id="TextSelection_21283410"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Condensed Financial Statements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed balance sheet as of March 31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) for the three months ended March 31, 2021 and 2020, are unaudited. The balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of March 31, 2021, and the condensed results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three months ended March 31, 2021 and 2020 are also unaudited. The condensed results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period.</div></div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">coron<div style="display:inline;">a</div>virus&#160;(&#8220;COVID-19&#8221;)&#160;pandemic</div> will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">concerning&#160;COVID-19&#160;and</div> the actions taken to contain or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">treat&#160;COVID-19,&#160;as</div> well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents, and restricted cash are carried at fair value. Financial instruments, including accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. Term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates. </div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_21282777" continuedAt="TextSelectionAppend_21282777_1"> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At March&#160;31, 2021 and December&#160;31, 2021, the Company&#8217;s cash equivalents consisted of money market funds. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21284755"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the Company&#8217;s facility operating lease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21282872">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands):</ix:nonNumeric> </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_21282777_1" continuedAt="TextSelectionAppend_21282777_2"><ix:continuation id="TextSelection_21282872"> <ix:continuation id="TextSelection_21284755">
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">386,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">386,919</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> </ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_21282777_2" continuedAt="TextSelectionAppend_21282777_3"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Leases consist of the Company&#8217;s operating lease. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company&#8217;s lease includes options to extend or terminate the lease. Periods covered by an option to extend the lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. At the inception of the lease and as of March&#160;31, 2021, the Company was not reasonably certain that it will exercise its option to extend the lease and was not reasonably certain that it will not exercise its option to terminate the lease, therefore, the periods covered by the options are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_21282777_3" continuedAt="TextSelectionAppend_21282777_4"> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#8217;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#8217;s program pipeline, including the Company&#8217;s lead product candidate, SBT6050, and other pipeline programs, including SBT6290 and SBT8230. Direct costs include expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and other vendors that conduct the Company&#8217;s preclinical and clinical activities, expenses associated with manufacturing the Company&#8217;s product candidates including under agreements with contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#8217;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#8217;s research and development efforts and have no alternative future uses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The</div></div> cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#8217;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.</div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was equal to net loss for the three months ended March&#160;31, 2021 and 2020.</div></div></div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share Attributable to Common Stockholders </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities.&#160;Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_21282777_4"><ix:nonNumeric name="sbtx:EmergingGrowthCompanyStatusPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1)&#160;no longer an emerging growth company or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2016-13,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January&#160;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.</div></div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21285634"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: </div></div></ix:nonNumeric> <ix:continuation id="TextSelection_21285634"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices in active markets for identical assets or liabilities. The Company&#8217;s Level&#160;1 assets consist of money market funds. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs that are supported by little or no market activity. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table identifies the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">386,369</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were <ix:nonFraction name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="P01_01_2021To03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between the Level&#160;1 and Level&#160;2 categories or into or out of the Level&#160;3 category during the periods presented. </div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Accrued Expenses </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sbtx:AccruedResearchAndDevelopmentExpenses" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,610</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sbtx:AccruedResearchAndDevelopmentExpenses" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee compensation and benefits</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services and other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283398"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases an office and laboratory space in Seattle, Washington. <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283416">The components of lease expense and related cash flows were as follows (in thousands):</ix:nonNumeric> </div></div></ix:nonNumeric> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_21283398" continuedAt="TextSelectionAppend_21283398_1"><ix:continuation id="TextSelection_21283416">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease expense</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">347</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">347</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash outflows from operating leases</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">397</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> </ix:continuation></ix:continuation> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_21283398_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining term on the Company&#8217;s lease was <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2021" format="ixt-sec:duryear">1.7</ix:nonNumeric> years as of March&#160;31, 2021. To compute the present value of the lease liability, the Company used a discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">8.5</ix:nonFraction>%. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future minimum commitments due under the operating lease agreement as of March 31, 2021 are as follows (in thousands):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 (remaining 9 months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,454</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total present value of lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,981</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283400"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Term Loan Payable </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (&#8220;SVB&#8221;) and borrowed $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction>&#160;million as a term loan. The outstanding principal amount of the term loan accrues interest at an annual rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction>% per annum. At closing, the Company incurred de minimis debt issuance costs and owed a final payment fee of $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P11_01_2016To11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction>&#160;million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate of the Company&#8217;s term loan is <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2021To03_31_2021_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.14</ix:nonFraction>%. Interest expense under the term loan totaled less than $<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To03_31_2021_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To03_31_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction>&#160;million for each of the three months ended March&#160;31, 2021 and 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The term loan is collateralized by the Company&#8217;s tangible and intangible assets, excluding intellectual property. The proceeds are to be used as working capital and to fund general business requirements. The agreement includes customary nonfinancial covenants and events of default that include, among other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">things,&#160;non-payment,&#160;inaccuracy</div> of representations and warranties, covenant breaches, cross default to material indebtedness or material agreements, bankruptcy and insolvency, material judgments, a change of control, or any material adverse event. The Company was in compliance with all related covenants as of March&#160;31, 2021. </div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_21283400"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The term loan&#8217;s original maturity date was <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P11_01_2016To11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:datemonthdayyearen">November 1, 2020</ix:nonNumeric>. However, in April 2020, the Company amended the loan and security agreement to defer principal payments for six months and extend the maturity date to <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P04_01_2020To04_30_2020_AmendedLoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis" format="ixt:datemonthdayyearen">May 1, 2021</ix:nonNumeric>. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification and is amortizing the remaining debt discount over the remaining term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021, the Company made its final scheduled payment to SVB under the loan and security agreement including the final payment fee. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21387192"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Stockholders&#8217; Equity (Deficit) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to its conversion to common stock in December 2020, the Company&#8217;s redeemable convertible preferred stock was classified as mezzanine equity on the Company&#8217;s balance sheets as the shares are contingently redeemable upon a deemed liquidation such as a change in control and in that event, there is no guarantee that all stockholders would be entitled to receive the same form of consideration. <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> accretion to redemption value was recorded during the three months ended March&#160;31, 2020 as a deemed liquidation event was not considered probable. </div></div></ix:nonNumeric> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_21387192"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the Company issued <ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">14,701,054</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of its Series B redeemable convertible preferred stock, including </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonFraction name="sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,673,388</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares issued upon conversion of then outstanding convertible notes and accrued interest, and </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,027,666</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares issued for cash at a purchase price of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.16</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">per share, resulting in gross proceeds of $21.5&#160;million. The Series B purchase agreement provided that the Company would issue, and the Series B holders would purchase, an additional </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <ix:nonFraction name="sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_RedeemableStockExcersibleOnAgreedUponMilestonesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">21,732,862</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of the Company&#8217;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_RedeemableStockExcersibleOnAgreedUponMilestonesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">46.9</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million in the event that certain agreed upon milestones were achieved or the preferred majority approved their closing. As of March 31, 2020, these future Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div></div> <ix:nonNumeric name="sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has reserved shares of common stock for the following potential future issuances: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying outstanding equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,308,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,316,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares available for future equity award grants</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,152,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,506,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying early exercised equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">76,293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">100,263</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%; padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying ESPP withholdings</div></div> </td>
<td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">19,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,556,911</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,928,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283369"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Stock-Based Compensation </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,285</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_21283369" continuedAt="TextSelectionAppend_21283369_1">As of March&#160;31, 2021, the total unrecognized stock-based compensation expense was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">59.6</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:duryear">3.16</ix:nonNumeric> years.</ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_21283369_1" continuedAt="TextSelectionAppend_21283369_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Awards </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2021, the Company&#8217;s equity incentive plans authorized a total of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,564,798</ix:nonFraction> shares, of which <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,152,910</ix:nonFraction> shares are available for future grant, and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,308,582</ix:nonFraction> shares are outstanding. Not included in the outstanding option balance are <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">76,293</ix:nonFraction> shares pursuant to stock options that were early exercised and subject to repurchase under the 2016 Plan that remain unvested as of March&#160;31, 2021. </div></div> </ix:continuation> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283401"><ix:continuation id="TextSelectionAppend_21283369_2" continuedAt="TextSelectionAppend_21283369_3">A summary of the Company&#8217;s stock option activity for the three months ended March&#160;31, 2021 is as follows (in thousands, except share and per share data and years):</ix:continuation></ix:nonNumeric> </div></div></div> </div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_21283369_3" continuedAt="TextSelectionAppend_21283369_4"><ix:continuation id="TextSelection_21283401">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,316,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">10.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">9.5</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">223,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">93,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">48.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">101,960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,227</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cance<div style="letter-spacing: 0px; top: 0px;;display:inline;">l</div>led</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,308,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:duryear">9.3</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">708,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:duryear">8.7</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_21283369_4" continuedAt="TextSelectionAppend_21283369_5"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The total fair value of shares vested during the three months ended March&#160;31, 2021 and 2020 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction>&#160;million and less than $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million, respectively. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock for all options that were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money</div></div> at March&#160;31, 2021.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>The weighted-average grant date fair value per share of option grants for the three months ended <div style="letter-spacing: 0px; top: 0px;;display:inline;">March 31, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">33.32</ix:nonFraction></div>. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> grants during the three months ended March&#160;31, 2020. </div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months<br/> Ended</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To03_31_2021" format="ixt-sec:duryear">6.0</ix:nonNumeric></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">83</ix:nonFraction>%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.72</ix:nonFraction>%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 6pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_21283369_5" continuedAt="TextSelectionAppend_21283369_6"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock.</div></div> The grant date fair market value of the shares of common stock underlying stock options is determined by the Company&#8217;s board of directors. Following the closing of the Company&#8217;s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#8217;s common stock is traded. Prior to the Company&#8217;s IPO, because there was no public market for the Company&#8217;s common stock, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included contemporaneous valuations performed by an independent third-party, the Company&#8217;s results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#8217;s business, progress of the Company&#8217;s research and development activities, the Company&#8217;s business conditions and projections, the lack of marketability of the Company&#8217;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#8217;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#8217;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key personnel and the experience of management, trends and developments in the Company&#8217;s industry and external market conditions affecting the life sciences and biotechnology industry sectors. </div> </ix:continuation><ix:continuation id="TextSelectionAppend_21283369_6" continuedAt="TextSelectionAppend_21283369_7"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term. </div></div>The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-point</div> between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility.</div></div> Given the Company&#8217;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </div> </ix:continuation><ix:continuation id="TextSelectionAppend_21283369_7"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free Interest Rate.</div></div> The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield.</div></div> The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction>. </div> </ix:continuation><ix:nonNumeric name="sbtx:LicensingAgreement" contextRef="P01_01_2021To03_31_2021" escape="true" continuedAt="TextSelection_21283348"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Licensing Agreement</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Bio&#8221;). Under the license agreement, WuXi Bio granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, under certain of WuXi Bio&#8217;s intellectual property rights, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and biological materials (&#8220;WuXi Bio Licensed Technology&#8221;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#8220;WuXi Bio Licensed Product&#8221;). The WuXi Bio Licensed Technology is currently used to manufacture a component of the Company&#8217;s lead product, SBT6050. The Company has paid an aggregate of $<ix:nonFraction name="sbtx:LicenseFeesPaid" contextRef="P10_31_2019To10_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> in license fees that were recorded in research and development expense when incurred. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to $<ix:nonFraction name="sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" contextRef="P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">10.8</ix:nonFraction>&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them through the termination date. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sbtx:AgreementPaymentAndLicenseTermDesciption" contextRef="P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.</ix:nonNumeric> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a>&#160;</div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_21283348"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party may terminate the license immediately upon written notice to the other party.</div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Commitments and Contingencies </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Proceedings </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnifications </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to rapidly evolve, and management continue to monitor the situation closely. The extent of the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the Company&#8217;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#8217;s clinical trial enrollment, trial sites, CROs, third-party manufacturers, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the Company&#8217;s key scientific and management personnel. The ultimate impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and most of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lab</div> based employees working remotely. Management will continue to actively monitor the rapidly evolving situation related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and may take further actions that alter Company operations, including those that may be required by federal, state or local authorities, or that management determines are in the best interests of the Company&#8217;s employees and other third parties with whom the Company does business. At this point, the extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may affect the Company&#8217;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change.</div></div></ix:nonNumeric> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>. Employee Benefit Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a retirement plan, which is qualified under section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#8217;s U.S.&#160;employees. The plan allows eligible employees to defer, at the employee&#8217;s discretion, pretax compensation up to the IRS annual limits. The Company does not match contributions made by employees.</div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Net Loss Per Share Attributable to Common Stockholders </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2021To03_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,191,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock options</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,308,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">550,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested common stock</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">76,293</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To03_31_2020_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock warrants</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ESPP withholdings</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021_EsppWithholdingsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">19,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total potentially dilutive shares</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,404,001</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,756,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_7" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">You should read the following discussion and analysis together with our unaudited financial statements and related notes thereto included in &#8220;Item 1. Financial Statements (Unaudited)&#8221; of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and the audited financial statements and related notes thereto as of and for the year ended December&#160;31, 2020 included in the Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> filed with the Securities and Exchange Commission (SEC), on March&#160;29, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Risk Factors&#8221; section of this Quarterly Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We are a clinical-stage biopharmaceutical company with one product candidate in a Phase 1/1b clinical trial, and we are focused on leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are applying our platform to create a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Our lead product candidate, SBT6050, is comprised of a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors such as certain breast, gastric and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancers. SBT6050 is currently in a Phase&#160;1/1b clinical trial as a monotherapy and in combination with pembrolizumab, in patients with advanced or metastatic HER2-expressing solid tumors. In this trial, we have observed changes in pharmacodynamic markers in the first dose cohort, and we anticipate providing an update on interim data from the Phase&#160;1 single agent dose-escalation cohorts in the second half of 2021. SBT6290 is our second product candidate, expanding on the potential of a TLR8 agonist as a payload. SBT6290 is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in certain bladder, triple negative breast, head and neck, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-small</div> cell lung cancers. We anticipate submitting an investigational new drug application for SBT6290 in the fourth quarter of 2021. Our third TLR8 program, SBT8230, is comprised of a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of cHBV. We are also developing agents that localize therapies to modulate important pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ImmunoTAC platform drives our development pipeline of tissue targeted therapeutic candidates as summarized in the chart below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g155579g25t34.jpg" style="width: 820px; height: 340px;"/></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred significant operating losses since our inception. As of March&#160;31, 2021, we had an accumulated deficit of $115.6&#160;million. Our net losses were $18.9&#160;million and $5.3&#160;million for the three months ended March&#160;31, 2021 and 2020, respectively. Our losses have resulted primarily from costs incurred in connection with raising capital, research and development activities and general and administrative expenses. We do not have any products approved for sale and have not generated any revenue from product sales or otherwise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect our expenses will increase substantially and that we will continue to incur significant losses for the foreseeable future as we continue our development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products, seek to expand our product pipeline, invest in our organization and technology platform, as well as incur expenses associated with operating as a public company. Our net losses may fluctuate significantly from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-to-quarter</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-year,</div></div> depending on a variety of factors including the timing and scope of our preclinical studies and clinical trials. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through public or private equity offerings, debt financings, collaborations and licensing arrangements or other capital sources. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, we completed our initial public offering in which we sold 13,225,000 shares of our common stock at $21.00 per share and received net proceeds, after underwriting discounts and offering costs, of $255.3&#160;million. Further, in March, July, and September 2020, we raised net proceeds of $153.3&#160;million from the sale of our redeemable convertible preferred stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of Our Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Expenses </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operating expenses consist of (i)&#160;research and development expenses and (ii)&#160;general and administrative expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of our ImmunoTAC technology platform, product candidates, discovery efforts and preclinical studies and clinical trial activities related to our program pipeline, including our lead product candidate,&#160;SBT6050. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our direct costs include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses incurred under agreements with CROs and other vendors that conduct our preclinical and clinical activities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expenses associated with manufacturing our product candidates including under agreements with CDMOs and other vendors; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consulting fees. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our indirect costs include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other unallocated research and development expenses incurred in connection with our research and development programs, including laboratory materials and supplies and license fees. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expense research and development costs as incurred. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-refundable</div> advance payments for goods and services that will be used over time for research and development are capitalized and recognized as goods are delivered or as the related services are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">performed.&#160;In-licensing</div> fees and other costs to acquire technologies used in research and development that have not yet received regulatory approval and that are not expected to have an alternative future use are expensed when incurred.&#160;We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are not separately classified. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that our research and development expenses will substantially increase for the foreseeable future as we continue the clinical development of&#160;SBT6050&#160;and discovery and development of our other development candidates and discovery programs and development, particularly as our product candidates move into later stages of development which increases costs considerably. We cannot reasonably determine the timing of initiation, the duration or the completion costs of future clinical trials and preclinical studies of IND and development candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which development candidates and discovery programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation, and recruiting costs for personnel in executive, finance, and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect that our general and administrative expenses will substantially increase for the foreseeable future as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercialization activities, as well as to support our operations generally. We also expect to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;tax-related&#160;services</div> associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance costs, and investor and public relations costs. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Income (Expense), Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income (expense), net includes interest earned on our cash and cash equivalents carried at fair value, and interest expense on our borrowings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comparison of the Three Months Ended March&#160;31, 2021 and 2020 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our results of operations for the three months ended March&#160;31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dollar</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,825</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">828</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,885</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,885</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,643</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income (expense), net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">149</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss and comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,867</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,279</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,588</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">257</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Not meaningful </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our research and development expenses for the three months ended March&#160;31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dollar</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Direct costs:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SBT6050</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,226</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,147</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,079</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical programs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">532</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total direct costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,930</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,679</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,251</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indirect costs:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel-related expenses, including stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,695</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">157</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facility and equipment related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other unallocated research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,825</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">177</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Not meaningful </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses were $12.2&#160;million and $4.4&#160;million for the three months ended March&#160;31, 2021 and 2020, respectively. The increase of $7.8&#160;million was due primarily to an increase in preclinical programs of $3.2&#160;million as we continued to advance certain pipeline programs, including SBT6290 and SBT8230, through preclinical development. The increase was also due to an increase of $1.1&#160;million in direct costs related to the development of SBT6050. The increase was also due to increases in personnel-related expenses of $2.9&#160;million, and facility and equipment related expenses and other unallocated research and development expenses of $0.7&#160;million. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses were $6.6&#160;million and $0.8&#160;million for the three months ended March&#160;31, 2021 and 2020, respectively. The increase of $5.8&#160;million was due primarily to an increase of $3.8&#160;million in personnel-related expenses due to increased headcount during the period, including new executives, as well as increases in salaries, bonuses, stock-based compensation, and recruiting expenses. To a lesser extent, the increase in general and administrative expenses was due to an increase in legal fees of $0.6&#160;million, professional fees of $0.5&#160;million, and $0.9&#160;million in other various general and administrative expenses as we now operate as a public company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interest Income (Expense), Net </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income (expense), net was $18,000 and $(37,000) for the three months ended March&#160;31, 2021 and 2020, respectively. The change of $55,000 was primarily due to a decrease in principal on our notes payable and an increase in our cash balance. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. Since our inception, we have funded our operations almost exclusively with proceeds from the sale and issuance of shares of our redeemable convertible preferred stock and debt financings. We will need to raise substantial additional capital in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, we had $374.2&#160;million in cash and cash equivalents. The following table sets forth a summary of the net cash flow activity for the years ended March&#160;31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(128</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase (decrease) in cash, cash equivalents, and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,654</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2021, net cash used in operating activities was $12.2&#160;million. This consisted primarily of a net loss of $18.9&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges of $4.8&#160;million and a decrease in our operating assets and liabilities of $1.9&#160;million. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges primarily consisted of stock-based compensation expense of $4.3&#160;million, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> lease expense of $0.3&#160;million, and depreciation expense of $0.2&#160;million. The decrease in our operating assets and liabilities was primarily due to an increase in accounts payable and accrued expenses of $2.2&#160;million. This decrease was partially offset by a decrease in our lease liability of $0.2&#160;million, and an increase in prepaid expenses and other assets of $0.1&#160;million after adjusting for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2020, net cash used in operating activities was $7.6&#160;million. This consisted primarily of a net loss of $5.3&#160;million and an increase in our operating assets and liabilities of $2.8&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges of $0.5&#160;million. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges primarily consisted of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> lease expense of $0.3&#160;million and depreciation expense of $0.1&#160;million. The increase in our operating assets and liabilities was primarily due to a decrease in accounts payable and accrued expenses of $2.7&#160;million and a decrease in our lease liability of $0.2&#160;million, partially offset by a decrease in prepaid expenses and other assets of $0.1&#160;million. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2021, cash used in investing activities was less than $0.1&#160;million due to purchases of property and equipment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, cash used in investing activities was less than $0.1&#160;million due to purchases of property and equipment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2021, cash used in financing activities was $0.1&#160;million. This was primarily driven by $0.4&#160;million of principal payments on the term loan payable, which was partially offset by $0.2&#160;million in proceeds from exercises of common stock options. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2020, cash provided by financing activities was $21.3&#160;million. This consisted primarily of $21.7&#160;million of net proceeds from issuance of redeemable convertible preferred stock, which was partially offset by $0.4&#160;million of principal payments on the term loan payable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Future Funding Requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that our cash and cash equivalents of $374.2&#160;million at March&#160;31, 2021 will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 24 months. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future capital requirements will depend on many factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the initiation, trial design, progress, timing, costs and results of drug the discovery, preclinical studies and clinical trials of our product candidates, and in particular the clinical trials for SBT6050; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number and characteristics of product candidates that we pursue; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the length of our clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome, timing and costs of seeking FDA, EMA and any other regulatory approvals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of manufacturing our product candidates, in particular for clinical trials in preparation for marketing approval and in preparation for commercialization; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of any third-party products used in our combination clinical trials that are not covered by such third party or other sources; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical activities increase; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of commercialization activities for&#160;any of our product candidates, if approved, including marketing, sales and distribution costs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the emergence of competing therapies and other adverse market developments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the extent to which we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire other products and technologies; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our need and ability to retain key management and hire scientific, technical, business, and medical personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our implementation of additional internal systems and infrastructure, including operational, financial and management information systems; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or costs associated with expanding our facilities or building out our laboratory space; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of operating as a public company. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through public or private equity offerings, debt financings, or other capital sources which may include strategic collaborations, licensing arrangements or other arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual Obligations and Commitments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2021, there have been no material changes outside the ordinary course of business to our contractual obligations from those disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in&#160;our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed with the SEC on March&#160;29, 2021.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Arrangements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Since our inception, we have not engaged in any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements, as defined in the rules and regulations of the SEC. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Judgments and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, stock-based compensation, and valuation allowances for deferred tax assets. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2021, there were no material changes to our critical accounting policies. Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Significant Judgments and Estimates&#8221; in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> filed with the SEC on March&#160;29, 2021 and Note 2 to our unaudited condensed financial statements appearing in Part I, Item 1 of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q.</div> We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based Compensation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">See Note 2 to our unaudited condensed financial statements appearing in Part I, Item 1 of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> for additional information. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an emerging growth company, as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earliest to occur of: (i)&#160;the last day of the fiscal year in which we have at least $1.07&#160;billion in annual revenue; (ii)&#160;the date upon which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> under the Exchange Act; (iii)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt securities during the prior three-year period; and (iv)&#160;December&#160;31, 2025. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_8" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative and Qualitative Disclosures About Market Risk </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Not applicable to a &#8220;smaller reporting company&#8221; as defined under Item 10(f)(1) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> of the Securities Act. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_9" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Controls and Procedures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As required by Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(b)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(b)</div> of the Exchange Act, our management with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. The term &#8220;disclosure controls and procedures&#8221; as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Control over Financial Reporting </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div id="tx155579_41" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II &#8211; OTHER INFORMATION </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_10" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceedings </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_11" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;1A.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Factors </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our results of operations and financial condition. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The risk factors set forth below that are marked with an asterisk (*) did not appear as separate risk factors in, or contain changes to the similarly titled risk factor included in Item 1A. of our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> filed with the SEC on March&#160;29, 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business and Industry </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an early-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing and optimizing our technology platform, identifying potential product candidates, undertaking research and preclinical studies and a clinical trial for our lead program, engaging in manufacturing for our development programs, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. We have one product candidate in early clinical development and all of our other product candidates are in preclinical development, and none have been approved for commercial sale. We have never generated any revenue from product sales and have incurred net losses each year since we commenced operations. For the years ended March&#160;31, 2021 and 2020, our net losses were $18.9&#160;million and $5.3&#160;million, respectively. We expect that it will be several years, if ever, before we have a product candidate ready for regulatory approval and commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates through clinical development. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates is capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution. Furthermore, following the completion of our initial public offering in December 2020, we have incurred and expect to continue to incur additional costs associated with operating as a public company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, we had $374.2&#160;million in cash and cash equivalents. Based upon our current operating plan, we estimate that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 24 months. However, we believe that our existing cash and cash equivalents will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have based these estimates on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the initiation, trial design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates, and in particular the clinical trials for SBT6050; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number and characteristics of product candidates that we pursue; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the length of our clinical trials, including, among other things, as a result of delays in enrollment, difficulties enrolling sufficient subjects or delays or difficulties in clinical trial site initiations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome, timing and costs of seeking FDA, European Medicines Agency (EMA) and any other regulatory approvals; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of manufacturing our product candidates, in particular for clinical trials in preparation for marketing approval and in preparation for commercialization; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of any third-party products used in our combination clinical trials that are not covered by such third party or other sources; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs associated with hiring additional personnel and consultants as our preclinical, manufacturing and clinical activities increase; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the receipt of marketing approval and revenue received from any commercial sales of any of our product candidates, if approved; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of commercialization activities for&#160;any of our product candidates, if approved, including marketing, sales and distribution costs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the emergence of competing therapies and other adverse market developments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the extent to which we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire other products and technologies; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount and timing of any payments we may be required to make pursuant to our current or future license agreements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our need and ability to retain key management and hire scientific, technical, business, and medical personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our implementation of additional internal systems and infrastructure, including operational, financial and management information systems; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or costs associated with expanding our facilities or building out our laboratory space; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the effects of the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of operating as a public company. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because we do not expect to generate revenue from product sales for many years, if at all, we will need to obtain substantial additional funding in connection with our continuing operations and expected increases in expenses. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">capital markets may affect the availability, amount and type of financing available to us in the future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially grants, collaborations, licenses or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants further limiting or restricting our ability to take specific actions, such as further limitations on our ability to incur additional debt, make capital expenditures or declare dividends. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we raise funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are early in our development efforts and we have only one product candidate in clinical development. We have a limited history of conducting clinical trials to test our product candidates in humans. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are early in our development efforts and most of our operations to date have been limited to developing our platform technologies and conducting drug discovery and preclinical studies. Our lead product candidate, SBT6050, entered Phase 1/1b clinical trial in July 2020, which was the first time one of our product candidates had been tested in humans. As a result, we have limited infrastructure, experience conducting clinical trials as a company and regulatory interactions, and cannot be certain that our current or planned clinical trials will be completed on time, if at all, that our planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of the early stage of development of our products candidates, our ability to eventually generate significant revenues from product sales will depend on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successful completion of additional preclinical studies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission of our INDs or other regulatory applications to allow for initiation of our planned clinical trials or future clinical trials and authorizations from regulators to initiate clinical studies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successful enrollment in, and completion of, clinical trials and achieving positive results from the trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">demonstrating a risk-benefit profile acceptable to regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">receipt of marketing approvals from applicable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing manufacturing capabilities or arrangements with third-party manufacturers for clinical supply and, if and when approved, for commercial supply; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in combination with others; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effectively competing with other therapies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developing and implementing marketing and reimbursement strategies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining and maintaining third-party coverage and adequate reimbursement; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to obtain clearance or approval of companion diagnostic tests, on a timely basis, or at all; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintaining a continued acceptable safety profile of any product following approval, if any. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do not achieve one or more of these requirements in a timely manner, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical and clinical development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials, including SBT6050, may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The research and development of drugs and biological products is extremely risky. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, can take many years to complete and its outcome is uncertain. We may face unforeseen challenges in our product candidate development strategy, and we can provide no assurances that we will ultimately be successful in our current and future clinical trials or that our product candidates will be able to receive regulatory approval. The results of preclinical studies and early clinical trials of our product candidates and other products, even those with the same or similar mechanisms of action, may not be predictive of the results of later-stage clinical trials. For example, it is not uncommon for product candidates to exhibit unforeseen safety or efficacy issues when tested in humans despite promising results in preclinical animal models. In particular, while we have conducted preclinical studies of SBT6050, we do not know how SBT6050 will perform in the ongoing Phase 1/1b clinical trial or in future clinical trials, whether any initial tumor responses that may be observed will be durable or whether adverse events will arise over time. Future results of preclinical and clinical testing of our product candidates are also less certain due to the novel and relatively untested nature of our approach to TLR8 and related platform technologies. In general, clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring their alteration. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">incur unplanned costs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be delayed in or prevented from continuing clinical development and obtaining marketing approval for our product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain approval for indications or patient populations that are not as broad as intended or desired; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings including boxed warnings; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to changes or limitations in the way the product is administered; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified Risk Evaluation and Mitigation Strategy (REMS); </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to the addition of labeling statements, such as warnings or contraindications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be sued; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">experience damage to our reputation. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treatment of cancer patients with our oncology product candidates may be used in combination with other cancer drugs, such as other immuno-oncology agents, monoclonal antibodies or other protein-based drugs or small molecule anti-cancer agent such as targeted agents or chemotherapy, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. Additionally, our product candidates could potentially cause adverse events. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance of our product candidates and impair our ability to commercialize our products. Because all of our product candidates are derived from our platform technologies, a clinical failure of one of our product candidates may also increase the actual or perceived likelihood that our other product candidates will experience similar failures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities&#8217; approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we eventually complete clinical testing and receive approval of a biologics license application (BLA) or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have concentrated our research and development efforts on product candidates using our platform technologies, and our future success depends on the successful development of this approach. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates based on our platform technologies in clinical trials or in obtaining marketing approval thereafter, and use of our platform technologies may not ever result in marketable products. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners or establishing our own commercial manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing any products on a timely or profitable basis, if at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidates are targeted to treat tumors that express specific antigens at certain levels, such as those that express moderate to high levels of HER2 or Nectin4. This requires diagnostic assays that may be subject to scrutiny by regulatory authorities. Commercial tests are available for HER2, but not currently for Nectin4. We may not be successful in developing diagnostic assays or securing the assays for use. If we are successful in securing a diagnostic assay for a specific antigen, it may be difficult to enroll patients with tumors that have the required level of antigen expression. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the clinical trial requirements of the FDA, EMA and other regulatory agencies, such as in Australia and South Korea and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The immuno-oncology industry is also rapidly developing, and our competitors may introduce new technologies improving the immune response to cancer that render our technologies obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The TLR field is also rapidly evolving and as competitors use or develop alternative TLR technologies, any failures of such technologies could adversely impact our programs. For example, companies are developing TLR7, TLR7/8 and TLR9 agonists, some of which are conjugated to monoclonal antibodies. Regardless of our belief that our approach to activating the innate immune system has advantages, issues encountered with other TLR programs will create a negative perception of or increase scrutiny for our technologies and product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We depend on enrollment of patients in our clinical trials for our product candidates. If we experience delays or difficulties enrolling in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. These trials and other trials we conduct may be subject to delays as a result of patient enrollment taking longer than anticipated, patient withdrawal or adverse events. For example, we have an ongoing Phase 1/1b clinical trial for our lead product candidate, SBT6050, which could generate adverse events that may cause us to delay the trial or halt further development. As has been described with other immune agonists administered in the presence of ADA in preclinical species, anaphylaxis upon repeat intravenous dosing with SBT6050 was observed in animal models. While our product candidate in humans is administered by the subcutaneous route of administration, if similar adverse events were to manifest, that could adversely impact our enrollment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our clinical trials will likely compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient enrollment depends on many factors, including the size and nature of the patient population, the severity of the disease under investigation, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the ability to obtain and maintain patient consents, the ability to recruit clinical trial investigators with the appropriate competencies and experience, the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our product candidates or trial completion, the availability of competing clinical trials, the availability of new drugs approved for the indication the clinical trial is investigating, and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To date, we have only tested SBT6050 in a limited number of patients with cancer and these clinical trial participants have only been observed for a limited period of time after dosing. As we continue developing our product candidates and initiate clinical trials of our additional product candidates, serious adverse events (SAEs), undesirable side effects, relapse of disease or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the SAEs or undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective or in which efficacy is more pronounced or durable. For example, a significant risk observed with systemic administration of motolimod, an unconjugated TLR8 small molecule agonist, was the induction of significant injection site reactions (ISR), and cytokine-induced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">flu-like</div> symptoms that prevented dose-escalation. Should we observe severe cases of ISR and cytokine release syndrome in our clinical trials or identify other undesirable side effects or other unexpected findings depending on their severity, our trials could be delayed or even stopped and our development programs may be halted entirely. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our TLR8 agonist containing product candidates, including SBT6050, activate dendritic cells among other innate immune cells. As a result, significant anti-drug antibodies (ADA) could develop that neutralize the effects of SBT6050 by reducing exposure. The development of ADA could also trigger hypersensitivity reactions that manifest as serious adverse events. For example, as has been described with other immune agonists administered in the presence of ADA in preclinical species, anaphylaxis upon repeat intravenous dosing with SBT6050 was observed. As a result, we have modified our dosing to subcutaneous; however, if patients experience adverse events (AEs), including anaphylaxis, our trials could be delayed or stopped and our development programs may be halted entirely if this is observed during clinical development. Even if ADAs are not detected in the early clinical trials, they may be detected after product launch and may significantly reduce the commercial potential or even result in the product being pulled from the market. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if our product candidates initially show promise in early clinical trials, the side effects of biological products are frequently only detectable after they are tested in larger, longer and more extensive clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development or after approval and are determined to be attributed to our product candidate, we may be required to develop a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Product-related side effects could also result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or ADA caused by such products, a number of potentially significant negative consequences could result, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to change the way a product is administered or conduct additional clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the product may become less competitive, and our reputation may suffer; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may decide to remove the product from the marketplace; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interim, topline and preliminary data from our clinical trials may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and treatment continues and more patient data become available. Adverse differences between previous preliminary or interim data and future interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, topline and preliminary data should be viewed with caution until the final data are available. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine to be material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate for its intended indications. Clinical trials are expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. For example, we cannot begin our planned Phase 1 clinical trials for SBT6290, our Nectin4-targeted product candidate until we complete certain preclinical development and submit </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">and receive authorization to proceed under INDs. We also dosed the first patient in a Phase 1/1b clinical trial for SBT6050 in July 2020 and cannot predict how our technology may work in solid tumor indications until we have completed dose-escalation and dose expansion. Finally, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has impacted clinical trials broadly, including our own with some sites pausing or slowing enrollment. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in reaching a consensus with regulatory authorities on trial design or implementation of any future potential collaborators&#8217;, clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in reaching agreement or failing to agree on acceptable terms with prospective CROs and clinical trial sites; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in opening sites, including delays in obtaining required approvals from institutional review boards (IRBs) and recruiting suitable patients to participate in our clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">delays in enrollment due to travel or quarantine policies, or other factors, related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> other pandemics or other events outside our control; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure by our CROs, other third parties or us to adhere to the trial protocol or applicable regulatory requirements, including the FDA&#8217;s good clinical practices (GCPs) or applicable regulatory requirements in other countries; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we or any of our potential future collaborators contract for clinical and commercial supplies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in the testing, validation, manufacturing and delivery of our product candidates to the treatment sites, including due to a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practices (cGMP) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">imposition of a clinical hold by IRBs or regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates, after an inspection of our clinical trial operations or trial sites, or for other reasons; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspensions or terminations by us, the IRBs of the institutions at which such trials are being conducted, by the Safety Review Committee or Data Safety Monitoring Board, for such trial or by regulatory authorities due to a number of factors, including those described above; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">delays in having patients complete participation in a trial or return for post-treatment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up;</div> </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits or the discovery of other safety issues; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lack of adequate funding; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For instance, the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the measures taken by the governmental authorities could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for our product candidates for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities, impede the ability of patients to enroll or continue in clinical trials, or impede testing, monitoring, data collection and analysis or other related activities, any of which could delay our clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our drug product is shipped from overseas and the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and measures taken by the governmental authorities could disrupt the timing and therefore our clinical trials may not proceed or may be delayed, interrupted, or stopped as a result. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any inability to timely and successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to achieve regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable drugs to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be delayed in obtaining marketing approval, if at all; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain approval for indications or patient populations that are not as broad as intended or desired; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to additional post-marketing testing requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be required to perform additional clinical trials to support approval or be subject to additional post- marketing testing requirements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy, or REMS; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to the addition of labeling statements, such as warnings or contraindications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be sued; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">experience damage to our reputation. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Any delay in, or termination of, our clinical trials will delay the submission of a BLA to the FDA or other similar applications with other relevant foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenue. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidate. The FDA has substantial discretion in the review and approval process and may disagree that our data support the claims we propose. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, principal investigators for our clinical trials may serve and have served as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, we, the FDA or an institutional review board may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current GCP, regulations, that we are exposing participants to unacceptable health risks or if the FDA finds </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">deficiencies in our INDs or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed or eliminated entirely. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates, but we may not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the product candidate may be eligible for Fast Track Designation. The benefits of fast track designation include more frequent meetings with FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to support drug approval, more frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers, eligibility for Accelerated Approval and Priority Review, if relevant criteria are met, and rolling review, which means that a drug company can submit completed sections of its BLA for review by FDA, rather than waiting until every section of the BLA is completed before the entire application can be reviewed. BLA review usually does not begin until the entire application has been submitted to the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies by the FDA may be eligible for all features of Fast Track designation, intensive guidance on an efficient drug development program, beginning as early as Phase 1, and organizational commitment involving senior managers at FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible, we cannot assure you that the FDA would decide to grant it. Even if we have obtained Fast Track Designation and/or Breakthrough Therapy Designation for one or more of our product candidates, we may not experience a faster development process, review or approval compared to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-expedited</div> FDA review procedures. In addition, the FDA may withdraw Fast Track Designation or Breakthrough Therapy Designation if it believes that the designation is no longer supported. These designations do not guarantee qualification for the FDA&#8217;s priority review procedures or a faster review or approval process. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain or face delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If safe and effective use of any of our product candidates depends on an <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates, if at all. Commercially available diagnostics are available for HER2, but not currently available for Nectin4. As an existing companion diagnostic does not currently exist for Nectin4, unless one is developed and approved, we may need to develop and obtain approval for a companion diagnostic for the SBT6290 program. The process of obtaining or creating such diagnostic is time consuming and costly. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect. If the FDA or a comparable regulatory authority requires approval of a companion diagnostic for any of our product </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval or continued marketing of such product candidate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidate, if approved, on a timely or profitable basis, if at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we obtain regulatory approval for any of our product candidates, they will be subject to extensive and ongoing regulatory requirements for manufacturing, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, sampling and record-keeping. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP regulations, as well as GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Such regulatory requirements may differ from country to country depending on where we have received regulatory approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. Moreover, if there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-marketers</div> fails to comply with regulatory requirements, the regulators could take various actions. These include: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issuing warning or untitled letters; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mandating modifications to promotional materials or require us to provide corrective information to healthcare practitioners, or require other restrictions on the labeling or marketing of such products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seeking an injunction or imposing civil or criminal penalties or monetary fines; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension or imposition of restrictions on operations, including product manufacturing; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seizure or detention of products, refusal to permit the import or export of products or request that we initiate a product recall; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension, modification or withdrawal of our marketing authorizations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension of any ongoing clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to approve pending applications or supplements to applications submitted by us; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to permit the import or export of products; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, the FDA and other regulatory authorities strictly regulate the promotional claims that may be made about biologic products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, and a company that is found to have improperly promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses may be subject to significant civil, criminal and administrative penalties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could harm our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA customarily approves new therapies only for a second line or later lines of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapies, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third line therapies can include chemotherapy, antibody drugs and small molecule tumor-targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates in most instances at least as a second line therapy. Subsequently, depending on the nature of the clinical data and experience with any approved products or product candidates, if any, we may pursue approval as an earlier line therapy and potentially as a first line therapy. But there is no guarantee that our product candidates, even if approved as a second or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our projections of both the number of people who have HER2 expression, are based on our assumptions and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of the cancers that we are targeting. Consequently, even if our product candidates are approved for a second or third line of therapy, the number of patients who may be eligible for treatment with our product candidates may turn out to be much lower than expected. In addition, we have not yet conducted market research to determine how treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Separately, in response to the global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, in March 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020 the FDA resumed certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> inspections of domestic manufacturing facilities on a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued using our platform technologies. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in our efforts to identify or discover additional product candidates in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to design such product candidates with the properties that we desire; or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable additional candidates for preclinical and clinical development, our opportunities to successfully develop and commercialize therapeutic products will be limited. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Manufacturing, Commercialization and Reliance on Third Parties </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third parties to conduct, supervise, and monitor our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct our preclinical studies, including GLP toxicology studies and ongoing Phase 1/1b clinical trial and any future clinical trials of our product candidates. Specifically, CROs that manage preclinical studies, GLP toxicology studies and our clinical studies as well as clinical investigators, and consultants play a significant role in the conduct of our preclinical studies and clinical trials and the subsequent collection and analysis of data. The timing of the initiation and completion of these studies and trials will therefore be partially controlled by such third parties and may result in delays to our development programs. Nevertheless, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal requirements, and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GLP and GCP requirements through periodic inspections of preclinical study sites, trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GLP or GCP requirements, the data generated in our preclinical studies and clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical or clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> including quarantines and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">shelter-in-place</div></div> orders. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or any comparable foreign regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We contract with third parties for the manufacturing and supply of certain of our product candidates for use in preclinical testing and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of product for evaluation in our research programs. We rely on third parties for the manufacture of a portion of our product candidates for preclinical testing and all of our product candidates for clinical testing and we will continue to rely on such third parties for commercial manufacture if any of our product candidates are approved. We currently have limited manufacturing arrangements and expect that each of our product candidates, including SBT6050, will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contract manufacturers must pass a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not control the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our or a third-party&#8217;s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and timelines and comply with cGMP requirements could adversely affect our business in a number of ways, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to meet our product specifications and quality requirements consistently; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an inability to initiate or continue clinical trials of our product candidates under development; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of the cooperation of future collaborators; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirements to cease development or to recall batches of our product candidates; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing antibody drug conjugate products is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing antibody drug conjugate products is complex and require the use of innovative technologies to handle living cells. Manufacturing these products requires facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at manufacturing facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">scale-up,</div> process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency, significant lead times and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that we or our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the early nature of our product candidates, the drug product may not be stable over time causing changes to be made to the manufacturing or storage process which may result in delays or stopping the development of the product candidate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in methods of product candidate manufacturing may result in additional costs or delays. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well established in the medical community, and physicians may continue to rely on these treatments. Most of our product candidates target mechanisms for which there are limited or no currently approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">efficacy and potential advantages compared to alternative treatments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to offer our products for sale at competitive prices; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">convenience and ease of administration compared to alternative treatments; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the strength of marketing and distribution support; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prevalence and severity of any side effects. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process, with uncertain results, that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may not be available, or may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, there is no uniform policy among third-party payors for coverage and reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Therefore, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a covered benefit under its health plan; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">safe, effective and medically necessary; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">appropriate for the specific patient; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cost-effective; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">neither experimental nor investigational. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot be sure that reimbursement will be available for any product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to a new product&#8217;s acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System, which may result in reduced Medicare payments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed, and the pricing review period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the Affordable Care Act) signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-licensed</div> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action, court decisions or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biological</div> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any approved products are subject to biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial opportunity will be limited. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are focused initially on the development of treatments for cancer. Our projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and trade secrets, a competitor&#8217;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have no sales, marketing or distribution capabilities or experience. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors that may inhibit our efforts to commercialize future products on our own include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability of sales personnel to obtain access to physicians or educate adequate numbers of physicians on the benefits of prescribing any future products; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product portfolios; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue to us are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary resources and attention to sell and market any future products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Risks Related to Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Licenses</div> and Other Strategic Agreements </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not realize the benefits of any acquisitions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license,</div> or strategic alliances that we enter into. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> agreements with multiple licensors and in the future may seek and form strategic alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our existing technologies and product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, or if there are materially adverse impacts on our or the counterparty&#8217;s operations resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may, in the future, decide to collaborate with other biopharmaceutical companies for the development and potential commercialization of those product candidates, including in territories outside the United States or for certain indications. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. We may be unable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> any compositions, methods of use, processes or other third party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Industry and Business Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could continue to adversely impact our business, including our ongoing and planned clinical trials, supply chain, and business development activities. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> a novel strain of coronavirus, was first reported in Wuhan, China and has since become a global pandemic. The President of the United States declared the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic a national emergency and many states and municipalities in the Unites States have announced aggressive actions to reduce the spread of the disease, including limiting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> gatherings of people, ceasing all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> travel, ordering certain businesses and government agencies to cease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> operations at physical locations and issuing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;shelter-in-place&#8221;</div></div> orders which direct individuals to shelter at their places of residence (subject to limited exceptions). For example, on March&#160;23, 2020, the Office of the Governor issued Proclamation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20-25,</div> ordering all individuals in the State of Washington to stay at their place of residence except as needed to maintain continuity of operations of the federal critical infrastructure sectors. As a result of the Washington state order, almost all of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lab</div> based employees are currently telecommuting, which has impacted certain of our operations and may continue to do so over the long term. We may experience further limitations on employee resources in the future, including because of sickness of employees or their families. The effects of government actions and our own policies and those of third parties to reduce the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may negatively impact productivity and slow down or delay our ongoing and future clinical trials, preclinical studies and research and development activities, and may cause disruptions to our supply chain and impair our ability to execute our business development strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, and our operations may be further limited or curtailed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> continues to spread, we may experience ongoing disruptions that could severely impact our business, preclinical studies and clinical trials, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption or delays in our operations, which may impact our ability to conduct and produce preclinical results required for submission of an IND; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties in enrolling patients in our clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">changes in local regulations as part of a response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">risk that participants enrolled in our clinical trials will acquire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA to accept data from clinical trials in affected geographies. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our clinical trials have been, and may in the future be, affected by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. For example, some of our clinical trial sites have slowed down or stop further enrollment of new patients in clinical trials, denied access to site monitors and otherwise curtailed certain operations. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> may be adversely impacted. Our ongoing or planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory agencies. We and our CROs have also made certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA, and may need to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, quarantines, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">shelter-in-place</div></div> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we rely, or the availability or cost of materials, which could disrupt the supply chain for our product candidates. To the extent our suppliers and service providers are unable to comply with their obligations under our agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, our ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and actions taken to reduce its spread continue to rapidly evolve. The extent to which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section, such as those relating to the timing and results of our clinical trials and our financing needs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory standards and requirements and insider trading. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulators, provide accurate information to the FDA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these laws, and the curtailment or restructuring of our operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impairment of our business reputation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of clinical trial participants; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs due to related litigation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distraction of management&#8217;s attention from our primary business; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to patients or other claimants; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to commercialize our product candidates; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for our product candidates, if approved for commercial sale. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe our product liability insurance coverage is sufficient in light of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claims, or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients with cancer and other diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conduct substantially all of our operations at our facilities in Seattle. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior managers as well as junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior scientific and medical personnel. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, we had 67 employees which represents an increase of 44 employees since January&#160;1, 2019. As we advance our research and development programs, we may be required to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage any future growth, we must: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identify, recruit integrate, maintain and motivate additional qualified personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates, both as a monotherapy and in combination with other therapeutics; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">improve our operational, financial and management controls, reporting systems and procedures. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our future financial performance and our ability to develop, manufacture and commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities in order to devote a substantial amount of time, to managing these growth activities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development and commercialization of new products is highly competitive. We largely compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, if ever, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. Moreover, with the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other products in a similar class as some of our product candidates have already been approved and other products in the same class are further along in development. As more product candidates within a particular class of biopharmaceutical products proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for product candidates in those class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Specifically, there are many companies pursuing a variety of approaches to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TLR-directed</div> therapies, including Apros Therapeutics, Ascendis, BioNTech, Bolt Biotherapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, CureVac, Exicure, Galaderma, Gilead, Idera, Mologen, Nektar, Novartis, Primmune Therapeutics, Roche, Seven&amp;Eight, Shanghai De Novo, Sumitomo Dainippon, TriSalus, and UroGen. Other companies using antibody-drug conjugates to target innate immune receptors include Actym Therapeutics, Mersana, and Takeda Pharmaceuticals. Immunotherapy and validated pathway approaches are further being pursued by many smaller biotechnology companies as well as larger pharmaceutical companies. We also face competition from validated pathway therapy treatments offered by companies such as AstraZeneca, Byondis, Daiichi Sankyo, MacroGenics, Pieris, Puma, Seagen, Spectrum Pharmaceuticals, and Zymeworks. We also face competition from companies that </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continue to invest in innovation in the antibody-drug conjugate field, including but not limited to AbbVie, ADC Therapeutics, Astellas, BioAtla, Celldex, CytomX, Eli Lilly and Company, GlaxoSmithKline, Genmab, ImmunoGen, Millennium Pharmaceuticals, MorphoSys AG, Novartis, Pfizer, Sanofi, Seagen, and Sutro Biopharma. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors will also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Unused U.S. federal net operating loss carryforwards (NOLs) for taxable years beginning before January&#160;1, 2018, may be carried forward to offset future taxable income, if any, until such unused NOLs expire. Under legislation informally titled the Tax Cuts and Jobs Act (the Tax Act) enacted in 2017, as modified by legislation enacted on March&#160;27, 2020, entitled the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), U.S. federal NOLs incurred in taxable years beginning after December&#160;31, 2017, can be carried forward indefinitely, but the deductibility of such U.S. federal NOLs in taxable years beginning after December&#160;31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or to the CARES Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, we had $89.7&#160;million of U.S. federal NOLs. If not used, $18.2&#160;million of the U.S. federal NOLs will begin to expire in 2036 and $71.5&#160;million can be carried forward indefinitely under current law. As of December&#160;31, 2020, we also had aggregate U.S. federal research and development (R&amp;D) credits of approximately $1.5&#160;million. Our NOL carryforwards and R&amp;D credits are subject to review and possible adjustment by the U.S. and state tax authorities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-change</div> NOL carryforwards, R&amp;D credits and certain other tax attributes to offset its post-change income or taxes may be limited. This could limit the amount of NOLs, R&amp;D credit carryforwards or other applicable tax attributes that we can utilize annually to offset future taxable income or tax liabilities. Subsequent ownership changes and changes to the U.S. tax rules in respect of the utilization of NOLs, R&amp;D credits and other applicable tax attributes carried forward may further affect the limitation in future years. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we do not currently have any products on the market, our operations may be, directly or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers and other parties through which we may market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the U.S. federal false claims, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, as amended by HITECH, and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them, and their covered subcontractors, that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the U.S. Federal Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these laws and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2010, the Affordable Care Act was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers. There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">th</div> Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unknown when a decision will be made. Further, although the U.S. Supreme Court has not yet ruled on the constitutionality of the Affordable Care Act, on January&#160;28, 2021, President Biden issued an executive order to initiate a special enrollment period from February&#160;15, 2021 through May&#160;15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the Affordable Care Act. We continue to evaluate the effect that the Affordable Care Act and its possible repeal and replacement has on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2021, unless Congress takes additional action. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July&#160;24, 2020 and September&#160;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September&#160;24, 2020, effective November&#160;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January&#160;1, 2022 to January&#160;1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale,</div></div> as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March&#160;22, 2021. On November&#160;20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January&#160;1, 2021. On December&#160;28, 2020, the U.S. District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs of pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Further, it is possible that additional governmental action is taken in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to comply with current or future federal, state and foreign laws and regulations and industry standards relating to privacy and data protection laws could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and our collaborators and third-party providers may be subject to federal, state and foreign data privacy and security laws and regulations. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In many jurisdictions, enforcement actions and consequences for noncompliance are rising. In the United States, these include enforcement actions in response to rules and regulations promulgated under the authority of federal agencies and state attorneys general and legislatures and consumer protection agencies. In addition, privacy advocates and industry groups have regularly proposed, and may propose in the future, self-regulatory standards that may legally or contractually apply to us. If we fail to follow these security standards, even if no customer information is compromised, we may incur significant fines or experience a significant increase in costs. Many state legislatures have adopted legislation that regulates how businesses operate online, including measures relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also constantly amending existing laws, requiring attention to frequently changing regulatory requirements. Furthermore, California recently enacted the California Consumer Privacy Act (the CCPA) which became effective on January&#160;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. At this time, we do not collect personal information relating to residents of California but should we begin to do so, the CCPA will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign data protection laws, including the EU General Data Protection Regulation (the GDPR), may also apply to health-related and other personal information obtained outside of the United States. The GDPR, which came into effect on May&#160;25, 2018, imposes strict requirements for processing the personal data of individuals within the European Economic Area (EEA) and the United Kingdom, including clinical trial data, as well as potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The GDPR imposes strict requirements for the collection, use and disclosure of personal data, including stringent requirements relating to obtaining consent, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party processors. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. At this time, we do not believe we are subject to the GDPR, but should this change, the GDPR will increase our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with U.S. and foreign data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and third-party providers to comply with U.S. and foreign data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We rely upon a combination of patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, product candidates and their uses, as well as our ability to operate without infringing the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued or that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner, including delays as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impacting our or our licensors&#8217; operations. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications directed to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-label.&#8221;</div> Although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, inventorship, scope, validity, enforceability and commercial value of our patent rights are highly </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">uncertain. Our pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. For example, our pending patent applications may be subject to third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-issuance</div> submissions of prior art to the USPTO or our issued patents may be subject to post-grant review (PGR) proceedings, oppositions, derivations, reexaminations, or <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review (IPR) proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidates or their uses could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> that is not patentable, processes for which patents are difficult to enforce and any other elements of our discovery and development processes that involve proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and if the license is not available on commercially-viable terms, then we may not be able to launch our product. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if and when patents may issue based on our patent applications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of protection of any patent issuing based on our patent applications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether the claims of any patent issuing based on our patent applications will provide protection against competitors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether or not third parties will find ways to invalidate or circumvent our patent rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; and/or </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">whether the patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot be certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect our intellectual property rights throughout the world. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent protection is available on a national or regional level. Filing, prosecuting and defending patents throughout the world and on all of our product candidates would be prohibitively expensive. As such, our intellectual property rights outside the United States may not extend to all other possible countries outside the United States and we may not be able to prevent third parties from practicing our inventions in countries outside the United States where we do not have patent protection, or from selling in and importing products into other jurisdictions made using our inventions in such countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products or technology and may export otherwise infringing products or technology to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Further, the legal systems of certain countries particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any such lawsuits that we initiate and the damages and other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. We currently have and may in the future enter into more contract research and manufacturing relationships with organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties at nominal or no consideration. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that noncompliance with the USPTO and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that our pending patent applications will not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not develop additional proprietary technologies that are patentable; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> will result in issued patents with claims that directed to our product candidates or uses thereof in the United States or in other foreign countries; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if enforced, a court may not hold that our patents are valid, enforceable and infringed; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may choose not to file a patent application in order to maintain certain trade secrets or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and a third party may subsequently file a patent application covering such intellectual property; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may fail to adequately protect and police our trademarks and trade secrets; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should any of these or similar events occur, they could significantly harm our business, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are currently party to an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> agreement under which we were granted rights to manufacture certain components of our product candidates. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these technologies or both, which would adversely affect our business and prospects. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We rely, in part, on license and other strategic agreements, which subject us to various obligations, including payment obligations for achievement of certain milestones on product sales. For example, with respect to SBT6050, we have licensed a cell line to manufacture these products under an agreement with WuXi Biologics. If we fail to comply with the obligations under our license agreements, including as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> impacting our operations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are terminated, we may experience significant delays, difficulties, and costs in developing new cell lines and identifying an alternative source to manufacture components of our candidate products covered by our agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sublicensing of patent and other rights; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the creation or use of intellectual property by us alone or with our licensors and partners; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope and duration of our payment obligations; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the priority of invention of patented technology. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described herein. If we or our licensor fail to adequately protect this intellectual property, our ability to develop, manufacture, or commercialize products could suffer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently own intellectual property directed to our product candidates and other proprietary technologies. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, some of our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents or patent applications or future patents are or may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-owned</div> with third parties. If we are unable to obtain an exclusive license to any such third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-owners&#8217;</div> interest in such patents or patent applications, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-owners</div> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-owners</div> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents may be subject to a reservation of rights by one or more third parties. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. For example, we have identified certain third party patents that may be asserted against us with respect to our lead product SBT6050. These patents may expire prior to commercial launch of SBT6050, if approved. We believe that the relevant claims of these third party patents are likely invalid or unenforceable, and we may choose to challenge those patents, though the outcome of any challenge that we may initiate in the future is uncertain. We may also decide in the future to seek a license to those third party patents, but we might not be able to do so on reasonable terms. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing candidate product or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing candidate product or product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may choose to challenge the enforceability or validity of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ex-parte</div></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-exam,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> technology, which may not be possible on a cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Competitors or other third parties may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-enablement</div> or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271I(1). An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-litigious</div> action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leathy-Smith Act), signed into law on September&#160;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our product candidates and other proprietary technologies we may develop or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">law-making</div> bodies in other countries, the laws and regulations governing patents could change in unpredictable </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Assoc. for Molecular Pathology v.</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Myriad Genetics, Inc.</div></div>, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse, including due to the effect of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may rely on trade secret and proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to seeking patents for some of our technology and product candidates, we may also rely on trade secrets, including unpatented <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other proprietary information, to maintain our competitive position. Elements of our product candidate, including processes for their preparation and manufacture, may involve proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#8217;s property, potential trade secrets, proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and information. We further seek to protect our potential trade secrets, proprietary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and information in part, by entering into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inventor.</div> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-ownership</div> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed.</div> If other third parties have ownership rights or other rights to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The term of a United States patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent. A patent term extension (PTE) based on regulatory delay may be available in the United States. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the PTE does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous PTEs in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Securities Markets and Ownership of Our Common Stock </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">An active trading market for our common stock may not continue to be developed or be sustained, which may make it difficult for you to sell your shares. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to our initial public offering in December 2020, there had been no public market for our common stock. The trading market for our common stock on The Nasdaq Global Market has been limited and an active trading market for our shares may not be sustained. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares at a price that is attractive to you, or at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The price of our common stock could be subject to volatility related or unrelated to our operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our stock price may be volatile. The stock market in general and the market for biotechnology and pharmaceutical companies, in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares at a price that is attractive to you, or at all. The market price for our common stock may be influenced by numerous factors, many of which are beyond our control, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adverse results or delays in clinical trials; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to commercialize our product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory or legal developments in the United States and other countries; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the level of expenses related to future product candidates or clinical development programs; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our failure to achieve product development goals in the timeframe we announce; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recruitment or departure of key personnel; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the economy as a whole and market conditions in our industry; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the expiration of market standoff or contractual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements; </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the size of our market float; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">political uncertainty and/or instability in the United States; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the ongoing and future impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and actions taken to slow its spread; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any other events or factors discussed in this report. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immune-oncology companies. Stock prices of many immune-oncology companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. The trading prices for common stock of other biopharmaceutical companies have also been highly volatile as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. In the past, stockholders have filed securities class action lawsuits following periods of market volatility. If such securities litigation were instituted against us, it could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. As a result of their share ownership, these stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If there are substantial sales of shares of our common stock, the price of our common stock could decline.* </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. As of March&#160;31, 2021, we had 34,903,497 outstanding shares of our common stock. Of these shares, approximately 13.1&#160;million shares are freely tradable and substantially all of the remaining shares of common stock will be available for sale in the public market beginning in June 2021 following the scheduled expiration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements that certain of our stockholders and the underwriters entered into in connection with our initial public offering. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Goldman Sachs&#160;&amp; Co. LLC, SVB Leerink LLC and Stifel, Nicolaus&#160;&amp; Company, Incorporated may release these stockholders from their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements with the underwriters at any time and without notice, which would allow for earlier sales of shares in the public market. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our 2020 Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares of our common stock reserved for issuance under our 2020 Plan will automatically increase on January&#160;1 of each calendar year, starting on January&#160;1, 2021 through January&#160;1, 2030, in an amount equal to the lesser of (i) 5.0% of the total number of shares of our common stock </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding on the last day of the calendar month before the date of each automatic increase; or (ii)&#160;a lesser number of shares determined by our board of directors prior to the applicable January 1st. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We could be subject to securities class action litigation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reduced disclosure obligations regarding executive compensation; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">not being required to hold a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-binding</div> advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, as an &#8220;emerging growth company&#8221; the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies, unless we later irrevocably elect not to avail ourselves of this exemption. We have elected to use </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest to occur of: (i)&#160;the last day of the fiscal year in which we have at least $1.07&#160;billion in annual revenue; (ii)&#160;the date upon which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> under the Securities Exchange Act of 1934, as amended (the Exchange Act); (iii)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt securities during the prior three-year period; and (iv)&#160;December&#160;31, 2025. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the requirement for the affirmative vote of holders of at least <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">66-2/3%</div> of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, as a Delaware corporation, we are subject to Section&#160;203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our amended and restated certificate of incorporation designates the state courts the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, and the federal district courts of the United States of America to be the exclusive forums for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against our company and our directors, officers and employees. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv)&#160;any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v)&#160;any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&#160;any action asserting a claim against us or any of our directors, officers or other employees, governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the Securities Act), unless we consent in writing to the selection of an alternative forum. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General Risk Factors </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company listed on the Nasdaq Global Market, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subsequently implemented by the SEC, and the Nasdaq Global Market have imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits smaller &#8220;emerging growth companies&#8221; to implement many of these requirements over a longer period and up to five years from the pricing of our initial public offering. We intend to continue to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time- consuming and costlier. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we are required to incur substantial costs to maintain our current levels of such coverage. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to maintain effective disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are subject to requirements of the Sarbanes-Oxley Act, the rules and regulations of the Nasdaq Global Market, the rules and regulations of the Securities and Exchange Commission. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly and place significant strain on our personnel, systems and resources. Company responsibilities required by the Sarbanes-Oxley Act include, among other things, that we maintain corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. We are also continuing to improve our internal control over financial reporting. In order to develop, maintain, and improve the effectiveness of our internal controls and procedures, and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain, or any disruptions or difficulties in implementing or using, such a system could adversely affect our controls and harm our business. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. In addition, we may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If we cannot provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, investors could lose confidence in our reported financial information and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business, results of operations, and financial condition and could cause a decline in the trading price of our common stock. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Accounting Pronouncements.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">New income, sales, use, or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted, changed, modified, or applied adversely to us. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> charges, and could increase our future U.S. tax expense. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our internal information technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product candidates&#8217; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party contractors who have access to our confidential information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">denial-of-service</div></div> attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our headquarters and main research facility are located in Seattle, Washington, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, or collectively, Trade Laws, prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_12" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unregistered Sales of Equity Securities and Use of Proceeds </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Proceeds </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;3, 2020, we commenced our initial public offering pursuant to a registration statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-250009)</div> that was declared effective by the SEC on December&#160;3, 2020, for 11,500,000 shares of our common stock for sale to the public at a price of $21.00 per share. In addition, in December 2020, the underwriters exercised their over-allotment option to purchase 1,725,000 additional shares of our common stock in the initial public offering at the public offering price of $21.00 per share, such that the aggregate offering price of our initial public offering was $277.7&#160;million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were $255.3&#160;million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates. The underwriters for our initial public offering were Goldman Sachs&#160;&amp; Co. LLC, SVB Leerink LLC, Stifel, Nicolaus&#160;&amp; Company, Incorporated, and H.C. Wainwright&#160;&amp; Co., LLC. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily in treasury money market accounts. Through March&#160;31, 2021, we have used approximately $8.0&#160;million of the net proceeds from our IPO. There has been no material change in the use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on December&#160;4, 2020. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_13" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defaults Upon Senior Securities </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_14" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mine Safety Disclosures </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_15" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Information </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not applicable. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td id="tx155579_16" style="width: 9%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;6.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex31.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on December&#160;8, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;3.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex32.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on December&#160;8, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Reference is made to <a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex31.htm">Exhibit 3.1</a> and <a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520312895/d66270dex32.htm">3.2</a>.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520304858/d67046dex41.htm">Form of Common Stock Certificate of the registrant (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</span> (File No.<span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-250009),</span> as amended, filed with the SEC on November&#160;30, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, by and between the registrant and certain of its stockholders, dated September&#160;22, 2020 (incorporated by reference to Exhibit 4.2 to the registrant&#8217;s Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</span> (File No.<span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-250009),</span> as amended, filed with the SEC on November&#160;10, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex43.htm">Warrant to purchase stock issued to Silicon Valley Bank, dated November&#160;21, 2016 (incorporated by reference to Exhibit 4.3 to the registrant&#8217;s Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</span> (File No.<span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-250009),</span> as amended, filed with the SEC on November&#160;10, 2020).</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;4.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312520290236/d67046dex44.htm">Warrant to purchase stock issued to Silicon Valley Bank, dated December&#160;22, 2017 (incorporated by reference to Exhibit 4.4 to the registrant&#8217;s Registration Statement on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</span> (File No.<span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;333-250009),</span> as amended, filed with the SEC on November&#160;10, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.16*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1671858/000119312521098283/d109083dex1016.htm">Amendment No.&#160;1 to Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated January&#160;12, 2021. (incorporated by reference to Exhibit 10.16 to the registrant&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</span> filed with the SEC on March&#160;29, 2021). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d155579dex311.htm">Certification of Principal Executive Officer Pursuant to Rules <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a)</span> and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-14(a)</span> under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d155579dex312.htm">Certification of Principal Financial Officer Pursuant to Rules <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a)</span> and <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-14(a)</span> under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 90%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;32.1#</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d155579dex321.htm">Certification of Principal Executive and Financial Officers Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Label Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain information in this exhibit is omitted because it is both not material and is the type that the registrant treats as private or confidential. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">#</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q),</div> unless the Registrant specifically incorporates the foregoing information into those documents by reference. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;; margin-block-start: 1.67em; margin-block-end: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 45%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SILVERBACK THERAPEUTICS, INC.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: May&#160;13, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">/s/ Laura Shawver</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Laura Shawver</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Chief Executive Officer and Director (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal Executive Officer</div></div>)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: May&#160;13, 2021</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">/s/ Jonathan Piazza</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Jonathan Piazza</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Chief Financial Officer (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principal Financial Officer</div></div>)</td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d155579dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Laura Shawver, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2021 of Silverback Therapeutics, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;To my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;To my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;13, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;Laura Shawver, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Laura Shawver, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Chief Executive Officer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(Principal Executive Officer)</I></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d155579dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Jonathan Piazza, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2021 of Silverback Therapeutics, Inc.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;To my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;To on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;13, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jonathan Piazza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Jonathan Piazza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Chief Financial Officer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(Principal Financial Officer)</I></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d155579dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSURANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Silverback Therapeutics, Inc. (the
&#147;Company&#148;) for the period ended March&nbsp;31, 2021, to which this Certification is attached, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), each of the undersigned officers of the Company
herby certifies, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to their knowledge: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of
1934; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;13, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;Laura Shawver, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Laura Shawver, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Chief Executive Officer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(Principal Executive Officer)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;13, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jonathan Piazza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Jonathan Piazza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Chief Financial Officer</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><I>(Principal Financial Officer)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;
1350, and is not being filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of
any general incorporation language in such filing. A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sbtx-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 13-May-2021 [11:11:56] {AM}-->
<schema targetNamespace="http://silverback.com/20210331" elementFormDefault="qualified" xmlns:sbtx="http://silverback.com/20210331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://silverback.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CondensedBalanceSheet" id="CondensedBalanceSheet">
<link:definition>1002 - Statement - Condensed Balance Sheet</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CondensedBalanceSheetParenthetical" id="CondensedBalanceSheetParenthetical">
<link:definition>1003 - Statement - Condensed Balance Sheet (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" id="CondensedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
<link:definition>1005 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
<link:definition>1006 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CondensedStatementsOfCashFlows" id="CondensedStatementsOfCashFlows">
<link:definition>1007 - Statement - Condensed Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/NatureOfBusiness" id="NatureOfBusiness">
<link:definition>1008 - Disclosure - Nature of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1010 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1011 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/Leases" id="Leases">
<link:definition>1012 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/TermLoanPayable" id="TermLoanPayable">
<link:definition>1013 - Disclosure - Term Loan Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
<link:definition>1014 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1015 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/LicensingAgreement" id="LicensingAgreement">
<link:definition>1016 - Disclosure - Licensing Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/EmployeeBenefitPlans" id="EmployeeBenefitPlans">
<link:definition>1018 - Disclosure - Employee Benefit Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders" id="NetLossPerShareAttributableToCommonStockholders">
<link:definition>1019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices" id="SummaryOfSignificantAccountingPoliciesPolices">
<link:definition>1020 - Disclosure - Summary of Significant Accounting Policies (Polices)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1022 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1023 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/LeasesTables" id="LeasesTables">
<link:definition>1024 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockholdersEquityDeficitTables" id="StockholdersEquityDeficitTables">
<link:definition>1025 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1026 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables" id="NetLossPerShareAttributableToCommonStockholdersTables">
<link:definition>1027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail" id="NatureOfBusinessAdditionalInformationDetail">
<link:definition>1028 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" id="SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail">
<link:definition>1029 - Disclosure - Summary of Significant Accounting Policies - Summary of  reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
<link:definition>1030 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
<link:definition>1031 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" id="AccruedExpensesSummaryOfAccruedExpensesDetail">
<link:definition>1032 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail" id="LeasesSummaryOfOperatingLeaseCostDetail">
<link:definition>1033 - Disclosure - Leases -  Summary of Operating Lease Cost (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" id="LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail">
<link:definition>1034 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1035 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/TermLoanPayableAdditionalInformationDetail" id="TermLoanPayableAdditionalInformationDetail">
<link:definition>1036 - Disclosure - Term Loan Payable - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" id="StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail">
<link:definition>1037 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future  Issuance&amp;#160; (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail" id="StockholdersEquityDeficitAdditionalInformationDetail">
<link:definition>1038 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" id="StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1039 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" id="StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail">
<link:definition>1040 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" id="StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail">
<link:definition>1041 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail" id="StockBasedCompensationAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/LicensingAgreementAdditionalInformationDetails" id="LicensingAgreementAdditionalInformationDetails">
<link:definition>1043 - Disclosure - Licensing Agreement - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" id="NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
<link:definition>1044 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sbtx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="SeriesBRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_SeriesBRedeemableConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_StockIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LicensingAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_LicensingAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="LicensingAgreement" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_LicensingAgreement" substitutionGroup="xbrli:item" />
<element name="EmergingGrowthCompanyStatusPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCommonStockReservedForIssuanceTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LiquidityAndCapitalResourcesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_LiquidityAndCapitalResourcesMember" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sbtx_AccruedResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TermLoanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_TermLoanMember" substitutionGroup="xbrli:item" />
<element name="SiliconValleyBankMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_SiliconValleyBankMember" substitutionGroup="xbrli:item" />
<element name="LoanAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_LoanAndSecurityAgreementMember" substitutionGroup="xbrli:item" />
<element name="AmendedLoanAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_AmendedLoanAndSecurityAgreementMember" substitutionGroup="xbrli:item" />
<element name="SharesUnderlyingOutstandingEquityAwardsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_SharesUnderlyingOutstandingEquityAwardsMember" substitutionGroup="xbrli:item" />
<element name="SharesAvailableForFutureEquityAwardGrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_SharesAvailableForFutureEquityAwardGrantsMember" substitutionGroup="xbrli:item" />
<element name="SharesUnderlyingEarlyExercisedEquityAwardsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" substitutionGroup="xbrli:item" />
<element name="SharesUnderlyingEsppWithholdingsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_SharesUnderlyingEsppWithholdingsMember" substitutionGroup="xbrli:item" />
<element name="RedeemableStockExcersibleOnAgreedUponMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" substitutionGroup="xbrli:item" />
<element name="IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" substitutionGroup="xbrli:item" />
<element name="UnvestedCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_UnvestedCommonStockMember" substitutionGroup="xbrli:item" />
<element name="WuxiBioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_WuxiBioMember" substitutionGroup="xbrli:item" />
<element name="LicenseFeesPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_LicenseFeesPaid" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AgreementPaymentAndLicenseTermDesciption" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sbtx_AgreementPaymentAndLicenseTermDesciption" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" substitutionGroup="xbrli:item" />
<element name="EsppWithholdingsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sbtx_EsppWithholdingsMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sbtx-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 13-May-2021 [11:11:56] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedBalanceSheet" roleURI="http://silverback.com/role/CondensedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfCashFlows" roleURI="http://silverback.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesSummaryOfOperatingLeaseCostDetail" roleURI="http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" roleURI="http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" />
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="loc_us-gaap_LoansPayableToBankCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LoansPayableToBankCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="19" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestIncomeExpenseNet" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfBankDebt" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_SBTX_IncreaseDecreaseInOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SBTX_IncreaseDecreaseInOperatingLeaseLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_SBTX_AccruedResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_SBTX_AccruedResearchAndDevelopmentExpenses" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sbtx-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 13-May-2021 [11:11:56] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NatureOfBusinessAdditionalInformationDetail" roleURI="http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#TermLoanPayableAdditionalInformationDetail" roleURI="http://silverback.com/role/TermLoanPayableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" roleURI="http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficitAdditionalInformationDetail" roleURI="http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationAdditionalInformationDetail" roleURI="http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LicensingAgreementAdditionalInformationDetails" roleURI="http://silverback.com/role/LicensingAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CoverPage" roleURI="http://silverback.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedBalanceSheet" roleURI="http://silverback.com/role/CondensedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurementsTables" roleURI="http://silverback.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurements" roleURI="http://silverback.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfCashFlows" roleURI="http://silverback.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LicensingAgreement" roleURI="http://silverback.com/role/LicensingAgreement" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NatureOfBusiness" roleURI="http://silverback.com/role/NatureOfBusiness" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpenses" roleURI="http://silverback.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpensesTables" roleURI="http://silverback.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedBalanceSheetParenthetical" roleURI="http://silverback.com/role/CondensedBalanceSheetParenthetical" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#Leases" roleURI="http://silverback.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesTables" roleURI="http://silverback.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesSummaryOfOperatingLeaseCostDetail" roleURI="http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" roleURI="http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesAdditionalInformationDetail" roleURI="http://silverback.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#TermLoanPayable" roleURI="http://silverback.com/role/TermLoanPayable" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CommitmentsAndContingencies" roleURI="http://silverback.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NetLossPerShareAttributableToCommonStockholders" roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#EmployeeBenefitPlans" roleURI="http://silverback.com/role/EmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolices" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensation" roleURI="http://silverback.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationTables" roleURI="http://silverback.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficit" roleURI="http://silverback.com/role/StockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficitTables" roleURI="http://silverback.com/role/StockholdersEquityDeficitTables" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_906284" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StatementTable_906281" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906281" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906282" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906282" xlink:to="loc_us-gaap_ClassOfStockDomain_906283" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906283_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906282" xlink:to="loc_us-gaap_ClassOfStockDomain_906283_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_906283" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906292" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_906293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906281" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_906293" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_906294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_906293" xlink:to="loc_us-gaap_EquityComponentDomain_906294" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_906294_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_906293" xlink:to="loc_us-gaap_EquityComponentDomain_906294_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_906295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_906294" xlink:to="loc_us-gaap_CommonStockMember_906295" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_906296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_906294" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_906296" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_906297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_906294" xlink:to="loc_us-gaap_RetainedEarningsMember_906297" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_906298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_906298" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_906302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_906302" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_906314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_906314" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_906318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_906318" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_906364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_906364" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906367" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_906472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockholdersEquity_906472" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_906473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_906473" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_906474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_906474" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906475" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_906477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_906477" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_906478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_NetIncomeLoss_906478" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_909911" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_909911" xlink:to="loc_us-gaap_StatementTable_906815" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906815" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906816" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906816" xlink:to="loc_us-gaap_ClassOfStockDomain_906817" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906817_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906816" xlink:to="loc_us-gaap_ClassOfStockDomain_906817_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_sbtx_SeriesBRedeemableConvertiblePreferredStockMember_906820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_906817" xlink:to="loc_sbtx_SeriesBRedeemableConvertiblePreferredStockMember_906820" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_StockIssuanceCosts" xlink:label="loc_sbtx_StockIssuanceCosts_909912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_909911" xlink:to="loc_sbtx_StockIssuanceCosts_909912" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_906444" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_StatementTable_906441" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_906449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448" xlink:to="loc_us-gaap_IPOMember_906449" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906686" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906686" xlink:to="loc_us-gaap_ClassOfStockDomain_906687" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906687_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906686" xlink:to="loc_us-gaap_ClassOfStockDomain_906687_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_906687" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906688" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_906689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_906689" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_906690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_906689" xlink:to="loc_us-gaap_EquityComponentDomain_906690" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_906690_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_906689" xlink:to="loc_us-gaap_EquityComponentDomain_906690_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_906691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_906690" xlink:to="loc_us-gaap_CommonStockMember_906691" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LiquidityAndCapitalResourcesMember" xlink:label="loc_sbtx_LiquidityAndCapitalResourcesMember_909585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_906690" xlink:to="loc_sbtx_LiquidityAndCapitalResourcesMember_909585" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_906455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_906455" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_906456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_906456" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_906458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_906458" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_906459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_906459" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_906461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_906461" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906462" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_921561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_CommonStockSharesIssued_921561" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_909534" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906507" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_906508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_906508" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906509" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_909531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530" xlink:to="loc_us-gaap_CashMember_909531" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906027" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906027" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_906031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_906031" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_906033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_906033" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_906034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_906034" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_906042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_906042" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_906044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_906044" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_906044" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_906044" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_906048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046" xlink:to="loc_us-gaap_MoneyMarketFundsMember_906048" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_906050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906027" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_906050" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_906078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_906078" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_906065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_906065" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_906067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_906067" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_906068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_906068" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_906070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_906070" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_906073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_906073" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/TermLoanPayableAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_906326" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_906324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentTable_906324" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_906333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_DebtInstrumentAxis_906333" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_906334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_906333" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_906334" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_906334_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_906333" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_906334_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TermLoanMember" xlink:label="loc_sbtx_TermLoanMember_906338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_906334" xlink:to="loc_sbtx_TermLoanMember_906338" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_906339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_906339" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_906339" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_906339" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SiliconValleyBankMember" xlink:label="loc_sbtx_SiliconValleyBankMember_906341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340" xlink:to="loc_sbtx_SiliconValleyBankMember_906341" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_906342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_TypeOfArrangementAxis_906342" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906342" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906342" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LoanAndSecurityAgreementMember" xlink:label="loc_sbtx_LoanAndSecurityAgreementMember_906344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" xlink:to="loc_sbtx_LoanAndSecurityAgreementMember_906344" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AmendedLoanAndSecurityAgreementMember" xlink:label="loc_sbtx_AmendedLoanAndSecurityAgreementMember_906345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" xlink:to="loc_sbtx_AmendedLoanAndSecurityAgreementMember_906345" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_906363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_906363" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_906391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_906391" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_906392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_906392" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_906400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_InterestExpense_906400" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_906402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_906402" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_906411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_906411" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_906675" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_906668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_906675" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_906668" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_906669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906668" xlink:to="loc_us-gaap_AwardTypeAxis_906669" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_906669" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_906669" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:label="loc_sbtx_SharesUnderlyingOutstandingEquityAwardsMember_906671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesUnderlyingOutstandingEquityAwardsMember_906671" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:label="loc_sbtx_SharesAvailableForFutureEquityAwardGrantsMember_906672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesAvailableForFutureEquityAwardGrantsMember_906672" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:label="loc_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_906673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_906673" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:label="loc_sbtx_SharesUnderlyingEsppWithholdingsMember_906674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesUnderlyingEsppWithholdingsMember_906674" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906675" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906676" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_906660" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_906643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_906643" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaap_SeriesBMember_906648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645" xlink:to="loc_us-gaap_SeriesBMember_906648" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_906650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_TypeOfArrangementAxis_906650" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906650" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906650" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:label="loc_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_906653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651" xlink:to="loc_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_906653" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_906654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_srt_StatementScenarioAxis_906654" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_906655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_906654" xlink:to="loc_srt_ScenarioUnspecifiedDomain_906655" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_906655_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_906654" xlink:to="loc_srt_ScenarioUnspecifiedDomain_906655_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906656" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906656" xlink:to="loc_us-gaap_ClassOfStockDomain_906657" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906657_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906656" xlink:to="loc_us-gaap_ClassOfStockDomain_906657_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_906657" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906658" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_906661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_906661" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906662" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:label="loc_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_906663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_906663" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_906664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_906664" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_906665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_906665" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_906666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_906666" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906528" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906528" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_906524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_906524" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_906525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_906524" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_906525" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_906525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_906524" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_906525_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_906525" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906526" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_906525" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906527" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_906529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906528" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_906529" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906531" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906533" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906534" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906535" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_906537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_906537" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_906542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_906542" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_906543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_906543" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_906544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_906544" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_906546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_906546" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_906548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_906548" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_906551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_906551" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_906553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_906553" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_906554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_906554" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_906556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_906556" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnvestedCommonStockMember" xlink:label="loc_sbtx_UnvestedCommonStockMember_906566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565" xlink:to="loc_sbtx_UnvestedCommonStockMember_906566" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_909644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_909644" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_909644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_909644_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_909646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_909644" xlink:to="loc_us-gaap_StockOptionMember_909646" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_906573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_906573" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_906574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_906574" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_906575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_906575" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906586" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906587" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_906589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_906589" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906591" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_906594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_906594" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906627" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930514" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/LicensingAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_906322" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_us-gaap_StatementTable_906146" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_906153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906146" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_906153" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_906154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_906153" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_906154" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_906154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_906153" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_906154_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_906154" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906155" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_906146" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_906163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" xlink:to="loc_us-gaap_RelatedPartyDomain_906163" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_906163_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" xlink:to="loc_us-gaap_RelatedPartyDomain_906163_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_WuxiBioMember" xlink:label="loc_sbtx_WuxiBioMember_906167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_906163" xlink:to="loc_sbtx_WuxiBioMember_906167" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicenseFeesPaid" xlink:label="loc_sbtx_LicenseFeesPaid_906328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_sbtx_LicenseFeesPaid_906328" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="loc_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_906331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_906331" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:label="loc_sbtx_AgreementPaymentAndLicenseTermDesciption_906336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_sbtx_AgreementPaymentAndLicenseTermDesciption_906336" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_906460" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_906460" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_906439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_us-gaap_EmployeeStockOptionMember_906439" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnvestedCommonStockMember" xlink:label="loc_sbtx_UnvestedCommonStockMember_906445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_sbtx_UnvestedCommonStockMember_906445" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_906447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_us-gaap_WarrantMember_906447" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_EsppWithholdingsMember" xlink:label="loc_sbtx_EsppWithholdingsMember_906451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_sbtx_EsppWithholdingsMember_906451" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906454" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_906460" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906467" use="optional" order="10" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sbtx-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 13-May-2021 [11:11:56] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right-of-use&#160;asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="loc_us-gaap_LoansPayableToBankCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LoansPayableToBankCurrent" xml:lang="en-US">Loans Payable to Bank, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LoansPayableToBankCurrent" xml:lang="en-US">Term loan payable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableToBankCurrent" xlink:to="lab_us-gaap_LoansPayableToBankCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liability, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 10)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020, 34,903,497 and 34,801,537 shares issued, and 34,827,204 and 34,701,274 shares outstanding at March 31, 2021 and December 31, 2020, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock , shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares, outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Beginning balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ending balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share applicable to common stockholders, basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Temporary equity, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Temporary Equity, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary equity, Beginning balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Ending balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Redeemable convertible preferred stock outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xml:lang="en-US">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:to="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xml:lang="en-US">Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:to="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xml:lang="en-US">The number of shares of new stock classified as temporary equity issued on conversion of convertible notes during the period.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xml:lang="en-US">Temporary Equity Stock Issued During Period Value New Issues For Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock for cash, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:to="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xml:lang="en-US">Value of stock classified as temporary equity issued for cash during the period.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock for cash, net, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">The number of shares of new stock classified as temporary equity issued during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of common stock options and vesting of early exercised common stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of common stock options and vesting of early exercised common stock options, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Shares Subject to Options Outstanding, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_sbtx_SeriesBRedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lab_sbtx_SeriesBRedeemableConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xml:lang="en-US">Series B redeemable convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_StockIssuanceCosts" xlink:label="loc_sbtx_StockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_StockIssuanceCosts" xml:lang="en-US">Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_StockIssuanceCosts" xml:lang="en-US">Stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_StockIssuanceCosts" xlink:to="lab_sbtx_StockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_StockIssuanceCosts" xml:lang="en-US">Stock issuance costs.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Non-cash&#160;lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">The increase (decrease) in operating lease liabilities during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xml:lang="en-US">Repayments of Bank Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xml:lang="en-US">Principal payments on term loan payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfBankDebt" xlink:to="lab_us-gaap_RepaymentsOfBankDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of common stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US">Change in cash, cash equivalents, and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Total cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Change in Early Exercise Liability Included in Accounts Payable and Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Change in early exercise liability included in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" xml:lang="en-US">The amount of change in early exercise liability included in accounts payable and accrued expenses.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xml:lang="en-US">Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertibel Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xlink:to="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xml:lang="en-US">Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xml:lang="en-US">Fair Value of Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Unpaid Issuance Costs And Amounts Payable To Investors For Redeemable Converteible Preferred Stock Included In Accounts Payable And Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Term Loan Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicensingAgreementAbstract" xlink:label="loc_sbtx_LicensingAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_LicensingAgreementAbstract" xml:lang="en-US">Licensing Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_LicensingAgreementAbstract" xlink:to="lab_sbtx_LicensingAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_LicensingAgreementAbstract" xml:lang="en-US">Licensing Agreement.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicensingAgreement" xlink:label="loc_sbtx_LicensingAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_LicensingAgreement" xml:lang="en-US">Licensing Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_LicensingAgreement" xlink:to="lab_sbtx_LicensingAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_LicensingAgreement" xml:lang="en-US">Licensing Agreement.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Employee Benefit Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Status [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="lab_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy followed under emerging growth company status.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value On Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value On Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Summary of Operating Lease Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Summary of Future Minimum Commitments Due Under the Operating Lease Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:label="loc_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xml:lang="en-US">Schedule Of Common Stock Reserved For Issuance [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xml:lang="en-US">Summary of Common Shares Reserved for Future Issuance&#160;</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:to="lab_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xml:lang="en-US">Schedule Of Common Stock Reserved For Issuance.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Activity Related to Stock Option Grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Offering price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Net proceeds after deducting underwriting discounts and commissions and offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of preferred stock, common shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LiquidityAndCapitalResourcesMember" xlink:label="loc_sbtx_LiquidityAndCapitalResourcesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_LiquidityAndCapitalResourcesMember" xml:lang="en-US">Liquidity and Capital Resources [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_LiquidityAndCapitalResourcesMember" xml:lang="en-US">Liquidity and Capital Resources [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_LiquidityAndCapitalResourcesMember" xlink:to="lab_sbtx_LiquidityAndCapitalResourcesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_LiquidityAndCapitalResourcesMember" xml:lang="en-US">Liquidity and Capital Resources [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashMember" xml:lang="en-US">Cash [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashMember" xml:lang="en-US">Restricted Cash [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xml:lang="en-US">Fair value,assets transfers from Level 1 to Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair value,assets transfers from Level 2 to Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xml:lang="en-US">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xml:lang="en-US">Fair value, liabilities transfers from Level 1 to Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="lab_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xml:lang="en-US">Fair value, liabilities transfers from Level 2 to Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="lab_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xml:lang="en-US">Fair Value, assets transfers into (out of) Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_sbtx_AccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued Research And Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_sbtx_AccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee compensation and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Professional services and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash outflows from operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Years Ending December&#160;31,</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2021 (remaining 9 months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Present value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total present value of lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease Weighted Average Remaining Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease Weighted Average Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Annual Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Effective interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TermLoanMember" xlink:label="loc_sbtx_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TermLoanMember" xml:lang="en-US">Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TermLoanMember" xml:lang="en-US">Term Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TermLoanMember" xlink:to="lab_sbtx_TermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TermLoanMember" xml:lang="en-US">Term loan [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SiliconValleyBankMember" xlink:label="loc_sbtx_SiliconValleyBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_SiliconValleyBankMember" xml:lang="en-US">Silicon Valley Bank [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_SiliconValleyBankMember" xml:lang="en-US">Silicon Valley Bank [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_SiliconValleyBankMember" xlink:to="lab_sbtx_SiliconValleyBankMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_SiliconValleyBankMember" xml:lang="en-US">Silicon Valley Bank [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LoanAndSecurityAgreementMember" xlink:label="loc_sbtx_LoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan And Security Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan and Security Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_LoanAndSecurityAgreementMember" xlink:to="lab_sbtx_LoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_LoanAndSecurityAgreementMember" xml:lang="en-US">Loan and Security Agreement [Member].</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AmendedLoanAndSecurityAgreementMember" xlink:label="loc_sbtx_AmendedLoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_AmendedLoanAndSecurityAgreementMember" xml:lang="en-US">Amended Loan And Security Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_AmendedLoanAndSecurityAgreementMember" xml:lang="en-US">Amended Loan and Security Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_AmendedLoanAndSecurityAgreementMember" xlink:to="lab_sbtx_AmendedLoanAndSecurityAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_AmendedLoanAndSecurityAgreementMember" xml:lang="en-US">Amended Loan and Security Agreement [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:label="loc_sbtx_SharesUnderlyingOutstandingEquityAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xml:lang="en-US">Shares Underlying Outstanding Equity Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xml:lang="en-US">Shares Underlying Outstanding Equity Awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:to="lab_sbtx_SharesUnderlyingOutstandingEquityAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xml:lang="en-US">Shares Underlying Outstanding Equity Awards.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:label="loc_sbtx_SharesAvailableForFutureEquityAwardGrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xml:lang="en-US">Shares Available For Future Equity Award Grants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xml:lang="en-US">Shares Available For Future Equity Award Grants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:to="lab_sbtx_SharesAvailableForFutureEquityAwardGrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xml:lang="en-US">Shares Available For Future Equity Award Grants.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:label="loc_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xml:lang="en-US">Shares Underlying Early Exercised Equity Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xml:lang="en-US">Shares Underlying Early Exercised Equity Awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:to="lab_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xml:lang="en-US">Shares Underlying Early Exercised Equity Awards.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:label="loc_sbtx_SharesUnderlyingEsppWithholdingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_SharesUnderlyingEsppWithholdingsMember" xml:lang="en-US">Shares underlying ESPP Withholdings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_SharesUnderlyingEsppWithholdingsMember" xml:lang="en-US">Shares Underlying ESPP Withholdings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:to="lab_sbtx_SharesUnderlyingEsppWithholdingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_SharesUnderlyingEsppWithholdingsMember" xml:lang="en-US">Shares underlying ESPP Withholdings.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Shares Available for Future Equity Award Grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xml:lang="en-US">Auction Market Preferred Securities, Stock Series, Title [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="lab_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaap_SeriesBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBMember" xml:lang="en-US">Series B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBMember" xml:lang="en-US">Series B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBMember" xlink:to="lab_us-gaap_SeriesBMember" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:label="loc_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xml:lang="en-US">Redeemable Stock Excersible On Agreed upon Milestones [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xml:lang="en-US">Redeemable Stock Excersible On Agreed Upon Milestones [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:to="lab_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xml:lang="en-US">Redeemable Stock Excersible On Agreed upon Milestones.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" xml:lang="en-US">Accretion to Redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:label="loc_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock for cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:to="lab_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock for cash.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xml:lang="en-US">Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xml:lang="en-US">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:to="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xml:lang="en-US">Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Preferred stock, Par or Stated Value Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Shares Subject to Options Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Shares Subject to Options Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Shares Subject to Options Outstanding, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share Based Compensation Number of Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Shares Subject to Options Outstanding Vested, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted- Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted- Average Exercise Price, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted- Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted- Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted- Average Exercise Price Vested, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted- Average Remaining Contractual Life (Years),	Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Vested Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnvestedCommonStockMember" xlink:label="loc_sbtx_UnvestedCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_UnvestedCommonStockMember" xml:lang="en-US">Unvested Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_UnvestedCommonStockMember" xml:lang="en-US">Unvested Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_UnvestedCommonStockMember" xlink:to="lab_sbtx_UnvestedCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_UnvestedCommonStockMember" xml:lang="en-US">Unvested common stock.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially dilutive shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair Value of Shares Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xml:lang="en-US">Share Based Compensation Expected Dividend Yeild</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Stock Option Awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_WuxiBioMember" xlink:label="loc_sbtx_WuxiBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_WuxiBioMember" xml:lang="en-US">WuXi Bio [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_WuxiBioMember" xlink:to="lab_sbtx_WuxiBioMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_WuxiBioMember" xml:lang="en-US">WuXi Bio.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicenseFeesPaid" xlink:label="loc_sbtx_LicenseFeesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_LicenseFeesPaid" xml:lang="en-US">License Fees paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_LicenseFeesPaid" xlink:to="lab_sbtx_LicenseFeesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_LicenseFeesPaid" xml:lang="en-US">License Fees paid.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="loc_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xml:lang="en-US">Aggregate milestone payments upon achievement of certain sales milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:to="lab_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xml:lang="en-US">Aggregate milestone payments upon achievement of certain sales milestones.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:label="loc_sbtx_AgreementPaymentAndLicenseTermDesciption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_AgreementPaymentAndLicenseTermDesciption" xml:lang="en-US">Agreement payment and license Term desciption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:to="lab_sbtx_AgreementPaymentAndLicenseTermDesciption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_AgreementPaymentAndLicenseTermDesciption" xml:lang="en-US">Agreement payment and license Term desciption.</label>
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="loc_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="lab_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Common stock options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Common stock warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_EsppWithholdingsMember" xlink:label="loc_sbtx_EsppWithholdingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sbtx_EsppWithholdingsMember" xml:lang="en-US">ESPP Withholdings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sbtx_EsppWithholdingsMember" xml:lang="en-US">ESPP withholdings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sbtx_EsppWithholdingsMember" xlink:to="lab_sbtx_EsppWithholdingsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sbtx_EsppWithholdingsMember" xml:lang="en-US">ESPP withholdings.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sbtx-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 13-May-2021 [11:11:56] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CoverPage" roleURI="http://silverback.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedBalanceSheet" roleURI="http://silverback.com/role/CondensedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedBalanceSheetParenthetical" roleURI="http://silverback.com/role/CondensedBalanceSheetParenthetical" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CondensedStatementsOfCashFlows" roleURI="http://silverback.com/role/CondensedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NatureOfBusiness" roleURI="http://silverback.com/role/NatureOfBusiness" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurements" roleURI="http://silverback.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpenses" roleURI="http://silverback.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#Leases" roleURI="http://silverback.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#TermLoanPayable" roleURI="http://silverback.com/role/TermLoanPayable" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficit" roleURI="http://silverback.com/role/StockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensation" roleURI="http://silverback.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LicensingAgreement" roleURI="http://silverback.com/role/LicensingAgreement" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#CommitmentsAndContingencies" roleURI="http://silverback.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#EmployeeBenefitPlans" roleURI="http://silverback.com/role/EmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NetLossPerShareAttributableToCommonStockholders" roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesPolices" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurementsTables" roleURI="http://silverback.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpensesTables" roleURI="http://silverback.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesTables" roleURI="http://silverback.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficitTables" roleURI="http://silverback.com/role/StockholdersEquityDeficitTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationTables" roleURI="http://silverback.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NatureOfBusinessAdditionalInformationDetail" roleURI="http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" roleURI="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#AccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesSummaryOfOperatingLeaseCostDetail" roleURI="http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" roleURI="http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LeasesAdditionalInformationDetail" roleURI="http://silverback.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#TermLoanPayableAdditionalInformationDetail" roleURI="http://silverback.com/role/TermLoanPayableAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" roleURI="http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockholdersEquityDeficitAdditionalInformationDetail" roleURI="http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" roleURI="http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#StockBasedCompensationAdditionalInformationDetail" roleURI="http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#LicensingAgreementAdditionalInformationDetails" roleURI="http://silverback.com/role/LicensingAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="sbtx-20210331.xsd#NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" roleURI="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail" />
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_905815" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_905820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_DocumentType_905820" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_905829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_AmendmentFlag_905829" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_905840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityRegistrantName_905840" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_905823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityCentralIndexKey_905823" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_905836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_DocumentPeriodEndDate_905836" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_905821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_CurrentFiscalYearEndDate_905821" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_905827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_DocumentFiscalYearFocus_905827" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_905828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_DocumentFiscalPeriodFocus_905828" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_905831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_DocumentQuarterlyReport_905831" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_905833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_DocumentTransitionReport_905833" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_905834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityInteractiveDataCurrent_905834" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_905842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityCurrentReportingStatus_905842" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_905844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_Security12bTitle_905844" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_905843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_TradingSymbol_905843" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_905845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_SecurityExchangeName_905845" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_905847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityFileNumber_905847" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_905849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityTaxIdentificationNumber_905849" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_905848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityIncorporationStateCountryCode_905848" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_905852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityAddressAddressLine1_905852" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_905853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityAddressAddressLine2_905853" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_905854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityAddressCityOrTown_905854" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_905855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityAddressStateOrProvince_905855" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_905856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityAddressPostalZipCode_905856" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_905857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_CityAreaCode_905857" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_905859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_LocalPhoneNumber_905859" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_905860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityFilerCategory_905860" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_905862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntitySmallBusiness_905862" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_905863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityEmergingGrowthCompany_905863" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_906882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityExTransitionPeriod_906882" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_905864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityShellCompany_905864" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_905865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_905815" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_905865" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_905918" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_905935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_905918" xlink:to="loc_us-gaap_AssetsAbstract_905935" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_905938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_905935" xlink:to="loc_us-gaap_AssetsCurrentAbstract_905938" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_905940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_905938" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_905940" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_905942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_905938" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_905942" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_905944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_905938" xlink:to="loc_us-gaap_AssetsCurrent_905944" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_906022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_905935" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_906022" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_906024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_905935" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_906024" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_906026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_905935" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_906026" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_906032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_905935" xlink:to="loc_us-gaap_Assets_906032" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_905918" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_906036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_906036" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_906038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_906036" xlink:to="loc_us-gaap_AccountsPayableCurrent_906038" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_906041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_906036" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_906041" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="loc_us-gaap_LoansPayableToBankCurrent_906043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_906036" xlink:to="loc_us-gaap_LoansPayableToBankCurrent_906043" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_906045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_906036" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_906045" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_906047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_906036" xlink:to="loc_us-gaap_LiabilitiesCurrent_906047" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_906049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_906049" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_906051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" xlink:to="loc_us-gaap_Liabilities_906051" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_906054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" xlink:to="loc_us-gaap_CommitmentsAndContingencies_906054" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_906100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" xlink:to="loc_us-gaap_StockholdersEquityAbstract_906100" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_906101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_906100" xlink:to="loc_us-gaap_PreferredStockValue_906101" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_906102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_906100" xlink:to="loc_us-gaap_CommonStockValue_906102" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_906103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_906100" xlink:to="loc_us-gaap_AdditionalPaidInCapital_906103" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_906105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_906100" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_906105" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_906106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_906100" xlink:to="loc_us-gaap_StockholdersEquity_906106" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_906107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_906035" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_906107" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedBalanceSheetParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_906158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_906158" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_906159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_906159" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_906160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_PreferredStockSharesIssued_906160" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_906162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_906162" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_906164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_906164" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_906165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_906165" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_906166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_CommonStockSharesIssued_906166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_906180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_906157" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_906180" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_906213" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_906214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_906213" xlink:to="loc_us-gaap_OperatingExpensesAbstract_906214" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_906220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_906214" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_906220" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_906222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_906214" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_906222" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_906227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_906214" xlink:to="loc_us-gaap_OperatingExpenses_906227" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_906229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_906213" xlink:to="loc_us-gaap_OperatingIncomeLoss_906229" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_906232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_906213" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_906232" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_906234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_906213" xlink:to="loc_us-gaap_NetIncomeLoss_906234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_906235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_906213" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_906235" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_906237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_906213" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_906237" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_906279" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_906279" xlink:to="loc_us-gaap_StatementTable_906281" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906281" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906282" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906282" xlink:to="loc_us-gaap_ClassOfStockDomain_906283" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_906283" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906292" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_906293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906281" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_906293" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_906294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_906293" xlink:to="loc_us-gaap_EquityComponentDomain_906294" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_906295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_906294" xlink:to="loc_us-gaap_CommonStockMember_906295" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_906296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_906294" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_906296" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_906297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_906294" xlink:to="loc_us-gaap_RetainedEarningsMember_906297" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_906284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906281" xlink:to="loc_us-gaap_StatementLineItems_906284" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_906298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_906298" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_906302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_906302" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_906472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockholdersEquity_906472" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_906473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_906473" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_906364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash_906364" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906367" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_906314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes_906314" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_906318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes_906318" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_906474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_906474" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906475" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_906477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_906477" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_906478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_NetIncomeLoss_906478" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_906321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_906321" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_906323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_906323" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_906479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_StockholdersEquity_906479" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_906480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906284" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_906480" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_906813" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_906813" xlink:to="loc_us-gaap_StatementTable_906815" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906815" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906816" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906816" xlink:to="loc_us-gaap_ClassOfStockDomain_906817" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_sbtx_SeriesBRedeemableConvertiblePreferredStockMember_906820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_906817" xlink:to="loc_sbtx_SeriesBRedeemableConvertiblePreferredStockMember_906820" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_909911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906815" xlink:to="loc_us-gaap_StatementLineItems_909911" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_StockIssuanceCosts" xlink:label="loc_sbtx_StockIssuanceCosts_909912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_909911" xlink:to="loc_sbtx_StockIssuanceCosts_909912" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CondensedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_906029" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_906037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_906037" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_906056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_906037" xlink:to="loc_us-gaap_NetIncomeLoss_906056" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_906058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" xlink:to="loc_us-gaap_Depreciation_906058" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_906060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_906060" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_906062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" xlink:to="loc_us-gaap_ShareBasedCompensation_906062" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_906071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_906071" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_906075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_906075" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_906079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_906075" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_906079" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_906081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_906075" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_906081" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities_906082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_906075" xlink:to="loc_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities_906082" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_906057" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906083" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_906091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_906091" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_906095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_906091" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_906095" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_906097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_906091" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_906097" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_906109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_906109" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_906116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_906109" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_906116" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_906117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_906109" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_906117" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_906118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_906109" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_906118" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_906119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_906109" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_906119" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_906121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_NetCashProvidedByUsedInContinuingOperations_906121" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906123" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906125" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_906128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_906029" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_906128" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_930510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_906128" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_930510" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses_906131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_906128" xlink:to="loc_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses_906131" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes_906496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_906128" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes_906496" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities_930511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_906128" xlink:to="loc_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities_930511" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/NatureOfBusiness">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_906124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_906127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906124" xlink:to="loc_us-gaap_NatureOfOperations_906127" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_906483" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_906484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906483" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_906484" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_906015" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_906018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_906015" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_906018" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_906132" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_906136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_906132" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_906136" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_906174" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_906176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_906174" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_906176" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/TermLoanPayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_906315" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_906317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_906315" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_906317" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_906639" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_906640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_906639" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_906640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906511" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_906512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906511" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_906512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/LicensingAgreement">
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicensingAgreementAbstract" xlink:label="loc_sbtx_LicensingAgreementAbstract_906093" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicensingAgreement" xlink:label="loc_sbtx_LicensingAgreement_906094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sbtx_LicensingAgreementAbstract_906093" xlink:to="loc_sbtx_LicensingAgreement_906094" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_906357" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_906361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_906357" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_906361" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/EmployeeBenefitPlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_906465" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_906466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_906465" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_906466" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_906389" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_906390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_906389" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_906390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_906486" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_906487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_906487" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_906489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_UseOfEstimates_906489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_906490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_906490" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_906491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_906491" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_906492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_906492" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_906493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_906493" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_906494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_906494" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_906495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_906495" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_930512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_930512" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_906497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_906497" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_906498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_906498" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock_906692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock_906692" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_906500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906486" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_906500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_906503" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_906504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906503" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_906504" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_906016" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_906017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_906016" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_906017" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_906133" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_906139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_906133" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_906139" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_906175" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_906184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_906175" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_906184" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_906189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_906175" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_906189" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockholdersEquityDeficitTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_906677" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock" xlink:label="loc_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_906678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_906677" xlink:to="loc_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock_906678" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906518" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_906519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906518" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_906519" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_906520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906518" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_906520" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_906521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906518" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_906521" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_906429" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_906394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_906429" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_906394" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_906371" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906371" xlink:to="loc_us-gaap_StatementTable_906441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_906446" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_906449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_906448" xlink:to="loc_us-gaap_IPOMember_906449" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906686" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906686" xlink:to="loc_us-gaap_ClassOfStockDomain_906687" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_906687" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906688" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_906689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_906689" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_906690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_906689" xlink:to="loc_us-gaap_EquityComponentDomain_906690" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_906691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_906690" xlink:to="loc_us-gaap_CommonStockMember_906691" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LiquidityAndCapitalResourcesMember" xlink:label="loc_sbtx_LiquidityAndCapitalResourcesMember_909585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_906690" xlink:to="loc_sbtx_LiquidityAndCapitalResourcesMember_909585" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_906444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906441" xlink:to="loc_us-gaap_StatementLineItems_906444" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_906455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_906455" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_906456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_906456" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_906458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_906458" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_906459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_906459" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_906461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_906461" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906462" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_921561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906444" xlink:to="loc_us-gaap_CommonStockSharesIssued_921561" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_906506" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_906506" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_909529" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_909531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_909530" xlink:to="loc_us-gaap_CashMember_909531" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_909534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_909528" xlink:to="loc_us-gaap_StatementLineItems_909534" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_906507" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_906508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_906508" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_909534" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_906509" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_906023" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_906023" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_906028" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_906031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_906031" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_906033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_906033" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_906034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_906030" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_906034" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906039" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_906042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_906040" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_906042" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_906044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_906044" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_906044" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_906048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_906046" xlink:to="loc_us-gaap_MoneyMarketFundsMember_906048" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906025" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906027" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_906050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906027" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_906050" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_906061" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_906061" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_906076" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_906078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_906077" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_906078" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_906063" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_906065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_906065" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_906067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_906067" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_906068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_906068" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_906070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_906070" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_906073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_906064" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_906073" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_906142" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_sbtx_AccruedResearchAndDevelopmentExpenses_906147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_906142" xlink:to="loc_sbtx_AccruedResearchAndDevelopmentExpenses_906147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_906149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_906142" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_906149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_906150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_906142" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_906150" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_906152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_906142" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_906152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_906267" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_906268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_906267" xlink:to="loc_us-gaap_OperatingLeaseCost_906268" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_906269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_906267" xlink:to="loc_us-gaap_VariableLeaseCost_906269" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_906271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_906267" xlink:to="loc_us-gaap_LeaseCost_906271" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_906272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_906267" xlink:to="loc_us-gaap_OperatingLeasePayments_906272" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_906286" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_906287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_906286" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_906287" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_906288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_906286" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_906288" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_906289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_906286" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_906289" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_906290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_906286" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_906290" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_906291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_906286" xlink:to="loc_us-gaap_OperatingLeaseLiability_906291" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_906300" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_906301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_906300" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_906301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_906303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_906300" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_906303" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/TermLoanPayableAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_906316" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_906324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_906316" xlink:to="loc_us-gaap_DebtInstrumentTable_906324" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_906333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_DebtInstrumentAxis_906333" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_906334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_906333" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_906334" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TermLoanMember" xlink:label="loc_sbtx_TermLoanMember_906338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_906334" xlink:to="loc_sbtx_TermLoanMember_906338" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_906339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_906339" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_906339" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SiliconValleyBankMember" xlink:label="loc_sbtx_SiliconValleyBankMember_906341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_906340" xlink:to="loc_sbtx_SiliconValleyBankMember_906341" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_906342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_TypeOfArrangementAxis_906342" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906342" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LoanAndSecurityAgreementMember" xlink:label="loc_sbtx_LoanAndSecurityAgreementMember_906344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" xlink:to="loc_sbtx_LoanAndSecurityAgreementMember_906344" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AmendedLoanAndSecurityAgreementMember" xlink:label="loc_sbtx_AmendedLoanAndSecurityAgreementMember_906345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906343" xlink:to="loc_sbtx_AmendedLoanAndSecurityAgreementMember_906345" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_906326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_906324" xlink:to="loc_us-gaap_DebtInstrumentLineItems_906326" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_906363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_906363" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_906391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_906391" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_906392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_906392" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_906411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_906411" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_906400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_InterestExpense_906400" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_906402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_906326" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_906402" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_906667" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_906668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_906667" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_906668" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_906669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906668" xlink:to="loc_us-gaap_AwardTypeAxis_906669" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_906669" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingOutstandingEquityAwardsMember" xlink:label="loc_sbtx_SharesUnderlyingOutstandingEquityAwardsMember_906671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesUnderlyingOutstandingEquityAwardsMember_906671" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesAvailableForFutureEquityAwardGrantsMember" xlink:label="loc_sbtx_SharesAvailableForFutureEquityAwardGrantsMember_906672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesAvailableForFutureEquityAwardGrantsMember_906672" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember" xlink:label="loc_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_906673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember_906673" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_SharesUnderlyingEsppWithholdingsMember" xlink:label="loc_sbtx_SharesUnderlyingEsppWithholdingsMember_906674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_906670" xlink:to="loc_sbtx_SharesUnderlyingEsppWithholdingsMember_906674" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_906675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906668" xlink:to="loc_us-gaap_ClassOfStockLineItems_906675" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906675" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906676" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_906642" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_906643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_906642" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_906643" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_906644" xlink:to="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember" xlink:label="loc_us-gaap_SeriesBMember_906648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_906645" xlink:to="loc_us-gaap_SeriesBMember_906648" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_906650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_TypeOfArrangementAxis_906650" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_906650" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember" xlink:label="loc_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_906653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_906651" xlink:to="loc_sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember_906653" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_906654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_srt_StatementScenarioAxis_906654" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_906655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_906654" xlink:to="loc_srt_ScenarioUnspecifiedDomain_906655" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_906656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_StatementClassOfStockAxis_906656" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_906657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_906656" xlink:to="loc_us-gaap_ClassOfStockDomain_906657" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_906657" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906658" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_906660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_906643" xlink:to="loc_us-gaap_ClassOfStockLineItems_906660" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_906661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_906661" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_906662" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash" xlink:label="loc_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_906663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash_906663" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes" xlink:label="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_906664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes_906664" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_906665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_906665" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_906666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_906660" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_906666" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_906522" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_906522" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_906524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_906524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_906525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_906524" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_906525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_906525" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_906525" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_906527" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906523" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906528" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_906529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906528" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_906529" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906530" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906530" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906531" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_906531" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906533" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906534" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_906535" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906536" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_906537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_906537" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_906542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_906542" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_906543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_906543" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_906544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_906544" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_906545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_906545" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_906546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_906546" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_906548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_906548" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_906551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_906551" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_906553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_906553" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_906554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_906554" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_906555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_906555" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_906556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_906532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_906556" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906558" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_906559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906558" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_906559" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_906560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_906560" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_906561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_906561" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_907024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_907024" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906562" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_906562" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906564" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnvestedCommonStockMember" xlink:label="loc_sbtx_UnvestedCommonStockMember_906566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906565" xlink:to="loc_sbtx_UnvestedCommonStockMember_906566" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_909644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_909643" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_909644" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_909646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_909644" xlink:to="loc_us-gaap_StockOptionMember_909646" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_906563" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_906573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_906573" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_906574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_906574" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_906575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_906575" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_906586" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906587" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_906589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_906589" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_906591" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_906594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_906594" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_906627" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_906572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930514" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/LicensingAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicensingAgreementAbstract" xlink:label="loc_sbtx_LicensingAgreementAbstract_906129" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_906146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sbtx_LicensingAgreementAbstract_906129" xlink:to="loc_us-gaap_StatementTable_906146" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_906153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906146" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_906153" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_906154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_906153" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_906154" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_906154" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_906155" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906146" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_906163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_906161" xlink:to="loc_us-gaap_RelatedPartyDomain_906163" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_WuxiBioMember" xlink:label="loc_sbtx_WuxiBioMember_906167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_906163" xlink:to="loc_sbtx_WuxiBioMember_906167" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_906322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_906146" xlink:to="loc_us-gaap_StatementLineItems_906322" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_LicenseFeesPaid" xlink:label="loc_sbtx_LicenseFeesPaid_906328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_sbtx_LicenseFeesPaid_906328" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones" xlink:label="loc_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_906331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones_906331" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_AgreementPaymentAndLicenseTermDesciption" xlink:label="loc_sbtx_AgreementPaymentAndLicenseTermDesciption_906336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_906322" xlink:to="loc_sbtx_AgreementPaymentAndLicenseTermDesciption_906336" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail">
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="loc_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_906431" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_906431" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_906434" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_906454" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_906439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_us-gaap_EmployeeStockOptionMember_906439" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_UnvestedCommonStockMember" xlink:label="loc_sbtx_UnvestedCommonStockMember_906445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_sbtx_UnvestedCommonStockMember_906445" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_906447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_us-gaap_WarrantMember_906447" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sbtx-20210331.xsd#sbtx_EsppWithholdingsMember" xlink:label="loc_sbtx_EsppWithholdingsMember_906451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_906435" xlink:to="loc_sbtx_EsppWithholdingsMember_906451" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_906460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_906432" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_906460" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_906460" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_906467" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g155579g25t34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g155579g25t34.jpg
M_]C_X1PG17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,3HP-3HQ,B Q
M,3HP,SHT. !R<C$U,3$X,0       Z !  ,    !__\  * "  0    !   #
M-* #  0    !   !5          & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M !K9         $@    !    2     '_V/_B#%A)0T-?4%)/1DE,10 ! 0
M#$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M $E%0R!S4D="                  #VU@ !     -,M2% @(
M                                                    $6-P<G0
M  %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')8
M65H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M<&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X
M    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,
M  0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX
M($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%
M0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                          !8
M65H@        \U$  0    $6S%A96B                      6%E:(
M     &^B   X]0   Y!865H@        8ID  +>%   8VEA96B         D
MH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M           6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                         &1E<V,         +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M            +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P
M86-E("T@<U)'0@                            !D97-C         "Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M           L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q
M.38V+3(N,0                                  =FEE=P      $Z3^
M !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M
M96%S          $                        "CP    )S:6<@     $-2
M5"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 0@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M_522^54DE/\ _]G_[21P4&AO=&]S:&]P(#,N,  X0DE-! 0      %T< 5H
M QLE1QP"   "/]\< E  "')R,34Q,3@Q' (% #Q-:6-R;W-O9G0@4&]W97)0
M;VEN=" M(#(P,C$P-#(X(%!I<&5L:6YE($-H87)T(&9O<B Q,"U1+G!P='@
M.$))300E       0^Z7E>5!7H*/]R2G41?]]9CA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P
M   !  (!+     $  CA"24T$)@      #@             _@   .$))300-
M       $    >#A"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #=0    8              50   ,T    (  R
M #  ,@ Q #  -  R #@ ( !0 &D < !E &P :0!N &4 ( !# &@ 80!R '0
M( !F &\ <@ @ #$ ,  M %$    !                          $
M         S0   %4                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   %4     %)G:'1L;VYG   #-     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !5
M  !29VAT;&]N9P   S0    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     (X0DE-! P     &O4    !    H    $(   '@  ![
MP   &MD &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ !VY&0<W.]7(LTR[]K;,C+J(8VQX:*_LX?4^M^[^O^C_ -&JEN7G
MUY#"W(NL9[7.8R[*=7]+W5V6.].S^MM_P?\ +7K8<Z!J?O3[G>)^]3>]_5_%
M-OEQR"UN[U76-:8<&YV=O=!<[]%N9[=[/WFJG39U&RO>[J-U3OW++<EKB0?Y
M(>SW?2^FO7=SO$_>EN=XG[TO>_J_BJWR1SNH-#B.IV/V@D!MV3)B?H[VL\$P
M=U M:?VG8-P!(==D@M)_,=[7>YO\E>LW.=Z-NI^@[O\ R2E2YWHUZGZ#>_\
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
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M%UO?_P"V9[]_K9\M?[]N_P#>T_ZU]>^CA_I=>_Z"(/YA'_//_&C_ -%UO?\
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M=;W_ /MF>_?ZV?+7^_;O_>T_ZU]>^CA_I=>_Z"(/YA'_ #S_ ,:/_1=;W_\
MMF>_?ZV?+7^_;O\ WM/^M?7OHX?Z77O^@B#^8/\ \\_\:/\ T76]_P#[9GOW
M^MGRW_OV[_WM/^M?7OHX?Z77%?\ A0__ #"5#7P7QI<EW8$]<;U72K&ZQ +V
M9ZA&.+GD_GW[_6SY:_WY=?[VO_6OKWT</]+KE_T$0?S"/^>?^-'_ *+K>_\
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M9FE2QYL.![]_K9\M?[\N_P#>T_ZU]>^CA_I==_\ 01!_,(_YY_XT?^BZWO\
M_;,]^_UL^6O]^W?^]I_UKZ]]'#_2Z]_T$0?S"/\ GG_C1_Z+K>__ -LSW[_6
MSY:_W[=_[VG_ %KZ]]'#_2Z]_P!!$'\PC_GG_C1_Z+K>_P#]LSW[_6SY:_W[
M=_[VG_6OKWT</]+KW_01!_,(_P">?^-'_HNM[_\ VS/?O];/EK_?MW_O:?\
M6OKWT</]+KP_X40_S!_^>?\ C0?\/]'6]_\ [9GOW^MGRW_OV[_WM/\ K7U[
MZ.'^EUQ3_A0__,)5%5L'\:96 LTAZXWJA<W)N47LS2O!MQ_3WX^VG+7^_+K_
M 'M?^M?7OHX?Z7[>N7_01!_,(_YY_P"-'_HNM[__ &S/?O\ 6SY:_P!^W?\
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MNDC02>S+H+D&XYXM[]_K9\M?[\NO][3_ *U]>^CA_I?M_P!CKE_T$0?S"/\
MGG_C1_Z+K>__ -LSW[_6SY:_W[=_[VG_ %KZ]]'#_2Z]_P!!$'\PC_GG_C1_
MZ+K>_P#]LSW[_6SY:_W[=_[VG_6OKWT</]+KW_01!_,(_P">?^-'_HNM[_\
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MBZWO_P#;,]^_UL^6O]^W?^]I_P!:^O?1P_TNO?\ 01!_,(_YY_XT?^BZWO\
M_;,]^_UL^6O]^W?^]I_UKZ]]'#_2Z]_T$0?S"/\ GG_C1_Z+K>__ -LSW[_6
MSY:_W[=_[VG_ %KZ]]'#_2Z]_P!!$'\PC_GG_C1_Z+K>_P#]LSW[_6SY:_W[
M=_[VG_6OKWT</]+KW_01!_,(_P">?^-'_HNM[_\ VS/?O];/EK_?MW_O:?\
M6OKWT</]+KW_ $$0?S"/^>?^-'_HNM[_ /VS/?O];/EK_?MW_O:?]:^O?1P_
MTNO?]!$'\PC_ )Y_XT?^BZWO_P#;,]^_UL^6O]^W?^]I_P!:^O?1P_TNO?\
M01!_,(_YY_XT?^BZWO\ _;,]^_UL^6O]^W?^]I_UKZ]]'#_2Z]_T$0?S"/\
MGG_C1_Z+K>__ -LSW[_6SY:_W[=_[VG_ %KZ]]'#_2Z]_P!!$'\PC_GG_C1_
MZ+K>_P#]LSW[_6SY:_W[=_[VG_6OKWT</]+KW_01!_,(_P">?^-'_HNM[_\
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MBZWO_P#;,]^_UL^6O]^W?^]I_P!:^O?1P_TNO?\ 01!_,(_YY_XT?^BZWO\
M_;,]^_UL^6O]^W?^]I_UKZ]]'#_2Z]_T$0?S"/\ GG_C1_Z+K>__ -LSW[_6
MSY:_W[=_[VG_ %KZ]]'#_2Z]_P!!$'\PC_GG_C1_Z+K>_P#]LSW[_6SY:_W[
M=_[VG_6OKWT</]+KW_01!_,(_P">?^-'_HNM[_\ VS/?O];/EK_?MW_O:?\
M6OKWT</]+KW_ $$0?S"/^>?^-'_HNM[_ /VS/?O];/EK_?MW_O:?]:^O?1P_
MTNO?]!$'\PC_ )Y_XT?^BZWO_P#;,]^_UL^6O]^W?^]I_P!:^O?1P_TNO?\
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M"FDW:4EKZ&KFJE3%4HBU/,[2I[,%W[<#N@B,4'[M_>ILJ4;QJZ-8<FNCMX$
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M_"44U7MC);,^.77V[L1UON/O.BV3V%V%MGK+']F;IK=M5F6RL&9Q.V8Z*,O
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M5E2CI*QGR_N.Y[BLQO[9%7PXGC=1I#"1:LN@R2&B'X9"0)%R5'#JT3N]=8'
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M<.B/F2UO]AADGT7ADOVB6Y9I"L*PH0L_AL2[BC% 6?1458], 3*80S=_=Q]
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MG_J/2'P7P8^,&\MA47R"IL?\R^JNGX?CY\]^VMR]-=C?Z/O]F"BR/P4WQL?
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M_:.EA4T_R6K=]1]IUF-^1=7VG#EZ#<,/9]3ANSYNQ(MP8J"GI,7G$WG)1-N
M9;'4=)%!#/Y]:4\:Q7\8T^V!=;"MN;-;RQ%GI*^'XD6C2<D::TH3DBG'/'K5
M8J::KI]*CH:]C=Y_,G9G8.\>V\MM[N[M?M/=73':/1^*W]V[ANY-X;AZ[V]V
M^D$6[MQ;(J9WC-/N**-)C10U/FQ=/-523?;&0(507$'+4]M!9)?6<-FD\<I2
M-X55VC^%7S\/"I%&( %:=5(A("AE"@@T!&:= YM&3Y2=?R]?5&PE^36RZKJ2
M'-4W555M>A[4PM1UM3;G=)=U4VR7H:2$;>I-V5$:RY6&G"0Y*55>H21E!"Z:
MXY?N1<BXNK"034\34\)UZ?A+5/<5_"3E1PIU8F)JU*FO'(STI,-O?YK;<SF^
MMT;=W7\P,#NCM&MI,GV;N7#UW<^.W!V'D\?*LN.R6\LS3"/(9W(8UD"T\TTA
MD@A A0K#^W[:D/+$L=O#*^VM#"*1J6A*H#Q"BM #Y@<3GCUK]$T!T4'#AU H
MMP_,#&[+K.M<;EOE=CNM<C7;DR>1ZYH3V_2;#R.0WF*P;RJZ_:<$282M?=AR
M-2V166%HZJ2HE=U+RNS6:3EMIUNFFV\W0"@.6A+@+32 U:C304SB@].MUB)U
M535ZXZ#(=9=H  #JKM     =<[R  '   PO 'M7^]-K_ .CK:_\ .:/_ *"Z
MMK3^,?M'7O\ 1GVC_P ^K[1_]%UO+_ZR^_?O/:_^CK:_\YH_^@NM:T_C'[1U
MDAZY[6IIZ:JI^K^U8*JCJJ:NHZF+KS><<])6T4\=515E-*N%#PU5'50I+$ZV
M9)$# @@>]'<]J((.Z6I!%#^K'D'B/B\^O:T_C7]HZ5%+0_)"AW+O+>M%A_D+
M2;T['I,CC^Q]X4^![+BW3V)C\Q4T=;EZ#?>?6@&3W;19.MQU/-/%72SI)+3Q
M,1JC0AHW>Q-%! U[8F"(@HOB1:4(J 4&JBD D"E,$^O6JQT U+0?,=.#5/RG
M>LFR++\F3D:GL*D[>J,C]CVJ*^H[>H*08^A[8GK%IA43=ET>-'VT>;9CD5IB
M8O+XR5-?J.7M(3ZFPTB/PZ:X:>&34QTK\!.='PUS2O7JQ>J\*<1P]/LZ'+J;
MY!_,3J[=^\]VY?9G='<Q["VAO[9>[L;VA!\@H<@:/M&LP60W]N39>_\ 8^8V
MMV%UGV!NJLVQCS7YS"9"FK:V*DCCF+K''H+[RVY;NX((4W"T@\)T93&]O2L=
M0BLCZD=%#&B.I J2//JK")@ &44]*>7RX'KW8'R4^>V_.V.S^XL?6_(KJ;<7
M;^+VOM[>^%Z7QO<VQ=LY;;.Q]OP[4V?ALG##45F7W%687;L IFR^3JZK,U89
MO+4E2J+ZVM.4[>SM+%KBQFB@+%#*\+L&<ZF(S106SI4!1Y#SZ\%@"JM5('J1
MT "TWR42B&,3%_(E<8O7Z]1KCEPG9HH1U&E=_%$ZH%**+P_Z-5RG^4C!V_AO
MW'[GBU<^S'ZK8=6LWECK\7Q*^)%7Q*4\2M?CIC7\5,5ZM6+U7C7B./KTD/\
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MY&<]>K%535:CAPQ]G6+=^4^6?86%V3MKL*J^4F_MM]9QPQ];;?WG#VWN7#;
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M/F1T\ON_YF2[*WIUK-N#Y:3=;]DYG-;C[%Z_GD[?GV=OO<&YJO\ B&Y\SNS
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M]ICZA%D@2-U#!T7>P@JPO+&HD9Q^I%\;"C/Q^-AAFXL,$GK>J+U7]HZ6F>[
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M_F9LZ::HV?N'Y;;2J*C9^ Z[FGVS-W%@YGZ^VDT[;1V.LF.CIWAVKM(U4O\
M"Z.,I%CUFD6 (LCAF)7Y:G $\NW. Y?N:$][?$^3\3?B/XJ"M:=5/@GCHXU\
MN/3=GLM\M-U;,QG6^YZOY1[AZZPFX*G=V%V%F(.V:[:&(W969.KSE1NC&X*:
MG-#29YL]7SY!*E%$D%?/)4Q%)W:0WCFY=AG>ZAN-O6Z9=)</"&*@4TDUK2@
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M[,S6)J=O9KL:?!]F2[ZS.W:W"0;8K=N97=;T)S60V]6;9I8L;+0RS-2O01)
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MF'W#?\<J3_SAHO\ ZG]^\&+_ 'TO[!UZ@].O?<-_QRI/_.&B_P#J?W[P8O\
M?2_L'7J#TZ]]PW_'*D_\X:+_ .I_?O!B_P!]+^P=>H/3KWW#?\<J3_SAHO\
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M5>O>_=>Z][]U[KWOW7NO>_=>Z8Z?_CY\O_VH\'_[EY/W0?VC_P"E'^$]7/\
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M;G9&[]R9/<E;\B\U\;I^H:3I7;NQLCV2VY\3O#!5$-? <?\ Q+'Y.&:CJJ6
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MU3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z9,O\ \#MK?^' ?_=3DO;;_%%_IO\
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MKW66#_/1_P#!U_WOW[KW0;?]RD_^2'_\=>_=>Z__T-W*7_F:G9O_ &J>N/\
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M7/\ 9I]I_P G3Y[OU3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z9,O\ \#MK?^'
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M_P J%;_YRS_]>_?NO=>_AN1_Y4*W_P Y9_\ KW[]U[KW\-R/_*A6_P#G+/\
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MNO>_=>ZP57_ .N_Z@:[_ -Q)O>CP;[#_ (.MCBOVCJ%@_P#BQ8/_ +4V+_\
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M[LQDM\9';>W!MS(S/00U&;\II/=>Z$C=&&^3W2747RAZYZ\VG_,CRF^=Y_S
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MU73+34QDIAY*@3"96A4-(]]:->1Q*D_ANCE@=(;)1DX'!^*N:@TH1GHVD0N
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M!9O%HQXT'VCS]0:?+UJ*D%MI?/NJVC-\<IJ;IK$5/^R[9[^8SG:!4WE74?\
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ME55LV6R6WMIS8^CRU9%*])59F&KEI2*9X@!IR1_R4I_^:9Z4VO\ ;Q?Z8_\
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M\)))MG]DO3?6"J_X!UW_ % UW_N)-[T>#?8?\'6QQ7[1U"P?_%BP?_:FQ?\
M[A0^ZQ_V<?\ I1_@ZV_QO]I_P].GN_5>O>_=>Z][]U[KWOW7NO>_=>Z8Z?\
MX^?+_P#:CP?_ +EY/W0?VC_Z4?X3U<_V:?:?\G3Y[OU3KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z9,O_P #MK?^' ?_ '4Y+VV_Q1?Z;_(>K+PE_P!+_E'3W[<Z
MKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=98/\]'_P=?\ >_?NO=!M_P!RD_\ DA__ !U[]U[K
M_]7=YCJ'I>V^R*B-59XL7URRJ]])/V>Z!S8@_0^_=>Z(-C?Y>.)V-LOX9;8Z
M5^1_<?4>?^#NR^Q.N^LM_4VUNHM^Y?=^SNU:;;%/O/']@8'?.S<IMF>LF79]
M$:6JQU/134Y\EB0Y'OW7NH>Y_P"6!T-NJ@RM!4[[[EP+;JP_S<V?O_+;,SNW
M=J[AW]US\]<_F=Z]I; W%G,?MYJN7$]=]BY"DW!LJ?U5.'K\<J2-/355;#4>
MZ]TK.K/@EB^MMJ?*NEJ.]^S\[VE\P=F;>V+V/W/@]M]9]79+9^(V1UEF.H]@
MY3JCK7K[;.*ZPVCN_:^T<Y,[95\?4U-=6)3>;_(Z"@HZ;W7NB;?(;^37U#1]
M94V$^%>VH^JZL[2Z0ZH[*ZP/8^<VYMONSH_I#NCK_N+;N(3>.<QF^O[E=T[/
MJ=EUD&U<Y+238>+^/Y&.NI',U/44GNO=*#K[^5=N'/\ 5;[1[C[KW#U7C=_]
M=CH'NWI3XZ4VQ:;8_97Q.V9VMV-V%T1TQOO>=5L3$5$7;&S]L=G9C;V\-^;.
MQVW9-VTF8KM4'G^WKX_=>Z,1OW^6CTSV)C<GC,UV)VW2T^3S_P ]MPD8ZKVJ
M/LY_YA^V=S;4[:H:(5.!G2+'[ QVZ:A]JJ5+12HGWIJ5U!O=>Z9NS/Y8G5W;
M>=[SS>[^U>QJ:3N+H"@^.F,.SMN=9;-RVR]IXBNZWS^VMQ[AW#B-J#(=Z;PZ
M]W3U1BZG:U3O(9+^!457E,?'Y*;)3 >Z]U8EMVBS.,V[M_&;CW)4[TW'C<+C
M*#<&\ZW%XO!5N[\W2TD4.4W/5X+!Q4^#PE3G*Q7J'I**-*2G,FB(!%'OW7NG
MCW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<781QRRL"5AAFG8
M*8E9E@B>4JKU$U/31EPE@TLD<2WN[JH+#W7NJD<)_-PV=N$;AVUM[XY=C;V[
M>H>]>E.A-K]>=9=L=&=B[6W;G_D3LGLO?/6.XH^[]O[M?K3'8#&T'4>;@W4$
MFJY,%-#&T/\ $$ECU^Z]T#'R0_FY;PJOBOG^Q_B=T-VE%V%0]";/[OW_ +KW
MKCNMLGMWXO8W=GR*W;\<Z.BWIMFMW8#V]DFWUT_OB.==N&JIJ;"87^++(XJ:
M.&3W7NC@?.3Y@]F?$WY#?%/%X':>TMS?&_<N,[MWI\QZW)4F6D[!ZUZ5V9N_
MI/K;&=U]?Y6CR<5'3;?Z:W7W'29O>U+/09&>HVC%6U4'A-!([>Z]T4OJC^8/
M\CMRYSXG[[[TSFQ.EOCGVWB<EC9NV-M= YCL;J7NCN^'Y)=S=/9/H+(]M8WL
MM*3XQYR38NT-I5/7^7R5'4X7?FX<_54\=:9H:7&5'NO=*>A^7'S@A^"F._F*
M9G<'QYIMG]U[6Z)WWUC\<Z#JC<>2KNF=N]Z=^]4;)V!CLUW)+V% _:>Y9.HM
M\5<NZ$J<)BX:?=+QG&!:.E:*H]U[HU&]>U?D[VQ\R^Z/C#\9]X=1=2;<^*O5
MO17979F[.U^J-R=P9[MG>W?^5[-GV3UK@<)AM[["@V3U=AMG=753YK<<-169
MBIRV0BAHX8DH*@5/NO='^8J3=5T#CT:R^DV&I0Y5690U[$@$CZ\^_=>ZU=_^
M%*'Q3[L^;F5_EO?&WXYX/ [E[?W%V)\I]ZX;"[GW1CMEX.HV_L3J?9%1N>HJ
M-RY57HJ6II8,M"8H2K/.2;6568"/EG<[7:[V2:Z8B,I3@3_@!Z=A?PY$?T/^
M0CT/KU3!\6?Y'G\]GX>]Q4G=W4/2GQCK-U0[,WUU_7X/?W?>Q=T['W%M;L##
M#&96@W'MR&IQ+9,XO(TM#E\<34(M-E\923LLBQM&XOO>9.7;^'P9YGI4$$!@
M000<'2:5X'&02,=*Y+F.2A*#4.&2/2OX?ET+>5_E5_\ "AK/;>Z_VQGNHOBQ
MF<9UQ\.NY_A#B),CWGLRIR.8ZM[]P#;4[*WSNO(291ILYW=E-M4]!1Q;A/BC
M2+$T9>DD:-BY>FY<K)(LQN9VE#AJMJ)-"C9H@XL@)'JS4(KAKQ(CAEK]K'(Q
MQ[/E_,YZ3F_/Y.G\]WL39F^=HYKXW?#RBK.UOBQU#\0NVM[83O+;5)N_L7K7
MH;<76^;ZJW+F):K<%=@<=V9M_&]3X7$5&3Q]!24V0QT<WFI#42^='QO7+>IZ
MW$NGQ'88.-:N& [.%9&(!)H2,T%.O&6,ZJKQ_I'@:_T*?B)_/Y=9&_E _P _
M5_F'4?.1NB?B5_IMJ<758>2B'=NREZ[%)6?'9_B_*T>U1D_NTJ%ZSD,JO]]Z
M<Q:JMH_8]N?O[ESZ']W^/+X&JO!JUUZ^.GU^7#'SZMX\8C*:?.OQ'C_O'^3H
M/?C?_(A_G,?&W9W=76U#\0/A5W#UG\@ML]<[9[0Z_P"Z^^<;E\%F$ZGWFO8&
MQLU25O7^[NN-RX_.8[=""6>1:\Q5D/[4L93WJ\W_ )?N_I2UW,KP_"16O"F=
M2,#^RM<UZ;=H655"8"@?$> K3\!]<]-?<O\ (I_GV]\[UW!O??NQNE\?_>#!
M[)V;_H^ZZ^2VR.M^FMO=;=8X#'[2ZRZIVKU/MF2GVEB^N.O]I8N#'XR@EBJI
M$C#RR32U$LDS*+;F3ENUC2.-V.FIJ58L6;+,216K')Z>2XC15&@5'S/YXT_\
M5TK_ )*?R./YR/R9VETULS*_"?X-]38[H?KD]/[!KNF_D#)B<P>K%S&Z-RTF
MR]PU>^.P-_0YFDH-U[TRF3BJO%%7FIJBKS/"B1!JQYDV.R:9EO9F$C:B&%1J
MH!4 1K3  IPQUJ*Y$8( HOIJ/I3^ >7^#I5;A_E)?S]=[P;FCR/17Q&\>X=Y
M?"_<^5-#W;LJ%HL]_+\V%5]8='0TFK+U(IZ*MV[6.VYH7#/EJO3+&:1?06#O
MG+$J(OU$VE&D\F&7D$C?AR-2BGH*C/'KS3(0JE1Z_$?,AOX/4?ETJLI_*U_X
M4'YCL38/9]7T-\.EW-UOV%\Z>S=O1T_<>RXL1+N3^8?#F8/D#%E: YAY*S$8
M],]/_=:!98FPQ"&1ZO2;TAW7E>""6!+B;0PCK743^FVL9T^O'U&,=-K)$M*)
MG_3'UJ?P>O4S:O\ *P_GM81\K3[M^&?\OCN+;^6R'Q+W VU.V.U,5FL#C=W_
M  @Z:H^COCUNS$1X#?.V:RFR%!M"A!W'!++/0[E>HJ8:B%*2H>G]VN-YY<G5
M%%W.I!<U6H_M)!*WX#^( KZ4&?/JSSJP T\"?Q$<37^#UZZH/Y7_ /PH/J,W
M39CL3H'X<]OPY#J3Y3=)=DXC?G=.U8*'M_8WS&[FW!\@NZ?[[5.SL_M7+T&X
M&[9W!]_@ZW"5.*;$4U'34JI)$C:V)[_E.8-^M,.  [J !42E"AQI0+0UP3PK
MBI>(U[?L[C\OZ&.% /3KAD_Y6O\ /WR>)AGD^+WP8I^U<UBOCSM7M[Y!0=L;
M7;N+OK8/Q5W3LG>'2VQNR\C4[GJ-IPXR#,=9;87<M9A,3B,GNRGVWCHZ^I;Q
M2--?]Z\MF1S]9<+#J+*JE@JLU=1 T5R&92"6&EF4 "E/>)&&=@*5SAB/^??F
M1YX\N !.^T/^$[W\Z3M7LOM+M_=O2?Q[I]T=K=B]@]L[NBPGR-V#C<%3[E[#
MW5F-[[ECPF/E%2V-PD.6S,XI8'FE,%.$1I'TER:P\V[#;010I._AQH .UB:*
M*>F3CI1'=*BJ@44^T_\ 0/2(B_X31?SA9XHIX^E^CVCGBCFC;_9F>OSJCE19
M(V!%.5(9&!N"0?P?;HYSV-@&$[4/]%O\W5S>@$C2/VG_ *!ZR?\ 0,[_ #B/
M^?+='_\ I3&P/_J;WO\ KCLG^_F_WEO\W6OKE_A'[3_T#U[_ *!G?YQ'_/EN
MC_\ TIC8'_U-[]_7'9/]_-_O+?YNO?7+_"/VG_H'KW_0,[_.(_Y\MT?_ .E,
M; _^IO?OZX[)_OYO]Y;_ #=>^N7^$?M/_0/7O^@9W^<1_P ^6Z/_ /2F-@?_
M %-[]_7'9/\ ?S?[RW^;KWUR_P (_:?^@>N2?\)FOYQ<CJB=*](%G(4 ?)?8
M3&Y_VE*1G/\ L 3[]_7'9/\ ?S?[RW^;KWUP_A'[3_T#T$70_P#(/_F?_);J
M#87?'3_574>:ZS[,P\N>V=E,WWYLW;65K<7%DJ_$O+6X/(4QJL=,*W&RKH8L
M; &]^!X\Y;'^&=]/S1@?V4ZV;U*G2 5_,?\ /IZ%H_\ "9[^<2+6Z5Z/-V1>
M?DSL *H9@ID<_;$Z(P=36!;2#8$V!T><=FH=,K%J8[6'\])_P=:^N'\(_:?^
M@>MT7^4K_*6Z@_E;=/U5%15.*[*^479>)H$[^[]6@>'^)>)XZV/JSJV*M05^
MV>F]LUXO'$?'69^LC^_K_5]O3TL>;UO4^[SEF)6V![5_RGY_+-*D5)+,Q?)(
MTK%F.?\ 5_+T'^$DDVS^R7IOKWOW7NL%5_P#KO\ J!KO_<2;WH\&^P_X.MCB
MOVCJ%@_^+%@_^U-B_P#W"A]UC_LX_P#2C_!UM_C?[3_AZ=/=^J]>]^Z]U[W[
MKW7O?NO=>]^Z]TQT_P#Q\^7_ .U'@_\ W+R?N@_M'_TH_P )ZN?[-/M/^3I\
M]WZIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,F7_P"!VUO_  X#_P"ZG)>VW^*+
M_3?Y#U9>$O\ I?\ *.B/=A]H_*+M#Y>;V^+/QFW?T]U!0]"]"=.]\=F;_P"V
M.L\[VYE>QMT][[T[0VUUCU1MO:-#O7KVEVQUK08GJ'+5FY]RQ5E7EFJZNDI*
M"*'P54CN=5Z"C,?S7.OMLC<.[=R?'[NFFZ,;%?+8=1=X8.KV-FL-WUO7X.[8
M[#W/W[LG:&Q%W$N^-DMDZ7J+=0V37[B2EIMR#!2M(:1:BB>J]U[K#M#^:=19
M[MS"=-[R^(W?O468J^Y>L>@MW;IW=N/J3/[:Z\[#^276DG:?Q=^ZCV;NW+Y3
M>%#V!MS3'N#^&0R+L_)-'3U35,+O4Q^Z]T#7QU_F:=F=C=)=!;?[GZ][$Z6^
M0?9/5_PK[:P_8N4V1UGN?:O>6P>]_DUT_P#&O?&[\!UYAM]4T'5\3;V[/QWE
MQN3J$R>-VYG*;*4<-95034"^Z]T9'9?\R_;&]:G/3GX^=E[)VM6=<?)OL;IS
M>N_NQND]L[4[:I?B!V[2=+=WT&1S65WK2T/2^,I=T9S&5N$S.[9:&@RV&GFJ
M"898/MY/=>Z >C_FR[B["S75]%U;\>ZM=I;DQWSJP?=N^*KL38NZ*[I?>WPV
MP&RLO69OK+'T>0QVU_D+LK(TF\H,C'/3U5$F1IIX((Q#-'5JGNO="QL'^950
M9.+JF&KZ2[HWGU](/ACUIWK\H(\=UWLW:G7O?'S1V!U!NCJ;#9#J9-X93<^0
MQ>3JN\-I_P!Y*K RU^+VI-NBEA26NAI:V:F]U[H1_A__ #"-N_+WL&@V)2="
M]P=)KO3IS(]^]/9WLZOV%DX.RNK]M]J+TMN[*5&,V1N+-Y#867Q.^ZJB>CH<
MH!)E,/7Q5<11TJ*>'W7N@8PG\XSHC.9W%;/I>DN_EW[ENK,)O>GV/4TFR(<G
M_I/S'RD_V4@_%V2K7<_VZ]^X[?I7.U.-'[2;/=<F)#$=7OW7N@(W3_,T^0J[
M4^2N*V'L3&9_%]7?!?Y:?)K;ORERE#M##93$=D],]]?(WIW;FV9?C;CMR9ZD
MW-L^AR?45)CJ&JBR)GSDQ6MJHJ2*H>.'W7NCR];?-C.]D=2_+?(572N[.HN_
MOB/U\=R;GZN[,RFT<]09BLW-T)/WAU+N"'<G7^=RFVYL/O#&H(<ICDJHJO$5
MD%13N3'X9Y/=>ZK=Z:_F-_-?MOJ+KO*8C/=55]/W5W=_+_ZEV!\HZGXJ]F;!
MV;%N#Y2X'L#.?(KKC ]2[\WOC*?LG*_':HVKATH-T462BP^1AW(*:59:O'5)
M?W7NK%_C]\S*G(;P[8^-_P E=S]0X?Y/=5?(C<WQYV=6;+CW3@]@_(Z:/J[K
M3N38&[L%@)QNW(=<;@K-I=M8J@W5@7R.1CQ&7IYWI*B:FGI1[]U[I;?!WN_N
M;NWKKOFK[YCZX'9'2WRC^2?1$\W5&$SV V-5XOI^OHUP$F/HMSYG.Y^KDCCK
M_!45E3.LM<8?+XH-8B3W7NBM]3?S1\A5]=_'/,=F]![YW?DMU=+?!OM3Y+=L
M=956R]N]3=2#YT;YS'5/6<F&VIN7=4W8&Z31=A8>^7QV-AJ9<7A)?O1-.ZBG
MD]U[H#NO/YH_;L'Q8W'EN]=F;QV=V_C^M^X.TMF]\[7V7U-N[9/9FUNG_FMA
M/C)O:? ]-MV!MZHV[5;?C[#VS#0+G)\>F>H*FIR<&F>E>G?W7NEO1_S,>RMG
MP_*/;O<O6/8F%Q>$[B_F9=>?'#Y*;=VEUQE]H560^'&V^T>T\#L*7JB7>F(W
M)N/(;>ZHZVRLE+FLN^/QFYLU@:NAJ)Z434U1)[KW0G[4_F.=FPTW:=%OCXK;
MES6?Q_RLZ[^(7QEHMA=B]>SY3Y(=A[YZ%VIWC'5;M@FKO[O]'G$[+K\EN7.U
M%345&*Q6(@%%3?>9&%H9/=>Z$/K/^8U2=N]C[)ZEV)\6.]LGORKV;W7NWNC%
M56X.I<=3=!9#X]]P[I^//9.P,SDGW?/1=C;YJ^Y]KF@VW%M]ZBAW!C*J/(BI
MI:=6/OW7NK MJYJLW)M7;&Y,CMC/;(R.X=N8/.Y'9&ZVQ+;KV5D,QC*7(5NS
M]TM@,CF<"=R[9J:AJ*O^QK*RC^Z@?P3RQZ7;W7NG[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW66#_/1_P#!U_WOW[KW0;?]RD_^2'_\=>_=>Z__UMW*7_F:G9O_
M &J>N/\ W$W/[]U[I^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TUYS"8;<V#S>V
M=QXNASFW=RX;*[=W#@\G"*G&YK YW'U&*S6'R-.2!/093&5<L$R7&J.0BX^O
MOW7NB;]5_P N7X<],2;7J-B]9[C6OV1NCIS=FSLGNGM;LO>E?MFL^.NT-[]>
M= X3#2;DW)7PT&RNH-@=C9G#X?"QHM *6KU3I-.HF]^Z]TF-S_RLO@GN_%X+
M;V9Z>W!'M;";8J]DUFU\'W!VQMO![XV;-W#G/D+C=J=HT6#W=0KV3M_:7>>Y
M\CN?!TN5,\>*R%=4)"/M9I:=_=>Z-]N[J+K/?^^MN=D[WV?C=U;OVILCLWK3
M"U69:HJ\0-@]S/ME^T=KY3;;3?P+-X[> V=C4G%7!*T<4#)&4660-[KW19]K
M_P N?XC;)Q?2^U]I[*W_ (GKOH"CV#2=;=0/WEW%DNF$FZFWA7=@]49K>?5N
M3WE5;0[!W'UIO?(R97$5^7IZJ>.NAI)IC/)0T;0^Z]U"_P"&V/AX-K]@[ CV
M-V#2=9=BPYN&;J?'=\=TX[JKKS^\W8F'[>W+/TAU]2;WBVSTS5YOM/;]%GFE
MP5/2O1UE/IHC2P22PO[KW3UN'X ?&W=>1VCN#<"=XU^]=I;.K>M*CLJ/Y+]Z
MXSM+L;JFOWCDNP)>INZ^QL-OC&[L[BZYHMWY:HJ\?C\[4U1Q*3S04,E/3SSQ
MR^Z]T=%FU&]E7@ *BA$55 5415 "JJ@ #^@]^Z]U6;\G/^WFW\IG_P -K^9'
M_P"^+ZG]^Z]U9C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z['U'^N/?NM'@>
MF+ ?YC+_ /AT;@_]RT]TCX/_ *=O\/3C\5_THZ?/=^J=>]^Z]U[W[KW7O?NO
M=1,C_P 6W)_]JO)?^X,_NK?"WV'_  =67XE^WK#A_P#BSX;_ +4^*_\ =?3^
M]1_ GV#_  =>?XW^T_X>G'W?JO7O?NO=>]^Z]U[W[KW3CB/^+G0_]1,7_0WO
MW7NJN/Y,?_;K'X2_^(GR?_OQ]]>_=>ZLV]^Z]U[W[KW7O?NO=>]^Z]U@JO\
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M<I3S5M*N/HGE,TU!124_NO="5U1\&_D-T9D=C[BZI[$^&.U,CUKU1F.@MD9
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MZX^1&S,1_,>S_P 6,ZDNUFZMW)OS<?;>0^/FVI-R9RBVWD]C[?VE39"CW/\
M<3T55#2)[KW3KNSYR_+[#;?[2P%+V?E-SS;6^;FQ>O>WOE%LW8>W<1\?>F/C
M9V)4]^2;?QG6.5R/0>Z-Q]1]G[9S.QMH;,W['O+ []@VO6YN#.4^1:FS4,E'
M[KW1DOD]N'(;Z_DM=B;@^7'8^"WKO_=7Q?W]*=Y_&]^Z=D;4[?[<J-J[X@Z0
M7;F$V;B-F=EUL>\,Q#AJFLPZX_'XO(9R-E%*:!H8)/=>Z$/Y _)K?FT_@?\
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MKW5F/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KL?4?ZX]^ZT>!Z8L!_F,O\
M^'1N#_W+3W2/@_\ IV_P]./Q7_2CI\]WZIU[W[KW7O?NO=>]^Z]U$R/_ !;<
MG_VJ\E_[@S^ZM\+?8?\ !U9?B7[>L.'_ .+/AO\ M3XK_P!U]/[U'\"?8/\
M!UY_C?[3_AZ<?=^J]>]^Z]U[W[KW7O?NO=..(_XN=#_U$Q?]#>_=>ZJX_DQ_
M]NL?A+_XB?)_^_'WU[]U[JS;W[KW7O?NO=>]^Z]U[W[KW6"J_P" ==_U UW_
M +B3>]'@WV'_  =;'%?M'4+!_P#%BP?_ &IL7_[A0^ZQ_P!G'_I1_@ZV_P ;
M_:?\/3I[OU7KWOW7NO>_=>Z][]U[KWOW7NF.G_X^?+_]J/!_^Y>3]T']H_\
MI1_A/5S_ &:?:?\ )T^>[]4Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF3+_ / [
M:W_AP'_W4Y+VV_Q1?Z;_ "'JR\)?]+_E'1?MP?#7XV[J^7?7WSPSW71K_E7U
M9U3E^D]B]FG<VYX(<-USFI=Q/58E]H4^5CVED*^"'>69@@K)Z1ZB.')S"Y98
MFC<ZKTA/Y@73O>?R$^-V8Z6Z%Q76%;N/=N^>HMPYG)]L;^SVQ-O83$=3=O[
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MG7O?NO=>]^Z]U[W[KW43(_\ %MR?_:KR7_N#/[JWPM]A_P '5E^)?MZPX?\
MXL^&_P"U/BO_ '7T_O4?P)]@_P '7G^-_M/^'IQ]WZKU[W[KW7O?NO=>]^Z]
MTXXC_BYT/_43%_T-[]U[JKC^3'_VZQ^$O_B)\G_[\??7OW7NK-O?NO=>]^Z]
MU[W[KW7O?NO=8*K_ (!UW_4#7?\ N)-[T>#?8?\ !UL<5^T=0L'_ ,6+!_\
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M!\7_ ,J%+_U*7_BGOW7NO?P?%_\ *A2_]2E_XI[]U[KW\'Q?_*A2_P#4I?\
MBGOW7NO?P?%_\J%+_P!2E_XI[]U[KW\'Q?\ RH4O_4I?^*>_=>Z]_!\7_P J
M%+_U*7_BGOW7NO?P?%_\J%+_ -2E_P"*>_=>Z]_!\7_RH4O_ %*7_BGOW7NO
M?P?%_P#*A2_]2E_XI[]U[KW\'Q?_ "H4O_4I?^*>_=>Z]_!\7_RH4O\ U*7_
M (I[]U[KW\'Q?_*A2_\ 4I?^*>_=>Z]_!\7_ ,J%+_U*7_BGOW7NO?P?%_\
M*A2_]2E_XI[]U[KW\'Q?_*A2_P#4I?\ BGOW7NO?P?%_\J%+_P!2E_XI[]U[
MKW\'Q?\ RH4O_4I?^*>_=>Z]_!\7_P J%+_U*7_BGOW7NO?P?%_\J%+_ -2E
M_P"*>_=>Z]_!\7_RH4O_ %*7_BGOW7NO?P?%_P#*A2_]2E_XI[]U[KL8C&*0
M104H(-P?$G!_VWOW7NBT<?[*C:PT_P!S=.G\:?XEIT_ZVGCW[KW7_]7>BVM_
MS-?M?_M5]<?^X.X_?NO="M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB+_
M ,SR3/P_RZ/G%+M9]RQ;BC^+'>#XB39S9]=S1UB]?9TQOB&VI;=*U""Y)QA&
M0"!OMR)M!]^Z]UKP?&C>.;Z][)QNZMOXC/[PZJZ6^5GR8[8ZSW)\8=D=V]D]
M,T.%J_Y3O9TFY>MOC+M#N.JJ=Y9O<V!WWLEJW.8R:L;;V:WMNN"FQTM/635M
M%#[KW0][&_F._*K=. P]!N3OS+]8]-93Y;XW8N3^8&8Z:ZX[0W+L[KC,_!C!
M]];-V/F8^O=@XOHS,9/?/?\ 4U>W9<MC<//%B6I'VR:J;/3TV07W7NBQ[5[,
M[CKOCM\-?B7O7L7>74^P<3U9_)EW-LOI4]'YG)[F^3M3V!\H-G;D^3.\\EOC
M(X6MW=U:G1=?M2%)\9'4TAVG3T<DV>%7!DJ(1>Z]T:FG^=G\Q_=VU_D!EL1V
M;U9UYV%CMZ97K2MZ7S'7])V7VK\;,]E/Y@G5_P >^NMW8'IO;VR]J;BSNR8_
MC_NS(Y7.U>[-SY.GRU9)C,SAI8<2U7!'[KW6ROLC#;@V[L_;&!W7O"N[!W-A
M\%C,;G]\Y/$8/ 9'=V7HZ2*"OW%783;-%C=NXFJR]2C3R4]#3P4L3.5B14
M]U[I4>_=>ZJA^6'_ &]2_E'?^&S_ ##_ /WSG5/OW7NK7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=(O97_ ?<?_AZ;I_]V<GMN/@_^F/^'IR3BO\
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M\W7OHI?X5_WH_P#0'7O^@P[YD?\ >%_QF_\ 1F]I_P#UC]^_J+;?\IDG\O\
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MXH V+ZWTF61([_Y#N3Z:R+_3W[KW0G?Q/&_\K]'_ .=,/_1_OW7NO?Q/&_\
M*_1_^=,/_1_OW7NO?Q/&_P#*_1_^=,/_ $?[]U[KW\3QO_*_1_\ G3#_ -'^
M_=>Z]_$\;_ROT?\ YTP_]'^_=>Z]_$\;_P K]'_YTP_]'^_=>Z]_$\;_ ,K]
M'_YTP_\ 1_OW7NO?Q/&_\K]'_P"=,/\ T?[]U[KW\3QO_*_1_P#G3#_T?[]U
M[KW\3QO_ "OT?_G3#_T?[]U[KW\3QO\ ROT?_G3#_P!'^_=>Z]_$\;_ROT?_
M )TP_P#1_OW7NO?Q/&_\K]'_ .=,/_1_OW7NO?Q/&_\ *_1_^=,/_1_OW7NO
M?Q/&_P#*_1_^=,/_ $?[]U[KW\3QO_*_1_\ G3#_ -'^_=>Z]_$\;_ROT?\
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M-_Y7Z/\ \Z8?^C_?NO=>_B>-_P"5^C_\Z8?^C_?NO=>_B>-_Y7Z/_P Z8?\
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MO?Q/&_\ *_1_^=,/_1_OW7NO?Q/&_P#*_1_^=,/_ $?[]U[KW\3QO_*_1_\
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M(^7][ :NU3CN;\)]>KO!,2M(S\(Z=/\ AX+^5-_WL3^(_P#Z-W!^[_N#>O\
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M *X>_?U[NO\ E 3_ 'K_ &.O?62_Q'_C/_0/7O\ H$#Z+_[SY[\_]$WU3_\
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__6W=OD!\ENM?C6G4$_9E7-CZ/NCN7
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MYMWXNRYY-]3QME=T[/V5TQC\GB]M;>J*>"EQJY2-:B6MI\;CJ>G]U[HR&,^
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MN[YN?(G<>Q^@MS=E]F=^]8QT^W]^_)WO.AZR[$WMC^SL;B/E7W-N_M/XN/\
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>7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d155579d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sbtx="http://silverback.com/20210331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sbtx-20210331.xsd" xlink:type="simple"/>
    <context id="P01_01_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_10_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2021-05-10</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sbtx:WuxiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_EsppWithholdingsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:EsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LiquidityAndCapitalResourcesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sbtx:LiquidityAndCapitalResourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingOutstandingEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesAvailableForFutureEquityAwardGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEarlyExercisedEquityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sbtx:SharesUnderlyingEsppWithholdingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">sbtx:UnvestedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_RedeemableStockExcersibleOnAgreedUponMilestonesMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:RedeemableStockExcersibleOnAgreedUponMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sbtx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P10_31_2019To10_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sbtx:WuxiBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="P11_01_2016To11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_AmendedLoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sbtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">sbtx:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sbtx:AmendedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="P12_03_2020To12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="P12_03_2020To12_03_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2021To03_31_2021">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2021To03_31_2021">0001671858</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2021To03_31_2021">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2021To03_31_2021">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2021To03_31_2021">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="P01_01_2021To03_31_2021">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P01_01_2021To03_31_2021">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2021To03_31_2021">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="P01_01_2021To03_31_2021">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2021To03_31_2021">001-39756</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2021To03_31_2021">Silverback Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2021To03_31_2021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2021To03_31_2021">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2021To03_31_2021">500 Fairview Ave N</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2021To03_31_2021">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2021To03_31_2021">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2021To03_31_2021">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2021To03_31_2021">98109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2021To03_31_2021">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2021To03_31_2021">456-2900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2021To03_31_2021">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2021To03_31_2021">SBTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2021To03_31_2021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2021To03_31_2021">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2021To03_31_2021">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2021To03_31_2021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2021To03_31_2021">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2021To03_31_2021">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2021To03_31_2021">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="P01_01_2021To03_31_2021">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn05_10_2021"
      decimals="INF"
      unitRef="Unit_shares">34905511</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">374205000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">386569000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4141000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4087000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">378346000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">390656000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1603000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2180000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">382199000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">394804000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4374000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2583000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5799000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LoansPayableToBankCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">495000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:LoansPayableToBankCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">844000</us-gaap:LoansPayableToBankCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">927000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">896000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11595000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9601000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2326000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13650000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11927000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">34903497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">34801537</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">34827204</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">34701274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">484147000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">479608000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-115601000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-96734000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">368549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">382877000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">382199000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">394804000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12239000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4414000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6646000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">828000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18885000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5242000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-18885000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5242000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-37000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-18867000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5279000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.54</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P01_01_2020To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-7.89</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">34773950</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">669033</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">34701274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">479608000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-96734000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">382877000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">125930</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">254000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">254000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18867000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-18867000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">34827204</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">484147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-115601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">368549000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">15714283</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">53174000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">664431</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5010000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-63787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-58777000</us-gaap:StockholdersEquity>
    <sbtx:StockIssuanceCosts
      contextRef="P01_01_2020To03_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">76000</sbtx:StockIssuanceCosts>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10027666</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">21458000</sbtx:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">4673388</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">10095000</sbtx:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">5350</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">47000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5279000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5279000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">30415337</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">84727000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">669781</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-69066000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-64003000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-18867000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5279000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">186000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">139000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4285000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">280000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">262000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-92000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2208000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2697000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <sbtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-240000</sbtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <sbtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-212000</sbtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-12201000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-7628000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-35000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-33000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21659000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-128000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21315000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-12364000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInContinuingOperations
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13654000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">386919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">374555000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">136000</us-gaap:FairValueOfAssetsAcquired>
    <sbtx:ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32000</sbtx:ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10095000</sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes>
    <sbtx:UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">201000</sbtx:UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NatureOfOperations contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1. Nature of Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Silverback Therapeutics, Inc. (&#x201c;Silverback&#x201d; or &#x201c;the Company&#x201d;) is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The Company&#x2019;s platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed at specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January&#160;4, 2016. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Initial Public Offering and Related Transaction &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On December&#160;3, 2020, the Company&#x2019;s registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; (File &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;333-250009)&lt;/div&gt; for its initial public offering of common stock (&#x201c;IPO&#x201d;) was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). On December&#160;8, 2020, the Company issued and sold 13,225,000 shares of common stock in the IPO at a public offering price of $21.00 per share, resulting in net proceeds of $255.3&#160;million after deducting underwriting discounts and commissions and offering expenses paid by the Company. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the IPO, all 77,074,884 shares of redeemable convertible preferred stock outstanding at the time of the IPO converted into 20,758,098 shares of the Company&#x2019;s common stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the Company&#x2019;s existing products under development. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $115.6&#160;million as of March&#160;31, 2021. The Company had cash and cash equivalents of $374.2&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million as of March 31, 2021 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily through the issuance of redeemable convertible preferred stock, convertible notes, and the sale of common stock in connection with the IPO. The Company&#x2019;s currently available cash and cash equivalents as of March 31, 2021 are sufficient to meet its anticipated cash requirements for the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date the financial statements are issued.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management expects operating losses to continue for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical development activities as well as the commercialization of the Company&#x2019;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">13225000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">21.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P12_03_2020To12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">255300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_03_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">77074884</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P12_03_2020To12_03_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">20758098</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-115600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021_LiquidityAndCapitalResourcesMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">374200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Unaudited Interim Condensed Financial Statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying condensed balance sheet as of March 31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) for the three months ended March 31, 2021 and 2020, are unaudited. The balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of March 31, 2021, and the condensed results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three months ended March 31, 2021 and 2020 are also unaudited. The condensed results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The full extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;coron&lt;div style="display:inline;"&gt;a&lt;/div&gt;virus&#160;(&#x201c;COVID-19&#x201d;)&#160;pandemic&lt;/div&gt; will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;concerning&#160;COVID-19&#160;and&lt;/div&gt; the actions taken to contain or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;treat&#160;COVID-19,&#160;as&lt;/div&gt; well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;COVID-19&#160;pandemic&lt;/div&gt; and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents, and restricted cash are carried at fair value. Financial instruments, including accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. Term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates. &lt;/div&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At March&#160;31, 2021 and December&#160;31, 2021, the Company&#x2019;s cash equivalents consisted of money market funds. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the Company&#x2019;s facility operating lease. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash and cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,919&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Leases consist of the Company&#x2019;s operating lease. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company&#x2019;s lease includes options to extend or terminate the lease. Periods covered by an option to extend the lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. At the inception of the lease and as of March&#160;31, 2021, the Company was not reasonably certain that it will exercise its option to extend the lease and was not reasonably certain that it will not exercise its option to terminate the lease, therefore, the periods covered by the options are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#x2019;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#x2019;s program pipeline, including the Company&#x2019;s lead product candidate, SBT6050, and other pipeline programs, including SBT6290 and SBT8230. Direct costs include expenses incurred under agreements with contract research organizations (&#x201c;CROs&#x201d;) and other vendors that conduct the Company&#x2019;s preclinical and clinical activities, expenses associated with manufacturing the Company&#x2019;s product candidates including under agreements with contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#x2019;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#x2019;s research and development efforts and have no alternative future uses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt; cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#x2019;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was equal to net loss for the three months ended March&#160;31, 2021 and 2020.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share Attributable to Common Stockholders &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities.&#160;Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company Status &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1)&#160;no longer an emerging growth company or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU&#160;2016-13,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt;. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January&#160;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Unaudited Interim Condensed Financial Statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying condensed balance sheet as of March 31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) for the three months ended March 31, 2021 and 2020, are unaudited. The balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position as of March 31, 2021, and the condensed results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three months ended March 31, 2021 and 2020 are also unaudited. The condensed results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the Company&#x2019;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The full extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;coron&lt;div style="display:inline;"&gt;a&lt;/div&gt;virus&#160;(&#x201c;COVID-19&#x201d;)&#160;pandemic&lt;/div&gt; will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;concerning&#160;COVID-19&#160;and&lt;/div&gt; the actions taken to contain or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;treat&#160;COVID-19,&#160;as&lt;/div&gt; well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&#160;COVID-19&#160;pandemic&lt;/div&gt; and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents, and restricted cash are carried at fair value. Financial instruments, including accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. Term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates. &lt;/div&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At March&#160;31, 2021 and December&#160;31, 2021, the Company&#x2019;s cash equivalents consisted of money market funds. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the Company&#x2019;s facility operating lease. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash and cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,919&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2021To03_31_2021">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt; 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash and cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,919&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">374205000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">386569000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">374555000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">386919000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Leases consist of the Company&#x2019;s operating lease. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company&#x2019;s lease includes options to extend or terminate the lease. Periods covered by an option to extend the lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. At the inception of the lease and as of March&#160;31, 2021, the Company was not reasonably certain that it will exercise its option to extend the lease and was not reasonably certain that it will not exercise its option to terminate the lease, therefore, the periods covered by the options are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#x2019;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#x2019;s program pipeline, including the Company&#x2019;s lead product candidate, SBT6050, and other pipeline programs, including SBT6290 and SBT8230. Direct costs include expenses incurred under agreements with contract research organizations (&#x201c;CROs&#x201d;) and other vendors that conduct the Company&#x2019;s preclinical and clinical activities, expenses associated with manufacturing the Company&#x2019;s product candidates including under agreements with contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#x2019;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#x2019;s research and development efforts and have no alternative future uses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt; cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#x2019;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s comprehensive loss was equal to net loss for the three months ended March&#160;31, 2021 and 2020.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share Attributable to Common Stockholders &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities.&#160;Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <sbtx:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company Status &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1)&#160;no longer an emerging growth company or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sbtx:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU&#160;2016-13,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt;. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January&#160;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Quoted prices in active markets for identical assets or liabilities. The Company&#x2019;s Level&#160;1 assets consist of money market funds. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Unobservable inputs that are supported by little or no market activity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table identifies the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers between the Level&#160;1 and Level&#160;2 categories or into or out of the Level&#160;3 category during the periods presented. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table identifies the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;386,369&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">374205000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">386369000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="P01_01_2021To03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4. Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional services and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;581&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,610&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee compensation and benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional services and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;523&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;581&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sbtx:AccruedResearchAndDevelopmentExpenses
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3610000</sbtx:AccruedResearchAndDevelopmentExpenses>
    <sbtx:AccruedResearchAndDevelopmentExpenses
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2063000</sbtx:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1666000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2634000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">523000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">581000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5799000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases an office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Variable lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Total lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash outflows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The remaining term on the Company&#x2019;s lease was 1.7 years as of March&#160;31, 2021. To compute the present value of the lease liability, the Company used a discount rate of 8.5%. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum commitments due under the operating lease agreement as of March 31, 2021 are as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 90%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 (remaining 9 months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.75pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total undiscounted lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total present value of lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,981&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2021To03_31_2021">The components of lease expense and related cash flows were as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Variable lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Total lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;453&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;433&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash outflows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;421&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;397&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">347000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">347000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">106000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">86000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">453000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">433000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">421000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">397000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2021">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum commitments due under the operating lease agreement as of March 31, 2021 are as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 90%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021 (remaining 9 months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,454&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.75pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.75pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total undiscounted lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(297&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total present value of lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,981&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">824000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3278000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">297000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2981000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Term Loan Payable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (&#x201c;SVB&#x201d;) and borrowed $3.5&#160;million as a term loan. The outstanding principal amount of the term loan accrues interest at an annual rate of 1.75% per annum. At closing, the Company incurred de minimis debt issuance costs and owed a final payment fee of $0.3&#160;million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate of the Company&#x2019;s term loan is 5.14%. Interest expense under the term loan totaled less than $0.1&#160;million for each of the three months ended March&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The term loan is collateralized by the Company&#x2019;s tangible and intangible assets, excluding intellectual property. The proceeds are to be used as working capital and to fund general business requirements. The agreement includes customary nonfinancial covenants and events of default that include, among other &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;things,&#160;non-payment,&#160;inaccuracy&lt;/div&gt; of representations and warranties, covenant breaches, cross default to material indebtedness or material agreements, bankruptcy and insolvency, material judgments, a change of control, or any material adverse event. The Company was in compliance with all related covenants as of March&#160;31, 2021. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The term loan&#x2019;s original maturity date was November 1, 2020. However, in April 2020, the Company amended the loan and security agreement to defer principal payments for six months and extend the maturity date to May 1, 2021. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification and is amortizing the remaining debt discount over the remaining term. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;1, 2021, the Company made its final scheduled payment to SVB under the loan and security agreement including the final payment fee. &lt;/div&gt;&lt;/div&gt; </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">3500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P11_01_2016To11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2021To03_31_2021_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0514</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To03_31_2021_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To03_31_2020_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:InterestExpense>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P11_01_2016To11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">2020-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P04_01_2020To04_30_2020_AmendedLoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis">2021-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Stockholders&#x2019; Equity (Deficit) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prior to its conversion to common stock in December 2020, the Company&#x2019;s redeemable convertible preferred stock was classified as mezzanine equity on the Company&#x2019;s balance sheets as the shares are contingently redeemable upon a deemed liquidation such as a change in control and in that event, there is no guarantee that all stockholders would be entitled to receive the same form of consideration. No accretion to redemption value was recorded during the three months ended March&#160;31, 2020 as a deemed liquidation event was not considered probable. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2020, the Company issued 14,701,054 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares of its Series B redeemable convertible preferred stock, including &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 4,673,388 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares issued upon conversion of then outstanding convertible notes and accrued interest, and &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 10,027,666 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares issued for cash at a purchase price of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$2.16 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share, resulting in gross proceeds of $21.5&#160;million. The Series B purchase agreement provided that the Company would issue, and the Series B holders would purchase, an additional &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; 21,732,862 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares of the Company&#x2019;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$46.9&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in the event that certain agreed upon milestones were achieved or the preferred majority approved their closing. As of March 31, 2020, these future Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has reserved shares of common stock for the following potential future issuances: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares underlying outstanding equity awards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,308,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,316,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares available for future equity award grants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,152,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,506,806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares underlying early exercised equity awards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100,263&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%; padding-bottom: 0.45pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares underlying ESPP withholdings&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;19,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,556,911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,928,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis"
      decimals="0"
      unitRef="Unit_shares">14701054</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis"
      decimals="0"
      unitRef="Unit_shares">4673388</sbtx:IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis"
      decimals="0"
      unitRef="Unit_shares">10027666</sbtx:TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_SeriesBMemberusgaapAuctionMarketPreferredSecuritiesStockSeriesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.16</us-gaap:SharesIssuedPricePerShare>
    <sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_RedeemableStockExcersibleOnAgreedUponMilestonesMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      unitRef="Unit_shares">21732862</sbtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_RedeemableStockExcersibleOnAgreedUponMilestonesMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">46900000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has reserved shares of common stock for the following potential future issuances: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares underlying outstanding equity awards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,308,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,316,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares available for future equity award grants&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,152,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,506,806&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares underlying early exercised equity awards&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;100,263&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%; padding-bottom: 0.45pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shares underlying ESPP withholdings&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;19,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"&gt;4,393&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,556,911&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,928,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 74%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">6308582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">6316569</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3152910</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_SharesAvailableForFutureEquityAwardGrantsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1506806</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">76293</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_SharesUnderlyingEarlyExercisedEquityAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">100263</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">19126</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_SharesUnderlyingEsppWithholdingsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">4393</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">9556911</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">7928031</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8. Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; As of March&#160;31, 2021, the total unrecognized stock-based compensation expense was $59.6&#160;million, which is expected to be recognized over a remaining weighted-average period of approximately 3.16 years. &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Option Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2021, the Company&#x2019;s equity incentive plans authorized a total of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;9,564,798 shares, of which 3,152,910 shares are available for future grant, and 6,308,582 shares are outstanding. Not included in the outstanding option balance are 76,293 shares pursuant to stock options that were early exercised and subject to repurchase under the 2016 Plan that remain unvested as of March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; A summary of the Company&#x2019;s stock option activity for the three months ended March&#160;31, 2021 is as follows (in thousands, except share and per share data and years):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Options Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subject to&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,316,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;223,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cance&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l&lt;/div&gt;led&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,308,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;202,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;708,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The total fair value of shares vested during the three months ended March&#160;31, 2021 and 2020 was $3.6&#160;million and less than $0.1&#160;million, respectively. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#x2019;s common stock for all options that were &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-the-money&lt;/div&gt;&lt;/div&gt; at March&#160;31, 2021.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;The weighted-average grant date fair value per share of option grants for the three months ended &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;March 31, 2021 was $33.32&lt;/div&gt;. There were no grants during the three months ended March&#160;31, 2020. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&lt;br/&gt; Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.0&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;83%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;0.72%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&#160;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Common Stock.&lt;/div&gt;&lt;/div&gt; The grant date fair market value of the shares of common stock underlying stock options is determined by the Company&#x2019;s board of directors. Following the closing of the Company&#x2019;s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#x2019;s common stock is traded. Prior to the Company&#x2019;s IPO, because there was no public market for the Company&#x2019;s common stock, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included contemporaneous valuations performed by an independent third-party, the Company&#x2019;s results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#x2019;s business, progress of the Company&#x2019;s research and development activities, the Company&#x2019;s business conditions and projections, the lack of marketability of the Company&#x2019;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#x2019;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key personnel and the experience of management, trends and developments in the Company&#x2019;s industry and external market conditions affecting the life sciences and biotechnology industry sectors. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Term. &lt;/div&gt;&lt;/div&gt;The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-point&lt;/div&gt; between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Volatility.&lt;/div&gt;&lt;/div&gt; Given the Company&#x2019;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-free Interest Rate.&lt;/div&gt;&lt;/div&gt; The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Dividend Yield.&lt;/div&gt;&lt;/div&gt; The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="color: white; line-height: 0pt; visibility: hidden;"&gt;
&lt;td style="width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.45pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,360&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1925000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">59600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To03_31_2021">P3Y1M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">9564798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_shares">3152910</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">6308582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">76293</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To03_31_2021">A summary of the Company&#x2019;s stock option activity for the three months ended March&#160;31, 2021 is as follows (in thousands, except share and per share data and years):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Options Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subject to&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.7pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,316,569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;223,647&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;93,973&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(101,960&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,227&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cance&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l&lt;/div&gt;led&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,308,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;202,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;708,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">6316569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2020To12_31_2020">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">223647000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">93973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">48.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">101960</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4227000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">6308582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To03_31_2021">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">708833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2021To03_31_2021">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2021To03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2020To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">33.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three&#160;Months&lt;br/&gt; Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.0&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;83%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;0.72%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&#160;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To03_31_2021">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To03_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="P01_01_2020To03_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <sbtx:LicensingAgreement contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9. Licensing Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Bio&#x201d;). Under the license agreement, WuXi Bio granted the Company a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt; worldwide, sublicensable, under certain of WuXi Bio&#x2019;s intellectual property rights, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and biological materials (&#x201c;WuXi Bio Licensed Technology&#x201d;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#x201c;WuXi Bio Licensed Product&#x201d;). The WuXi Bio Licensed Technology is currently used to manufacture a component of the Company&#x2019;s lead product, SBT6050. The Company has paid an aggregate of $150,000 in license fees that were recorded in research and development expense when incurred. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to $10.8&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them through the termination date. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party may terminate the license immediately upon written notice to the other party.&lt;/div&gt;&lt;/div&gt; </sbtx:LicensingAgreement>
    <sbtx:LicenseFeesPaid
      contextRef="P10_31_2019To10_31_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">150000</sbtx:LicenseFeesPaid>
    <sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones
      contextRef="P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">10800000</sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones>
    <sbtx:AgreementPaymentAndLicenseTermDesciption contextRef="P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.</sbtx:AgreementPaymentAndLicenseTermDesciption>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legal Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Indemnifications &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The global &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic continues to rapidly evolve, and management continue to monitor the situation closely. The extent of the impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on the Company&#x2019;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#x2019;s clinical trial enrollment, trial sites, CROs, third-party manufacturers, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the Company&#x2019;s key scientific and management personnel. The ultimate impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and most of the Company&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lab&lt;/div&gt; based employees working remotely. Management will continue to actively monitor the rapidly evolving situation related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and may take further actions that alter Company operations, including those that may be required by federal, state or local authorities, or that management determines are in the best interests of the Company&#x2019;s employees and other third parties with whom the Company does business. At this point, the extent to which the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic may affect the Company&#x2019;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;. Employee Benefit Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains a retirement plan, which is qualified under section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#x2019;s U.S.&#160;employees. The plan allows eligible employees to defer, at the employee&#x2019;s discretion, pretax compensation up to the IRS annual limits. The Company does not match contributions made by employees.&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Net Loss Per Share Attributable to Common Stockholders &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redeemable convertible preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,191,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,308,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;550,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ESPP withholdings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total potentially dilutive shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,404,001&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,756,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2021To03_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redeemable convertible preferred stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,191,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,308,582&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;550,176&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested common stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,293&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ESPP withholdings&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,126&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 76%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total potentially dilutive shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,404,001&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,756,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 76%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 2%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">8191580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">6308582</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To03_31_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">550176</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">76293</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To03_31_2020_UnvestedCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To03_31_2020_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">9154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021_EsppWithholdingsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">19126</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">6404001</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">8756005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200496306584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Silverback Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SBTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Fairview Ave N<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">456-2900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,905,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200487844056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheet - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 374,205<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,141<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">378,346<span></span>
</td>
<td class="nump">390,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,603<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use&#160;asset</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">382,199<span></span>
</td>
<td class="nump">394,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,374<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,799<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Term loan payable, net</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,595<span></span>
</td>
<td class="nump">9,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,650<span></span>
</td>
<td class="nump">11,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020, 34,903,497 and 34,801,537 shares issued, and 34,827,204 and 34,701,274 shares outstanding at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">484,147<span></span>
</td>
<td class="nump">479,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(115,601)<span></span>
</td>
<td class="num">(96,734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">368,549<span></span>
</td>
<td class="nump">382,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, and stockholders' equity</a></td>
<td class="nump">$ 382,199<span></span>
</td>
<td class="nump">$ 394,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200488461576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheet (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock , shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">34,903,497<span></span>
</td>
<td class="nump">34,801,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">34,827,204<span></span>
</td>
<td class="nump">34,701,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200488451448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12,239<span></span>
</td>
<td class="nump">$ 4,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,646<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,885<span></span>
</td>
<td class="nump">5,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,885)<span></span>
</td>
<td class="num">(5,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (18,867)<span></span>
</td>
<td class="num">$ (5,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share applicable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (7.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">34,773,950<span></span>
</td>
<td class="nump">669,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200494679704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,174<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,714,283<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (58,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,010<span></span>
</td>
<td class="num">$ (63,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash', window );">Issuance of Series B redeemable convertible preferred stock for cash, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock for cash, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,027,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes', window );">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes', window );">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,673,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(5,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary Equity, Ending balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,727<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Ending balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,415,337<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">(64,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,063<span></span>
</td>
<td class="num">(69,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 382,877<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">479,608<span></span>
</td>
<td class="num">(96,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">34,701,274<span></span>
</td>
<td class="nump">34,701,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options and vesting of early exercised common stock options, Shares</a></td>
<td class="nump">101,960<span></span>
</td>
<td class="nump">125,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(18,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 368,549<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 484,147<span></span>
</td>
<td class="num">$ (115,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="nump">34,827,204<span></span>
</td>
<td class="nump">34,827,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued on conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock classified as temporary equity issued for cash during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413521480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sbtx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sbtx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sbtx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200494627944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,867)<span></span>
</td>
<td class="num">$ (5,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,285<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash&#160;lease expense</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,208<span></span>
</td>
<td class="num">(2,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(240)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,201)<span></span>
</td>
<td class="num">(7,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Principal payments on term loan payable</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(128)<span></span>
</td>
<td class="nump">21,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">Change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(12,364)<span></span>
</td>
<td class="nump">13,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">386,919<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">374,555<span></span>
</td>
<td class="nump">24,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses', window );">Change in early exercise liability included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes', window );">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities', window );">Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in early exercise liability included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in operating lease liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413457800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Nature of Business </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Silverback Therapeutics, Inc. (&#8220;Silverback&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The Company&#8217;s platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed at specific disease sites. The Company was formed in Seattle, Washington and incorporated in the state of Delaware on January&#160;4, 2016. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Initial Public Offering and Related Transaction </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On December&#160;3, 2020, the Company&#8217;s registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-250009)</div> for its initial public offering of common stock (&#8220;IPO&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). On December&#160;8, 2020, the Company issued and sold 13,225,000 shares of common stock in the IPO at a public offering price of $21.00 per share, resulting in net proceeds of $255.3&#160;million after deducting underwriting discounts and commissions and offering expenses paid by the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the IPO, all 77,074,884 shares of redeemable convertible preferred stock outstanding at the time of the IPO converted into 20,758,098 shares of the Company&#8217;s common stock. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to a number of inherent risks which include, but are not limited to, the need to obtain adequate additional funding, possible failure of clinical trials or other events demonstrating a lack of clinical safety or efficacy of its product candidates, dependence on key personnel, reliance on third-party service providers for manufacturing drug product and conducting clinical trials, the ability to successfully secure its proprietary technology, and risks related to the regulatory approval and commercialization of a product candidate. Additionally, the development and commercialization of new drug products is highly competitive. Products or technologies developed by competitors may diminish or render obsolete the Company&#8217;s existing products under development. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $115.6&#160;million as of March&#160;31, 2021. The Company had cash and cash equivalents of $374.2&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million as of March 31, 2021 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily through the issuance of redeemable convertible preferred stock, convertible notes, and the sale of common stock in connection with the IPO. The Company&#8217;s currently available cash and cash equivalents as of March 31, 2021 are sufficient to meet its anticipated cash requirements for the 12 months following the date the financial statements are issued. Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern for a period of at least 12 months from the date the financial statements are issued.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management expects operating losses to continue for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the manufacturing, clinical and preclinical development activities as well as the commercialization of the Company&#8217;s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413443672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Condensed Financial Statements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed balance sheet as of March 31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) for the three months ended March 31, 2021 and 2020, are unaudited. The balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of March 31, 2021, and the condensed results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three months ended March 31, 2021 and 2020 are also unaudited. The condensed results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period.</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">coron<div style="display:inline;">a</div>virus&#160;(&#8220;COVID-19&#8221;)&#160;pandemic</div> will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">concerning&#160;COVID-19&#160;and</div> the actions taken to contain or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">treat&#160;COVID-19,&#160;as</div> well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents, and restricted cash are carried at fair value. Financial instruments, including accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. Term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates. </div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At March&#160;31, 2021 and December&#160;31, 2021, the Company&#8217;s cash equivalents consisted of money market funds. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the Company&#8217;s facility operating lease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands): </div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,919</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Leases consist of the Company&#8217;s operating lease. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company&#8217;s lease includes options to extend or terminate the lease. Periods covered by an option to extend the lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. At the inception of the lease and as of March&#160;31, 2021, the Company was not reasonably certain that it will exercise its option to extend the lease and was not reasonably certain that it will not exercise its option to terminate the lease, therefore, the periods covered by the options are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#8217;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#8217;s program pipeline, including the Company&#8217;s lead product candidate, SBT6050, and other pipeline programs, including SBT6290 and SBT8230. Direct costs include expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and other vendors that conduct the Company&#8217;s preclinical and clinical activities, expenses associated with manufacturing the Company&#8217;s product candidates including under agreements with contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#8217;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#8217;s research and development efforts and have no alternative future uses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The</div></div> cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#8217;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was equal to net loss for the three months ended March&#160;31, 2021 and 2020.</div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share Attributable to Common Stockholders </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities.&#160;Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1)&#160;no longer an emerging growth company or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2016-13,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January&#160;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413544648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Quoted prices in active markets for identical assets or liabilities. The Company&#8217;s Level&#160;1 assets consist of money market funds. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Unobservable inputs that are supported by little or no market activity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table identifies the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between the Level&#160;1 and Level&#160;2 categories or into or out of the Level&#160;3 category during the periods presented. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200414770248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Accrued Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee compensation and benefits</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services and other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">523</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">581</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413454168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases an office and laboratory space in Seattle, Washington. The components of lease expense and related cash flows were as follows (in thousands): </div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease expense</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">347</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">347</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">453</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">433</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash outflows from operating leases</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">421</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">397</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The remaining term on the Company&#8217;s lease was 1.7 years as of March&#160;31, 2021. To compute the present value of the lease liability, the Company used a discount rate of 8.5%. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future minimum commitments due under the operating lease agreement as of March 31, 2021 are as follows (in thousands):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 (remaining 9 months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(297</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total present value of lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200414945064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan Payable</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Term Loan Payable </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2016, the Company entered into a loan and security agreement with Silicon Valley Bank (&#8220;SVB&#8221;) and borrowed $3.5&#160;million as a term loan. The outstanding principal amount of the term loan accrues interest at an annual rate of 1.75% per annum. At closing, the Company incurred de minimis debt issuance costs and owed a final payment fee of $0.3&#160;million, both of which are amortized to interest expense over the remaining term of the debt under the effective interest method. The effective interest rate of the Company&#8217;s term loan is 5.14%. Interest expense under the term loan totaled less than $0.1&#160;million for each of the three months ended March&#160;31, 2021 and 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The term loan is collateralized by the Company&#8217;s tangible and intangible assets, excluding intellectual property. The proceeds are to be used as working capital and to fund general business requirements. The agreement includes customary nonfinancial covenants and events of default that include, among other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">things,&#160;non-payment,&#160;inaccuracy</div> of representations and warranties, covenant breaches, cross default to material indebtedness or material agreements, bankruptcy and insolvency, material judgments, a change of control, or any material adverse event. The Company was in compliance with all related covenants as of March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The term loan&#8217;s original maturity date was November 1, 2020. However, in April 2020, the Company amended the loan and security agreement to defer principal payments for six months and extend the maturity date to May 1, 2021. There were no costs or additional warrant issuances in connection with this amendment. The Company accounted for the amendment as a debt modification and is amortizing the remaining debt discount over the remaining term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021, the Company made its final scheduled payment to SVB under the loan and security agreement including the final payment fee. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413249896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Stockholders&#8217; Equity (Deficit) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to its conversion to common stock in December 2020, the Company&#8217;s redeemable convertible preferred stock was classified as mezzanine equity on the Company&#8217;s balance sheets as the shares are contingently redeemable upon a deemed liquidation such as a change in control and in that event, there is no guarantee that all stockholders would be entitled to receive the same form of consideration. No accretion to redemption value was recorded during the three months ended March&#160;31, 2020 as a deemed liquidation event was not considered probable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2020, the Company issued 14,701,054 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of its Series B redeemable convertible preferred stock, including </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 4,673,388 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares issued upon conversion of then outstanding convertible notes and accrued interest, and </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 10,027,666 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares issued for cash at a purchase price of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$2.16 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">per share, resulting in gross proceeds of $21.5&#160;million. The Series B purchase agreement provided that the Company would issue, and the Series B holders would purchase, an additional </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> 21,732,862 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of the Company&#8217;s Series B redeemable convertible preferred stock across two tranches for aggregate proceeds of </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$46.9&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million in the event that certain agreed upon milestones were achieved or the preferred majority approved their closing. As of March 31, 2020, these future Series B tranches did not meet the definition of freestanding instruments or the definition of derivatives, therefore, they were not accounted for separately or bifurcated. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has reserved shares of common stock for the following potential future issuances: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying outstanding equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,308,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,316,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares available for future equity award grants</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,152,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,506,806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying early exercised equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%; padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying ESPP withholdings</div></div> </td>
<td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">19,126</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4,393</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,556,911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,928,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200414902712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8. Stock-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,285</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> As of March&#160;31, 2021, the total unrecognized stock-based compensation expense was $59.6&#160;million, which is expected to be recognized over a remaining weighted-average period of approximately 3.16 years. <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option Awards </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of March 31, 2021, the Company&#8217;s equity incentive plans authorized a total of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>9,564,798 shares, of which 3,152,910 shares are available for future grant, and 6,308,582 shares are outstanding. Not included in the outstanding option balance are 76,293 shares pursuant to stock options that were early exercised and subject to repurchase under the 2016 Plan that remain unvested as of March&#160;31, 2021. </div></div> A summary of the Company&#8217;s stock option activity for the three months ended March&#160;31, 2021 is as follows (in thousands, except share and per share data and years):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,316,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">223,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cance<div style="letter-spacing: 0px; top: 0px;;display:inline;">l</div>led</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,308,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">708,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The total fair value of shares vested during the three months ended March&#160;31, 2021 and 2020 was $3.6&#160;million and less than $0.1&#160;million, respectively. The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the Company&#8217;s common stock for all options that were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money</div></div> at March&#160;31, 2021.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>The weighted-average grant date fair value per share of option grants for the three months ended <div style="letter-spacing: 0px; top: 0px;;display:inline;">March 31, 2021 was $33.32</div>. There were no grants during the three months ended March&#160;31, 2020. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months<br/> Ended</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.0</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;83%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;0.72%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock options was determined using the Black-Scholes option-pricing model and the assumptions below. Each of these inputs is subjective and generally requires significant judgement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Common Stock.</div></div> The grant date fair market value of the shares of common stock underlying stock options is determined by the Company&#8217;s board of directors. Following the closing of the Company&#8217;s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company&#8217;s common stock is traded. Prior to the Company&#8217;s IPO, because there was no public market for the Company&#8217;s common stock, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair market value, which included contemporaneous valuations performed by an independent third-party, the Company&#8217;s results of operations and financial position, including its levels of available capital resources, its stage of development and material risks related to the Company&#8217;s business, progress of the Company&#8217;s research and development activities, the Company&#8217;s business conditions and projections, the lack of marketability of the Company&#8217;s common stock and preferred stock as a private company, the prices at which the Company sold shares of its redeemable convertible preferred stock to outside investors in arms-length transactions, the rights, preferences and privileges of the Company&#8217;s redeemable convertible preferred stock relative to those of its common stock, the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry, the likelihood of achieving a liquidity event for the Company&#8217;s securityholders, such as an IPO or a sale of the company, given prevailing market conditions, the hiring of key personnel and the experience of management, trends and developments in the Company&#8217;s industry and external market conditions affecting the life sciences and biotechnology industry sectors. </div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term. </div></div>The expected term represents the period that the options granted are expected to be outstanding. The expected term of stock options issued is determined using the simplified method (based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-point</div> between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility.</div></div> Given the Company&#8217;s limited historical stock price volatility data, the Company derived the expected volatility from the average historical volatilities over a period approximately equal to the expected term of comparable publicly traded companies within its peer group that were deemed to be representative of future stock price trends as the Company has limited trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. </div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free Interest Rate.</div></div> The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield.</div></div> The Company has never paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. Therefore, the Company uses an expected dividend yield of zero. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413453336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LicensingAgreementAbstract', window );"><strong>Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LicensingAgreement', window );">Licensing Agreement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9. Licensing Agreement</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell Line License Agreement with WuXi Biologics (Hong Kong) Limited </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In October 2019, the Company entered into a cell line license agreement with WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Bio&#8221;). Under the license agreement, WuXi Bio granted the Company a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, under certain of WuXi Bio&#8217;s intellectual property rights, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and biological materials (&#8220;WuXi Bio Licensed Technology&#8221;), to make, use, sell, offer for sale and import a product developed through the use of the WuXi Bio Licensed Technology (&#8220;WuXi Bio Licensed Product&#8221;). The WuXi Bio Licensed Technology is currently used to manufacture a component of the Company&#8217;s lead product, SBT6050. The Company has paid an aggregate of $150,000 in license fees that were recorded in research and development expense when incurred. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event the Company manufactures its commercial supplies of a product produced by the Licensed Cell Line using a manufacturer other than WuXi Bio or its affiliates, the Company will become obligated to pay WuXi Bio aggregate milestone payments, upon achievement of certain sales milestones, of up to $10.8&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has the right to terminate the license by giving at least six months prior written notice to WuXi Bio and paying all amounts due to them through the termination date. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">In the event either party commits a material breach under the license and fails to cure the breach within 30 days after receiving written notice from the other party of such breach, either party may terminate the license immediately upon written notice to the other party.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200496369192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Commitments and Contingencies </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Proceedings </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnifications </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to rapidly evolve, and management continue to monitor the situation closely. The extent of the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the Company&#8217;s business, operations and clinical development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#8217;s clinical trial enrollment, trial sites, CROs, third-party manufacturers, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the Company&#8217;s key scientific and management personnel. The ultimate impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, management is conducting business as usual, with necessary or advisable modifications to employee travel and most of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lab</div> based employees working remotely. Management will continue to actively monitor the rapidly evolving situation related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and may take further actions that alter Company operations, including those that may be required by federal, state or local authorities, or that management determines are in the best interests of the Company&#8217;s employees and other third parties with whom the Company does business. At this point, the extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may affect the Company&#8217;s business, operations and clinical development timelines and plans, including the resulting impact on Company expenditures and capital needs, remains uncertain and is subject to change.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200415102424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div>. Employee Benefit Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a retirement plan, which is qualified under section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the Company&#8217;s U.S.&#160;employees. The plan allows eligible employees to defer, at the employee&#8217;s discretion, pretax compensation up to the IRS annual limits. The Company does not match contributions made by employees.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413450216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Net Loss Per Share Attributable to Common Stockholders </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,191,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock options</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,308,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">550,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested common stock</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock warrants</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ESPP withholdings</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total potentially dilutive shares</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,404,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,756,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200494683288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Polices)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unaudited Interim Condensed Financial Statements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed balance sheet as of March 31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) for the three months ended March 31, 2021 and 2020, are unaudited. The balance sheet as of December 31, 2020 was derived from the audited financial statements as of and for the year ended December 31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of March 31, 2021, and the condensed results of its operations and its cash flows for the three months ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three months ended March 31, 2021 and 2020 are also unaudited. The condensed results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year ending December 31, 2021 or any other period.</div></div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the Company&#8217;s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to accruals for research and development expenses, valuation of equity awards, and valuation allowances for deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">coron<div style="display:inline;">a</div>virus&#160;(&#8220;COVID-19&#8221;)&#160;pandemic</div> will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">concerning&#160;COVID-19&#160;and</div> the actions taken to contain or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">treat&#160;COVID-19,&#160;as</div> well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents, and restricted cash are carried at fair value. Financial instruments, including accounts payable and accrued expenses are carried at cost, which approximates fair value given their short-term nature. Term loan payable is carried at cost, which approximates fair value as its effective interest rate approximates current market rates. </div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are comprised of short-term, highly-liquid investments with maturities of 90 days or less at the date of purchase. At March&#160;31, 2021 and December&#160;31, 2021, the Company&#8217;s cash equivalents consisted of money market funds. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash consists of a deposit securing a collateral letter of credit issued in connection with the Company&#8217;s facility operating lease. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands): </div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,919</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentrations of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to credit risk from holding its cash and cash equivalents at one commercial bank. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. Cash may consist of deposits held with banks that may at times exceed federally insured limits, however, exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the balance sheets. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Leases consist of the Company&#8217;s operating lease. In accordance with ASC 842, Leases, the Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company&#8217;s lease includes options to extend or terminate the lease. Periods covered by an option to extend the lease are included in the lease term when it is reasonably certain that the Company will exercise that option. Periods covered by an option to terminate the lease are included in the lease term when it is reasonably certain that the Company will not exercise that option. At the inception of the lease and as of March&#160;31, 2021, the Company was not reasonably certain that it will exercise its option to extend the lease and was not reasonably certain that it will not exercise its option to terminate the lease, therefore, the periods covered by the options are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company does not have material short-term lease costs. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For real estate leases, the Company does not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All research and development costs are expensed in the period incurred. Research and development expenses consist primarily of direct and indirect costs incurred in connection with the development of the Company&#8217;s ImmunoTAC technology platform, discovery efforts, and preclinical study and clinical trial activities related to the Company&#8217;s program pipeline, including the Company&#8217;s lead product candidate, SBT6050, and other pipeline programs, including SBT6290 and SBT8230. Direct costs include expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and other vendors that conduct the Company&#8217;s preclinical and clinical activities, expenses associated with manufacturing the Company&#8217;s product candidates including under agreements with contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other vendors, and consulting fees. Indirect costs include personnel-related expenses, consisting of employee salaries, bonuses, benefits, and stock-based compensation expense and recruiting costs for personnel engaged in research and development activities, facility and equipment related expenses, consisting of indirect and allocated expenses for rent, depreciation, and equipment maintenance, and other unallocated research and development expenses incurred in connection with the Company&#8217;s research and development programs, including laboratory materials and supplies and license fees. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to the Company&#8217;s research and development efforts and have no alternative future uses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are capitalized until such goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. The Company estimates the period over which such services will be performed and the level of effort to be expended in each period. If actual timing of performance or the level of effort varies from the estimate, the Company will adjust the amounts recorded accordingly. Since inception, the Company has not experienced any material differences between accrued or prepaid costs and actual costs. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The</div></div> cost of employee services received in exchange for an award of an equity instrument is measured at the grant date based on the award&#8217;s estimated fair value using the Black-Scholes option pricing model. The estimated fair value of the awards is recognized into expense on a straight-line basis over the requisite service period. Stock-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized, and any previously recognized compensation expense is reversed. Management evaluates when the achievement of a performance condition is probable based on the expected satisfaction of the performance condition at each reporting date. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. The option plan permits, but does not require, the inclusion of early exercise provisions in individual awards. Proceeds from early option exercises are recorded as a liability until the underlying restricted shares vest. While the restricted shares have voting rights, they are not considered outstanding for accounting purposes.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s comprehensive loss was equal to net loss for the three months ended March&#160;31, 2021 and 2020.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share Attributable to Common Stockholders </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities.&#160;Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since the effect of potentially dilutive securities is anti-dilutive given the net loss of the Company. For purposes of this calculation, redeemable convertible preferred stock, stock options, employee stock purchase rights, and unvested common stock subject to repurchase are considered to be common stock equivalents but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be antidilutive. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1)&#160;no longer an emerging growth company or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2016-13,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</div></div>. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January&#160;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy followed under emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413553240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value On Recurring Basis</a></td>
<td class="text">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets that sum to the amounts shown in the condensed statements of cash flows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/> 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash and cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,919</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200415095304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value On Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table identifies the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374,205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">386,369</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200415105752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,610</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,063</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee compensation and benefits</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,634</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services and other</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">523</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">581</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200414814952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Operating Lease Cost</a></td>
<td class="text">The components of lease expense and related cash flows were as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease expense</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">347</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">347</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">106</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total lease expense</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">453</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%; padding-bottom: 1.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">433</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.5pt;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash outflows from operating leases</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">421</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">397</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 74%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Commitments Due Under the Operating Lease Agreement</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Future minimum commitments due under the operating lease agreement as of March 31, 2021 are as follows (in thousands):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 (remaining 9 months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 0.75pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total undiscounted lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(297</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total present value of lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200415426520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock', window );">Summary of Common Shares Reserved for Future Issuance&#160;</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has reserved shares of common stock for the following potential future issuances: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying outstanding equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,308,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,316,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares available for future equity award grants</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,152,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,506,806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying early exercised equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%; padding-bottom: 0.45pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares underlying ESPP withholdings</div></div> </td>
<td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">19,126</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; width: 3%; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;">4,393</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,556,911</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,928,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413295320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Compensation Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="color: white; line-height: 0pt; visibility: hidden;">
<td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.45pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,925</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,285</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Related to Stock Option Grants</a></td>
<td class="text">A summary of the Company&#8217;s stock option activity for the three months ended March&#160;31, 2021 is as follows (in thousands, except share and per share data and years):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subject to</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Life (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intrinsic</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,316,569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">223,647</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101,960</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cance<div style="letter-spacing: 0px; top: 0px;;display:inline;">l</div>led</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,308,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">708,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.97</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 12pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The grant date fair value of stock options was estimated using a Black-Scholes option pricing model with the following weighted-average assumptions:</div></div>
<table cellpadding="0" cellspacing="0" style="margin-top: 0px; margin-bottom: 0px; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Three&#160;Months<br/> Ended</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31,</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.0</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;83%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;0.72%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom; width: 13%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;&#160;&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200415103256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following outstanding shares of potentially dilutive securities were excluded from the computation of the diluted net loss per share attributable to common stockholders for the periods presented because their effect would have been anti-dilutive: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable convertible preferred stock</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,191,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock options</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,308,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">550,176</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested common stock</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock warrants</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ESPP withholdings</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,126</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total potentially dilutive shares</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,404,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,756,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200494676840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (115,601)<span></span>
</td>
<td class="num">$ (96,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,205<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,903,497<span></span>
</td>
<td class="nump">34,801,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=sbtx_LiquidityAndCapitalResourcesMember', window );">Liquidity and Capital Resources [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,415,337<span></span>
</td>
<td class="nump">15,714,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="nump">$ 21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after deducting underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 255,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">13,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of preferred stock, common shares issued</a></td>
<td class="nump">20,758,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock outstanding</a></td>
<td class="nump">77,074,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=sbtx_LiquidityAndCapitalResourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=sbtx_LiquidityAndCapitalResourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200494609672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of  reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 374,205<span></span>
</td>
<td class="nump">$ 386,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash</a></td>
<td class="nump">374,555<span></span>
</td>
<td class="nump">386,919<span></span>
</td>
<td class="nump">$ 24,180<span></span>
</td>
<td class="nump">$ 10,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">374,205<span></span>
</td>
<td class="nump">386,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash</a></td>
<td class="nump">$ 374,555<span></span>
</td>
<td class="nump">$ 386,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200488374648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Recurring [Member] - Money Market Funds [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 374,205<span></span>
</td>
<td class="nump">$ 386,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200410849464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Fair Value, Recurring [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value,assets transfers from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value,assets transfers from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value, liabilities transfers from Level 1 to Level 2</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value, liabilities transfers from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair Value, assets transfers into (out of) Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200410879320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_AccruedResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">$ 2,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services and other</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,799<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200410939032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases -  Summary of Operating Lease Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413228536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021 (remaining 9 months)</a></td>
<td class="nump">$ 824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">3,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of lease payments</a></td>
<td class="nump">$ 2,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200413517208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease Weighted Average Remaining Lease Term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease Weighted Average Discount Rate</a></td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200415651896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan Payable - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember', window );">Term Loan [Member] | Silicon Valley Bank [Member] | Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember', window );">Term Loan [Member] | Silicon Valley Bank [Member] | Amended Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sbtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=sbtx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=sbtx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sbtx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sbtx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sbtx_AmendedLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sbtx_AmendedLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200494553736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future  Issuance&amp;#160; (Detail) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">9,556,911<span></span>
</td>
<td class="nump">7,928,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingOutstandingEquityAwardsMember', window );">Shares Underlying Outstanding Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">6,308,582<span></span>
</td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesAvailableForFutureEquityAwardGrantsMember', window );">Shares Available For Future Equity Award Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">3,152,910<span></span>
</td>
<td class="nump">1,506,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember', window );">Shares Underlying Early Exercised Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">76,293<span></span>
</td>
<td class="nump">100,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEsppWithholdingsMember', window );">Shares Underlying ESPP Withholdings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">19,126<span></span>
</td>
<td class="nump">4,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingOutstandingEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingOutstandingEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesAvailableForFutureEquityAwardGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesAvailableForFutureEquityAwardGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEsppWithholdingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sbtx_SharesUnderlyingEsppWithholdingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200416529288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Additional Information (Detail) - Redeemable Convertible Preferred Stock [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion to Redemption value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock</a></td>
<td class="nump">10,027,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember', window );">Redeemable Stock Excersible On Agreed Upon Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock</a></td>
<td class="nump">21,732,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock | $</a></td>
<td class="nump">$ 46,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember', window );">Series B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B redeemable convertible preferred stock</a></td>
<td class="nump">14,701,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash', window );">Issuance of Series B redeemable convertible preferred stock for cash</a></td>
<td class="nump">4,673,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes', window );">Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes</a></td>
<td class="nump">10,027,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B redeemable convertible preferred stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200496908408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,285<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,360<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200487841880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Options Outstanding, Beginning balance</a></td>
<td class="nump">6,316,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Subject to Options Outstanding, Granted</a></td>
<td class="nump">93,973<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Subject to Options Outstanding, Exercised</a></td>
<td class="num">(101,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Options Outstanding, Ending balance</a></td>
<td class="nump">6,308,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares Subject to Options Outstanding Vested, Ending balance</a></td>
<td class="nump">708,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 10.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
<td class="nump">48.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
<td class="nump">2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending balance</a></td>
<td class="nump">11.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Vested, Ending balance</a></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (Years)</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (Years), Vested</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="nump">$ 223,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">4,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">202,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested Ending balance</a></td>
<td class="nump">$ 25,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200520698056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.72%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200488245928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 59,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">3 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">9,564,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">6,308,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,404,001<span></span>
</td>
<td class="nump">8,756,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair Value of Shares Vested</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share Based Compensation Number of Options Granted</a></td>
<td class="nump">93,973<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Share Based Compensation Expected Dividend Yeild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares Available for Future Equity Award Grants</a></td>
<td class="nump">9,556,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,928,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 33.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares Available for Future Equity Award Grants</a></td>
<td class="nump">3,152,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember', window );">Unvested Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">76,293<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200411009368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing Agreement - Additional Information (Details) - WuXi Bio [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones', window );">Aggregate milestone payments upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_AgreementPaymentAndLicenseTermDesciption', window );">Agreement payment and license Term desciption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event the Company fails to pay all amounts due to WuXi Bio under the license agreement, and fails to pay the amounts within 30 days after receiving written notice of such failure, WuXi Bio may terminate the license with 45 days written notice to the Company.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sbtx_LicenseFeesPaid', window );">License Fees paid</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_AgreementPaymentAndLicenseTermDesciption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement payment and license Term desciption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_AgreementPaymentAndLicenseTermDesciption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sbtx_LicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sbtx_LicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sbtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sbtx_WuxiBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sbtx_WuxiBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140200416558360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">6,404,001<span></span>
</td>
<td class="nump">8,756,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,191,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">6,308,582<span></span>
</td>
<td class="nump">550,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember', window );">Unvested Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">76,293<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_EsppWithholdingsMember', window );">ESPP withholdings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares</a></td>
<td class="nump">19,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_UnvestedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_EsppWithholdingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=sbtx_EsppWithholdingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MIVX?5+</TF]TAX:$Y#O*Y)($B![W"[ @]VE1I,6]G/ 9+F("L)"IQ9? @1<
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MD=&(26, O^\%1+EZ,0O4E]CK_P!02P,$%     @ FX*M4@VS-[-;"   "!,
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MT'!11VE8XZ7)7C;@^\JYN)O( </;=?$O4$L#!!0    ( )N"K5*.S! Y8@4
M ",,   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*U7VV[;1A!]]U<L
MU*(7@)!XD2@IM0W828KF(841I^U#T8<5.1*W67*9W:45Y^M[9DDQ=.,8#= 7
M<Y>:.7,Y,\/Q^='8=ZXB\N)#K1MW,:N\;Y\M%JZHJ)9N;EIJ\,O>V%IZ7.UA
MX5I+L@Q*M5ZD<9PO:JF:V>5Y>'=C+\]-Y[5JZ,8*U]6UM/?7I,WQ8I;,3B_>
MJ$/E^<7B\KR5![HE_UM[8W%;C"BEJJEQRC3"TOYB=I4\NUZR?!#X7='13<Z"
M(]D9\XXOK\J+6<P.D:;",X+$XXZ>D]8,!#?>#YBST20K3L\G])]#[(AE)QT]
M-_H/5?KJ8K:9B9+VLM/^C3G^0D,\*\8KC';AKSCVLMEZ)HK.>5,/RO"@5DW_
ME!^&/$P4-O$7%-)!(0U^]X:"ER^DEY?GUAR%96F@\2&$&K3AG&J8E%MO\:N"
MGK^\]:9X5QE=DG7?BY?O.^7OQ0\O:*\*Y7\\7WC88,E%,>!=]WCI%_ R\=HT
MOG+B95-2^5!_ =]&!].3@]?IDX"OI9V++(E$&J?)$WC9&' 6\+*O"?A7XTG\
M>;5SWJ),_GK"S'(TLPQFEO];7I_&6\_%%/*[;S9ILO[I,V#QADI"V^XTB>>F
MN2/K%9]O4.MD+94]"N[*6.&-4-Z)(@B&-L.;PM0U3B[(J4:\H(+J'5DF((Z$
MKQBY;F5S/SCAT)RCT6)BM!V-]F!'"5M:.J?V"B]QJ^GC1]D@5$%](.S"(P9V
M4LNF(!'JW+$F2[E*6L+-!K->-0=JO+Z?NM.UW/F"[["H%:R4,HP#UQ45 TE1
M5!*:'"JC6+2@;$J^^DIZ07< #6'#C'*B,>+022L;3]1+2*W[  =N,(<Z78H=
M@H)37L,PTFJ11LR?WG%9D^"!*LR>C3H%O>#6'*6(2558\@,='$S=AMN=U!V%
M+ +,6/27*#N+L .HKRP\JOON(^X^@=Y!D$/SQ'VTCZ0BA!AP&^-'?R#46K/C
M-,[%JV8 ^ZP(D!/703991NLXB>+5\L0+8N/JNB6K<+O^CU42(?.%[DH.:QGE
MZRS*-IL3Y& KL#JI6EB"1WAVWGF0Q[I3$PB+ZP2L<FH908$^ ()8?IO$49RN
MHSS/_V4('(E".A0*:!9MAPS@"P"7%8H15K]-YTDN6C1'T(L0H\/G@.VC?@[6
M.,=)+(A*U\LG\Q7&N-:!Z[=(XYB>$5T>+',$2J!ZIYC(4&?3I/<E%KSL0_!3
MJ(>%> )F02'+4C'I4HLTB=99&FWR=,+88]WWE0PBR2%P?S0"\[3!'N%")N4!
MD1VDIX<Y6>;S[2DG?=O14)(A[ )FL%ST:1FXAS3(,PV C]R7LJ@45$K!0ZV:
M>E3+OXWER2);SF;()2FPJHT#37-Q%9QXV"FAP,'$OO.=G>1UC*949>B5FM<F
M-H@]0#4AL8RVAZ=C(:H&7Y6.^70G]QY*@RIU)WDY<<.<0;(H'._[\-@4*M=T
MJ-J^*!VUF$&>,.UPVZD].,:UG#-Y/+[[,?]V4C)5F!N.+"?A$^$/QOU^<'!O
M-+8U]KY%ZV"*H5R&9'#-\2QVS\X^)6W\1N!RQA_JD,:SV]Y*AV%D]3W#33MT
M&/GR*"TJ(8^R>!.M-BF?DCQ:Y=N3OKR32H>J8_\&/Z;:Z#3)Z<VB9)5&VR06
M2;2*\V@3YX_X0!('01_(%LHA%P_]6.=1NLTP$N(HS;-'U%_>WMQ@2?,5=QE>
M.)%LHR3-,:VR;7;VUG@D:QNM5CD\2<0ZVJ:;*,X>W5T6D\6M)GL(ZRE_D,%T
MO\.-;\<-^*I?_#Z)]^LSR#B@U(2F/53C^7HU$[9?2?N+-VU8 W?&8ZD,QPI;
M/%D6P.][ ZJ'"QL8_R^X_ =02P,$%     @ FX*M4O2+M\=L!0  Z@L  !D
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M!IUHPO8'XY8G%+Z47F)64S3S#'SV03;EV/$<<2Y$L?G]MTG4'[^Q#;6R2 @
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MEQD]QM&P )TOM';-!SO8/>_/_P502P,$%     @ FX*M4@&:B]O< P  BPD
M !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULI59M;]LV$/XKA#<,+>!:
MMNQL:6L;B+,-+;9B0;NN X9]H*631(0B-9**XG^_YRC;45K'6+$ODJB[>^ZY
M%QZY[*R[]151$/>U-GXUJD)H7B6)SRJJI9_8A@PDA76U#%BZ,O&-(YE'HUHG
MZ73Z?5)+94;K9?QWX]9+VP:M#-TXX=NZEFZW(6V[U6@V.OQXK\HJ\(]DO6QD
M21\H?&QN'%;)$257-1FOK!&.BM7H:O9JLV#]J/"'HLX/O@5'LK7VEA=O\]5H
MRH1(4Q880>)U1]>D-0.!QC][S-'1)1L.OP_H/\?8$<M6>KJV^I/*0[4:78Y$
M3H5L=7AONS>TC^>"\3*K?7R*KM>=PV/6^F#KO3'6M3+]6][O\S PN)P^89#N
M#=+(NW<46?XH@UPOG>V$8VV@\4<,-5J#G#)<E _!0:I@%]:_JHPS;$IQ53HB
MI#LLDP!@%B?9'F33@Z1/@,S%.VM"Y<5/)J?\L7T"0D=6Z8'5)CT+^$ZZB9C/
MQB*=IK,S>/-CE/.(-__O48J_KK8^.'3%WV<<+(X.%M'!XO^E\3S(RXDX191;
M%@)#>RD-9)T*E?C4_JG$1EEM2Y5Y\>R-A?TO>#R'1:T"Y>*M$;]EP6[)(:6S
MEV,1*A+7MFZDV0D D8.2,L$**3+VQ]SPZ/W)K_;W[+MO+M-T^OJ@&I>SU\\G
MXB-:Q$7W7Z"/C\BB=-(PSI"F%,::%W2?Z=9C)X_%K;'=BPJ%0G2L2'=,<6A2
M2],6*''KR L5O,AL79/+E-080TVC%?[; M"-LWF;A?T;GK>[B+1/>3ZH0AOK
M(X?@3E@H<UC2/ 1A7?0IBT)I)0/YQVGO%!"W!$HD[%:K4L:(K6CD[@%$ED@/
MB[#[-6$>@ $4.%_ :YLXV2J%V&.!$$Q&+F :"R^A_V %;0C;ACU\.YM.+EFD
M,1DGXO<!JTKZR-+Q.&-=] ;F#A,8%@WI*=5=3$00FJ0/PJM[4?=SH'$*P7=.
MA4 &90NP8JR'J$S.441[9$'6MD4\(F^C&AS5>#C;EE7T>N# <SP'E<G3)2^D
MTOZ0Q1/81PKMN49D?H^06.^ Q)L ^9U/P67']04]'% 9]0GY+&PDW;=9%>'0
M*H,FKQGW9';C-EM<]/A?IG$0[V>9(!7[L)$N[&*SQP:$)_CAIM_BX :7$[$/
M \[ ,TKWZE\7<.%L':WM@,LA"SWB^#'1IQ.AL%USWCMZU_?ZZ60,/$U.3?-D
M<$!B_Y?Q&L#3 /7LS\KCW^--XZH_8!_4^VL*CJ92&8^>+V ZG?QP,>KWRF$1
M;!./VZT-.+SC9X7;$CE6@+RP-AP6[.!X_UK_"U!+ P04    " ";@JU2^I11
M+=0$  "?"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM5DUSVS80
M_2L[ZDQ/CK[L-&YJ>\8?S30SS=23M.FATP-(+D4T(,  H&7]^[X%*$JR'1TZ
MO4@@N/MV]^W#$A=KY[^$ACG28VMLN)PT,79O9[-0-MRJ,'4=6[RIG6]5Q*-?
MS4+G657)J36SY7S^PZQ5VDZN+M+>O;^Z<'TTVO*]I]"WK?*;&S9N?3E93+8;
M'_6JB;(QN[KHU(H_<?RCN_=XFHTHE6[9!NTL>:XO)]>+MS=G8I\,/FM>A[TU
M226%<U_DX7UU.9E+0FRXC(*@\/? MVR, "&-KP/F9 PICOOK+?J[5#MJ*53@
M6V?^U%5L+B?G$ZJX5KV)']WZ%Q[J>2UXI3,A_=(ZV[Y>3JCL0W3MX(P,6FWS
MOWH<>-AS.)]_PV$Y."Q3WCE0RO).175UX=V:O%@#31:IU.2-Y+25IGR*'F\U
M_.+5K6M;'<%R#*1L1;?.1FU7;$O-X6(6$4(,9^4 =Y/AEM^ .Z4/ &@"_6PK
MK@[]9TAMS&^YS>]F>13P@_)3.EV<T'*^7!S!.QWK/4UXI_^E7KK3H30N])[I
MK^LB1 _1_'TDZMD8]2Q%/?N_6#X.MYA/Z7@AO_)*&;KWKF2NL!WHG7<M19PG
MBB[]GU!L6& Z93>0U(8:]<!4LH\XRU1N\2(9K0IM=!3@V*A(RNO !"-!<!X!
M<)[AT7MLNYHT<BKZ@*Q#R.<N.4_I][V(JBQ]#T0UXF\(0P;CH6R03HSL ZT;
MMH C':CSKE"%X9Q"W4?I$C]B.E5:UC#6QE#!<*XX<5(J*\\85L%9^&Z( TI7
MD:LI?=(KJVL-FTC_]-5*J)0XGK_VVG,E/%6,+'#JF H7FR&%G*K@2_DC(JG6
M]39.Z3VDWV9H&3P!&]\B:DO282^0B-2N+3)0*\^<NYSJECYI6YJ^D@8<!)+T
M'K1,2S!]CQ"]E :,Q.@.Z'GCMT";$VJ<J2 $WYJ4EE2)&0>.L=P%1+6=\D/#
M<& "V ]]7;/PABUDV'M9%YL4[)DCZ'=MHD!>[Q+//30:TM[BBEP;![Y$=5 D
MU4G)C?;;)%0:\$&8IR"P)<;T4.93CA)^UG8/R!I,)[O<YVPS9#4REG6+H:O;
MOJ7.1>QI'*_<<#$?U-BIS;95.X+1;5":9+@35JN^,/7(+44/!Q1 @];%47NB
M^<.3TRA8\ /O\2P*]))3Z4(,6;JI:T:M0R_G44X6QXCS4QJE6]&Y2;)-_'(X
M+J>GX9-$X9PT^M1Q3[-KC6,CX2M47D;G\[!R-8Q%XZ.F!W(.F-N#WAP#42L,
MK/#"G!+@/*N*S3 %AN9JL!%5[ =>_ .02.U'P/XNRT01NFQP*B*&CBB .FE/
MC%GE=V!SK5! Z7SG/)@5Z@^)2[VRT60*QU#??W>^7+SYZ:"F[1[JZKVRI>"B
MX;@FY<K ?5^B3&$%,S!_L@2 DU["4QX12OPQ;)'<5N3R;E!NEC*&K-+58=(%
M&PVMA2?#KE:@\$&9?GN(7Q#0G@[PK>#'4CX'$K?K#&QDEK]0'^0/U2.,P4?N
MM\_O[UXM?DP9K0RFK]GM/5]89U\953Q_\](G?+9W:6K9K]+5,,AQM3'?G\;=
M\?9YG2]=._-\=<4E985*R' -U_GTS>L)^7P=S _1=>D*AJ\(+G1IV> &S5X,
M\+YV&"K#@P08[^17_P)02P,$%     @ FX*M4NPHJ8F\ @  [ 4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&ULI53;;MLP#/T5P@.&#0CBV$DOVY(
M3=MA?2@6).OV,.Q!L9E8J"RY$MTT?S]*=MQT6(,!>TBL"WEX#BERO#7VWA6(
M!$^ETFX2%435QSAV68&E<'U3H>:;M;&E(-[:3>PJBR(/3J6*T\'@-"Z%U-%T
M',[F=CHV-2FI<6[!U64I[&Z&RFPG41+M#Q9R4Y _B*?C2FQPB717S2WOX@XE
MER5J)XT&B^M)=)%\G(V\?3#X+G'K#M;@E:R,N?>;FWP2#3PA5)B11Q#\><1+
M5,H#,8V'%C/J0GK'P_4>_7/0SEI6PN&E43]D3L4D.H\@Q[6H%2W,]@NV>DX\
M7F:4"_^P;6T'$62U(U.VSLR@E+KYBJ<V#__BD+8.:>#=! HLKP2)Z=B:+5AO
MS6A^$:0&;R8GM2_*DBS?2O:CZ759*;-#A!EJ7$N"N1+:C6-B;&\19RW.K,%)
M7\$9PJW15#BXUCGF+_UCYM012_?$9NE1P%MA^S!,>I .TN0(WK 3.@QXPU?P
MKEB=QORE3A ZAZ]4H(6Y<621I$5^<O2'V95TF3*NMNC@Y\6*+?DU_3K":M2Q
M&@56H_]._W&<!!+X5B!<FK(2>@>^'8E_K! .5%6,WH-M(;,"I(.'6BBYEIR5
MFJO&K=JVRFB0O+M_#V8-G!JXT816"P4+?$1=^R Y^LODP_EI#P3'8'"N>@]X
M2 27EL;;-^=I<O;)P5U_V0=LM;I^H.JY@% \%1R@DANY4OAL V1\<Z'E !0P
M]U<=:,Y%\=H,2^*!1.(),H[+ T,$%77E08*"Q9(KK5DM*%E*:AGLDY4;CJ<-
M<=:($Y/Q0[9R57L0QV<L=K4[8/^WLL<''5BBW80YXQBJUM0T8W?:C;*+IH.?
MS9LYR ]_XPNG<,VN@_[9202VF2W-ADP5^GEEB*=#6!8\CM%Z [Y?&T/[C0_0
M#?CI;U!+ P04    " ";@JU2>7/!(R,#  #D!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6RU54UOXS80O?M7#+1 3VKT8<MQLK:!)$W1!;J%$6>[
MA\4>:&ED$:%(E1RML_^^0\I6G4630X%>["$Y\^;-</BT/!C[Y!I$@N=6:;>*
M&J+N.DE<V6 KW(7I4/-);6PKB)=VG[C.HJA"4*N2/$WG22NDCM;+L+>QZZ7I
M24F-&PNN;UMAO]^B,H=5E$6GC0>Y;\AO).ME)_:X1?K4;2RODA&EDBUJ)XT&
MB_4JNLFN;V?>/SC\*?'@SFSPE>R,>?*+#]4J2CTA5%B21Q#\]PWO4"D/Q#3^
M.F)&8TH?>&Z?T'\-M7,M.^'PSJC/LJ)F%2TBJ+ 6O:('<_@-C_44'J\TRH5?
M. R^11%!V3LR[3&8&;12#__B^=B'LX!%^DI ?@S( ^\A46#YBR"Q7EIS .N]
M&<T;H=00S>2D]I>R)<NGDN-H_0??^^_&.=B@A6TC+,(-D96[GL1.(9"!.].V
MW+\MF?*I,:I"ZY8)<6Z/D)3'/+=#GOR5/%/X:#0U#NYUA=7+^(0YC\3S$_';
M_$W C\)>P#2+(4_S[ V\Z=B(:<";OH)W+ZR6>G_>B"\W.T>6Y^;K&_BS$7\6
M\&?_>Z/?SI/E%_#?<L%C@U ;Q>^4&P'\@AT)77G;>0P'IH;.$&J20JGO4$G5
M^S<%#LO>2I+L<D!.AL^EZOF:H;:F!6+8TK0=)P\/D5'\5HAF'\UDE2?;,=F0
M",0/9,N!K#LGRWH48#A*FHJCF2 S8\ =EJ)WZ$^E!:QK%@#6AEY5T AFNT-D
M-> B?CX5<#UY;"SBBQ$%'K"R\1,V\1/FQRR=/&"%+(J>5FGT-[0DO<VY:[26
M@P)%^.G=(L_R]["(LZLL+A;IY.ZL C"=[X.#>3Q-%WR<0U&D<78YGWQB3.=K
M.*\8+N=Q?C6%(DZOBI=(!V$M5^+&C%=Q5LPF]]O-AG6$&M^L,-09'^3SD]OD
MT9!0K]SE<-7S>);.XC3-N(C+8LY6\6^/(#E3GA;M/NBK8_J]ID&$QMU1PF\&
MY?K'?=!_[O=><E<4UAR:7ERR8MI!4X<%F2[HV,X0JV(P&_X,H?4.?%X;KN>X
M\ G&#]OZ;U!+ P04    " ";@JU246ZK$)@0   I,P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6RU6UMO&[D5?M]?0;A%D0#R17+L7#8)8#M)Z\5N
M-XB2+8JB#]0,)7$S0TY)CA7UU_<[AYR+E-'82=N'Q-(,>7AXSG>NI%YNK/OL
MUTH%\:4LC']UM ZA>G%ZZK.U*J4_L94R>+.TKI0!7]WJU%=.R9PGE<7I[.SL
M\K24VAR]?LG/WKO7+VT="FW4>R=\79;2;:]583>OCJ9'S8,/>K4.].#T]<M*
MKM1<A4_5>X=OIRV57)?*>&V-<&KYZNAJ^N)Z>DD3>,1O6FU\[[.@K2RL_4Q?
M;O-71V?$D2I4%HB$Q)\[=:.*@BB!CW\EHD?MFC2Q_[FA_HXWC\TLI%<WMOB;
MSL/ZU=&S(Y&KI:R+\,%N_J+2ABZ(7F8+S_^+31Q[@<%9[8,MTV1P4&H3_\HO
M21"]"<_.#DR8I0DSYCLNQ%R^D4&^?NGL1C@:#6KT@;?*L\&<-J25>7!XJS$O
MO)Y';0B[%'.],GJI,VF"N,HR6YN@S4J\MX7.M/+B$7]2_O'+TX"5:?YIEE:Y
MCJO,#JQR+GZQ)JR]>&MRE>_./P7'+=NSANWKV2C!7Z0[$>?3B9B=S:8C],Y;
M,9PSO?,#](;V^X^KA0\.L/GGR )/V@6>\ )/#BQP+;WV).7W3GEE@B1,#@GR
M.\B(CVLEEMI(DVE9"(^G"H83O%C+.R462AD!DZVD4[G01F36D#GKL 78PEI\
M.IF?B)4RRLFBV,)0,E4%#)6=4"JG0;PJ" 9_^L.SV>SL1Y[UYZNK]_Q]^N/C
M$W%EMF2IRBF3*5HIK,&E,#9@7K!"5A5D*Q>%$JM:YY)'>5$J@AS>\USZ@'E"
MUF%MG:8M8A/M:D)ZL01;>:+?A^H\2)-+EWMQ8W.&,HNGX?AJ?M/P.A$8.3SU
M4Y5#?KU)G[I)$#PM^:Z5]2"%:XL_+8%W5_/K3D2?C*QS3=*]-4$Y78)5V(3Q
M>-*1G7<J)-V2(LI*FBVMD[7C%[)@$4;W+1D7,(QLW5I&W&8WHP<-C(5K=RPA
MGX:50,F:/"X$7ECO)P>G9M*OQ1(NW8\O <0IA!'2.(;<*1<T?:Y8TXZ'V^PS
MD^!/:UODRGF2U_3ICT+]JR:4/H*;A4V&Q]"\8PV$M5-*E-&I*'(J>SMGDOAP
M!OZ<$G4C]A,6Z)#DWJA,E0O@+Y$X$QN\ #>01BZ6SI8)EE%]@_86*='2#:-;
M)5UB\*L%(B\M:P!T1$0GS(<:-84W"DXP)DS&GX"1T;C[/$MC:M#Z'[#.6I\T
M)F@K;<C00*"4!L&<2$[(G"GX"G@5(?/?$<QXJ4G#(Z'9VT(5''X,!=D"D[+:
M.7JU,\6  ^\I4C7L+:5V)('.#2;KO(FVDC#D>]NMK-<Q%SAH*T2@DS^H([KS
M8$U_=@V&'G6&\!W8/-GSW' \DE]:T'&0;LRZB.-<^PPFJ?)]M^I4(4FWR6L^
M?'&V"UEXNV\<@]OO;?T;]NF8RU9Y&IK6)F>_# PG?36K8 <+)=27"IA1'0R7
M->#38)%PL0_&J<!(*#Q)#8QJFY^,Q.R+-F9?C ;;3YYY? ND0@O*#X7K;Z/
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M>M;JZ]FHOCYTQD,"'-+2-Q$0'_:L,6TBNFN$+LYWA:>,F@T. PJ*H*CS(=R
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ML$.&8(51L9GQ/4?78]KI+D5-QZ\S_14,L#C?8ROS-3FGJX"T>E''OB%XQ)[
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M_BXC?@FVXM]"+&P(MN2/:R7A&6D WB\MTH3TA19H?QWS^C]02P,$%     @
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MTNFC-Y,I'8&"64PA82:'C$Z3@25JVC.0J<*O=[D$FZO*D+W9.^[<YAIQHT!
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M,Z=K$;4SH/U,*;M:.(+VHIW^ U!+ P04    " ";@JU2C?3M0/H"   H!@
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M5C-I#61ADJ?A+(DA"?.X"*=Q<4(#,C( GU&7W-!=O-9Q483I+(,DCL.TR$[
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M[ %\OY+2O&[L(-M^2\W^!5!+ P04    " ";@JU2.L7)YN,"  "+"0  &0
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MU,C52&6\W;0E>&H(@C,$+U0.2.A_(8$7^#WRR67Y%-).[GV6NUB+KB!!5Y#
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ML,"/!4@3@.NY$/IC8OI1]_E)_@%02P,$%     @ FX*M4E&PX<N8 @  #0<
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M9:G?*Q#&0-\7G*OMQCCH7L#T/U!+ P04    " ";@JU2HZ2Q?)$"   O!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R-55M/VS 4_BM'$0\@%=*Z
MEQ341@(JM$F@512VAVD/;G/:>/B2V4X+_WZV$Z("*=M+X\LYW\7V.9WLE'XR
M.:*%9\&EF4:YM<5%')M5CH*:,U6@=#MKI06U;JHWL2DTTBPD"1Z3;G<4"\ID
ME$["VERG$U5:SB3.-9A2"*I?KI"KW33J1:\+]VR36[\0IY.";G"!]K&8:S>+
M&Y2,"92&*0D:U]/HLG=QE?CX$/"=X<[LC<$[62KUY"=?LVG4]8*0X\IZ!.H^
M6[Q&SCV0D_&GQHP:2I^X/WY%OPG>G9<E-7BM^ ^6V7P:C2/(<$U+;N_5[@O6
M?H8>;Z6X";^PJV.[$:Q*8Y6HDYT"P63UI<_U.>PED-Z!!%(GD*"[(@HJ9]32
M=*+5#K2/=FA^$*R&;">.27\I"ZO=+G-Y-KU%9\G *2RJ6P&UAIO2EAKACDDF
M2@'72@AFW458 [,2X5%FJ.%;@9I:)C<0(.!RHQ%]$,#Q#"UE_ 2.@$EXR%5I
MJ,S,)+9.L*>-5[6XJTH<.2#NCNHSZ/<Z0+JD][B8P?'1R5N4V-EM/)/&,PFP
M_8.>C4'LO+?0@5M&EXPS^]*!.7WQ9CK!\<_+I;':/:!?G[#W&_9^8!\<8/=>
MX%BCKQC/?0Y"29N;D[;SJ:!& <K7US8=D\$DWK;P#QK^P;_X21M5E37<HR*#
MX0&N8<,U_)3K05G*H909,RM52HL9\/!:BNIX6]_$\(.0/DG&[4)&C9#1IT+F
M&HU_FUO*W7W2[+>K+"^@C7_T@?^4G"?M_$G#G_S'011O5+A*^_=A)!\> #D?
M]]Z)B??JW[=25S<;)HV#7[NT[EGBS.BJ/543JXK0$I;*N@83AKGKZ*A]@-M?
M*V5?)[[+-/\1Z5]02P,$%     @ FX*M4GZ=UX@& @  H@0  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&ULI53;CM,P$/V5420DD*"YM(5JE49JMT*L
M!*+J ON >'"3:6*M+\&>;K=_C^UD0Y':OO"2>.PYQ^=XQLX/VCS:!I'@60IE
MYU%#U-[$L2T;E,R.=(O*K>RTD8Q<:.K8M@99%4!2Q%F2O(\EXRHJ\C"W-D6N
M]R2XPK4!NY>2F>,2A3[,HS1ZF=CPNB$_$1=YRVJ\1_K>KHV+XH&EXA*5Y5J!
MP=T\6J0WRXG/#PD_.![LR1B\DZW6CSZXJ^91X@6AP)(\ W._)[Q%(3R1D_&[
MYXR&+3WP=/S"_C%X=UZVS.*M%@^\HF8>S2*H<,?V@C;Z\ E[/U//5VIAPQ<.
M7>YT$D&YMZ1E#W8*)%?=GSWWYW "R"X!LAZ0!=W=1D'EBA$K<J,/8'RV8_.#
M8#6@G3BN?%'NR;A5[G!4?$9GR<([6%05]^?$!-RIKMC^U%ZOD!@7;_*8W&X>
M$Y<]\[)CSBXP?V%F!./T+61)EOX+CYW(06DV*,T"W_BZTI^+K27CBOGK"N=X
MX!P'SLD%SJ\M&N=3U1#8X2$4$2M8/+F%&F&#OK'_)GQ#(\\=Q?5M4C@B,S #
MJ14U%M(,*G:T5PQ,!@.3_S.PXK;4>T6P883GE%_GGXVFR:MS.N.3EO.WUU6[
MYLJ"P)TC2D8?IA&8[D9T >DV=.%6D^OI,&S<(X+&)[CUG=;T$OC&'IZEX@]0
M2P,$%     @ FX*M4J/?7EEP P  (0P  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&ULM5?;CM,P$'V&K[ BD$""39RTW8O:2KTA5MI%*\KE ?'@)M/6
M6L<NMM-N)3X>VTG3PJ;N2L!+$SMSSLP<V^-I=R/DO5H":/20,ZYZP5+KU548
MJG0).5%G8@7<?)D+F1-MAG(1JI4$DCE0SL(XBCIA3B@/^ETW=R?[75%H1CG<
M2:2*/"=R.P0F-KT ![N)CW2QU'8B['=79 %3T)]7=]*,PIHEHSEP105'$N:]
M8("O)KAM <[B"X6-.GA'-I69$/=V<)WU@LA&! Q2;2F(>:QA!(Q9)A/'CXHT
MJ'U:X.'[COV=2]XD,R,*1H)]I9E>]H*+ &4P)P73'\7F/50)N0!3P93[19O*
M-@I06B@M\@IL(L@I+Y_DH1+B &!XF@%Q!8B?"D@J0/)40*L"M/X$M(X VA7
MI1Z6N3OAQD23?E>*#9+6VK#9%Z>^0QN]*+<;9:JE^4H-3O<_@<S1C2 <W9$M
MF3% ;]$@RZA=1<+0-2_WHEW35V/0A++7QN+S=(Q>O7B-7B#*T:>E*!3AF>J&
MVD1D><.T\CXLO<='O&-T*[A>*C3A&60-^+$?GWCPH5&BEB/>R3&,O82#E3Q#
M2?0&Q5$<-<0S\L,_B/4.CCM-Z?CAM\1ZQ\X[;H!/G@Z//&(D]=Y('%]RA&\,
M,VUV@-*R,*5!HV\WQ@!=:\C5=P]]JZ9O.?J6CYXJ51"> DJ%TDT[:%R2=!R)
M+7OKOI%F?:C*8PN;_KHAM'8=6ML;VOY4?+N%? ;R._J)II31U)R#+X0QV*(A
MX?>'GYVY.09H"FDAJ=ZBP4("E,I59A[5.G5HG?^Q*.<U_?GIS)E)I6GSGS\2
M.FE'1Z2^J!U>>!T.."]<H=$@06DDB88FWWX6?';>?NE)_[*.YO(?[,G1Y6,A
MCNF HWTECKR^)_,YN&O3%%6_&.,33.TSW/*I@0]N!^QEJI=E\F!:$]4<#'Y\
M0@_4*,_H":/?PXOWX<7>\&Z)+H]:=F37G,"[>HW?/'_V[$3)Q/N:B9-_7CH&
MYB2;^^MO2PC>5U[<^A]%!._K)_87T%,+,SR)W];K@ILB"@]:GASDPO6:RIS8
M@NORAJMGZWYVX+JX/^:'^&J$&^;'MO]U+=:>OFR>S36[H%PA!G/C*C*5)T"R
M[$?+@18KUW#-A#;MFWM=FAX>I#4PW^="Z-W .JC_%?1_ 5!+ P04    " ";
M@JU2,:U2?AP#  !3"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RU
MEFM/VS 4AO^*E4F[2!NQDR8TT%:" AO2T"HZQ@>T#VYRVE@X<6<[+?S[V6Y(
M2V\")+ZTOISW]?$3Y\2=N9#W*@?0Z*'@I>IZN=;3(]]7:0X%50=B"J69&0M9
M4&VZ<N*KJ02:.5'!_0#CV"\H*[U>QXT-9*\C*LU9"0.)5%445#Z> A?SKD>\
MIX%K-LFU'?![G2F=P!#TS70@3<]O7#)60*F8*)&$<=<[(4=]$EF!B_C#8*Y6
MVLAN923$O>U<9ET/VXR 0ZJM!35_,^@#Y];)Y/&O-O6:-:UPM?WD?N$V;S8S
MH@KZ@M^R3.==K^VA#,:TXOI:S'] O2&78"JX<K]H7L=B#Z65TJ*HQ2:#@I6+
M?_I0@U@1D-8.05 +@I<*PEH0NHTN,G/;.J.:]CI2S)&TT<;--AP;IS:[8:5]
MC$,MS2PS.MT;:I'>YX)G(-4G=/ZO8OH1?3Z#,4N9_H*^H>'B^2(Q1GU1%(;\
M,*<2%+H&!7(&&3)G"5U4NI* T*52%2U3^$B+Z?$'$N-C:Z8IX]9+.67'UR9Q
MN[R?UDF>+I(,=B1Y1>4!"LE7%." ;)'W]\O/(&WD^+G<-[@:9D'#+'!^X0Z_
M/J=*62 .'KK[:>;1I89"_=WC'C;NH7-O[7#_+33EVQ@M9)&3V;=SUDNB*$Z(
M(3);A;$9=Y@$;1PNXY[EU6KR:NW-JW[L-Z4Y*OR1E1/TJ])*TS*S[?KDG,RI
MS!2ZNX)B!'(?CJA9-GH'V''C'K\-=KP!,0YQ.VH':["WQ9'8/);ML ^;O Y?
M OMD9MX<.N* +I8OV2IJ]%W24K\(>+M9NOT.P)/&/7D;\&0#9$BB("%X#?AF
M'(EPW,;Q=N $+PLA?N7Y/J>F@<X?0*9,F4+WZC-.5JHP>0?H9%FQ2/ V[+7N
M6;6(@R1<H[XEC& <Q.$.ZLMB1_97NRW4AX,!NF4ZMU\E,_ RTLLJ1EKO07I9
MKDCT1M+1)L*$!/$ZZ<VP5IBL<_97OOCVNF6^D!-6*L1A;&3XX-#HY>(&L^AH
M,767@)'0YDKAFKFY]8&T 69^+(1^ZMA[17./[/T'4$L#!!0    ( )N"K5+$
M]<\"BP,  #$+   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+U6;6_B
M1A#^*R,K4N^D-'X#0TZ !$FJ1FI4%)KKA^H^+/: 5[%WN=TUY*3^^,ZNP3@7
ML%I5N2^PNYZ79YZ9G9W13JIGG2,:>"D+H<=>;LSFD^_K-,>2Z2NY04%?5E*5
MS-!6K7V]4<@RIU06?A0$B5\R+KS)R)W-U60D*U-P@7,%NBI+IK[-L)"[L1=Z
MAX-'OLZ-/? GHPU;XP+-TV:N:.<W5C)>HM!<"E"X&GO3\-,L[%L%)_&9XTZW
MUF!#64KY;#?WV=@++"(L,#76!*._+=Y@45A+A./KWJC7^+2*[?7!^B\N> IF
MR33>R.)/GIE\[ T]R'#%JL(\RMVON _( 4QEH=TO[/:R@0=II8TL]\J$H.2B
M_F<O>R):"O'@C$*T5X@<[MJ10WG+#)N,E-R!LM)DS2Y<J$Z;P'%AL[(PBKYR
MTC.3A9'I<RZ+#)7^">Z^5MQ\@P^WN.(I-Q_A9YAF&;?\L0+N15T%EDT2,8P7
M5N(1,Z12618(-U)L41ENUW.B%Y7"#)P/^.L!RR6J+W !/NB<*=3 !3P);O0E
M'=+ZCUQ6FHE,CWQ#L5F$?KJ/8U;'$9V)(X8'*4RNX4YDF+W6]XF3AICH0,PL
MZC3XP-05Q.$E1$$4/"UNX</%QR/R^K?#3=SP'SLW\1DW-P73&N3J0-)O]!WN
M#9;Z2X?U7F.]YZSWSEB?IJE"ER\C79[*C=MM65$A_ T7IXBN32;.I+W4VTDP
M\K<G4/0;%/U.%/=:5TRDZ,)$Q2GQ,[K13=6DK:K9-%6C+2&G\-7.^BU\81!$
M@R1)3L-,&IA))\Q6'=?)N'M)Z58X6+\+F*X5$JRG#?'WP LD?((B.91U1[8&
M#8#!.]3"L+$^_)%9&+[)0A0.XFB81*>S<-W O.Z$.5<R)9XUK)0LH0VZJ[F<
M*>7K-Z7<2ZZ#,^4<!L>>&71B;.C[%\D/6YTX?(?TA]'1?O0C"V#O[=4][ V"
M,.CWSO![[(EA_%Y(@9XH2)G.3T*.WT#N)8,X'@[/(#[VV;"[T?X?Q)7M*+6
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M"(X)4P/D]P6EXNU%35#]Y3#Z 5!+ P04    " ";@JU2RW#=$Z "  "+!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R-55%OVC 0_BNG2),Z:9 0
M6J@J0(*6;GNHALK::9KV8)(CL7#LS#90_OW.3LB8!%%?$I]]]]UWWSF7T5[I
MC<D1+;P50IIQD%M;WH6A27(LF.FJ$B6=K)4NF"539Z$I-;+4!Q4BC*-H$!:,
MRV R\GL+/1FIK15<XD*#V18%TX<9"K4?![W@N/',L]RZC7 R*EF&2[0OY4*3
M%38H*2]0&JXD:%R/@VGO;C9T_M[AE>/>G*S!5;)2:N.,K^DXB!PA%)A8A\#H
MM<-[%,(!$8T_-6;0I'2!I^LC^J.OG6I9,8/W2OS@J<W'P6T *:[95MAGM?^"
M=3TW#B]1PO@G[&O?*(!D:ZPJZF!B4'!9O=E;K<-) .&<#XCK@-CSKA)YE@_,
MLLE(JSUHYTUH;N%+]=%$CDO7E*75=,HISDZ65B6;SHSJ2N%>%=1KP[Q<'5A6
M?0*UAD?&-;PRL45GS5F2P[?2NWW63%J8&\M)(<+XGFNUS7)J/_Q$IN'%<)G!
M3##*LDQR)=#4H9U2\\0=/JD4!5P]H&5<?!R%ELIRY,*D+F%6E1!?**%/"-+F
M!N8RQ?3_^)#D:#2)CYK,XE; )Z:[T.]]@CB*>RUX_4;COL?K7](X9QH[*Z_Q
M@AWH2EN8:A(N0[_^-5T9J^E^_FY)=MTDN_;)KB\DF[^5=.$IDT5=P!67<* ^
MF+.ZMB,-JL@63C<-IYOW<=HI0;=+<'LX1Z<=Y+;?C:(/+6P&#9M!*] S-YO.
M6B,"ER02&@N:[NXY1NU 47<8MQ$:-H2&[Y,GY3N>HDSAP%&DYPBU T67% I/
M!D2!.O-CT$"BMM)6LZ+9;2;MM!HP_]RK,4T?1\:E 8%K"B4)J&NZ&GV5857I
MQ\U*61I>?IG3WP*U<Z#SM5+V:+@$S?]G\A=02P,$%     @ FX*M4IE;_IJ+
M!   BA   !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULS5A;;]LV%/XK
MA+&'%D@C4;)L*7 ,.':R!5BZ($%2#,4>:(FVB4BB2U)VO%^_0U*6?)&5H-N*
MYB&AI',.O^]<R0S67+S(!:4*O69I+B\["Z66%XXCXP7-B#SG2YK#EQD7&5'P
M*.:.7 I*$J.4I8[GNCTG(RSO# ?FW;T8#GBA4I;3>X%DD65$;*YHRM>7'=S9
MOGA@\X72+YSA8$GF])&JI^6]@">GLI*PC.:2\1P).KOLC/#%!$=:P4@\,[J6
M.VNDJ4PY?]$/M\EEQ]6(:$ICI4T0^+.B8YJFVA+@^%8:[51[:L7=]=;ZC2$/
M9*9$TC%/O[!$+2X[80<E=$:*5#WP]6^T)!1H>S%/I?F-UJ6LVT%Q(17/2F5
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M6+9*G6'9%XV)N]Y^7-Q^&/WT$U!+ P04    " ";@JU21QQ@N:0!  ";&@
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M;%!+ 0(4 Q0    ( )N"K5+;8\=?[P   "L"   1              "  :\
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M2P$"% ,4    " ";@JU2-AK=:\X"  !,"0  &               @($5$P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ FX*M4K@-+-A[
M P  2PH  !@              ("!&18  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( )N"K5(E$'!1/ 4  &$7   8              "
M@<H9  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " ";@JU2
MU($' #T"  #%!   &               @($\'P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ FX*M4D,&.5#I!0  T!8  !@
M     ("!KR$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M )N"K5(-LS>S6P@   @3   8              " @<XG  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " ";@JU2N#@V7YD/   "+   &
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M970Q,RYX;6Q02P$"% ,4    " ";@JU2CLP0.6(%   C#   &0
M    @(%M4   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M )N"K5+TB[?'; 4  .H+   9              " @096  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ FX*M4@&:B]O< P  BPD  !D
M             ("!J5L  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " ";@JU2^I11+=0$  "?"P  &0              @(&\7P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )N"K5+L**F)O (
M .P%   9              " @<=D  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ FX*M4GESP2,C P  Y 8  !D              ("!
MNF<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " ";@JU2
M46ZK$)@0   I,P  &0              @($4:P  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( )N"K5(M2)5UT (  "<&   9
M      " @>-[  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ FX*M4B^-1ORF @  WP4  !D              ("!ZGX  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " ";@JU26^8/&(T"  !A!0
M&0              @(''@0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( )N"K5(AI#P_,@,  '0'   9              " @8N$  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ FX*M4HWT[4#Z
M @  * 8  !D              ("!](<  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " ";@JU2F<GT@\P$  #C"@  &0
M@($EBP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )N"
MK5+8,!7+-P,  -4&   9              " @2B0  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ FX*M4LJMC,;V P  5PT  !D
M         ("!EI,  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " ";@JU2.L7)YN,"  "+"0  &0              @('#EP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )N"K5+.C:H]IP(  ($(
M   9              " @=V:  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ FX*M4M?QQ_>I @  6P<  !D              ("!NYT
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " ";@JU2U8UQ
MBH\"  "*!@  &0              @(&;H   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( )N"K5)1L.'+F (   T'   9
M  " @6&C  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MFX*M4J.DL7R1 @  +P8  !D              ("!,*8  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " ";@JU2?IW7B 8"  "B!   &0
M            @('XJ   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( )N"K5*CWUY9< ,  "$,   9              " @36K  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ FX*M4C&M4GX< P
M4PH  !D              ("!W*X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " ";@JU2Q/7/ HL#   Q"P  &0              @($O
ML@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( )N"K5*6
MVLKNY@(  -X(   9              " @?&U  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ FX*M4A4J-CM,!   ?A   !D
M     ("!#KD  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )N"K5*F']7R$ ,  #(1   -              "
M ?/+  !X;"]S='EL97,N>&UL4$L! A0#%     @ FX*M4I>*NQS     $P(
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9>&UL4$L%!@     T #0 (PX  /G7      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CondensedBalanceSheet</Role>
      <ShortName>Condensed Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CondensedBalanceSheetParenthetical</Role>
      <ShortName>Condensed Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Term Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/TermLoanPayable</Role>
      <ShortName>Term Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Licensing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/LicensingAgreement</Role>
      <ShortName>Licensing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Summary of Significant Accounting Policies (Polices)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices</Role>
      <ShortName>Summary of Significant Accounting Policies (Polices)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://silverback.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Summary of Significant Accounting Policies - Summary of  reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of  reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Leases -  Summary of Operating Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail</Role>
      <ShortName>Leases -  Summary of Operating Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail</Role>
      <ShortName>Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Term Loan Payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/TermLoanPayableAdditionalInformationDetail</Role>
      <ShortName>Term Loan Payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future  Issuance&amp;#160; (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail</Role>
      <ShortName>Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future  Issuance&amp;#160; (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silverback.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silverback.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Licensing Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/LicensingAgreementAdditionalInformationDetails</Role>
      <ShortName>Licensing Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d155579d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="d155579d10q.htm">d155579d10q.htm</File>
    <File>d155579dex311.htm</File>
    <File>d155579dex312.htm</File>
    <File>d155579dex321.htm</File>
    <File>sbtx-20210331.xsd</File>
    <File>sbtx-20210331_cal.xml</File>
    <File>sbtx-20210331_def.xml</File>
    <File>sbtx-20210331_lab.xml</File>
    <File>sbtx-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g155579g25t34.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d155579d10q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 75,
   "dts": {
    "calculationLink": {
     "local": [
      "sbtx-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sbtx-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d155579d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sbtx-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sbtx-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sbtx-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 306,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 18,
   "keyStandard": 241,
   "memberCustom": 14,
   "memberStandard": 17,
   "nsprefix": "sbtx",
   "nsuri": "http://silverback.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://silverback.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Fair Value Measurements",
     "role": "http://silverback.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Accrued Expenses",
     "role": "http://silverback.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Leases",
     "role": "http://silverback.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Term Loan Payable",
     "role": "http://silverback.com/role/TermLoanPayable",
     "shortName": "Term Loan Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Stockholders' Equity (Deficit)",
     "role": "http://silverback.com/role/StockholdersEquityDeficit",
     "shortName": "Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Stock-Based Compensation",
     "role": "http://silverback.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:LicensingAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Licensing Agreement",
     "role": "http://silverback.com/role/LicensingAgreement",
     "shortName": "Licensing Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:LicensingAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "role": "http://silverback.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Employee Benefit Plans",
     "role": "http://silverback.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Condensed Balance Sheet",
     "role": "http://silverback.com/role/CondensedBalanceSheet",
     "shortName": "Condensed Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Summary of Significant Accounting Policies (Polices)",
     "role": "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices",
     "shortName": "Summary of Significant Accounting Policies (Polices)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://silverback.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://silverback.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Leases (Tables)",
     "role": "http://silverback.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Stockholders' Equity (Deficit) (Tables)",
     "role": "http://silverback.com/role/StockholdersEquityDeficitTables",
     "shortName": "Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://silverback.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Nature of Business - Additional Information (Detail)",
     "role": "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail",
     "shortName": "Nature of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_LiquidityAndCapitalResourcesMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Summary of Significant Accounting Policies - Summary of  reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets (Detail)",
     "role": "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of  reconciliation of cash and cash equivalents and restricted cash reported within the condensed balance sheets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_CashMemberusgaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Condensed Balance Sheet (Parenthetical)",
     "role": "http://silverback.com/role/CondensedBalanceSheetParenthetical",
     "shortName": "Condensed Balance Sheet (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of  Assets and Liabilities  Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "role": "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Leases -  Summary of Operating Lease Cost (Detail)",
     "role": "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail",
     "shortName": "Leases -  Summary of Operating Lease Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)",
     "role": "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail",
     "shortName": "Leases - Summary of Future Minimum Commitments Due Under Operating Lease Agreement  (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://silverback.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Term Loan Payable - Additional Information (Detail)",
     "role": "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail",
     "shortName": "Term Loan Payable - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn11_30_2016_LoanAndSecurityAgreementMemberusgaapTypeOfArrangementAxis_SiliconValleyBankMemberusgaapLineOfCreditFacilityAxis_TermLoanMemberusgaapDebtInstrumentAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future  Issuance&#160; (Detail)",
     "role": "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail",
     "shortName": "Stockholders' Equity (Deficit) - Summary of Common Shares Reserved for Future  Issuance&#160; (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sbtx:ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021_SharesUnderlyingOutstandingEquityAwardsMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "role": "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail",
     "shortName": "Stockholders' Equity (Deficit) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)",
     "role": "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Summary of Share-based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "role": "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)",
     "role": "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail",
     "shortName": "Stock-Based Compensation - Summary of Activity Related to Stock Option Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)",
     "role": "http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail",
     "shortName": "Stock-Based Compensation - Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "role": "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "sbtx:LicensingAgreement",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Licensing Agreement - Additional Information (Details)",
     "role": "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails",
     "shortName": "Licensing Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "sbtx:LicensingAgreement",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021_WuxiBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sbtx:AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)",
     "role": "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_RedeemableConvertiblePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "PAsOn12_31_2019_RedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2020To03_31_2020_SeriesBRedeemableConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sbtx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Condensed Statements of Cash Flows",
     "role": "http://silverback.com/role/CondensedStatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Nature of Business",
     "role": "http://silverback.com/role/NatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://silverback.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d155579d10q.htm",
      "contextRef": "P01_01_2021To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sbtx_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments upon achievement of certain sales milestones.",
        "label": "Aggregate milestone payments upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_AgreementPaymentAndLicenseTermDesciption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement payment and license Term desciption.",
        "label": "Agreement payment and license Term desciption"
       }
      }
     },
     "localname": "AgreementPaymentAndLicenseTermDesciption",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sbtx_AmendedLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Loan and Security Agreement [Member].",
        "label": "Amended Loan And Security Agreement [Member]",
        "terseLabel": "Amended Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "AmendedLoanAndSecurityAgreementMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in early exercise liability included in accounts payable and accrued expenses.",
        "label": "Change in Early Exercise Liability Included in Accounts Payable and Accrued Expenses",
        "terseLabel": "Change in early exercise liability included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ChangeInEarlyExerciseLiabilityIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy followed under emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_EsppWithholdingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP withholdings.",
        "label": "ESPP Withholdings [Member]",
        "terseLabel": "ESPP withholdings [Member]"
       }
      }
     },
     "localname": "EsppWithholdingsMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in operating lease liabilities during the period.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B redeemable convertible preferred stock for cash.",
        "label": "Issuance of Series B redeemable convertible preferred stock for cash",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock for cash"
       }
      }
     },
     "localname": "IssuanceOfSeriesBRedeemableConvertiblePreferredStockForCash",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_LicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees paid.",
        "label": "License Fees paid"
       }
      }
     },
     "localname": "LicenseFeesPaid",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_LicensingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement.",
        "label": "Licensing Agreement"
       }
      }
     },
     "localname": "LicensingAgreement",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/LicensingAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_LicensingAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreement.",
        "label": "Licensing Agreement [Abstract]"
       }
      }
     },
     "localname": "LicensingAgreementAbstract",
     "nsuri": "http://silverback.com/20210331",
     "xbrltype": "stringItemType"
    },
    "sbtx_LiquidityAndCapitalResourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and Capital Resources [Member]",
        "label": "Liquidity and Capital Resources [Member]",
        "terseLabel": "Liquidity and Capital Resources [Member]"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and Security Agreement [Member].",
        "label": "Loan And Security Agreement [Member]",
        "terseLabel": "Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_RedeemableStockExcersibleOnAgreedUponMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Stock Excersible On Agreed upon Milestones.",
        "label": "Redeemable Stock Excersible On Agreed upon Milestones [Member]",
        "terseLabel": "Redeemable Stock Excersible On Agreed Upon Milestones [Member]"
       }
      }
     },
     "localname": "RedeemableStockExcersibleOnAgreedUponMilestonesMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract",
     "nsuri": "http://silverback.com/20210331",
     "xbrltype": "stringItemType"
    },
    "sbtx_ScheduleOfCommonStockReservedForIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Issuance.",
        "label": "Schedule Of Common Stock Reserved For Issuance [Table Text Block]",
        "terseLabel": "Summary of Common Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForIssuanceTableTextBlock",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sbtx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesAvailableForFutureEquityAwardGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Future Equity Award Grants.",
        "label": "Shares Available For Future Equity Award Grants [Member]",
        "terseLabel": "Shares Available For Future Equity Award Grants [Member]"
       }
      }
     },
     "localname": "SharesAvailableForFutureEquityAwardGrantsMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesUnderlyingEarlyExercisedEquityAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Underlying Early Exercised Equity Awards.",
        "label": "Shares Underlying Early Exercised Equity Awards [Member]",
        "terseLabel": "Shares Underlying Early Exercised Equity Awards [Member]"
       }
      }
     },
     "localname": "SharesUnderlyingEarlyExercisedEquityAwardsMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesUnderlyingEsppWithholdingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares underlying ESPP Withholdings.",
        "label": "Shares underlying ESPP Withholdings [Member]",
        "terseLabel": "Shares Underlying ESPP Withholdings [Member]"
       }
      }
     },
     "localname": "SharesUnderlyingEsppWithholdingsMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SharesUnderlyingOutstandingEquityAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Underlying Outstanding Equity Awards.",
        "label": "Shares Underlying Outstanding Equity Awards [Member]",
        "terseLabel": "Shares Underlying Outstanding Equity Awards [Member]"
       }
      }
     },
     "localname": "SharesUnderlyingOutstandingEquityAwardsMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank [Member].",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance costs.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.",
        "label": "Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertibel Notes",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibelNotes",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes.",
        "label": "Temporary Equity Stock Issued During Period Issues Value on Conversion of Convertible Notes",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodIssuesValueOnConversionOfConvertibleNotes",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of new stock classified as temporary equity issued on conversion of convertible notes during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Notes",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes, Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleNotes",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock for cash, net, Shares",
        "verboseLabel": "Issuance of Series B redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued on conversion of convertible notes during the period.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Notes",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock upon conversion of convertible notes"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleNotes",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock classified as temporary equity issued for cash during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues For Cash",
        "terseLabel": "Issuance of Series B redeemable convertible preferred stock for cash, net"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssuesForCash",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan [Member].",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities.",
        "label": "Unpaid Issuance Costs And Amounts Payable To Investors For Redeemable Converteible Preferred Stock Included In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Unpaid issuance costs and amounts payable to investors for redeemable converteible preferred stock included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "UnpaidIssuanceCostsAndAmountsPayableToInvestorsForRedeemableConverteiblePreferredStockIncludedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sbtx_UnvestedCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock.",
        "label": "Unvested Common Stock [Member]",
        "terseLabel": "Unvested Common Stock [Member]"
       }
      }
     },
     "localname": "UnvestedCommonStockMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sbtx_WuxiBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Bio.",
        "label": "WuXi Bio [Member]"
       }
      }
     },
     "localname": "WuxiBioMember",
     "nsuri": "http://silverback.com/20210331",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r125",
      "r153",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail",
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r30"
     ],
     "calculation": {
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r186"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 16.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional\u00a0paid-in\u00a0capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r155",
      "r157",
      "r189",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r157",
      "r179",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r46",
      "r54",
      "r223"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "verboseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows",
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail",
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r66",
      "r107",
      "r109",
      "r113",
      "r116",
      "r196",
      "r198",
      "r213",
      "r260",
      "r271"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r40",
      "r66",
      "r116",
      "r196",
      "r198",
      "r213"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": {
     "auth_ref": [
      "r16",
      "r132",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of series or issue of auction market preferred securities.",
        "label": "Auction Market Preferred Securities, Stock Series [Axis]"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": {
     "auth_ref": [
      "r16",
      "r132",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both).",
        "label": "Auction Market Preferred Securities, Stock Series, Title [Domain]"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r158",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r25",
      "r56"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r57",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r7",
      "r57",
      "r63",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r51",
      "r56",
      "r61"
     ],
     "calculation": {
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows",
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Restricted Cash [Member]"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r64",
      "r66",
      "r81",
      "r82",
      "r83",
      "r85",
      "r87",
      "r93",
      "r94",
      "r95",
      "r116",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail",
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r124",
      "r264",
      "r276"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares Available for Future Equity Award Grants",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 15.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020, 34,903,497 and 34,801,537 shares issued, and 34,827,204 and 34,701,274 shares outstanding at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r154",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r99",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of preferred stock, common shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r261",
      "r262",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r13",
      "r127",
      "r262",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r32",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Annual Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r33",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r67",
      "r134",
      "r137",
      "r138",
      "r139",
      "r221",
      "r222",
      "r224",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r54",
      "r118"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share applicable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r73",
      "r78",
      "r80",
      "r92",
      "r117",
      "r133",
      "r140",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Fair value,assets transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value,assets transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r205",
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r207",
      "r208",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r144",
      "r145",
      "r150",
      "r152",
      "r205",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r144",
      "r145",
      "r150",
      "r152",
      "r205",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r205",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Fair value, liabilities transfers from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Fair value, liabilities transfers from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Fair Value, assets transfers into (out of) Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r209",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r58",
      "r59",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails",
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails",
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r43",
      "r106",
      "r220",
      "r223",
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "calculation": {
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Operating Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021 (remaining 9 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r66",
      "r110",
      "r116",
      "r197",
      "r198",
      "r199",
      "r213"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r66",
      "r116",
      "r213",
      "r263",
      "r274"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r66",
      "r116",
      "r197",
      "r198",
      "r199",
      "r213"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r28",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableToBankCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.",
        "label": "Loans Payable to Bank, Current",
        "terseLabel": "Term loan payable, net"
       }
      }
     },
     "localname": "LoansPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r96",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInContinuingOperations": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.",
        "label": "Net Cash Provided by (Used in) Continuing Operations",
        "totalLabel": "Change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r51",
      "r52",
      "r55"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r41",
      "r42",
      "r44",
      "r55",
      "r66",
      "r72",
      "r74",
      "r75",
      "r76",
      "r77",
      "r79",
      "r80",
      "r84",
      "r107",
      "r108",
      "r111",
      "r112",
      "r114",
      "r116",
      "r213",
      "r265",
      "r277"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows",
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r107",
      "r108",
      "r111",
      "r112",
      "r114"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r231",
      "r238"
     ],
     "calculation": {
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Years Ending December\u00a031,"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfFutureMinimumCommitmentsDueUnderOperatingLeaseAgreementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 13.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use\u00a0asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash\u00a0lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r235",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease Weighted Average Discount Rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r234",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock , shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheetParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from Issuance of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r182"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r119",
      "r275"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock [Member]",
        "verboseLabel": "Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail",
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r151",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r151",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Principal payments on term loan payable"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r192",
      "r284"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails",
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r63",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r4",
      "r10",
      "r61",
      "r283"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet",
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r140",
      "r186",
      "r273",
      "r281",
      "r282"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r73",
      "r78",
      "r80",
      "r117",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r278",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds after deducting underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share Amount"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value On Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r157",
      "r178",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverback.com/role/StockBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r157",
      "r178",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value On Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Commitments Due Under the Operating Lease Agreement"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r7",
      "r61",
      "r259",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r158",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r163",
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Stock Option Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Each Option Grant Estimated Throughout Year Using Black-Scholes Option-pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r37",
      "r64",
      "r93",
      "r94",
      "r129",
      "r130",
      "r131",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail",
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A.",
        "label": "Series B [Member]",
        "terseLabel": "Series B [Member]"
       }
      }
     },
     "localname": "SeriesBMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Share Based Compensation Expected Dividend Yeild"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares Subject to Options Outstanding, Granted",
        "verboseLabel": "Share Based Compensation Number of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r165",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares Subject to Options Outstanding, Ending balance",
        "periodStartLabel": "Shares Subject to Options Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Shares Subject to Options Outstanding Vested, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price Vested, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r156",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitSummaryOfCommonSharesReservedForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r173",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfFairValueOfEachOptionGrantEstimatedThroughoutYearUsingBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Life (Years),\tVested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair Value of Shares Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Preferred stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r64",
      "r66",
      "r81",
      "r82",
      "r83",
      "r85",
      "r87",
      "r93",
      "r94",
      "r95",
      "r116",
      "r133",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r69",
      "r70",
      "r71",
      "r73",
      "r78",
      "r80",
      "r92",
      "r117",
      "r133",
      "r140",
      "r183",
      "r184",
      "r185",
      "r193",
      "r194",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail",
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashReportedWithinTheCondensedBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r92",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://silverback.com/role/LicensingAgreementAdditionalInformationDetails",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r133",
      "r140",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares Subject to Options Outstanding, Exercised",
        "terseLabel": "Exercise of common stock options and vesting of early exercised common stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/StockBasedCompensationSummaryOfActivityRelatedToStockOptionGrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r133",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options and vesting of early exercised common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option Awards [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r66",
      "r115",
      "r116",
      "r213"
     ],
     "calculation": {
      "http://silverback.com/role/CondensedBalanceSheet": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet",
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "terseLabel": "Accretion to Redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r36",
      "r66",
      "r116",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary Equity, Ending balance",
        "periodStartLabel": "Temporary equity, Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Ending balance, shares",
        "periodStartLabel": "Temporary equity, Beginning balance, shares",
        "terseLabel": "Redeemable convertible preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://silverback.com/role/NatureOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/StockholdersEquityDeficitAdditionalInformationDetail",
      "http://silverback.com/role/TermLoanPayableAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r97",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/SummaryOfSignificantAccountingPoliciesPolices"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r232",
      "r238"
     ],
     "calculation": {
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/LeasesSummaryOfOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/NetLossPerShareAttributableToCommonStockholdersSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://silverback.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r285": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r286": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r287": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r288": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r289": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r291": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001193125-21-160519-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-160519-xbrl.zip
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M<"^GU3#PWN-/KVAQ!,_-'"?^^(HV8<U^ @ED6M=4XZ;U!#P9?\27OH=#X?'
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M_#QI'GS\<OV]^YW$R^OO6#"X^R!+A/-5Z;8T'"][ZWNK6M7PEMX=[=KMCNM
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M0(JHTDT1F3;RS@-HZ]'C0VF,#WWXM3?.W#8+@X&K"B+BU37J?%96T$A"I0'
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M?Q\EY*BYO(JSZA3 7IR<<:5<+7(PD4U!#4VB+H4XQ4%;'J4G\+QPA!\QM3(
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MM_#2$>48[ /'?<X66._$5+C1W*VXD1VBMV7-MZ5AA,/0YH$P-\B^GT7?,JQ
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M$"1/O\&N'>-H)K0NX@]-F)4)<QG+9_>)5(:@R_T!^V*[S[-E-$V=RJGSQG)
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M0$R\8&T@43NILI1F<F\MSA5#TFM3OF Y5Y[,N]JZ]D4L7Y:L,2$K*6?5.JY
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MM"AF3*Q#H^##*PKQS&MFNC'@(^ <Y_>#]L&BAA6CR8_IPDA)H93L(Y%E+<7
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M*DQOGDK;DEX',XS3D>?DWU*);11EL#)3:CEH@%%""^@G(2!E4@ BKG!W_*N
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MQF)1CB3Z#18S*0D5WRV-<[[-$6JS:&.Z0JX.I;^-LKVEDY-$J.<C$-"Y'*5
MD?GL8%C#<#@)<Y:?!E!*I(N%5>ELP8-&9<3+1<,OE/T(<_7111VU#A/"0#1N
M7^9U3!.\]",1Q-Y#:EZ=A$9<]FX>!,42A@^CI;%&6;UD12.UU("]EHG9]U2*
MF!"F _*RK!65?HKLSU2+#E8-!) @=7<W)YM*H9M(NEK/MB4N;QWK%"LZQ4K)
M.4:F#;-+6'%/%N4:N5,9'[N.^3E)XW@E#Y'7YP'0F4:JNN&?Y.=,T8M=18G/
M=,:1U8^ +I5"G)<)E:0Y)6G%$KRJ#!HI14?L;E$:YM@LDY2=1?LI98)5Z3K5
M!]EK6M_*N[R?[F.&I>=Z. P=]Z%[F2HDSV#Z >JI#<JYCW+?&)/4@9BI$OBE
MZU'Z06C*A,/9#++IXI03&?IS:E!B]4,VLD8"USR=WR_O>9#9S.DB]0UV_^GA
MM-F1E1FB5/BJR52%Q:1M?+Y]T:3'X>_S]G'SB'V>6&'4 -()O]62R^32*;F1
M5AV1$9W]";^XWB-W5 W.I+K1Y=V-GQAFXM&"K&BZ4<5;O ,?SLC\FR9 9NF3
M16^DLA_ZOFM8/+JAGRTU.J\J:+*X?FK9%DP]4Z!4FM53O<U8C\_?YBU(7&$%
M,P23E4@(JJ$ZN1V(6+#Q?-P-]F'$=ZDLQTG=#4S#/1S9[EA0"6;8;_A SW5"
M>K(G'-&W(HZGTBR'TI:#*@4T)\_G2+^2<6.&%TJSAQP1*EWQ:)AP'D%XH]TZ
M$T[2](MS;9!A],_0DH\LFE0,$J3+VY@ ./VXR@B/U4E,--$9,NM#8Z*7(<=D
ME&0[3>^GT$E:7)A6?B% 35D?9[68MWMMWG-!FT372:1Z21NA'V(A,!&E8C>D
M_DL<LQB"*9O4 $XN"5>))2VUFY)YD6E&95;'WTT+LX.F$_$O-4T%LJK ^9,L
M7&RK%,U/47%C,COFY8(J*S_?L@=DGC*SVUE?)OS)RKPM68:LV^&H[[G(N)&1
M)1P16 @CC'.L*,/6;"R($?:(=<TG,@LE]MED(X P#YH-H+(T)DMO:8/V^:.+
M9B[XPQ?>DY7DNU8&VY!,TP0',KLWOJ.8K !$J;2Z(Q)/_TV'8F#9TK,J>^:4
M#MZVI)E-N0XB (O'A$_!/D.10Q6#IB;0(1WOL&EKDBR30[_)SF0!B$QWR;3I
MM[B3K&$M*521DMO(W"7MVS2:N*EH\>+&XA(/-JX2G2NTCU/E?!QEV26GEBK/
M@_6GN2SF$&!-: )OU2C1.O:T9%M]HI,J<91$HY^PSEIQR:E,FIW8WBC]>="M
M/3YB]Y8LJ:ALPMFF9OG28X.7K#\A*)]Z3P3/6)@K2L'L>K&'08G*E)^9IJT,
ME2NDLTN=Q'>2JRZQS>UV:^^TRGI/@M0G$J32Y-MQ376]BPS@EED\W&A9>3<"
ML\BI)UUV(/@XC])7@#Y[K/\CZR=$)8&2).RJLJJ,#5(>J$>TAN?X6:FA6/J)
M\,I,IT(/_4@5^61S8)![8^#:L4L0%6)<*#9T =XE>.<VH[1<6;EHPK$!\JP;
MB^N+O1Q4#<*W@GBQ8MR^7Z0+9-9/NH0RP!Y78ID887S6P2F!X4>1XD[GS\P&
MXH"(J 02",L]% 7HA"&_5AC .,7BIA#E9S9'=6GD,T,!VH/CYL\^,R>I.R@_
M\Q.6;[+'Z2G/;H&*%\%J?TNBLI+@D%DK-6>=XVED6#.NM8=#\/OJZH)BH_RV
M@-GI&)=9[Y KD>/)%=872OZ?#$J06?90I5;-+]8G21@9,]< 52/RZLN]8&/1
M :012GF],$A$(E7!I!%Y>&W85JJD%_=@X6.7*27_\Z-(,]08GZ1C2^Z<(W;K
MN1@'J,0,^;;J/VHDF:64)RBJ1P5FC)4H& Q$.H0D=;'*!QT+FL#(QR/VQ\"R
M1526:^()TH.>7%IH,I]+[^(X]J"FBM, HV-=%Y**:1.F2DR''D;L^4>K21MQ
M==AK![?4+M1<V6EQX_]G[TV;VS:RA>'O3]7['U"^F:?L6Q!#4A(EQ7-3)6\S
MFIM$'MM)GOF4 H&FB!@$.%@D<W[]>Y;N1@,$-W$#253=FY%)L-%]SNFS+P6<
M63]%R4HN\=H?KWYM< _$IW^ 6RZ2,B8RL_0?D*PF]BOU-U_K:Y[J "R-6C8:
M04U+U!BSW+4G)V21I[4P(HM^A'D5T5-H3B*L2J>8GJ!-.3VP'31S(RL4G/F^
M<(1N16MUFA<\__:NQM#?.S3S+?DHXL\H; Z;C]>>6?T"N"<.#/"V".#6;0K2
M'E084LR /("<@!18PY:#T.N4/;VGFP_6,M*NNCICO(0$/J<$/I?!9\Z1Y[%4
M@9NQSZV/TT)!UU/6EEYTF:5DFAS3F/#.0#.+03>WPHR&4=/H!=+9T+MI_'Y*
M+\O=;#;91SA55:EQN@>UGC08X)Z#C#S@W-2<IN<QAWB'W\#!G@\=W$P"? %9
M:'\=2"?D1".K@B9Z+7$(SEA/_3/]G1X[EN^B&+KEG#NESO*7!H[)>P>ZL! C
M;K8<A50*R2V_U;!>VK>ML,-IC[;A'J#/U;P+K78C$\ZH6(FMEAS!1D$5F$7J
M=SR90VOG;$X6?F>65*$E,Y5YJ?J!YZ=+."8^$^M%^DI4PC2+2![G)M'#4Q_[
M@C"@$+"@L*;)UCO>;+V+0FK>H:;KG=8XL!DV6Y.N.$4"]<A6O)A11I[TTV\_
MO,?QS@">O\714SJ4\NYSZJ1972,Z30[BCPII%F--1PT9;T<>UME+M@&&8Q30
M'QCH+G]KHXZC/ )2=?I'-AH3&[/NL]AZ(T?&(WKB-!LGUBTKJMUVIZO3L?YQ
M_^8S?J$RLEK6KY3S1>O)[^P9FT"MUG6P<"W NG(/M4M,4@"HZ$G9GNF9)<M
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M_ 20NQ^\!;CXZ0< ,PHP^A52%K[3?+BX>WQLD3B[U.*L-]]U4)$ R*P+Z"9
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MB-NS^ADH",@?8O'OS(^)UA)>.=?506. C0"LW"R!8SOQ!(SB<, B'19Q0?#
MWU)G$(]JI*(G!DX6I,A[]"(VRC#8%(@V8%B%&K&JP/*J]DF*\R83FTD%-GDF
ME1;Y"6S9A6OGN!-)+;#+6$C'&ZDJ?(8G!Z\>#IJV]>FHT9T[I(_B*$GRXT5
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M!4&[+ !:UM^C)Q [L8U2YG8<^P$]5_0Z "A)DZ.BVSE^01"F(%?A;;FW207
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M;7U251EN/OL V0-#G!1.GSKP,7%:J8J.].DY]N:X0Q]^XEDR0I:3[LCY,^*
MRQ@9-(=5_5CE>[>LV^E.KFPO W,?<*-8?5$TV7N^1ZZAD1"I3!@>^"'Q:EQM
M #O5>K&OXXV)VE[Q:>#^_J.#^<.)=#5BI@C].5&AQ;04!DS$V,$<XV"":_;]
M 8@-3$]J[5M0;#E4L;W SVYC%6_9S[XH(E$5V2.IF[>8YI5HH4] LS&0.)C&
MBJO5N*=T[<(B9M!]2(YE!J>5B]%">$2%X[G?,Y7]1)C"A#F&DG/HH/\/"V[&
M239^ONIMI/%SJ;NS5:@3ECESE#%;JE:E-1Y]$*V4-/*#-?0]H&RUQ%0/Z.XS
M>D!7KG2^P2;0Q1>LN;TY9=B[_^_FC]= ?[?0IQIOZWF=-!:U^K96:>E0<9CE
MFT!8J_:(WG,KYV*@<ZH51@.X68!;T'_\>;#;^QVH:#AX,=5P<",KK8/Z%=LS
M[H$Z./_S.0318&!C&&AO$P/K7-4-=?2;?QKJA5N8BS@[H:'I[P>O9:\SY^$&
MV-NB$+"466?.DQ-[2=$\6YZR<J5R]B5<M_O1\Y=9O8V4X4YXR\60#$3#M\#C
MDY2'86Z#*8X!);]J!-SG\)=); 3]0O0)/T%'YF8][3W[O'UM7UY/.]KW@*J&
M:*;[D72U)[U61-/IV9>]:;_W1E&U1<G3R)3MR!3GT?$#\H^A&U"Z^TR)8CU@
MFG C5[8I5VX5$O2O#?[P-X+_#IC$N=VY[-HWG78C66I)-E.2I1YDT[$OVSW[
MNCV=ZG(HLJ6Q:FIBU0@'_K#$-Q&[/G8T:2R;W5LV[Q$'[Q4*=JRG7O7L[LUT
MD[1&_M2!:.98-GLEFDZ[;7=[6Z::&IDVL[V C<!94>"\__SQ(W4NP.15;".U
MOI!9W;?]#-K<H"M^@T.F]BNWDO'X=P.3NV \-W:GNW&U=Y.X;:ARWX)Q]U1Y
M89]O7H5J(D\G/*:DL;RV(<$V=^-O[,O+GGW3F3&ZI#&<:F,X;=!2MF^ZUW;[
M?,LXG\71S7%BR[UK>:95X,][(,"24%AYCM<:,V96X*XUV66#H)KOLN(ZKS"N
M:$%'1=U^C>HWL",Z_>P3]QBFP0_$+M\XB?#4Y-3MSC4Z[]TT<XTJ-+EKV:KM
MC'!AF>BJ;,\VMQF?KMIY/QH'T42(SR ,?5?DR#;7OPT VW(JR"?A1@\A]DCG
M@EJBD::P9SG_%>&O3_AS3?RID1"Q!BX7M 9!,81"Y4!](4+L@![%J?!4G6*B
MJCBI/"@:RTY>W/L"WQ6+(;P">W\%6#SK)+)<*+%>TA)1EL"CR:NF0*@I$-(K
M=9L2E3T6"#70;PJ$UJESZ=6\SN4+-D?D_?],'1+Y[_?8)O&O_?C['ZW-EQ#M
M'=--$493!G,T&&C*8&H6@*A?S![]K-33! T13SR*(!I3FRII\SPS-K%AY_1W
M._=+2YM:>-4F]TKS_!2,;T/O70YAN809L;P+P104NN//3]*J7Z=Y\G0VZ4UW
M>LKISJ,')TX?Y8Y0]:&/?04\=I3GU<B#!?+@;W**(?5D]7"8<9+&U'2J7A)A
M3^'*38H%"6JX];<%0._GXG?M\UX-*E,:,BE+AWJ1247'U4,/B.^.2-<-6<+Q
MI859X[CJ9C;9X*1^FVS,_Z-3]RC_T$H6!#[KH?(=FI%7"JIO1OY>V-WKQG[?
M-VH+&MK&4'O5J%9-SEHMDPH;K-0QD[ P2JZLYL@C;G>JVJS\H^L5TH^6F@JW
M.3VM&I]EK*RRFXW-RMMD:' WZF/GJC*WL?@_,ZX6*<-E0(A1P2[H4XM[(+?@
MR9DD!K7(_QG&)8KNM-M_>6VI*W>.VS<LB,[EN6VI_X %\?WL!+KS5O?:H!7>
M<:MW5;%I]?'4-<J?Q-S+LR1UXG1Z%?I.A)[^YK49V[4HN L'=ZQAC"K&?X&N
M#GH[9=1% YQ@B[W$D[]^[U1=I:U<]..>B+C4I$B9"#TG6_IV#!JDIQ_]H_/B
M1V.$A$Z:L?*QX2G98EEH9)DN,LQH]NB"(29+I1#_@J-($E"'N:L F87F]YA&
M_$N4_DND>8(QI<O>TYC5\J">^958SQTL<GG3FO8^,B3E6! ;U6!WB"-X$4)N
MRF-U^X7479IC[QA3[/FJ">_,@6^ ^5AC2IU&9-$TD&_P>AJA,3=I>VMPYD3N
M#U$L/\+G.DL:G>4QNEX63X03O_CQW)B=I94(_"II554IE%/7YU^0:=I?X:*4
MYZ\V$T&FD]0MOG864U$SJGPMW:EBLD^G>H2Y3/;W0]0#,20*"V$.?Y8.HYAX
MBR.Y>#189T?36?1+S :<+@O)QSN]F4R5"1'IP,WOB_A^(/N=Z7/LKK"V=V%?
MW51,)N5%;<0,L_3=-K_(19L97WNG)S#=Z6%-G_RD<KKY-OH$FL/L*QM+4B])
M.3IU.Q0CY;W1:I5I:$<4,[L[KPD;HWMSRP)Q*F<;Y^4X9GOGB%EIWPF0+NCW
M"UR'</<]/\B0#O)AE^^_\2MP5AS"-$ME1=9[)T8M(U'S.F]'.)]KN12!7Z6V
M8)!WH</%>CMY,ZE>8"<]QQ2^QEF,-S)%/8WG)3%"$I[J1G/-RGWKD+Z3K/\G
M*!#XLUCH,9O4>XA0W&UW>M9'P"FOP]H>?,\ Q0*K:EV\55)V*I2A_;M:]F"!
M'8A'8LFZRFK^9UHTMT"FCR#MUY^,MK"D]J+=6<;LG%:45]"JST'/@3LS CQ/
M9@WZ-*^?Y<CSZ_%E*9:#6".J!+$$%H%471\TO685+]IPA5V!6?)#DF!PB_6H
M7<MS4H<^(B/DU0_3%V_:Y[G0]333$;5_%VF=2C17I[WS56CO8GFG"EV%792,
MKE:$^;R24>-'QM?E,L)>]R]SRPPO9Y<9%GZVS-^EI2^VMW3]=UW'4K.K=5K&
MK;J<+G;J7*Q:[=31I4Z%@->>*YY,UTAB&2;*QLJ@3( >!A7M@GY6+I:K*?F0
M05*@%:IRW>$.M$VSSUW("[37+>SD[C:W8@E4_*Z"(_NDAUL.S.QS"ZK[]C[W
M\!','M%<B.9"U.%"?%+QTWUN M,?T*.8%;NH[GH;/_D#8;W\%WDNFONYW_MY
M^_ 0BP<GW>OEN .R1'7>W><F?G.";)OBXB!*0*R"FZ4I!YE+7V]4$"RUIJ9<
M6^6&(L]H57UY+&V+=Q$_W49;XQT-JER%)BXV3A.[KR;9(#DH]5)J>,KL(-5_
M)2+Y]?.[/\8BYI$))JUTEY[[TZK3K*C#XQTS@I"(C_YB6NFO3"M:(S>TXB\B
M'G7GE#&9]#,S6?"F=3E=@-"PBSJP"ZUHDK*W*H-X7J>([KG=VU>QVH[G@35:
MXS(]8S#K3'B-;KB9V\V39>]"SOO^6QPEY?3ZY4J,U\C+/+=OKFHD^D^"YR<K
MD<4*:N+2!>GKJ8L7UZUVC6AF'7:RQ?KF@UU[ U?Q4(_^S+4;]]BQ*3IZ N_I
MJ#HO%T@U3+G!F@KAO<O $'E@Z<2I%&8ZK0;=AE29NU\^+.W&Z-@WVVAM]ZI1
M9]909Q1!U%BCZ;8ZTY5)C4)S)&MO[3*N$^#[;N5 73ULUJG;3)7-<YU36^^3
MU6U<5(WFIO)$,*RYSL64Z27!*>E^5!C4733-IW$!U1-BC;Y0.WWA4(^^80?(
M#H8;LU#<P]6I1Z?>@]AD<P5KLG8C,!J!48NU&X_YL=E=1D)I1;. TS&E]I]-
MNMMN/(V=6 ]R6#&;=(O.]$ZGU3N2]( FFW2MUI,WK?,FF[2>[&)A-NGF'?6P
MEGV^[9&4C2>BZ;W?^"(.8>W&%]'X(FJQ=A/=/1POPV^RIV?C9-BBFLA O@V]
M][*S_I<(/]J7[^&J?6U?G]?(HFQ,B65HI#X.B5[K9LL)0L?-9K;CCUB9@F:Y
M*=:>D''=NFK<% ?%6W3GEWVX,2[MF\OCFXW=>#$.:9>-75B3M1LO1N/%J,7:
M?ZT8(SK=5+_XR<K-X"]6:09_N9]1%E_T@+V!X\?6(RH&. =!3B&14T$\JF%;
M9=P!3BS YAK+3.+;C&ZL*BP^P#E(OUE6T]W,$+[S13/X""2!2&B 2U@WF*PT
MN7M9F+1;G45S"8'(4&OU'T4P:5E(C8[25BU?J:N2+.60(AZ!X/2C1X%3-6 C
M;A8X<G@-/N#Y@X&(!>;7]$7Z) 3_3LW)L<9H5*MA'S09)YCD$X\20A3]($EI
MPJ%7NAM5,T)<FD1D\:@0' WB!$'%Q)[")(T*Q7:M 6\;61!YQE"<P6'$I. B
MK/8BMG;7MK$PUP0I96H^)8WYPHDIPL18/DL%<">GN-"3R;P9+NN<JS@S;VD6
MN+'>*"57 'WY#J"BV<!^ZD;/SUOG52E1B$^Z^[&0MZ0N?63F<L7E?;3D0 %@
M/(%IDXCPQ8]A-#WW2Y+DJJ*VW=)S?%8=\63"QJQ)1Q)AF"9)-N+/UA_W]./R
MVLT:TTRK-!TY#\@T&>FCO<5ED'E5\RK4O K#WI!WY'(H2Y V'.M-X+A?SP"G
M$2@4BJ>A6,.O1Y$G K )TB%1$8^<JISGZ^3X_:' ZU'U7GW0T%*&_9S90[WK
MS<\>>LT[L8PA2*^-J)TEYU&94ZNL?$;5+)_2G+%%URM1\[P!1S>SY_FL^8*5
M?[U.T'<CTUQ6MPR?;0F7FGFW6U>7NI]W'^]==2/O16/4GD?8UTN'HI<,/*\V
MPOE9VUV=&X*88S3]3+*.^X&_1X&WS.SFG<&Y<]AP+NH.#60W!]EU;(5R*D9%
M6L9!E?]<7S2).4LTS.)0G06_&M$PT,G4C(QGY.1TSK<4+5_FO]L)?VN3U;!%
M=*!S$^'L7JM='<ZN2:);<Y]6N4^/40"4%?CIY BNTJ;]'_/NTF\:<)_ TGR6
M?VB<S7(+G77G^H6NI[/5_M)(ON.\J9_\Y.O9 /U:/BJ5(DFMN#23J-ZW=8=W
M$V'U 4!U)R&UL9MYL>S-!.-WVF&[_;O9W+IMR4=X/< 9I\G[(EBW9=>IR<AW
M$G@;NX?MF??P/R*./"<9ZM99,^*HBW(:"EIM.:/!FJ+&M9Q.O6J7^AIVM9G/
M]1P?Q6I9$K-.N;=;VUG'KW!=Z4XH_,^,S#QB7V4XX&<&O^X+H%;DU\&3,TG(
M3\QK#K4P4$RBW?[+:TO1R#GNVE"W.I?GMJ7^ ^K6]S.)LG/>ZEX;H07>:JMW
M5;%;^7'^.<:LSI+4B=/IW]!W<*OSGYEN)HO\3&O.:72L88Q,X+_2R'WQ(X72
M,-*#F=G8$?BOWSLK.>)*47\I!UN7/E"X^3A*(WW.F(]#D8VBN)+!CM7SFRY7
MR6_J;3&_:;F;NW9VPNZ"@XLB@IY QQ$\KT*"&.BK"@J>%8."*K/%"/Q9?1%$
M3RWKO>,.97)+@LKY.$L33*])>/:Z_RCHUP\B%+$3!!,K%O_.?,P12X#8_ '(
M^#"U_LP\EJ\M:QD'\[;SVXJ$3IKB-'O!O[6*MI;OUUC/3^$2NM./HWYA_:8P
M^Y:SABCXWBJ JBI$#(?Y*M)B'I+,TX-_%3*0C*RF(O7X!>+I3RJ3F?H1:$*X
MI@<(=M,H3EK6!QU&QE^X041T-R,;ZN[CO<W!YZI]1UE<W"ULBAQ_%G(=(#NU
M.B=J ;W'8AS%*3] &5X($UB)(20_A*?A31.YIOCF#E'9PV]!UW2'B].V8!MI
M['C":UD?8Q]3@Z+9I^L+U\D23-*@M!789!A9XZP/6%<'5ME%\U[*8)H&N,Y6
M\^#P3A*%)#3P>N'MHJL(O!>-IA@3WZR0:@P)NH7[:ES?@<,KPZDT"?#;T0I7
M208*I5.8LR48_= -,LQ%(05X!(AQ0A%E"3WE,)6-18S:+%.8 T@%<D1Q@%M/
MAW[LG8U!%D_L2O  /6=!FG"V%C";/"EOX(=.Z/I.8(V!0%)*(.3M(+4@Y03B
M403T4^?1\0/.87#&>!MQ7: \5R0V/0KJP .=UL/?1&,-5X1"C"^)P?[&[7!R
MX0QBZ",#%@DL.HZCAQCS.V=<"OA.4&(8OJ3P4L0/' =W-N\5"''/S\$!+_R3
MA:W\(0H ?#NCS>F3/V^IC$5>3@Q$C.0D/X.WX*5Z1*IP^=>VNFD 1LP(G+I9
M&"CW#*Z$D(8EA1@Q+J*0#$+\N_P^ ' $0@=(&I"*B<=(K'YH.?$H 0X>/F!"
M"Q!;XIAG)KV&H"]DTJ<"#L T$ ]B#CZ6VA;A'^\/$4"4"'6LZ6OLA$XP27QZ
M(S")/)-4WB-Y+:CS&\IU'X2=$TO8 OI5AFO?C\8 P1'8QAD9SWB!LB2-)?P#
M_ZL(_&$4$<\ P>V+1TX,"GP0RAYB'>@KG,V"$N%F,3P&N@)P$ !?DB%AXHYQ
MYQ8FL%J)$VAVH/'_ *# 7".!]XLT"SY;3IN\1[CE4D!\%1,\.?"PT%!!!!C5
ML2\D*  F#BL.\&O HI>4;XD&3ODH"C3T U J1 Q8F-Z5Y0P&>%FD  MP,GWB
M^CG! -!3X0Y#,$X>)OFJB1* VGA:OS"@MXKB?+6/PH#Z*4[:A851O]94+K H
M1%1!7T!NBU1#_(HR/3D-&_^ME*$''M!H86YPOD $ I$XD2R?Y+3TX@NFM'*?
M9OV4U*M<-X>K/@:2\^'#D0 NXEDOM<:#WV\\C7OD@XR-_#"59&LFPB-OQ8V1
M%J7O8^CE=UU7#--I7ZG$>L7CAP[)(JD'$%A9HN80R;/MASYR\HGE10)UI!3%
M%OK1@,$8F@U  V"7C7-M+<I5D@+L6U7^BU._%'GXKFA&_(VX=17;#$#XX"\9
M/21D&'^L=.>!5"03IZ"8 (F#<!4Y'R^%7JU!'(U8(,I$4^,E^C&4=Q%\CTH&
MWT]G#*3QC5 .]B68ETA_4?$MZO:1/(J)=%CIAE^P\FZ(4\R!]=FD& MX$X;[
MQD8U!LI_?>,USV!I#^\89&D&3YE@4;)I^CXH>.(F\'(ILD<)7-86F*.H7S_Y
M0:#E 6X&X("G@17PKKBH^67P;8 B.1N I>V3UCB*,C1^!B9T_9"]R'@#L8HF
M]A0',M C]9?H*2R<#2R:".^)UIPW*O,:,5:*?ZJHGH7AA&GC/ZX.E!9L9<3K
MKZW/0$[(23.@-GS$YMQOH )4\7SRT+"B.>LRD80RQ5G#8RMXK K_6/_"V-DT
MQDQN$ KD;&/'ST-NB?9NE TO+1E!&X'+/48TCQURWA"WU0M(#1A=[XD0Q/R8
M1\GJ&?RBR*FSA+3;'.7% " B?X^!-/G\\\IO2D6)2]?>8&AM*IJV@-5-Y;4E
M_?3;#S\!UPP3:K 1"P+&<^IBYI@"DGM>7&_,&5VX@]>[<9MO-V'W>4[VFY:E
ML6=I],W.P]T\]'O+1QM7 ^!NN>-; <K+3^A)9'B*')HLAG[/_I]OO?'1JO;=
MQ'KY]P@@_K_PGU?P"U:9E@+[)J7/;-C?A=8]V/OH2NVV.S=%9DK1-S3R0E32
MJ!:*(N#P'SZZL_+17Z(^WFV_5H_2/SNO7[6L7]&#+UT5I=5MO;*V8,UM.INW
M)H'_G8EO8.\EH!K+T@$+.&K@/0$C1^]1GW>),LGFZ / )TX=$%D@8\SC2:<-
MZ/C(Y5#'!R47+ !03)4O;^/[_PH_/!M&3ZJ4F=T]A!?R%;'#-YE"AR)J]#HH
MUY!"D8WJU,CYBN=-$ 9P(!L..X"CH])/WC-\DX\^\I1\J9&7N:GR:A':P")Y
M8 =JEFAGV[S7S]GC1UX_IZ$OB];"\GFNQ M(5_#X3&&&L0*T?1RRIJ)0L*51
M:4@*QU-'LZW/;[[TVI?MUI1&1+H0:")Y>3^L-Z,JVI"NXH,0R4?X;4FT=MHL
M3CLW7Z+\[S\^21_[;>B]RWV'J'? 4C\+C)%D"2HV=R$:.Y_!V*,K]5/DLF+S
MS4_^^#W[Y@/$S,<_<1#@(T8MOA@^Z#<3\QO\]3/5E*FQ )=MN]V>GLZ,.J!B
M" , C6'-QF"_Q1[QI]FQ!L&@L)Z& L,RA'UO?^K^WA2 .]D3XI%#4CFM&M2?
M:'4=75GH(,G ,O<YHI!?9_[?/)JJ+UHN&U7=KK%X;$48.N1F(/J22F>! U9^
MX -=%2-"["I@.]V*@.4^J,@4F OY(OD5 TAB'"4D>X)4;9M];!PS8%F%WA3)
MJI%G)?FO$N1G%KI,HKE753>8^UG]4FGVO\++;O-WW0_>\IL^XXOTTS,-@(+>
MO-5[N71/DTZ[-3W\NM#4I.B</J$[56;Y.CQ'C@=RBB-1FCH-7)D'GV-7*4J2
M)+42_YOJ>3"F*/Q3[,,^0K20R047&92.@3YI*</-8)<8]E"0T3HQ*HA8M0<D
M7W1^:TRM8^[,- ^U(JS,XM"3K %#&._ "/3)+-X%\<_F=P/'#Q+%0BJ J&&=
MS5-(*3IOKD3>7[F2=,.>MP'H$V1N &"45H(Q7\(OAE8P&(G+9>C/T#L8X;J5
M9$3J]L4EKS]-+\9Y6^6TV H2V.&5*=D^Y:UMHR"W*GVNNF-#N:'BOE-O#R2!
MKW.S*/=M8]FV_(*U<VXWEW([G7^ZT23<)1)I"SGC>TF3-;QVLQU'6TM-7TRY
M91UDV03\K;ZI()^$3ZHQY8B1_DTZ<9Z8A;<")$2%1#+%D(L&+*73\..KB2$=
MPXR,O2C9Q"O:Q8W.%D\^6!">SV%-#G%7BBCC3<7H0E7IQKQJZ[<$,E+ 0>EX
M2S]\$*$+ILL[/\'L2@#-YIHY-?[H]65&NV496"-"+N!M.2=IXYLV'_\);-(
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M=9U$>5S+,"HF:;'N6'8IR5UIB#&C&SG?_%$VLL81VBBHON:96Y)]*>=L <"
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MDP6.19R@ZSHX4_YAI6[9RATNRW*%',"#P5C,HX '^E&8T9-]$8J!G\HZ/PK
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MY/+-CF+V&MC,S +M-/'='4T1;*R:>@N2^W0H8BL+G2"(7)(="YMQ'KE0N=K
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M6%O6E\@RLR!D1[G8\3%JF-O4:H_JQ/@;K!A 4E1GC0M=WNF\&&"(?6[23$&
M)\!,,O3';*0+KG! J%(K^&$4 #/,&TC3DMABN8\=.(,LQ>H%W>-8I4]Q)^/\
M5070!3[LSI-N@EAG6V '>LQU5L7DG- <3"R'] 76%? .Z#Z>YF@"N<^6]:Z
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M;=X3A!Y/)/!,7W@&W0P17?#@;FS:3O?U)F1C;AY;-3>(:=^_1,#&N@J16>@
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M@4RPV<RC*,16E(\6(R&1!^A@++)#=QQ'WR:%:!O'FXKTQK&,G*1PMYB@392
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MF[)<9%3#>(2#)3I;[YOV;K6G_^EGLEK(9C&1FS*7M\U-BV<\3[,F(-WE]>D
MO<U)"1?HL_$@=+?'EBE' ]/H-<Q87W:WK%FG1,"C''OTBW MH>\5XBE=Y$4'
M5DX4+M@KI#E.SN?I@D[\"S,M%]8P78E>IZ4#ADRR>1DJTH%A:NC.M:8V(<G%
M>(RQT<EO"I'3D.OSCBM -=VN?OC;VS_%GV'ZEHCT>/*%6ZN>-J23]:IJ7!T#
M*&^KK61DKLG #" >CG1:SM?8U<4=+SHLDQ/6)?G*:UH=3*]<E[KC%'CF.^4W
M='3 X17+I/>?6/WHL"QL$/I*-0B%'EC<UN$BGC12+0N,:;MAZN*!EU'@*]-Y
MH\LXVC#-#)6!>Y].[B.\<C+R(T?2],&6#K+N%/50F$FP+P<$9.&'ZK.9+S!]
M+IW]FG["O-?A6(L+-(TR:3?0MH.] WVX<'<OV0 8V KK6*W5,_7-WG15V\5<
M8.+/R!'OHK1BT?M>U+O#_%S3!MQ&E\:O6SZ//,5[R<S7&Q4KNBOK^@52"M@,
M<U(:Y2MO]40;JGXG)Y<=44J'^ %$B&P=E[D.<7!AC9E?)4@PH='AM40>&H0D
M1M9H>NL9*LZ=[DN[[[H4\DGZC1YEVXKW#&T,1$97JZ_G<D/\V.+?Q3OY)C1Z
M@>)"Q8=M;M@?RO;(OW$N@-,RXBC^>&R[(2Z3ZU,8\^B%+(^SN#_X)HM_P-:G
M&@OF]E[F.$O>4(?PPCN6E3I&MM0[$(H,+V+:B:>2GZF]_DEE!<I:DR!ZH"P&
MRLK-N=;7D!I_6:&U9E"*U_M2$[G1Y1$;77Z7&UV>3:/++W6H?W*K^MM9G);8
M+Y=W(S>U;009('V _,M.6*W5K\(WRDXD%R8QP53\^E)2@QXP$\OFPETNW#UZ
MX4X4:L8F,#Y".#9#?_*NS[O^">]Z)/E0F970DE.O?(K3WSE4=:K$BY$.AW87
MJQ\95IAM2[8MS]&V*(XP,0447 7J:5@;S6\?VR/R0JK0B%RSE?_[%><+\8>0
M4F-MO![B9=F&9!N2;<@SLB&<4*@+)+HYJ1H%/OL$;L9".UU*F10T/M7X:";C
MKNC@O/CJW'7[,Y(7^D$V,MG(9"/SA(T,%[-"A0?(EYM2M62CIJ_6,^^*4X*<
M B9R>Z#PIV=)O&PKLJW(MN)IVPJOG&R(+2_0/D=DSHKC9%M2H^,KVRA"QTR*
M :0\ C];F6QELI5YPE:&P7%G,.,(@;9=<6>0$M>9Z1T3)%L.QY9[=WS<TS \
M*0F,U+5A0P:X+V"O%$B1A8-"^.IKNOI8A/[Q[^@Q;N2O[Q1\O?K-VZ^_>_?;
M;):R6<IFZ0F;I=1G$9RN^"T"^]>T3 ^PYT$(,QDZ6/0QR\( S 8@Y)@*SH8C
M&XYL.)ZZX4!VA'9_WNIYJ^>M_F2WNNO_WQ8'= L!6S\"^W\<AT7L>R9R^)=[
MJ6G;#:%9"IU3H;;>1Q!NV\!BW"QTZ_36 CCV@@1:UOVP2W-K=O3ME'P,;.CM
MBW 3FGKV  ]MTVYJ3FVAJ^>ZM5Z-T)@ZE!C' K>6IF\4Y[B)^]#6Y6:$B"/]
M\H7>G2\<;C[0-'!KC-R/_<M]>6B%>_ED9!'HI=D4* O"-&G#SA)Z.< /QL;Z
M G4!SUN *'[F@>L'M$%2N%ULI.]&^XG/@*RO5B]#NJ\&5\!R@XKP:1Q; .6%
MX$)>('U@:9ZI!*\MCCA:!'$[^@5WE=I"L-;F28+2-2^BO8A6TM[-C]W-6.]U
MF+0#;\)SS<0A981XN/XI>XBPT*1[D'MRZ8&O,8/7+?K*T4\6B$?T=CH6 DY#
M5Q"CTR+R;*&IFN<V: 7CP1PUC>175V?5 *9-U)C;2I!LCKKD+%M)#VH G:VZ
MOJ>YE4[6ZM8 =RJZ/N]#78-.QV;.6C9QX>;2LX>&*EH@9"-Z800HA"$0 !RP
M)/#=Z^H]16_[MMW&KO:D=7S6VYXPO4C?N#[7\VV<_%Z2<#6,DFN,C;05C8=/
M@B]MF;)B2HHCC K_3!,CW*+/__W+N"V4W$(7-A9@LHRW8E"4YF7V,X[E2S1]
M]_PX8Z-4 +8M(CW+I%?:&D]2<X-EAE7#I8[ /;>TG>E3W;4/H05R8) E9J#U
M:D?'6\,B6>@NK*3?VC?''+533\:)[M<?2][9SW1INSY3ML)CD:S-64>_=-8+
MYX5/4A>!SZ4GHT,+OB]->I7=C=]\];>7O\42MW6=H(K#U\X#B]=^G^"/#]XK
MO#9O.@"(PA,+ II=CE;RY%KSLU,#C1+8Q&<K@)YCR!7WYE[!#__L8[.%9U,O
MJC4TQG-G!0-6"*T7XQK8T;.C>AF,B9.@P833C6@=\H2C#DDSK,W6_X1!BO1*
M^K!B,#VDR[4R@QZDA.$INE, ?MI=O*\%[A9OR I+2RZ,A3!&,?"=;9"Y$=+R
MV\RX,-?GM($#+(UMCEPP@NB7GX??<#X]3%_#EU&/"]Z;>)3><&5C),V,3=AP
MZW]^%0K41PMIQ[9&.SL<K6U[3)K-]1(&'*39!>%)^7-EI?GD8^9$4N=9JFYV
M-.&>MC9X+=?%*;&-?!K*Z;G@=5&(B^#+TV1-Z5:O5N_8V\:[G.19P]L;L$E\
M:2T.)F_I./[&(UU[5 ]^XY=WZ@)/ )IB[**GR5UD1@U25T8G:R7)Z=7,1><8
MP-E]F;=_Z!A+XZ@PB,C]X;7D?OI/M?/X=[_/_?3/LI_^%TY\_B_CV/S^? I
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M%2P*B9B*$&+<M=U[82FHJZW(NOES(MH]51,UXSQA.Q)2R)9EQRD $Z6W;Y
M0*R(%_OHM$ROOO^?;U^_^/S/NJ;HKEOFIP+5BP2DY2QWN[KNVF);G[R?;K*4
MTEF/1*C0CQ^57 RM09KUF[/U/R,'Z:7)(K%WX[H^IV,,&@KN=#>IJQY4K>RG
ME*Q(+UPN7K+"%#Z=B"'<J8MR(_ZLU: VMV?F GLNL#]^@3T&MIS.D&R-D'+W
M8V\9H<4P"F=E)\&Q\(&#G8NV/[9YR PR[[FDD2('!Z]46J1,XJU,TNN,#\ZF
M)YN>9VYZD&TU:B?X,,J;)UE8^*Z19Q69;C50EA*%,__J[??G97"R3<DV)=N4
M9V%3VF/)N6'5+8E!I/M*2""'+J?(.\$)9%!*5,.H& ,%C5RW1;<%L?';K_K?
M*B"(M4KX=O1?WEA>;2*PA@_G:(*S8<J&*1NF7\,PQ>WOE9I&P2B"]I?S&7^7
MZ@@JZ<>VKC8&7/+LF<J(KYBQ7RQIMM:=H3KTFCMS/!!*#]R.0R\=WIWQ+7ZY
MRO8DVY-L3YZ@HV,)7DB(TH9'U+..;+#=5GP.@>2HYL9VKYJW46/8)-L8;+:(
M/5#/Z" "/ZEPW3>O7VKRIE_=M*T+N81D%E#DW_SEU1ORDAYT??:-E 9G) -6
MY8 MV[%LQYZT';O UX7V"HK61(.>Q1P581WY_52-0UFG.6>T 0ZO,KE!LH0O
M8 E/GA30A"-5DUB)T4\!"A3RU)JX3M+5XEL!0[OSH-(4X$=A(*Q=ME_9?F7[
M]:3MUS81 =6J^1K8>H#1&#2>FBN5Y*QHK$\76)B#FV:=8?,\EL2LA=F\T^Q&
MEZX?39YH2:%R3Q8%7IATK? 6B&H2Y.L9Y*_H3):]1-GOO"+B4*(QH>BJ6O1'
M2YJJ1K0\^OTXB+*IOL9MU5JK%) #LN/%JYR:^^!:;O[RW9O?VOVM9T+%8[VS
MZ3U8QLSLRM@VO.G:OG_!1(M E8='6!0Z.7_\9$.?#7TV]$_8T*?4 D7T_/9M
MS582Y0 8E#/VL(C=>W*!13TTZ; INT9=5-RGZ,\8)!,I8B9L*8 N2-JJ^O0Q
M-%4&_7$]4N V!\,)#6KZ4C9GV9QE<_:$S9EP[X=.4VD;5 -!QFQ4F38Q:M:.
M%XJA/?"B$CYS6[9K3!'O,;2,K,V!?"?],&^EAOJ*0N5J0/<)W?PUVOCT\^^B
MU-17J+.NV3;%F^#[YV6X@T\<Q41"K<;G+H%^CO*2%-O?EMGB98N7+=ZO6X'=
M%[<<0AE4(C1L1< $/!INK0B[ORLI\FK8+)!'-KR((?+'EY-F$I$7X_'+:<]1
M-@[9.&3C\'3<H2CWR&SXBU+5X/!H-Q4#/@(AP+S]-&A?*N6*M-\*6P=Z?&-Y
M(<J&2C\RR!K:D!=,-#Z@,I*#LFR%LA5ZRE:HIBW)R:%M^7<F[-J-S##W)2Q$
MWOMY[^>]_V3WOJ,2/0>/0ND0*C[,],5N1I THR]LK0.:B2P8C-[04SI,EF"]
M'H7[]E?JM_Z&RWL]<Z%) JMM;EH,Q:_6TVZ$H8>RZ(4FL'A?-I8%NX%_UW"'
M9)UDKH2=C>[2C4>A9V,("7/<5DV\:BIMV>\KZ:H&[ULWWAAGT48)1'?09-F#
M P ?FMJNI/N7Z\([Q@N&-@5Z 9K\S7Z9794C^;5*=@HW%_>&XY<EA?+MJ=0'
MX:XL;JE0AE.EM(H73_A8 J/8&BVEY58H=0(+W2[IKA <M[)',GLJGG[VL-*>
MRM>R*GW4M5\;U6E=:QE%&-:,'3:61P3P[9]0Z^B>98\'9I$J"I>M&NAS]0+5
M]N^]:7O60J;O,(=#$3GC0BC"\EQHA7N8&+UCXHPEH$5*A$QP<_:=?B6"FS]E
M@IMG27#SZXC0?P]CXXX!$%[B_#B"R9J)M=G"%'TX;![E[/R7S\VA"C1H,-G*
M%7>&05YH=X3M1TE6F1J3'A>U*V:@Q)69YA&;I>7Q<L7\YT@OP\2CCO%2V5^$
M1LUH82(=3)D0KR6>1'KZI2S[7CH.!R/N-/9ZCA=5-^7=1 ]Y>9LR)TYH-U5<
MJJK) R!?M9\PSE8[X7%\/P5Y"43BH#BS0/O/J;WSW(%87Z5*Y\WE\-0+87+8
MKMK>R"(]M-MJ5RWRVL'5*;JZ(C<$.W6)&]":6V4HF:^JIZU"-H^]E"/RFEN4
M2?FM OX93\H.!_9/^3,SG&(@8<7DZ1_"7%KMM'U6-TN!XDF@^H7:%^#3\KI<
M(@Y00I@E_D2('%=R7C&A;3NG+Y[/_'31W?NP8FF*!1[[14]JO>Q&*>=VX+U_
MIG2<+\.:9K:N7:*7L(A&$J0 N<'*IGM;*C4O&VR13Y#$=T!#P?@^+"M_>4=F
MWJF<[LKIKL=/=T4O*V5BF%/Y.D+97 #+5B%;A2=L%9:H\SW%*7*,RK=Z;(^A
M[2.4W%F)0:E#\8? IPW-F;('Q4NV(=F&9!ORC&P(!P5U<5T*F1Q+O0@';9^(
MGZ#JP=)4/<4HUZ*01%$,_24VBVE4<E=T<%8R("?;DFQ+GK(M2:4%7?*.D<<Q
M5K%<GB_79^.0C4,V#D_;. 3>2) \EAUJ!$G98BX3!%0'9,J">X)^IHM69I7-
M3#8SV<P\6S.CRK^+_8Z(;;9=<2?%:6[IW*Z5T2-:&!4Y1NU?BJ<BE^E#FX9;
M$Y+8Q^1L8=.X83V4)KNJ?V]RNH8S.M #W<A?103MYL0/]?;K[]YE$Y5-5#91
M3]A$I0X,0S75B8'E"+F7?B"[H#P\W-%=]"&58O#-KG#YWFPXLN'(AN.I&P[4
M9')_4][J>:L_Y:T.P>*NX@[K;7& RJ"B)[OR.(I>V!-N3'JD0?]^J<%$=)T9
M'!HZ403YZN<H\EIJT@D],!=@.B*1NFVY!O^^:>]6=_M2N!@]$67$ ??#N%6"
M\C/"TS>B7ZT:T>L IKW6Z'7D/JBMIM#N5Z,&;EDZ<ZIF/6$]HB=<+R(5^5GD
M5]*5=7VH^C[0P'WUMY?F\RI%IC;N5S2_12"BE#!;\(G62$01=#/<1Z-9(* ?
MZZ%")Q#PE1/HZS\!S>4VPK(I6:K<OLV=6V,I>I_X_CG49AQF/S5>VSO(;7.M
M59(1!@?ET;0<J-RBJ [2=K:M=KNR8VX$F1%A19".IXH>J^Q]$?8<M^G5Z@>=
M#,C+:D,<\RV 7Z$K?7)#%7VXU\O2)4KH&2#"]"N1'^/7X98MM(K92^ R^A)W
M/)S(KCQ;+/!WM)K1JK&FD2#C4AUI0*OF%B;D1NBSK?=PJ1NC+SMTO5G[&_^5
MUUD/"O !E7J@?ZL>%Y* $<NJ:$)S #>RH!W!VA),GXF%GAF'WO2!58A^WVB[
MGT@*(RC%7<$O>[7Z;Y9_MM6\J;K->-#NR@#PGQ0!Z###HF!M8LF[<:I-@4K[
MZMA/K,6#"77CLG[PKT0V6D#66R,F<?AV_UST(L-=25M_E)5?G)E WE0X--@"
MX.*[&IK5]++<+$-?#$;PKJ*7+WC[,LR3/J8#(&J#!AV*?_K=8H//WT<\8MLH
M4]U0WG3:*LJY3^Q8LWG;E9@E3Q*\(!88VJ#&(;2=RF9/OEH-?5GO;"W\5+;T
M\%O:05N\5&6M&*ZK)1Q!#N'*M%8_R5)<FV5+SMAXB/PSA,QT;A2]/#U.>WG8
M=3!Q\7RA#5]L;8F2C:HD?SP_[L]32S];V_?-V&$]PC2L_10)/>L9'3FQ>Y*Y
M7SYS19B;;1D=RQ67#LGO5=2CJ!=(DXU7*<!1[00T0_^1K5J6TJ3HC;D$IBJ_
M#Q5],9KNO[QZL_8\W.OP;'@,\BK;7GC>E-7-['7CY#SW95'C*:K^?1^[07@,
M(031/ZAO(S<N/TKC\I]SX_*S;%Q^2HMX*C0#D_KM?[T.Y&QF08-7)_:971?Q
M07P41'[.%FZ1D'B3_58O<M H4L-3T9!!"$=F6*@OI&,5(99Z229"DYX+5ZMO
M+X3L_+SNJNHHQ(LNG#1KM;IW98B+2\]S;HIA%0:D===;Q_N)^$UHB;R@/R%N
M$7E,38FR\2U\#S1W"F=PH8>A"W1#Q*J1JOKZ9RZ?-G+CS4JPE#3L_B&4(-_W
M=,%3^4BIN0]Q4M02L"&8K<ZYM<*?0U;O@U?[F>M5 QF%S?SK/Y8:GY7O5U_!
M,@_[KAUO]KSXB^.)FRMNFA"W?U-0&/!#!SHS_XES73D,;-AY.7"#_KF5LEY=
MCT-HIVZ'$,QQL.:N+JNFU/2%]@Y/OQ2N8GXNY%-ZD.C[-%G*XJ_N6MLMYP@J
M")G0RL!50SX-KUE7[VG1[2%A$E('"TN54R+V4G-'.UVDS]2UOG?]G5]S3!^N
MX?BY@.7;'<>[TX;[RC40[?08B&S#B8@#?5I7N_(%/1="X\8XT",13["C;9H&
MY=!T6Q[(;6;<C+"*!HY0 01V6&QC<RB'U0$'"WV 9&BOC\5A9NA57Z8E58M(
M*_*FTFC1#]GK.&02C4=RTAUO$8CC3H96VRAD ^\0-&!<#B4O8,UV8J_3.R#U
M-O9] "*%$,)O.V0391,WO>FN15$+WA!T_.!E>- P I)UL5P<0YQB5)T^UUT'
MPOF&#ZJQT7!:#A$\)(5.9&>$:'[/SZ\1L[RQ1?^:X)N18?%S<PO);G5=M;R/
MP3HOXRVG&(;\)44\M:8A7IHYP6_?X&"M D,^YVQ#DGA#GX 'BN,I6@5BZT![
M)7!0^840)1S*(K3$R8APC@ ^" VOL,.Y+&X?M)!VC %#0GO'!E""U!-&AZ*[
M0K5%Z1IWA6B=C[1$:UC<[F27L6'"5:K>W48I'3BAR\>O3VKPDUU;.A:I$_Q>
MGV#L1S +1",KA0&Y^9GK(4EUC6R6DN&56Y=V>[8)BI>K:V\[![6=5<\JBXWQ
MVAA0D)9QW=Y4&^V9BL:05E^M9S<G40_75D21 H<_UGG5"+^'NR0R!*W8TGN,
M*+V$4*5U$WM*-E0\.EI\82_2BMFR+ZP@HK(/10AY+4[H.V/KRP/D?J)"(L;]
M%L+:/U=*T<(CQ<6J)GD]NS$4S5PK&8W2L:T2G)._43Q#I+9!E[W67#<(7DX)
M?9TSD%>KU[.!# 999F]A@O'8SO%:.@?H!58[>B;F7:(=O'R4"AU2PW0=@8:2
M9P/OP<&3FN#$J'?M35<<UK)M>4[I.>4]Z0]O]IC=S]7E[VZ*1EEZF'\%(B%\
ME:JY;6L6"^AI73!34U/<0,F39O>3V-.^Z"3]QZ[<9*50>G!8,(0SD)?72-*-
M,59,ZYU80.=*I@*4[-F(HN*BJV(SZL/0HN>#]-2.<1_@(>^4I7 #P?CP--40
MRW]T#:[!2,F7%M>RKX!I^S=ZJT6G[/7$#7N@O^]\?1?=+CKJZH>OEWQTR8R+
MY?_H#&9-V[S PY%!*K>ZZ#"P^AS\7%MLIPG#E-^%!MX^-[0/&5;)".LB\<;.
M?P?'YHHL]@WJTN(J27EBNOBL?'\S%E@0)<HJ%!#N@K.D3K#/ 1_-;YF].L^&
MS=KY(.H\&66.O^WKDNN!\Q>*C<ZD T@S:7H6B3KV^S!QVZJX:5HZS#8,YUBJ
M?28_O20=*J;Z+F ]]-8BONRS4!$MPOYU\FCN@6@_5QNQ6AP**XB ,Y\S@ ,?
MIW/S]X!\D8%* J6J)IPPF)]6C$V3#8B#1$(&?K#8XK*JZ[9$':G74_F1%RTM
M@=MJZ-ID//U*5+>2%U&H%\?YAH-P6U1UP8<:?:$)*UXF%]_0[(G28+NF.@:'
M%2KHP;>*MUXS0*D1=W=IEZRM1-P7AU+Q!/[\5#!-?Q%PHZBC5XLOY&XFQ;KX
M":SL7[]^^X5DOC Z6F=+?H]O_1?61O/[J]7+GKTP\U<7-WZ(G^+5^ ?^2FL*
MJVJ&V32EQ 5\UL*W#! 9A?MX=D/]FFS#!0J7,Z;(CI-W7_WPQR_^_)FYBI)_
ML!0;%GLP)*S72XXJ.X*<VHM7H\?EB6)02*  !>(M9GJ?4;#W:F'$9:7%295C
MX*>Q<>> YXO';/1AFAS1GBUY7A5=TOT1R\#87I:M$B.?!")6Z5#TPB74RP..
M-8#1BFX(L!+VE<H1'^G#!H\E]*,P;[DD>=2ZGODIG[!-?5+EP$ ^?K=OX:)R
M=HZMQ9$\:H"48)_XJ>I!R2*C_5A\_+O";S;>4@,-**<F/93@GA$+I?O^(6.V
M:[NE\R07VC_5&N7O/\N%]EQH_U^^B)-07_,BFAV&/6)%Z\K"BGZ1$/).L&M(
M/%AUW(.?UNR<E,VF'1O.&%1(3P'D)J5]-;3F(D3W(G%:ED,-CR+GD*>J<7^6
MS!6H0-5M7^ H.DT06<Y/"E#ZQ(;?;[ 3<8DHMY&XO:U(8&S=P$'1[LS+/':L
M\[CU1.Z!6$10^"4">!XF2^*0KI1AY.0I,YZ3?\/6(Z4,-__5O*?%"94,^D!Q
M2K\KNRX0E-F/D_B7'9RF%.AS4]ZT#)2GGU0HEW&HTY75X7KL^C+4TQ"NUW74
M)\%KV[H9@R2+0#FP5!80B 91T2#<OC9;35,&<%9M%69X7JSMKA*HWW715VF,
ME'$8#PNI77;V@@$Y+^_#870(F@^X@'/=3>_!79,U(3 >9/<2FN\'=9H$D(^[
M2?"^V?1J+TQ*1>$L5Q>RI'@O!O?O#241$E%:TG W.9;TF&+N>;!@I@-HZ701
M[QI14,XPC U*-RQ(+-$/+>-#?P_?^+Z42E45LC;T[ <)]G6(/JW$TR,9XX<O
MZGORDG%MIZN!1D_+5KSFYJL\F?^=5)>B*5^'-;LF$[QY7]R(8)0C2UFGI/3:
M!L)?Z^D.Y&?K-X:JE^O04F[EEWU!:](V1%<"E/WB?5GB[+$<??)\AKJ(G6B<
M)-&NJ+BK)A1U50,FETC8(H_(I9.;BJNA\AYH8T)[8.]<"=XV582*;_[RW9L4
M[^U^]I=7;_HP6S,&+,6%&YJ2'S(Z=K.C*O9-)/75G]'&(].IXF.7NN*\\S,M
MR. A%Y9;?%)#9EW03 NNQ,32X<F*8-6&?=SWH3[-F!$9+GEI#]Y1NR9S*"A&
M13&$4G@?D#'61X)9DSTT6=,!4\0:&<B*G6$Q](A_*<_^?HX5%:V7[K:D[29Z
MA*W)J6GB-"Q'+@X7FY.#T)SKV LC&3*Z3"!DB=HFDHK<WX<R$0[173,;ED)S
M5'QAE+5IJQ[WIYZL?3$%"[%#Q5%*Y&@K:[T8*]%QN96S]S2OL?IO)URY33F6
M#A3^M-M^'5BM=3-JYZ>=C^!;.M $'$S!9FA9Q_$=+G_.CDGO(EHJS<NC:*C3
M[2%_E'(!'[1<HQ;-%26<XF6_7=H<CQ\V_# I0GI?8BF-J%^D!5]7#/#FQCA6
M\9$<9IS/J#3E+5R 332,4!;K("M+O6DG@R@!VIG0[AP&\<<9=CS%D*Y736&R
MCWR@<:YS\6GEZ7@O=2BI\/1KH%QC@=6AP%QLL:[$_.-\U ZTLN+!5"CY?S>H
M<J_>#6SM\"L&.!@$G1/ +/73P5'2NEVQ+8XB'A2%34.!8NIP"650>[3=#>'2
MZ7=L[AQ./5"^ZSWAT$X=B'AVA;)%W?+9<5IJ:S.S'R21 @#".9M\3U6;$N(U
MOJN%.'P,7:UB+VRB;./&PS4A!K*D='[<BTS?/WBAG--7Z7@3P8EP5CVV$N%0
M!W=UHVD(#5FCP4YQ0H5NC1-7IO^CHRDVK9Y"Y$*I48''WC_095]K+[=^:,T%
M$)!;W18J&K11Y4OQJ/0X^(^SV(-,"Y-I83(MS"\?_%$$PUK R@,G9\A0#359
M,KE69H'+-B#;@*=L ^A:6\ED"\6L,1T@D6=Y$G+-#+C5BV,D >)H7P/RFY8?
MK7+!2_E\!WU#VLLW\)6.'9P!?, =&NYBR^E(]L,M:]EZ7H9)825;JFRILJ5Z
MRI8*#8B2JB7[$G!31JK-T+OJMI)";,?=*;6K13#VO2D'M*R@WR;;BVPOLKUX
MTO:"B7WZQ$A8IF?J9D1=:9^ C[4 5Y'*=B/;C6PWGK+=**M_:*X?0.#&;(8%
M&JC:[L9>^ &.8&N1<@$L3#=(B4#^%']C@0[Z?RS+73754 G/2R0"W62EY6QA
MLH5YXA8F>";K).LR@5S-J2BEJ/J/+-"1S40V$\_(3(3F4X7/31!!V1)D2Y M
MP1.V!"[@4!3CRL!C"3UU*QP3#A67?!P)F;AE)IN-;#:RV7@>9N.!>8K'%P/+
MS<V/TMS\>6YN?MSFYD_V!1Z_&3L?S_EX?IK',Y!/3.;:)SHAL2%BUOJC?1.^
MD<'#HY1AUETA"0!V[=ETXA/6_XN] )[^YE++RDJJPW5H)"FM>2H XE1V+'1[
M<*_8ME0JXT#?FG2^11;)M2OZ6%/#M=U &:^Y.4VHA*W5PCK8/),/&IQVM<D\
M^2:OV*%CO[.E<K5Z8UU6_=I@=C(@>Q:]TT[U?M-5UV6L8NU^B0:$=K=[P0^F
M*P3O?;5Z6=-L*)'JA3F[4=$(Y<,+TU7$/K*HF+-O*Z$D8Z+4R 3+$V=C-_L9
M%BBB;>'7%DJEG\;MS8$;C[CO==L&1$&Z2'P'FVOX+QJ%)(E '_GHTH<8Y8!8
MP^$78<]<&NZD5!G[(:.IB(1NH%B5U8K&X1X*PDRSIN^$A<-L3?T>JW;H:%/M
M1F'9QL\.50_V_VE3K-'1>2HZ.AE[;K5*FVK"O#@N.+^R?YBME[!(BHV*792-
M#+:@2^]Z;<J-'6=TU7UU71D!<9Q4C-2O,B5K58(S_G ;H1V,*H-JT2#%M,D4
MVZ&?U&S'K[-BYGW_ODF8D7CKB,.3/K^DW2U \YXA/QQH;%SW8-3XLUQ_79<W
M-)6W=(Q8:F^'E1H4[3P FSNRM\GX._7%GGR%C;2\P:RTUKLM5PI,G28%LSJ.
MU^AU0Q,=ME*[$1=Z$Q@PI<L>38$\@ZP_PN?$%H??K73I50WOGW]&,54U*#O1
ME[D>>Z U:3]$[42GMV#:IJB5!@R7<I2K$,[C=\P^TBK[UG-?&#U"+S/:S\1L
M^Y+581U5D6YQ(VI-*#^JABZ2$*O[MFRE"'AH!Z'O%?]U)CY3VR1?_R'PNM!@
M(B<X-N('WT.\<&WZJGRJ]H="6"BJ(3"!<%^V*4#,^!OA(M 3>#I\5CF]%=88
MIGMAR2MSU?K -@R#>9">:&,V*&_)CU)#A:\,-"_T1M;>?VR/TX[R"B*(8S=C
MXWJF!N,5/+S.21=P=WE[* >^(<6>Z-XI.RBL8IYW5=</'%.OH4'2,B,(_F)<
M;/I7$W.%6[89^P$*+55]BDR^:#GW.@_U2>DAW%59H0)=2/PWGO818L\_@NIG
M(T_.K+F#Q$*B<E V""+6[E&]]$9\-XH _CYRG-<B9U2J7BM?50BTP.'.$AEL
MS!#D%?Q->0((L<QOPAWCIJ&RV9>'5F^.,1FJZW9[$GT.BB/&0]N]D"4+91C>
M2X>6 KNQQE4H-$7_PBI<H",OVIQG_:=^I%]WIT!6>AWUU>4(8.X;#/C8D*4'
MRQGYYLG<A='1'6).6\E,W>]F7^3YVHFT#SOLK%C+\AS)ZX:G_= W/_\RK/';
MS9YF4T1QI$M#+BPJR<VFC^(FD5^)_+2B5SZ:@Q#_Z(AS>(-%7&[V#8?^2BN!
MHU#<8X%[LEH)E+3NIZ6 QW9HF3!>A:]!V4;14S\()\O"M(&6Y+H7T24PA24D
M(UC2QF,QD5-F32?FBXF\6T$^,019'LUZCG^L.06JAR.Y&:,C$"Z$*)OV9:6[
M.*PV/K<=1PZ_WWS/7JV^&@>E<Q!EA:B6<$'F;1U$/<*K^ &4O)F.FMJ:7=Q5
M=T:D%GXL!$OIF_A?< HEB#5B"(6+QOB-U@G)Q8,R?\_6B?U>9O0GIY2%G*,L
MYO%P#?N\HU"D/=+^A4_!8PH*=V.'%J/3,?4AB)Q$7A3J+(=C]!J#/V$L%='!
MX"MROF-+>X,7 !(Y!?-;E").KE&6[Q[I692'*:GKBJFHQXYIB;K;\L0O(G/L
M&(@XN(]8#G7)Z"5HJ6WV43-<("!#*SZ,-MY>K8((=GJ>.KX=ENS2%V->)I5L
M4D+3Z#_%XR^R<7%"AVTC)UI>(90,EL9VV+F8KION'[?[HJ^0;*/)%'O'<4E(
M*>;S+E #\B]I(K (!AW! S9GW=Z9Q)K8;)QW"5N9L3,AC74J!]NT@>TUS)-1
MB$/'E7[3WLFC<4=12+NJ68GG0TRWQM2P)7V2D3N 3/=HI]5J.!V%:C&RW CS
ME!DS1U/FSS2^5EG0XXKN7KA8#IL>&C:]KOIN-!OB!"I"YM'E>$(2<E.,O:3P
M=Z,<S3WY=D-Q([[.3=U>D]57179:8[0%&V/5V</,6];8Q>ZT?Y@=U\1@Z-BO
MV]/J?7EBK57:Q/OJZ.D)Z5\@02.L=3'I:N2TC:@%"3;='_QL^*Y+/'5@S%]'
M82'AR4N2/%R4"%RTM$(:\:B%?3:-_6=RQ$DBX($A6L:2/#:6Y(N,)7F61/D?
MTQ']Y%8U2Z&HQ6VC+@B+KK"ZFA/I8?L9;*;JJQ:L)B66/W$=T5G,/&_1=73G
MQO6X11(+5[?SHH;EA5CA0"XETJEKEUI=:RQ%!Y9Y?7TH?,>*<'IV:*F CP\<
M&N%\D+?:;,JC'&_'XF3ZRW2*=:M=:94J.5@TQ1RJXO%HD=>_]"!T4\35JXX\
M,SA..Z5X0#&8AH/,@ VUIFSD:GRP:BBUJVG$1_5MF4:S@:]6=+T$?)(TGOAU
M;K!MA!&3GSW ^>7PS>CP80"\-"(7&B6#6O6^1L9C2',SF,J/*"C*(<@JK_M2
M]:'H72HA/AP;9:7$]K]:W>MUA"<-C*[,$,GZ.J@+-27NRD083&9_YQ1-Q2,V
M+6 3>O# @_CKA<&Q5Q'G5GF9$<_+[*?'^3<,004#,U*&M^+8K&KD-WKDTVB$
M>.[\SL 3_^X/JRVD J*H*<5TK^FQ$"K(X?O%%^O5%Y]]_B=9^?]]]>[*/RUJ
MV/U^A';\71/NI:L*I;&RFU%AAQ<T6ED=][6LO+THVN_&KF;4 D2C>8XQ->4!
M[EBI5^_)RL3/XU)Y_!#_70EYHZ%$/.?+A;IPU37]Z/7E5]__S[>O7WS^9WWQ
M(PU2>8 .'#W#=[R_OOCLB\_<0F\H3-Y@CP^JBVQ$4^!4/B)+RGDS. M0#Z\:
MK@=9^B"5BJ _P0(9Z6]L\BZDS#Z4@$M+OCI<WDQ40L(\N<VV/92L,W'N?M-<
M';WM?XYTE^1E8;$.95R2'[^XW]!*&4H=^P]]!Q&: $?R"\FNJ"*I<27WIYX&
M,((R1,6:S0Q4ORCP[_VOB[XGR\![5'[)B=,MIU%.FI,8RINVD[1SLD%E'RE0
M F<NUSDY%\ 1R$V%#,5-"6&UXQ[Z8.13(C'=W/ [(;)13O>X._UX\%%O22.M
MTB\\ <_LVV58&2V;GE5_9\2^;*I!PKOJ*]K5Q90)K0O$\GRP'\JB9YG7A6WZ
M:^U/IB NK#1"K^(L+*PK&]=0;&:BV[/!K9#=:QJ$0U GO'81J:>8*D[%*%JG
MLB]W?OY,I[A?+U\SS-X:]4L)2!VD(L:DP[(G>-^#8G8D"'8.8Q!:')/?.7F!
M:76<Y:B-C2\J'^CYVBQ&S#F'<SZ'HVI$BJ'!Z%G).D)GL"RUEG%9"9PEA0*A
M/?OL)GY2'/D)_L&J[0MYR>2G$UQIR\2)0<('TE=>LT"*(63AD&7D>H3QEBM)
MXN;AV9./Z6G\\5.+X;XJ.?D6,KDVTQ%@(@EV5K?'7\,2D(K-V _Q@"MUTVH(
M$!0[&23#6LHJT+IK-V-OM-Y,%'Z:!0PX*DN >,_AH=S:0.:=$_X,^M.G,6&H
M!X8D<16+74,"LAD4=KS:CN$P0>)EBVSZ+M;G'O",H6:@ZNA1C4@V$J0W@I85
M&3T._-+BZ<L8L(5Z&3RZFS;2_//%JD% 0!ZW(A4 .3$7]]HNF.O94PO(()18
M>*78UO*"8#8<5ZOO9>!YJ< K:-4 ;,M-U0>\B:P]@>PMFX7;2MI<W$W2BJM9
M@"6LCCQ&[^J]VONBN0.N^YY='LGR71@R%N4SA54_9(9>/U4E(K[FE(I(ZRLY
M&/S.R9<;^@9 C=NB'@UHOS3,7"@21(^^OI21+AGDL'!4UX3LP-_'JM^O^&:L
MXXJ320YGU7Z;F/1AWTE %_0$.6D@G/S:=:'G?GMB.&31P:<,@D%TK5X<-8WR
M!XV.8UF1#3P=Y;0%R?* ,5\W(KN<[/?W;5VF^UD4?$.B759<?)T/%AW,?L&2
M7Z"-&1$M@XED_-EN!PFG)$!IHXGWI?QE: ?6N>S*C#W3.O_\,!6H:0#.H)8*
MG'O%*A)AX+FR>N%T6G.]UFRN6*HS-BXB8MQ>$T,32]%T&/0I5>1_W+.O,N-!
M;JG,+96_O!6!9898;"@J;$O$\&=.0_43M<'GB.$NH^N*GW;EXS,B9*N1K4:V
M&K^DU;@8V9(+PBVR.P'7T>.-6_H7.(5[9#@M1$3C"OQ#3O!*/L[E;2-V'OET
M-3(F1"E_XTY2P+?&AC,X)RW&A1A0#)/(!XLNYH*&FA1L11Y-XR2IWZ)&\82;
MO!]IZ;R=N:P^(' X +^DK'W/MT]Q\@/[=CU)1^U'>MZ8B?+"?U'P+]P1Z1#^
M1P\E3EW<(ZT>\W(YBEQP>:4[+,VI2%"I85!]LJ_/(E%#:Y?CX!K@IQU!]T6B
M&<'UB BNWV4$U[-$</W"I_Z_G +ZE6QZU;_O5V_1V"@9_.]21?)7L[0;3"!]
M7U2ZZ>_2F/2FD(#B(8#5?WW0/Z#:\HGGW3KX/MROA%$\ZBC&-AE@<"A8NZUZ
M[2TT[6N<65/1<\YG*[(,[7[6;Y5DPOV1"/^NTG-6^J;3Y]#4=4\SWPMT#]"0
M3=&A\4ZZDRI1 H?#-^)<'4V!R%)0A[(<0IL!':3%EH'Z<NHNIN6U%,AEC]):
MEGX*K64;I*18++X'=H5A_8F6NQ2.FWL*QI?ZIY]I7O+'4*R09BU7_/>-6]SX
M?!2?WYI@XII2<?=5.U^?]-6^K&^7*EZ% C-CCTA70F5Y%?EH+NR2V4/HPO9H
MNK_\[0W]XN<*)^O-R;XA4$*EFA81^L__[?/KR:-+I-&<K+0T>['S<MOOM)"$
MI"Z9T[??AWHW*J_+#WWI4?VV#Q^0QUE*.WKX+/)L,-Y6'-<&XUV@5H.)1U^2
MX]'H4';19'T8U_G\^J=9,D#XN6LQ1))"4"DZB$5]ZBM!7!5#(7"I =0I-X8P
M4;$0^PG3*I1).VSR$'IO]KD9(0"WBX-)K!-I1X:%PH,PJE-Z@)*E9,UFLB)7
MO.YJX"YIC9VS4U>T Y& V)>U %ME%2M$*;1JE33HG:!U:-K-6GW(J%:]Z[\"
MOFNS:;MM$?I6G;JWUA_)_VHIN*K+&R[L>_X)1F7&;CW$9-NBVQJRF4^+>+CC
MTKQF(^)V>D*4O;)12?%[[..IXR@P=$P"'/#',MQ/KL\CQP^ZG7)I8#O@RW]Y
M]6:13$-^&PF-\-V;D<)$Z0A3 B3/)"9063 YL>C-ZJ7'K<DB_(X1MD&+7O[Q
MZQ&I4SI:OJ8):0\T?B\96&?+M.@*G78&8YZ#<:'$4M_3#;T4J9[%VCF.)]H<
MY\8KU'?1]MQNN;B=0""G"Y*V2L4E)3&"/(=L32;6,;$U"TM8+F/1/#<4G^SM
M>?9G9X7\(D('W&IP*QTO2C^=KPO,%;=Y&^7/UDJ9#]USP0<I@4@=&]X4U_6$
MX$$:P!XX[6)?$C59]=62^FE\OH435&)*S8 9J"3)C 4"Q GR?\E?9)#/=>FL
M"X^P+4CY+[\^.O$V?_GNC=]G L+ %#&'1#I+LA+]KIR_/H/#%77?T3$/+.N4
M ])#[ 4',^P7<X&*+GQ\8/D/YSOV0W<\%OT]NRAD4U-[VQJTXDYC!S[VR$:T
M( (,Q!YS2JR%@\S!I)CA2A=C[QWZ.DS:UIK%.PX9870E8T%;;.M;3LQ8&FJ
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MMW<5O9VJ*MF\E-QZ[N%4ZTMK?>GMYA7@QSOUOA738 0Z6EW5\9N\2E'5_;1
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M.;[JY:%.CFV,%TL!WJ,AM?#V. V=_Z&S<)*VB0'A+.=ZP_/+HO,-M!(.LWR
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M23QRW_,R1T#LFW $#_+0GW]ACVP>&S]MVSBFB(<\\=7JM8EX5[^ R.SG7[S
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MLM #4[UT! 60^&;?(IV!,W6L(#$0$N-+STSFO"MH]$=)<^GF65M;M19]5W'
M %J1N0G9H+2MA?OSK0S\K^^89[1+1.H 0X&4#7('MVU]&Z@SP$@1;*9EHI"V
MN==\<M]VDD@LN@YHL$M&E'8=-XW):HRZ'HD+V-%A/5;!\M,)+B@;VR!TA0W#
M*RXM?STTL%$$-N^Y' 0SSU40Q?;,T?1+./[)GN?'G#P6#TLXA,Z,7=7+0VFF
MV^0&6I1=@L611A\Y4"+)QQ'M#MA6-?<ECXV1XE:210.GU#8T>TS/S*AG\P/@
M*%H?%%6F6!-T,/M@:FJT TK?D]+3J,UC497@.N'G2TN')KY']^DE;/W3WHC?
M>)P#8UB:/1T*P]1Y3[T#[<P,  !C<KEK##Z:)0PR8UIF3'M\QK1V2A85S@?&
M.[&M#(!/049QW!]!NQ?M9J8\S_8CVX\G;#^$-L.E=L4<! /@>L8+"4WA3P>J
M*XYJN6^E7#0S_IL2XBF:2 7F(GV6(X0PMR,;GVQ\LO%YXL:GIFT)6X"4N'+$
M=*<8>4@]I05 5!J7)O;),S8=1ZBMK1)H&#P<NF^QO2WHRC>E5I=NM>.!>3@L
M 23D;L#><W1O@3CPA[NVKMH^<U!GHY2-TA,W2B.J@F6/OIVHBVP9K!GA7VA%
M8K';6'F\+ZF>&:Q_@>X5=)VXVMK#$\.S2LY,DMN2QNND#F =#Y'$D5Q;YTQ+
M0G3Z;49L<G(\4K5RKO/.6BPDXWE72AG#^DM!"B?E0'] 3IB96S#SU+=:5(DH
MC[M$X-T1NY%G_\$)]8=5)9UV?*Q);NG7+0<##$$(_5?,N&I?&N7IT^?R1?GS
M-3?_]&O-:,NP2_*<:=Y\SQCSPG+7G69#%U&V6O;5)+0J])[:T:-1DQ_P+6)*
M/@1'T3!<+!72=+8*PPWZ<RCJ<5E-A8T'QLR(MO!T1A;"J9CSJ4]<A& R,5X1
M'U"_]C7E -1P^6'NT9^@699@&E:P7ER0/AMMY:$/XAG+,(CDZW-V\-AXKIW^
MEU 2T7J4#-C1?$#X>3<I'WCJHYZKP>=9T7QM60#O,R(FN:@TEG.'O*[Q !I[
M!&#"'S^YXP];C^%=K;<!#YT% P=$@R7HEV-]DNW;C#3![2BVX9:LD: ,0D.M
MHL^T\V(7</V1[LX8"84_0-PJ4"T7&S)'KR:\ TH()_!ZM#$KG9<_Q(3[6\)"
M]R2*.)>29S-]D/6T$]BSUOD;93*N3Q6]^H?/,H8\DW']+U_$ 7YQ* N%&2\9
M)0/UR9DKYI#/:F?5P'$8F)4B632,]*HXM,R%;V:8S3K'J@S(\73)0<,'?;D:
M ]$EX0($2'+\MG'-=Y)-2RA'R3-[5Y;<%F;<F@OO9KVZD;O9LP,P4H6L=:#C
M#T_?1BKAT!H4R%3]ZT06G'X8M^I83PEN)M@V :4L('NN5F_/''883AYK6O.(
MYKA/VDX1SC+*'Z?0(&9.16PR*'GY(!.@Z.1$N(-)+5O/I$I#3"/?[T[*@]*7
MKIWNW+E<]0%U,X7M!?9@)1\/; \4ND7&%)V626R)1]T55:VPN\ 3NWC&1A9<
M.<S#8 BL4IE!-5CI(V5W&X"1YP[O]*#G3E6-;Q16?5I$ 'OT+Q.*ZD/^-'95
MOZTVTZY)IB!K5(EL%4AC-4+T=W3,^'@^)U6U^ *+%[9(#>-K.6OSR<Y.\YEK
MK:19U?QWWCM5HY.E9+QA=\Y5FJ(CONR&SU:M&2\PZ/XJA!U_^DCAVEL&+;Y%
MJ4"Z5[__)?HPOVU>_$T(SDS."%,BE$3OF&\+7(DO(T3\EQZ_#PAJ/N5H]\>8
MZO)KUE>>I=^'EGQOHDX??7;AR<CLKG7&8%_"M!:UD"3$#%Y,77Y2\:P!WOGQ
MK$WZ%QPMVPJ3SH@#7(!C72HGH#6551XXO@H,_:JN=E@:\+724VIS%0Y@]I?:
M+DU;2<^W3RB[!2-R.U$P))*GWY<]U=DV"AVVD;'XR=<=;^2/@&C^7(DW%IK2
MS0\ZGP][)#K4OA1RAD*Q_O"+4,ZE<RLD#U0+4#Q(S%&0[F.<N#]FZ?"4)G'V
M0:2KGV8P-C30&NK&HW>7 JN0I%<="2,^%=48C&SHVV(G*,VE5DD>I6&-A$DZ
MLW7=$QL]-AU1W6(>W$_?VA#3*D_#O&J%'*';\GJ0G'8]LA]4]?TH=@*H/;K;
M@"6^&37!@2(&&-SBP ?JO?"P[#&O3;^*"PS2K0B^1_]F:[_$C6WU1B^D5[GK
ML-LAK2*&M._5L;AIVRTO9OR.6]UX$6_H\+_1=V8FARUB$MH+$VRX\_1/P<_'
M;.P*,.$.D?!O-AFT>ZXC(V988KI- I+)FWT&$^AJ6?O'97H^)47:5T?=PN]+
ML%2!CH2I(!R;2B=V8^QI+RCF:?$F@611U(16S !OZU$\][N&+D#W#'(.$UPG
M^VG_/WOOVN2VD66+?K\1]S\PYLZ<L&] -9+<?K7O/1&R;'=KIMU26/;XQ/D&
MDF 1%@BP :)*G%]_<J_]R)T R"K9*I5:0L3$M%4D@40B<^=^K+T6C<3Z;4_>
M;2C],RJ-I:_YG5KSY!0DJRB/W0UK5%H,FCC#K6LV,3C\F&EG7M("I\NY8((@
MZ_HQ(SM8.TKU2HL2?4FTM#="M)FWD3:*(L:D8S-"YI7'M:?91_$J<K7&NT7-
M342/;_V%/'W^7\^^>_#H:W5%A*;91Z/4M1K,(?T@9?D<$;D->E%_%:K+J!^L
MD22==9FC*\[=F_<6B[0BQ%6RNI VQSEA""R=8+<H11 "Q0/H6W9"[_I;V(+A
M ZY0;8>7Q]\X0#0W$#^KP$N"'LZX/=#M'L_QTTPB<X5IX'-?4^D@S"!\K]2;
M&KAJ$L!VVC5_JO)$6B431D'*R.W00,1@U+O[(UOA86/,K,6+ **=?,#KIO ]
MY-,MP6$FZFYNCA52_.%\Q3<R*2%W CH &Z!9/>\@.:=;!:-IO?4.I .3%-YL
MEBZY#"S&:T'^#:@<Q#:4S4#N)T($E>7Y#9^/TW:3<EXNHT1HB)8H!9"EE%+=
MJ$Y'"Q,\CV)?PSJ**L"_GN)9]1RME&25S*QCOAMR'/QZ!BLRZ!MS!</I8SUR
M03E!W#1*.JUY9A*LZ*P5+,F:/(FU@&:(>[H)PX"\(OHG.\ \PW_Z%[5)@[LK
M17N(K^4#-'URY+-/L09T%!.KQXEEVA$C1L*;Z7G3)VN>SUSK\'4Q7I.I0O>F
MN8TMFFXAS02[XEA*B*2QIG%OI<-9I)VU-Y4EJY1-4:VV]J?C:_EA6G++T#,\
M<N8C31.)(+5>!_M<,T37_$.121CB1PRNDTE%P[K(Z\NPE8#A0;HRA"-=YZ2[
MDZ5MGE<*I$&:]@ ^\\B-(HPU:PWW361J#_*W,5W+B8_=78NKO.H3PY=&A5,+
MS6&L/!$JJY'ZNV#=LA^FU.M^P]T<E7+^6^A>G&6)K:->A7AH1)498ULPXV*/
M-YS.DE&S F@=0NXVYQ8TA*2(W6I9^OT9JV#V20C6C:7(1*+)9Q>'TD<><*T'
M6#<7ET3:(&'':0$EKRH>DK?SB;6<@0+O:XWU\T<S4& FFYO)YNYW%SY-PT"6
MR:9\]VLKLS^(!!K!*-?%97,H5:%FW:QZCL*'K'6M5":@L9$G/F_4@!"Q#<O#
M<;)0QP)?HJ(,Y5#G,SK^D1J=LS0"PC!9^'BO>$2(NY32R<"ED/R?"FR+RUQT
MT5^A\166?)J0 QU'PW'&!C$W!#&0UCD2O6S9@566@7/\8SKJLGC6:;DYS:(A
MVK:;,TU\0UT\R.Y/$--/BU]F,F<NP'9BFN(3-9Z>*&&YR^1':9P_X0.W>A],
M\:K9F]8\A>JU\0>E=%^1#FBC&:.))T!6G#/9DCLDM[0\F#X[7)!#_BJ9$Y\S
M%M3Z!+58'($P!5/-0Z):?3%%)0[\Z5%H//P'[A\!W0[[FRANC^-PGU/1]>G=
MQ;Z;6GOCI><1%"0-4:Z@5D"/=#)'O&'I>=\%<<+E78J.6+$;M%:8NNR@7>/^
MJ6-.J"Z:"VQI$LV-DND(.TN(-HFAVV/_8Q1:@@5;$+%&5:E ([N&^/[;H@+4
ME@FQS0M/NCO>025!]-,;J]SO0LC1K&% >XKA!"KDLM@NPN<B0$6;2&C-*?8[
MZN.+3MU4P9;IR3='>W!%Y!B<QK7\R)BE&94YE;A9DJI:#3HFW%_%"GLL&IU&
M@T2[0_%[662]?\RAEQ:OW8E"DZI>&; !9W%8&9?EE79K>+;/2!QP4#GY)/ T
M7<+8^8-)!S;NE&(X6[SDT+=J;@SOD881DV!%!F*.(DTH'"Z1[/U.T_QO"YET
M3S[<)"#J6;WN.T4V?JL.UO-8U;HA%SZCEH:Y\SNK^ZF46GA3H#CF5(P(UL.*
MQ"*?<LXZVS,4C0A><Z,0876I!L#:C OF1.(8K!.?,;$8[O.8YG6\7R648(6^
M"[$#?/O'#Q]]?0<0L6%5-@]7"A.#J*"LF16A#4?$5=GV=#R8+BI1W[42B/S:
MAY B6SS=AJA&.(1)R0\RM:R(D2\NJV8)V5U^_9P]?!',) ZUR9X@*I:$P$A4
M@=_9P@Q3H/B@8)]#7$:RHIP%K4EO-69%^QJ@Y,H:?>P1.GT$@?W6#8&;UXO\
MDO4MZ8^1C]2'"OMP)J]U.L*8R;_V:Q\-:O0?=W.N!J<%,8U,RF5.!RMEN!%<
M%@UX*E=A4-A[5?5NAA$6XU4!'M4U9TXU3:K;6=[()14+:M[3]-X$GK1"D/).
M1NKA&P?A'B)P7K-RH X"5-W)*WSK%P0AQ,-ONN!XT^^"A8+;@C\_2K.Z>#?:
MS+ ./A))#(=(X:I<]R+C*Y=9L%HK:?32Q3K.D< 0A%WPB0/^*WE^</<*P.RZ
M3P>4J5,2XX\?<A7E.048UF[X%ZP-BIW#[(=KO@@^>I4+]_I;G[C'#Q\\_CSS
M4Z,;QL^)F S8"AKGKSFX: _24'V@\"J9JW2J>%JH%$B1<2$R6P*GEY-5Y1+B
MNI3YV!0$T NA,\'X5JQYY,F+NV(E=/,Q^:._=>/L>.STA"2,L*/@0JIX=Z(<
M1)LNQ/,RLZSP%]%HR.PQLPN1&E"FHMGM^@/Z2WAITMG$_@5Y#&)'-/&3@J]4
MST$=%$%\:$&R:@"*;7<6C[EN"TT'8 G'5)@.U04( X1 -/5:>:9D5KEZ54O5
MTV'O6FU))L_#:G+6M[))#.(J/I@F=O9-5:X4S<M!-][P2-9MXGRZZ_.8$S[<
MBA-=0DE"L-XQVH2JYGJQEK;_")GQ[J%F0H?>X51[EL1NTV(4T4_,XOK *XI
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M_<7BQ_"7AH>I"D;A2:C5I4VV!O=R23U7UB/:%YIZA46-8S$B$V BI4:,<\I
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M11:0LOQ05WFG+P!A^'!U.!>5DCCT=IG"R*=CD2W&:+ARF5G@*RF56-;<4'Y
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M02",!>,%PJEWYLRB]Y*LD;V4RN7X.;=D6%;62[<^9G\&J>Y3>Q:-NI:0@S]
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M)2P@8E\BC4V]; &&\%HK4N"<\\ 9"]8(I'$""D_746X"4FP3T9*+8!_:@B8
M ,2AYDB"?.1.>ZOS6&.^E%;<<S#][[)<JPAJV-E<O$RK.42QE0[3Q%20V(95
M$NZ$UC1[8W3+,5+93GB,D_IX^GKO/TS\->*9-&]\)G\=:[XXBB2WJ:GOB,S2
MI*?$CJK=GBYF!&1M>=FTU*AK:?LP?:"\E-?L8^MU<UU#]("FF7G+:N>#J3 I
M"SBP@TO@ "[[,^@0* &N%=,9TQ40G(,>7GA0RG>;7B-4=FG_O,EN-B#9V]_,
MC93")TP^HE7:>>%,D.@P6NC1ZN.WRL-13$<O]UL6"%5%G9%E?0\V&Z1@RD>N
M8#!$'[T]#0[R6,1R M_L7F]:^3)OFE(L]=")O1,W\^GS_WKVW8-'7\MVW%-U
M.#@&,Q;M9BS:#WE90>ZWN0%G+MF!S'55N8:(,2A;C#TZQ>DW]1HZQ8,.,J(>
M9$VL_)#[Z!'7%$7D(L<)Y7:F3W@IPO03KYVKU4M#7AJ@V]#;GV:V20?5P'\'
M4I,=IWV_A-;,T1F?&H#CJP%L4C"0\.P9&(DC<[(*=]^GQSWY5[\6!AY%4]:2
M8-_-E,2H)9+'$-LS"U$645Q5RFEYJG-A(D5*9#?!(M+1-A:XN8&/PGXQIL.T
M83%\F"^'\5*-)ZS;NCD@S6JK7[]TP[5X D8C91!XT8[VU"?%Q>5%IHKU'/=\
M;@S^<IV?6VH[?4KLS,P ^F1U^#3SC2V2;*VJ0H#N("=US*0BV:?W#C?@!WF@
M>3K7O KL.7+%\1D%H.RI.ER'B4 "_%\V;[*NID7T!'@X,>,X8]->HD]\BY=H
M%I817B/G\A#4:*1)!S"'TPKX-))ZN64^N8R3_@I.C(%,-\2IA>85Q+6B)(4P
MCA 8:T<F&.0FIL)\B\X80?PKA;?<:ZY!OZ_ENR\>SC7HF?KB/:6^N"L_Y[W;
MA<]J!OT/.O&FG%;5J UVO:B5(+QN:M=_A,BOI(3(*8>%DWOJ\D[=9A"$,;YP
MZ+%[!B8^6U +DP0.H*+F9RB\T=$LA(EOZ^+82?!9)?5>Q+3ZL$._1*\V.)3M
M!%Q?-2MKI["8@MJ5]Y($X\=H(6W%&*[8^Z8ET4%.HRNJS0/75Q%#%$N(4&-A
MI?J.UBE9)7VFZ+.ZIN.VA.S4)O@?#$(D2D0]M^WBL9&N#@%7>)"&YL)[&B5W
M*8=W4>(QQ#4);[=OA_U[G">@/%!;%E@KR3>LB0@-;>A4_A&->9)1'*82-?OC
MTX?"$,)='QT EAK2%%WL#\/2]YZP)3(F KZ,'5^;'8O_V!6FA? W<E4IUU)5
MB\\?:KE3VQC=""+J!![TBB-9F=B.>O\HB!,'<\A:[^<]UO+8AV4B6"WR,AC%
M#=(I&-,&Y3[MFE@LT5DK?5>ZAV7M21L.78I*!-V^I=#61P%X^]3.>6$M1*T6
M]PB^RZT:D$W@7D&!#W/ $+E-2"BG5DVR30OS8DT>CJMV*/YL29\=NCY=B:,5
M7(KU*]$#N<^?ZL9^(=N6T(V?X$M/7SSY5!QAZH[8%:XR,\28"YB'IY=^N;BD
M8D0Z$L:>=[3RN1$ AP\6@P",L:2*8+@+3?!.Q!A@E0U1 UZ)%:6F@I%NF[<*
M!=$L)1,X(%D:OQA"CW Y@2&?N"VJ.1T!1NT990E+>6R@[4=_L_;YE,4VMQ0&
M9@!+*U;?DSTEJ.Y.TL9&N,L6PJ]!7U]&#8)R>>&HA"TR3@)$?M//Y[=\?%GD
M.\672+R*W19Q"-K"+\M:.G.[ALMOF!@%5],NK@5$O^S;<,6.^LCUB'!;S5/J
M#I#0"Y5Y6K1Y*1<,)^LK43 T"J6-L1:NJIQ^MDI:6S^ZM,T/:7HER2<,%3._
M_V7Q%SG_OZ.OOXA?_REB1V 7_O+=BY\^Y>("#)R=JF^6*.# FGI<^@.M-1,[
M]$X2[S6Z8Y3PW!4,M1;\?5-'2.'CS[5O3%7-I J<!. ,JFC(X.CCVP@Q5V$D
M7I"3,JMR$AB]S/=2Q%X\"9MO\<GWWS_YU!H2Y G^,UQ\W220K8DL0F(7AFMY
MX%4>'-]G&&._U\S\)0 D+?WQ?_P_7WWVQ9^^>?R09R2LLTHX#/[T;]Q93/3@
MB\NJ60+_ASI#G.8;)VXB?\16VXO;I//I9X N6U_2<9I<V9N>V'4"#YN.Y8BF
M\BN(Y;GM-1'>M<67=,'K&XYMKED*HB"HR67/WF.C6X2KM][)">/8L -BS5>#
M!XP#3/*!Q!.?&',L$5:;,V9Y];C01%;4E_DEK\HD_46/@H+4$P>X3-M[=&\Z
MMR_A'D_7N$LAV0_QWY0KB\0DL0+)) M%'6D7U('+UV$<*)I%HT&9*;2<GUH(
M$_&0[I^"VN8UAU:%QRVN9-:UO*'/%2://*.RVT4<D%BSP69\J9XH-0\"E<'3
M/^[^"/;CB\Q?9= :3F0FK$T0A[%I@U4"=L/.;_V,D#&2A<055> O?70"PXAO
MIG[8RVU95&MF,A[_'8TGTM:82^F74)L,UA1PDO60_D=PK,G'%A-K5BR,XIRW
ML"RJ,AB(2!XR6C*9=PAP#6[/<:M1^?%%@Y<)*"BD+:6:R:!4-7Q1<[)4CT04
M>I/EJ[5GV1J\>")UD"$"Z8<]RK]HMO+E3[=VZ#1!]_.(0(0>@_R-\.:&QRBB
M\8_6N7@ZF"B@KB:*.FD58YB[X(RVQH=,C$'U9SK5@5<@S0*JZ7CWL*RE9,"Q
M?4)UD%(7R$$U.J4*,4<$MPY1 KFDU-_+QT-^FD^EC IU29(H6!&IQRX)! ,4
MP!L4RP9%W#\VE0IW>!=EU[NKND9TTL!G$B/42<BF)$$RX]&.I',O59PDB$R5
M =WK"-=$Y%BP1?,N!]X/\1Z!7B5)+G''[V#AC-:=Z/'9%2]4=UL-&LY:*=QX
MV%4GP$Z+G3AVSI#!4BA87$.32R9,DG@BZV0'D4/H-MB(-8K. C[U*R1@LEB)
MHJ@TF'+54REW6L(49XXIIK+1ZCRW8CBIM3"97OUN=/A]=)@Y1JQP:\U"3K(<
M:763.2ENJHB]!;3)5W>%-GDW1OXG1-D_Q0Z-YV'BG]6' F:5ELT+\B3(FMT
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M+F),M^!0GLWU#2(]JI33E%CB3E%JOY<_1]%Z+!-^*0/V[M@OQK<B4<ZDKGE
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M5K^#/I^<-!^ I/?R5U1P)$"^RL:K3"_5-52P+)Y1=)Z%&*".$H&3HM 0G:*
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M3<:F$]]Q%1;#CNC(K?>K.>85&4F7U:$&$4SO!"X\+#Y _>GWFQY(:7TG&;7
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M$_;YF%Y,Y$9+#S-@1TM>B1U"*-RNBQ4IIJ=?IS.A*%X9'Y?4)YKIYZ;T$ \
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M&< Q%8TCHJ4A3?#27"Q>\O@H[RZ93YY'"R*G8SOU41@N'#FN9<UQ]*D)FMC
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M>S0LAD[DUTZO^FQBV2-1<'[IGUA:#*X<K/UTZ7^,["ZJ-PFB"_9"N6T3Z!B
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M6!XJ@><I)%!\U*"*^4"57]XQ]4%QF(7"K#(.+51X)3/XMK+06 K->6<3#FY
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M%-*33JV,HC&1,3!0AXZ,BZAX4"_Y8G+]APV>6KGMJ:D1PS%V17=0 UUO%8T
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M,@0^6#G75G/61#ANZA<C8@**V"\H@M)FC/!+Q5)9@SE^J?WT4*!@%>=X-5-
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MK+:HI)K%W$+P(.<\M35-K:H*+*K+"@\8&EJ7F&D9;&8M!6 W?$FYT@]4NQ=
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M 6V*$@24\SS9)/$20N_"7>] <&6NZFF!H8-PD^M]0S9TCW5"9,P6^1OKE(%
MG#?)(AT39+MAR>A*KD'Q1)2)CJ7ZB@ZN7"9_]WR*WJA?;-8H:',IDS9(26.Q
M7X>M=8'UO^6VE@U8AQZ' *>7EDS%VC+C-TRO0W5+*%CRNZQ(4!VC<4[4/(OD
MM*P$ZDJN3F9XPN,X8_"O0V!>0\X2H(_MM=%7YG.^"RD>F0ZI(]YA8>29"%)8
M6!3X&R>+U, Z9R_H@O-J<AMM'!A^9P$9T\W;2;*M^7HJ49GUI'#$G]W?:(7O
MTP6U06'THJ0W%YA(< CH!M,\! 7)>)%SW$=PG40"6F^V]D?'A*G=JYMN+F3#
ME"M[5>&.$R6O]]3T,&QR#<&A+2LOGOV;L7V WHO3FI9GQ3&1W?;)#B_EV$6/
MY$_BT>?9!QRV/W&#HZ[=]AGC]&1&4'-A.7F?P5O;6B#P*EQ^I*/%&HNA&?7'
MOW),>,O4G2A/)_.$L(B'/V9 E%  94".C.IALWKXD0M?V.2B\RS @L,&1<1@
MO&IA _+>L&YHP#&$"_!A%!JEL!\G4.$"3%0A&DB>%,3$C9M +).LL,"$:9:W
MZKYXRT)"?I:0=]#!X.>&;63W#Z(7]0@UOU&-\RS,MP9-U2\MG$NU\,!IF92$
M#"EG3NB:.2:HTXBA[WTIM/,-X66"Q$HRE"K]5R%5.FPZW#"]#/NTO["H2$+J
M/[);=;/L3WYC0CRR&^/="0.G\A04HK$RE/*+7I(?/5@C($UPDAP=29VS+O3)
M>HI.A' N^V89"RG\7V4WOZP1\M!.$AZK&2.>QU-74V!=PKX8Y:@X5$$SQLQT
M.)$(#EI(%,;'JTDTX*V4X@^G5!\3SJ@>\X]9W73"U9)T+F#OAO'P^<0LN$H5
MSY.^[5%;I/O7?4Y_Z<A3I%Z>_ *';RJ-!C[QA8$Z!I[]@Y':P-;0R!X<4]F\
M'M*1M]3>+,$BH^0LJ=+:K\!RE9=KYWH9&MBFN!/@L5)+LE-$$.V6"E%UT1KP
M(+84/(@_B240)D,1EG9.NQ44!YD):&+\(RG:I%ISU.20RG,2L!S@0H0/KR9K
MA]24E"/&_=.[@X.(/FW3_^.] R*Z1"+H)2)>XB0QMB[#XM4U?^R=[.[DP?[!
MGU5#-643N=!;)F.[D3)66MQ@I<7#L=)BK+3XPC>QS89(8"!/ZF:2)FL55EY<
M@E!J3B:\.>DO*3F=(E6]&/8B^"G:(W>R["X+BD0%8D_N>1LHU634K 3]$F68
MT89BG=_!41>I/#FL&W94AV^GO'7-*7G1$,V00HJ3+&+,LF:<K25,^3%;MDLO
M\O'C69.<9X<.^"SJS5[8#1D=ULT.ZUMP(ZAKH^](X(KP+.]HD6)"'U:AZ="+
M3YD5"8LNG-1A5@Y>C\4%)\;_Q;L\9[:8Z'THW-'#A-=Z?\Q]&%HYM<(2M(]F
M6>$SEI)=(#KR*CM%F23NCR;^T"YULV:R@+N*.?\BP 5B4%2B!,+XX/$#J<H(
MCF#!VZFJD(6&DEI=YU6);C9ZL*;VQV=4=)A5Y,_14*U[2Q4F(9+ARTS4_Q8'
M;>H3IBA-6?APG 5D>@:O2F7*U$E<@<J%)]&7TOA[Y;[T9MG,E!DR9X,->G@!
MQ7 YU81[<P9#P1"CA!*#+ZAR%^SZ["/\=Y6LN0 /EN\X">X&BT+P ,O\U/D$
ML9Y## EAG!%)S7 9L90ZJ0T-1JVAXJ@*:]Y&7!8XS.DY-U&E4$5./>\!1U.?
MHR)!*Q^KAV!P:S]!WE6*>)!XU+ZU@+\NS+2VD\7O1MBIME=OS>& WA9;@&L4
MBLL^<V-KMC:K4BX6P1UXQD>3"]PB27>:Y"T'FR\H\DB LEZ5V:4UX*UKH]CP
MQ':LF]I9]X$4E>1*2(W"2<.6@ P41UJ;3$KP,NN2DO&5 W.GJ+UD4; CL;IP
ML>.RMAM07)MKIVY.;_D\UB10+7J50),),XM23.Q)L!8+SSU$EG2 NIX&*X..
M*=B/"1S3TM?(J#R@O\I:F]=B>B.A2E \=\F:VU?1ZH'C&G:!OAF->5"Y;/'2
MZ/8GS_Q6Z!0LR\Z@0B_R OI[!*NDW#Q+3$ ^&]PLXR'>>HCGFD:TI>.;>I!\
M_]!X'JDOT+1SG3MEH-4P\@:RDEO39J1&&]]YE6C.V130):$&,RI=\34WU)/M
M7RT%RE56?\"H*U&"<6P=2[5.40?B<00W8N;8.=G>1V>[&GM%F3*(T'(FI(EH
M:J&;ZNV(14*I$;"?PF28)K-@N/4:S-B8X"XSE4PAL.SYQT*S&9<82#-:[/+B
MAPZVE8UN[@Y2 HM-DT*YW1Q6T>/^/*[*L^9$-^Y42=ZHS X#.@7JC%DPKC.M
M1 4CS6DU"-NO9 .S96B"+MCY,OBR3$MSE\F'@;Q\3GJK(2RUC(U)G^H9G> +
MK*E?4HR>+2AT)J+H'V]^>#=Y-F^FNMS!#D3<"'0]$M\/4Y=+7X3B/KJE9'TH
M%;EA%["G6+G.=A"7DGWQL!?\U;CC-FX94Q#PEYTR'B/8Q @V,8)-7*4@FCEI
M90?K7LQ[)7&FBKOFK&1S@LISX>@V%-BA !LUU($O(NU>IEJ'XBKD79!$2<'3
MUWLIK)4M-SR#HA+SLD(^U9+2%60]L;X24?E3WP1YP; 8:H,\HWJUC,;\HW_/
M<\7XIFO>"G4U7/+&AWM5W&)365[6X"6-.%RC !P%X%<L -E$-N9/RH'9Y0HD
MCV]I(>F%_:SP\%IXF"-S2:PR[&>M:XYW+Z1)"89#&0+;,!ZDGS>_1DDS2II1
MTGS3DL:83$N?;=0&_;1<27DF"II?V .3[D!P!(F*&1_^AJ(U&-KZ@<HC*G<,
M_\,=)$6J3/0@SD (5>#^E8W/%V+K%WA[\O+22CY#68_R2HS$3O;=4,=+,X)_
M@D]:#ME]H^@;1=\H^KYBT:<>7/"KHG* (*(") $Q-18U76$!3T<9,<J(449<
MI8P8ME,P,PP&PJ7#"<#IVYME%.I12('T-*O12CDM&ZKO'Q8*5. TH[S&$!:2
M(@X=XZ^I)3:9G[2-TWJDFAN=*W>:E6V-*7VZ$9LWOT(0U9O+T0;L5JPLVS7?
M83,<# M12_EEZG+L/TJY<P57&1N)J$H3M@TA/WE3&!;4<@G'F8Q>#@-ORCE3
MVKVQPM1OVLV%:!FBR6^T!:6^SK"\&F9JDH&\/2WQCC67)M.NP^@HUA]C@*!V
M^2GWA!"<K\_.4.,:IX%SQJ>E"BDW=HK<VB+[1X_&3I&Q4^0+W\0BA3"7[%+N
M'A44/8([EOX\*Y\C/$7NCAAR\AGV00H24&+ZNL]-80&JL*GK5@D740QO"](Z
MJF9&.X%*3ZG89K-RH'X8;F\<3G5W%81')(#OH+('_@JP57S-GO^*FK\+8;8]
M;G9/X5"C;IHA]AK,W,VWLO[F:T; +$JQ&8)@,[1%E^H]X O3\^L]M+XIE$4B
M,V8A<!*A H%ALK$X(;QFMS<D=LLQ(IT&RN1:J3S9 3TED1?:NBKMC\8E4OAR
MWTO>+[#@#PNE%*;(@LV*,R?E$9.\+([13BTVU$FLZ34R;0@9M^52>3AM?D+,
MJKDA&)%"8%A_P8Y45LI#'5\+\,;AP&%Z%_,7@L0E5@<<"807:R9_.MP_>,0/
MF0D$'HVI:"E[<>J*%AR]T/_E.\;:56D>BE^?(E08'5U:)S$%&?()3B88.HQN
MAE#LU72X]N5MFU\!:/SAT6SO2$Y>D' &W^;EQ_D)%L^300KS=_CDWGTV:9<L
M*>_@#?:JNS0IO5DINQ--$BXU7?LXX;WY+I @8&/SR"1M*T7\DP8Z4)]NCY:6
M!3?'4.YDIS*@%PZLVYFK(B3%!YO!WL=Z/+W\!7@@9[B=X7^D':D$[6+)PW53
M2$%D0[L:J_"HA+.1)AK%\].2A,&[9FND'I J2E([B4?1)24MD+;2?O%Q38E&
M% 1>LXB G"'2#TCVNM:M$L,<#<)CCK5ZA#&.B]%*<Y1?_^[Z,<13D^VA?J T
MK]D9(G/]S7]S!4@[K$H)#WD-&VI)31R*:3P5?Y<6ES&/DXG(&$;%I)SR#"&1
MRY-LEI'V::6TSQ7'R;$ A":AH< VUDG>R7>;8:FQB:8L*"LDIA]] H@5*0A*
M%HWS&']H!('6+Y?4=;3A<5-BM$&KPG\$00GR1WA$K<"G?0[V1Q1>N*IS5U"(
MR:RDS\K1::1%-V#3X121@HYM/(N(Q%T94FH^ED..0>@Q"'WSB:J$VT= 7* (
MZ,,+B*_I;2L0%L?'!%1,'8UQSP.+;LL4@*78MLT*G5B6@]1=0@:9PI@A?-3O
M926W#<,=C(GS41Z-\N@KED<=X;$!] 3;:]"+- !3W/1?J?W%]JEE%0G4":&A
MG;NR/4&<(N(;%$<#)<#,>MPX0DWA4X_M/92/BT7C#-$T.!1@.ML\"AW3UUE0
MQV0"0V(..>[7KT;9-\J^4?9]Y;+/?0314V,@EV3,=AG("=;$_Y(0E0@Z<'*:
M@'R9KR<(36*J*/M-]_T'2P,]2$)8".F>3>$I)YQ76/IB W^/BCKQV.O8YB//
MG.LK--- @^0A9LXC-XSFWBCR1I'W38F\)(3Q4 AT*IL8T@!$%W*K() !XJX2
ME C+FT5))+ #]W#&A?GDB9!%\S=(,,0H!>!].H9'[2-HCW)GE#NCW/F*Y0X;
M.)W&DV1(- Q15B(B,T*^8[\P2"<3N.(*3B'Z+!J$6>M;-4RY,3]),F0HWVZ)
M46C])'.+/GG=#K&W'G GVEXH-$F2PNX/_&B)9XV<"!PII=X\CKJ-XALC<#35
M1I$YBLQK%9E=V:6(9\D"^]N(FL?+(4LUIO4MEUY+\O#AWM'W]_XL^U_ROA(I
M6Y5G#$-LB"'A_XN]8;I*<Z<P0LB_E+]7X#H1)\%QZF)*U<5+)_GH. /]:3G2
MRN6)O%50L *K=@>K3D3TEHRJK:++"K)UNV(:S5,)\M'',$@I0X &^F&"2Y[C
M33AHN,?2__H,/#9L+W'SA ZB41B/PG@4QE^5_4JUF',GI*(H].8N;2LG"5N6
M.+'IVM:-%A W"*ZYQ(H89Y!KM?9D0TBP% .1.'0:,29G9"(BW@W6/K(-;=XJ
M3=1J3UM1:&C,D=0<TS1H@Y8$K0>VI1>(%#X4W&#&*!2I%X"RD;[8F8BH+U&I
M7.CC+L^*29V+O(]M;%0L9P0^S,)31+\T6WD<B\4 8._8,G7I+5.#]693+:DU
ML*'OF!^9Y<K1P;U=2\Z4W<F8"K@C-1(EE*PQ7+Z03#+%N!:ZGQ$9]>&#/UL&
M00(U-\9-;,[0;M;:9@)(Q](T_ <=W+:6"C1%,#25:,2<]6RX&@_'7ZX05[OQ
MG57^\]!'=1^I$-+\$N$1L>6@RF L"->RS2*",:&CJ\8()6")'O&\>ZBF3#L-
MB>ZLDQ[8G_P=3,1380VC F$LR&?LA\'/.0](<^P(N\&.L,=C1]@WV1%VF3KJ
MUNWJ]T(*FWJ"B<^N?Y]N+<+%WT55]Z8:'A147&-+&B.R];!XNF-(2<:X;])L
MMOA +<$#&@T"FK:Q<H5VH"<U(G]>O*7!<&>('OKB[FRY<NGNI?W,FD$ZTY(E
MOZ>4=E8W2M31=!4[3UR/LMA4 PV1TS&-Q#)KZ%.KIBVXZP1G>EVV$^**@$/S
MAW('4+VY+F_$03G"/N_:9O+FDV(UJ90I$":OH[X% IEGUF\W>=?(;?X\8;U"
M1BS;YN()"&5Z&9IA@FW7OQ4AU7]OJZQ.,PF,4U&[2\G,Y =I..Y%I@1+X0&!
MRD;O2?4J&;*8L+\6%-6A$= OG\$Y@1G0Q&94*0)O;)>\.=5L;-8KOL^3M7+;
MSMPY/(>FIG_F_$'W!SHV?:,L0_#:4%"U:,TIH+SM M .0R,$)&O!0_',FF/#
MS2?O?(&MY;6<^K[B-L]18@I_4P"ZA;6%);.(#9)-IU;(*K,!SYK\:,T,@6S+
M"=.Q\;N--_YSVO!HDYQ@-*+RC9;]DW-'3AUM#,R;"33[!1Z1@[-<>_^/@Q"=
MTXA;[\*'>F!D&*RF\&LD3G  V]^_^61O%0MWN2NG($P6E^?A YB1!'W&^@0'
MI00VM$AE[H1))9($A@)%>1UZXH 5K)<&W 'J9X2:OP@WK_2*$?YDNFMQK' +
MPH%0<_)</;[P5$\XH=5=#KY@81MGZ8.'[D10T4J"/?,\R98X='0#8$4H5;G(
MTG:>(3MBVF((_8SW-SY0U;F8(R6U=('P'!1%@5=:Y1&#CFA8/ZX),=VM%QBZ
MBD=^ZB4,$;9YQ3R XA[C" P[,KXBN/D[QD0^M9WL_/S'4].#NW':B"\!SM.J
M<@CPOUKEZ^G$%9RKUOB@+^,&FRM+38K[BH9][J@3VBZL'W?J=02)N\!%M5)#
M9>[NDE ZFT\'-N,%MM^NF^T8TTI%*"'U^+Y@22<9W)26<Y!HH,A4(Z5354EQ
M&(K['8G6:25A:+8@5%)@ %?6/)&3C1QUFBGKU++:WO.I_S@:/G\ZRL&P.)&5
MY@EG5'+:%;EY8(K;$(K]M(/UB4;)YYC$5B<.J4(DZ&'?D>C", 4"1Z*)SPH3
MU"[\.1().PB-$! 1[O41$>+K[EZ2O?7-;LGW J BR[K'R]J)W+.K'J6> EE3
M()^<558PDLO^>YMRWS4_E[PB @HF*CG/U8C;"(?6-IIA"S;"CG8%'J%.WHN#
M%=XV4X=JBLM_0IR7O?HMVNN"*13 14B6G279J?- ,BMFQ.3!ZLDR^!D^S$35
M)&TN(ZS<<9LG&NX!VY,.P/[DMQ/L1(ITG)6CANB:II!LY_E)*?&5WJ+A_5C+
M0%QAI,VG\?(Q=A*F!>"=='Z(/G=X$0F113NZ$%"$TS,^,N IA+K2(8R(6NMI
MU*@L<>8H'<$:"VG)..-TFAV7E: GDO2(S1$RQEF!F>J.[6_^9!M&R-=PHI2O
MV7*F6:I>YC:KZW*>>7?(B$4N-&'Y@_%,FDBK$/U.J2A?C)NO*/&!L(]QD]&:
M=XIO5"K+?+!]+EY-IDLT\*HOF4SQ>D2B&I=OD7;OQX3CM>?$3RYIZB[ B7B;
M(XV_";]SIQ4S$#GKB?&06W1*/?LQ_2%"-UM/?<C+%(LA-Z*!;TL=E>59VD%,
MZE(YACNS4ELB<B OQ@ 9+MBS_H2#TB>T%099F_R<U&GRK\G?\G(&T_H3@9]-
MF26NL]#P\F/LSC7(>"&S@Z*>*)N5Y#;-4B$=)J9M&D>$@KKNH+*0#9A4LZ1P
M]=Z;C[E;"VD=FH#8FE>+NAV3V+<UW??HR9C$_B:3V%_3)D8M [J'V;NSI9"<
MA.C)NY?/0S9J2'H*6-^24[VGX!&#X1MS0*&_W\'X)&GXCQ;>>71P>,#B\$69
MIGL_@JGX8?(;!K'?-96#Y[_%P["D,<!VJ%N,@/Y2@89D2Q2][#N=V]&C!D>G
M!JN2R@XI UQ)89@1\2$3R]$K4JH<*A]$5J>";]<%MNN_G-6"FMLRC11S17AN
M:W,/NU29(H(F:&B(X5TK+F2=$&;H*EE;8EM.A"-:)'((OV7"8]!A69TGBE.[
MI*JJ);8E5=L!QV&)/.1X&?8%6BWJK-2NL\I45JXPGE*0AB-K5]S+?:H :92H
MT,RZ::UD<R;7S4(Y?O@SX7X&%E?,]6?HR0TRNE(L$<TD^^FSME$$U^,V@55J
M7(>?7GQE:X:%CQ[XV+HL"W4C9VUZ[,C&@,_.X37BGBFX(-L$;<'^H4N]]; /
M6SQN285=)3DSC?JO2F2G1CA25YQF55G0B/1 ZE4G(+_@BT\=U6KP9F;3$H7B
M:41#3=L,DS85'RR*C+B$,4>,S8F3:#<EWCW,4V+K=?5)D5_I#=9 GPVSFTA]
MQ1*G+$9:91O:Q3T4> &H0T/A+)^/;C:,>9ZMX)[]R9O8NC;U. 3'5SC\MLC4
M3J(/3Y9H\&DMI<3>:K?1\/X)='5)E8FR43:<:?8:Z)O(MJ1+ K[SX#11*0\!
M ?/V:#P^,HYMCV*%[5*-4[POSS 0\V.)1FJ"6WC[L#;4"M&[\5>\5R4B(50#
M4AWDX21HACFF9<+P6:%^OQ Q=V&JQ>3NL:O#GQ#>E]YA$V"TORD0PG$CG'-8
MY+%R9E=_5GGOLSR:8P,/'HZWE'[)8=V5JU'2 2&6"EH)&8YHM^8<^4H0A!D/
M]S"T>14SOP7D<;MK/5@2BA'<3Z/[.^S^#M7#QUI[L=$5W1SRE9N&G>ES;S.I
M#[S"Y^>>E\ME5M?*\:'A5 T:#@Q[HU0CG6X-A;[T[7GVFR7Q=(L8MF#"*)$'
M!#)O>UBJ>6Q]UDU%(HZEG%=.TTF]KN$XZ%?5\-<YZAGE-&0.Z#JC4X8#\4)5
M;?;>8DII)1:6+4LTN"0(CE4=4V\)>8D0[.+2DR;2T4WA3?CKG05"UVJ(Q$IH
M1Z(%3^3OL&:2\TI1XI<KF0B$.I=4RO#S?-6M-CGY2E2.\;/:<07=R3D<0\QH
M5=/,RT*>U=8;^OQE(?"#D.R!:0'-?(KFS;%'+YWR8.H:?X1M <("CK<&[_%!
M<=$1V1ML.=<,,D!XF_!7?'#8ZCAH#;;O^A59X<<>LI41>GM6DVQ>MNSD\/Y=
M+MLBX^HHZ?L"H[U 4RLW7E)\?C2_Y5<UR>NRL[0@N+'7XV)4P.0U4O>CV1U3
MOV^G:EG2DQO+?,%-N,/,P]W-.+VHSM.&%+*5:-FY3DM-TMC5L&*)[YA&8L&?
M>%L0'635GCJAP4BT=]L>9#V[WVQ6^(VQ'J/%1C'*L73YI8_CBL3ADM<Y,W!X
ML:?T'0C.3>>F%K!Q]G5\F;^Z+&"'MYB9I*:EY /^ROF+/MO8TKI<2A6?$MBN
MR)%%V\!C]R?/X#/1W"-Y%\0I=J'UC3\_""F1\9H-58PK:/^9EV15\)!]L92<
MO25/.-IH)PFXF/BYG""I389$"@QY2EMI7!?;% ,_?)=^K.7%U"2Y)%THNRO)
M4-M]/VA@+J@V"ZD@1-#VIBDX_OP>%2Y^7NJJ7?GA1].$S7)ZMW3NX58XGDH,
M1U2[S$V2X@DUW0:<E#=[P<]>V%'!VZ1'AM'T!L,O"7/4%D$D6?$!9Q,%!5>5
M6,>Y:3APT$E=G+E0H8!;L[^UY2LI%2V;.:R%^ !J>FT0PGPBNY^ $#KP0,+>
M 5-QEP7G>,#NA\J'@Y170,H*F6]OXBKJD:&/0-J?*FE3;+?4Y_*G3S'Q+:6_
M)^49IW2\$4*V"D<X0/9CIES*H;BP& W5LD"?9\I5<+.Z1/#7Z5 J/7YOZ&(F
M:Q_C$S[#OG2@"'X($HR+]#!&A;XUEL:$Z&.2YYTGU_1)#MM8?$.U7SK["3K:
M[F#M>B$O"^L_G$VJ;,5Y#',O1#V56'!F-(3GJX*22S!(II@'S)PL6-<M_(8T
M'[OZS*S4>#S-+C%8UZ6*.J7O']S?[!WR812OG@-X)" S_]ZVT+=Z78/  ([#
M14'M]*PQ+V D)AM8)2\62B .K1 KU/T)YE/&Q5J=PU];,A':3M,X_BCNV( 6
M\^$(E-=XI@-K%_\)37"JZH41</S0:#=G;>>(*I[C9O[IQH>OX7*O@OAM7CN"
MO\*>^=3[)+[0S(1_D[8Y*=D/[ZG JX@->8/@U%DYSGXE*4)YF^\$D(F?#L_Z
MM.>UBQDFG@N^C(5= O)@C@=#[:,+\ON,:??;)-H>'XQI]S'M?OG(/5]8,/_-
M%A?2F-&J2+=:LR5E'X,==0/1] N4#%Z/F/FM%S=O3C0XE\V-6AL*I]NX&D7!
MO.V_S?.WWD\9W( UF](#(4LTE%IBM.,HGPWR:6RRI!0;%KY_>M@O.(53L8(N
M.[X9)PTXOJG&Y\OG-(4S,-S<J<R"..+G36.Y2[2O[ZIA%'_NJ$[^,GTUXY3)
MM\4^%O.INV\W7L=='!N<4DI@B-N22.:#IO;W-CWFTX=):=A4&,O86R8?R.CD
M.O1% @;D6BN9X";2^&EY5K#WR@ZGB>_5%,<)#BJXKUALTLFL1XT=$_I+!WU7
M/0",(F*; I<K:)S+']Q$RBTD@47D+B"4JPJ/*8?3DI9;C>) &17 4%)(2I/
M'%A;8 ES3-#.]V49V#D9.? (6)Q5( A.HP(PV&P9[/>6($)8PE$BC/-5<'QF
M:\(F;'T;Z5GI<:Y6KERQ#**V6W0*V>M *8&.0D4G*3H,.,HYRA<$[X1!SG8+
M69C8F0_"[!)S($@L6GW<&[YGYMSXP5A;$%W^(X6<;5C<1/R&R,7)V<8M.A<K
M17PU<06I<"R43 F?\F21M_.F-6'@P1BJUSV#CN-8*_ IZ]5;HNENZS.P*N%-
MJU+903<D"$#>;A^6V YQUZ=DDJFN*%^+X8-4]XZ)B5'6@AHOX'%S$0[$VI54
MZXQ88:7%/-0M=*ZF( 9)C4K[I!85E='.USJD%8(HTQ146LP@2526-MAPW4O8
M6/;V,\^V;I.Z)/'-LE'!39B9%8%>HJA_3ZU3>J5D',)J; J<;,S3X#C/")Q8
M<4,Q_W"QQW )&&^#3EDG![%"]K,;KW2*[.377K5Y5LO-4J%J\T*A5^=8VJ%8
M:"RS MN'N776=W/0WS;F0\AZI4LT,2*<13Y &&I#=/!<11+^L#]YYP260^J7
MFZQ!D@"IQOW)O\Z'\E^ _FZI+(9>_@QT][K.:&;#V7@>3?[;,/EO_.33 X^>
M2F7PL[!E?HGV]K[6_8Z:;S?-]SR<Q2;YR!VSI8^TQHAH5,[FK-:*<$1@G6$6
ME$&B%RD])THZ3VHXCWEY-AT\E9M%[&U2A_@([%]=@GZIDQS]LQ9UC8]@ZQQ/
M!7X&KR#/<1K7FJ&)E](T.!.@EX: B;B0>*1CY*I!>R+ N!M1%@6?X??DEL/;
M3-+?TW/O-NCIIE%[A40^*.TW^&%9IN0_<V9Z>&?U*X$G[V$LZ/?K5%!)?]05
M(1M:0AZ_[K_;]Q^ 'T>&PW&;I23;?#'_*W6TWXHM\,Y5IQT>37B*23OX!N.5
MB;#H\/ $R!*T(NH5M2RA&[P3K7?XZ0(- QXB%^3K))&%PT,WG0$#T_/\V=N7
M[W@$>JL'V>VQULNK.PGRC((J*%'Y/D&-(@R8Q*-;:*M,S3:+U@9137YG+J3R
M ,P66%==-^W6IZ6QG_3<EJ9XJ$&X"G\05AF&)?29W,(UX/,(,2JM4EV[IHX8
M#@BPV&1?**"3?/3/P-@Y[**)2ZJ"ZPJU2R%U!,H=6MV]P@TA*?.ILDS2GF#[
M.(8S2-)*(!V>#+2HX#7];YKVB@KLWK]TTHNR<'LH942BPMFJCK7$3",#IC15
MOMV?.9FI_:'TQJB'H\M_17L?$QA+[DNC-#,<J'))Y="^1LNKUMKQ 52]2K@K
M9,,;KDFO73<9NHP$2IG$VZ5)C2^AXNK2=_?S-_]\]6+O\(E\Y0HFQ.%T<W)>
MC!]BU\.<-9@FC.L-JBQ)68(<<_$X'($T:SI*E1=2O*V*[-:<(,IAX7"5L).J
MP<C[!'P#D!"Y@FN8$BU;1%DC4(@C,F6R_T\<PK>":^51.708ITF62Q?#5)/'
M6NO''8@AF1]?X'<<M]--_?&NN02+D5[(GZC85Z5 AZ@*',8,X=K\8W!/TSBT
MAW$CL,:"K0X&6<D4: G'/#2W8V;[%F:V#\?,]IC9_L(WL0IM-G!LQ=.0,HXK
M_KA64R,UWNNB0(T[7FLXK.NC!51/"DGY]V!Z!\RI8JKZP85GVF[:LO)%^2B+
M5R@OYVQ+L'2.#8LP?"HQLWVX&*>+58E.1Y#*CAP$_!2?O"D<)E$)I]3-:#SR
M()'76.O=:3:B?YOV(OE[3LDG<&M"+1>A>77?$Q[<+^1CAZTPN&:(VE5OL+Z'
MHQ+23*XK-QUVE;L&E+&*M7F>TUT>#SZ9P27H"<!NHZYHJ6FG=<3FZ[J/LP)/
MR<@60B D4I5EX;I4++J"M3BMDN6MJ/FK:!=@S< L5E&C$<BG0H,UN(=!'9]R
M-\S0'HSQL3%G& <93-=DTOCFUX F=%PF.=FE]1P,EU8V9ZG]YV/)VNV5B8^/
M1L4^*O:Q9,TV8M@ZIL;-3PK8C*#B?;=!Z>FS%L(>DE7I'I<W/'_[QH!G4M8_
M\248Y*+EF/HCV2W%%E0&1:0A@FZY%J1P#,;D)5-TYG"D!$<D39ID:H1]Y%):
M43[8G&*[<A;2-8G5ZXWAT5/2NTB#5>5QE2PI2(6M5$MDFZL1@$%JY6VC9VZ[
M,BW3J-;ZM0*UPJ P5 U3"9B(>=(TD,"P=UV:.I, YQ 3X'4L,&5<"6U*MRD2
M<K,5A!( H&H66&QJ$<7%69%WOOT0P-^K!(RHEJP/CFW QJ1%'X!((=N'*LTH
MB5"M"4B3SU"(9%%+08Y(PIB.*.6Y5#*$98)JM#?==H0[(9*"@#IH\5 -CJ)Y
M-(X>BI5"W.F!P1/\J<I<@X,Q2"YQDP/7$L6ONPL?0W%TOV=]CR;8M"4?.+%M
MQ6ZUC0M24.2_1,UR'.9Q)7%HP1$9_E[N7L;.9<[VMPUGIE-DC_35GG%4G /W
M(*B8!5 #O18A\DQY@K'FJUW.F/;82C<KS\Y.Y/5\AO6T;Q[S39^U%ZY>90VG
MN+O]H8L@>Y=P(KCZ\AB[LZ6A%-^G!:APZT==-*[[TF,D #VUM* -;U8MNES;
M!L[=]8^\=IO^";K!+IBXO:J!2 )8^7K:YNC=2D^3KT(,VBQ-ED)V2D-5-<+D
M'N*<V+_4BA<!'YHOVD(H1HH$) 9K(A @Y,<T5/E&"%-G"7MY#0**^V)?/8Z$
M,E[1F9.>H#H"INQI4!Z=*7'4X1<" :6Q8"$.,K0!9NZFL>KVTD+]+#I+WX=$
M<'S.2J6 7<.1VD,/"FE@9KC^6!&#@?[H#BO..$GE [.PXMC(M6@Q!)TS(1-*
MQW+)/U]Z&/W2'P@G K;;7KG8DRT3B069'-@X)7GDKH!S[%P58YS"$66!ICSC
MLOFX@2X$VYL3XEL8%+E3(V])$)K .K<'!WEO4<2,]6/ZB3O:D TVQO%"I2C6
MV_[D?2E@V@VCMX5Z<=,JW=G$L+DY7&+M.;8+%[2YY%PVI53]XALU[SXW^7LX
M!2M6>JB=+6!:1UHQ1XA7CI%%YKO^&",KGO#*K5H6J7B^>5@J)4,2(!B56M'O
M*EQMD_4=MDM#'IVB+J$(]MLRW:1M5%HOB,V/0D>Z]JL 0>D6"VJYH+/3:C^F
MX.]M4C04^51+W::@0V7Z--K7*!)5WD9]]M850N&'FX9V6=1$?T[<CLQ1J=*4
MW34U-F-<"CB0"^U44F1B7&$HC+Y0CU<HM>9BTDB53>*@%Z?OMJ( ##I:Y$*9
MZH-P%"ZRZ7MPS2(-0NRQX2'@&BVD@FOCD\/HZ07^4SD^3)*7V(]1')OM-(P\
M+C:@@.5A-\XILV'"XFF7-'XYC,Q7(V&P,P::B8 L%A>RCOKR<^!#=<ZH#C\(
MQ8P9V$B31_T ;.*&>J](=DZU!%6.C*RX-XNG._DMV/A+I9>5:\RQ^43?9;K9
M>=D4(_ G9ZHH9.&,]60[H7\,E7&%5,>IUW"H"IF6;.<Y'1RZ39@/_1T+UA)J
MSN!=&!\&:9?C7AAKY76P8/0K?22<(QXNE[B#K?S50B?9,\RU)UH;1#037V3,
M/>?[QZ@4"2EQ,8\ I\J13:G=?*V@3!8I]\+/RZJ2/O=D'I8V!#SB&X,^Y@(F
M_^)>T:=H"46[/4WFK,/]Z=FX"L/[IP=0WTGK4_A&0P4#AD*D$JQ?PNJA.*?(
M=.R'N0!WA BLV.L@/0M>_9+1IC :M#VMZ>#&DW^UR0='14C2U<ARJ^?D>1/$
MBRM%70N5,72E*HTU)\U\"DNAKO*UW[H^BN@+IO0A8Y1/@MHG('MAVBJ_!!AS
MP%,+BX<]$O HMMZQ^E2X1A'4#_RF!N7Y;TF-4(Q-./>VAP39A&W1$Y<QV8TA
M0H Z_%XI,F9_XTPW;1L3&Q"K V8N0?6,DK1V3JPX\*?=NBR4/8J;[40A8^I<
M=@HW*F)_.3I(D<RBINE@K$43QP7J\93Y7/G,HA,3%6OAZW+G6%XU90SZ.E,B
M+E4D@K87G8H%#\Q #PM>N8 ^<\]V24="#.?^R2F'CQD>*!P= WXJ5%D?[#AT
MG?0+]9)9S53EE0^QTJ*YGJ%6QI&I;OIZ8-@XHDWCUMS&E.453'92H1H^0?=>
MZOB.'6TB4LV$IHITMUC4Z_?;Q$,_3W=S/GI:)K)9.82 :R0R5+V?EN@AYR=4
M$UXYDROG:!F&W!%RM1$L18T?<K!1(W$^Z]Z7IE[0UFT*XFMJ#P1K<3J)_FM.
M/>[0L/-CLOUV\,;)V6VBS*#1 6L5.BZRQ6H)5'0+)*(-,%8-W.*J@7MCU<!8
M-?#-5PWT@5A4[U.7A/7W4+/NH2_'88TI_V)9%@[Y8\E7(S!.])(J#PD[#6AJ
M-N//L8(AUXZL ZS#7A"DMUC%4?L &ABG6>EON$V&\DU-VY2K,RC0 IXV^OSO
MZ>+7U!D')LM)-LN:88QR3TNC<;TLICH_9@<?,W,26D&-"BL2@-XYK13EF*+L
MTT!E'SL^$DZA.>"T!%,="#_-5*PMQGFE_FOA0B"KRV74MNQ+_BA'8,,>-.\>
M/7=%[U][-H2D6-,<3%S.R4AN<&I*G_&")V6K3 %0R&T0 IW*D]#5!%&R/_FG
MWY/XJ##]M)U-F,&2<E38+<$0KC+]<_@D-)GAMYQ\PY%G-9?3QL%2W@XXC Q6
M!:]-W0Q1$NE";$ISV)=5UTM>0(GK*+HH-G;15B6L#D1].9;X2"]29A?0GD4Z
MK4P_2Y-N%X#M:,U.LDF+3@::3YP*]<2\,:\.[C=LL\>'A5_O@8$'EAGY=R<E
M)L+)#&L+[B@/!0$\RK(ZABW]AQ$J5&X@Q =HO%UZ8K HBST\_YH)C#K60W@9
MP\G>#PJ\MM0\0\EU&])8&,<-SX+S=FC=M*G_YHYUJN&\P"<3JI.%J@H.,O@R
M!3EW"%I,X.C'TK??$3O].'H0TPC,Z1"%,_,LS9RK]"=/PL"YA-3"K&C"() S
MJ*0I*Y.81C-?L$_%:X1)(T&0>Z#-/\B=HXW(^-,?8!%SEW*]F2?759R ,<1V
M,3J;""LB%/=CB/W$(5,V>VS)PC7K#>K)8*T2\KLQ.5CV$6BX"#T6(_.0B-DY
MU2:-JK#B<\-*,);.139?Z!Z.A0VMK\9/ZQ-R^[%OEN-%+&QB:[' ?CTTT#YQ
M5]@R$:P'8G&/_\Z3&39T8 +!8,[IN$_@AYSL $J^8*4=R Y0>E@NX1/S^.EE
M3:09<,<?297B4'7K\-/.,!P!&^.E:,9.S5E6(#0*I_P$*"L\B91GGBR7TL$B
MS[6?-3_!GDU]V2S#5!\):IJ*),W*A%,C_NZ-0R']I2G(, CZ ,V-LER6)I\\
ME+LI+'57M5 FT\P21S>'9RCD[5U.5HM4HE'KA]@4"?U>JD"RXO<6VV$$Q*".
M/O(W@[W<52!"Q(-0^VC<27)%">1/)=F\Z7WA3@^?T%NY\(5,0#.83MCE.!3,
M=Q&25G.AJY\[ :0T)$-JA-CRDY@R<X@DG@U"-._[QJ*7F#=?G'A3O%P@9\KV
M^"3B6#HKP6"I?!5XQ#,:J/-(L:$UUO)A"*P-/GPL,%&\5*G27<$V$ZLN*KB[
MV,Z;*KJ2#B>@R0K8OS*C*!D?PUK53<@M^GV7R?82 \E/1'@Z?F DI./R\Z;\
M"$Y-0RYHGF1+T;F:/0,O@M#%= 2M-FP74J;C(]8BBB4?[@5+D'Q3,QEHW [+
MP&]T-P]Q@6RB<LP,79,UT+3;+J!]?))RII[XV@T\;C C3R,EPD"5>IQL(CT<
MPN11]V2',J'>\&B2F3'TF)T-DH;3V'B4S(+&4':+Q!]^?BC^\+)B\?_V?_Z3
M^V+G+L]7N">*X__Z[N [^K<\F/XM8YC15J 7Z(I1+/GI) HV?\96YC?L88PI
M6=7P:_W)_RGZWN_X&WS,VT3(08* ?/O+)#DMLU0O!'V8PNG^>/C@P8-'3_[?
MX=%WG3#P$Q@^5D"C#-$X,,SITZ<F,$QQX7AQ/MM/VNJEO2)>&%R]H_W8J6A2
M_2YYV(YCWQ@CYYCW%8>O)_A=>YJ2$%_SLUW7ZY&=OQ8<P" >K7<(;X:*YR4W
M>W=X,7]EM?P+>A8NK0?<P@DO(?RWHO_B88P79YZ#A,,L2'."<_G13QL-=);,
M/QR#:X39DZ+D>;FRJ,,% -YOY<KML!I79 )LGKDWQ>2%FSML(N(3?F\Z.3HX
M.I!0QG+)!2-;N-7AWU7=HF&/Z>DHO#8Q]%K%Y4<B?X2#RX-^MW<H,WCG1\1H
MN/17_5SNR_3<N[=W].#@X.#)77DC]Y0E-6'X)'@J ^.-LJDB?\[&B4:;]?!P
M"@^=PG/9!?,Q'4LI0U<BHJ&G$N"5P.:$0$3SIZ/#?7@,)@'H45UDN3 .>3\9
M\)BA.0/1@2D+]Q'K_!'QE),D:)B#?,Y+CCF47"R-?$K@\9U@M/=P^NCH 8W>
MD+9O^1!Q<C?M* &[[VVT39\H1'8>)3\Y/L82T\8-W+MM)^,J_NGHT:/]1[Q$
M<-1R*DP'&Y$ [LSCY!!3;2UXR(N&6B8(I0Y;7W4^.6]3S[G=3/LHF*-8:NWT
MF4(43)4>?SIZ\&#_7F<4/Y?A8N.[87M8DJ4;TD-T*HNUA[.S4/,>8/X.1P9@
MK;U;7M_E6"5!M$_*,PI7'1[\V:)>X'-ASX<(I&".U$$-<7B>!D#&JD]OL.4=
M;SPM@=^X/OBM?P.9#A(/=-_\I.89^O=D"6?Z>;D_>?WZ^73R[I\_3%Y3,]('
M^463+3#P_G,&UES2=NX2ENM7A8<Z%/K5O^\C;02X@F>4?.^\:XK/WAQD'\M>
M;K#LY?Y8]O)-EKU<ILUTZW;UKRMJG9B[;"49<E1)7A-1, ZEYZM?WK"DI( S
M%[>>2+\4_!!U,X!:1,:=G"'G*VJI7D^X;D-!,+GT@>1U13'(GS#D(4;,(5DQ
MAX'!ND6[@1*H'[,EEX'_Z?'^0:3*M$9UX_@5J1#KEF=8*LD$.YP+$^(AL2$D
M]-A_S$;C BVU>EYE,RZA5B1[:MLA6& ,E&:Y!J;5@+-F[EO$3KI_=/_.[.Z=
M^W?[MMU]MNW&@,P7%Y"Y]X4%9.Z- 9D;=NM?.&*&JB<DG]^Y @LS3"#FIH(N
M7S6UWL_8:,1]\S!YHYS]XN3L_2],SMX?Y>P-R]F?D'WY'6?R7@1"NE&^CO)U
ME*\]^?K@"Y.O#T;Y>L/R]0W%9U\9F(91LHZ2=92L7<GZ\ N3K ]'R7K#DO7E
M1^I*N^'Z"_F"H\\7)4<W)$IXD"Q*."%PZX6+>9[Y<WKA3?C=T,&5;WPX(']X
M(2_PY=M>\.1"<ZA/XCW=GXU=]#@IJ_,%\P8!IA\_5/EA!=MP8NK<Y.BN&VAG
MI7T[9-LG&0@BVG8I9;JV*3TTY];\COIJ4\J^'DPG^']WGT[T@R;\19P5_9(7
MY&?"@]ZH:'8Y-RJK56+O>M^7<]Z^U<WQ@O*>5+YUCBFR28D=DF$0;P>="G*U
M+J F^OL+="M\2_%?WX6RZ,MX^.=H(K8"/ED5H2T]>"[B0W9O__ *SR<.PE1R
MG#3-ZB_??W]V=K9?N_G^<7GZ_;-J?I*=NOI[EQXGU?>(^OG]X<-'AX\?//[^
MX.#@\/#)O<.C!T<'\-_'3QY\GSY\>/3H('4?[QWNGS3+[_[Z;(F4!.E$F,,;
M:NMZCL,@9$7*T(?Z*D74].566"=9(<^JDX8E42L3F!>M==2Z4D-K_EQZ-MX2
M'3QFX;$B=/*?N(<NM?KS\=Y_3__S>WSL7X<J WKI_\><_K^[S]4QGW^L/N&P
M?'E'X.C+/ )'6X[ #VMJ]=EULQ^-F_V*-GM_]]+FG<0Z9<LIP$-PSD['/697
M@!<@WJKW=Q'TO,DONL?A]=_]]:W?6!DVJZ6TP:Y2\AM)C>M/V_\JCQF)B>2O
M^[=UH]TRJ7K_2Y&J!_?Q5^G#1P?W'\)RWY?M13*.RDVI>^ ==0]T#(M88.XH
M;.]OM2S>VB:6=[:)Y8J$+C6PL,SE#I:?R_W+?TNOA<4+>@00904VW2#T?RY/
M;?/*@4K]R6T6^[?N--[[(D[CT9.#HWL/S6G<9N.\(JJ*,N 0O,4%JB?/CBOG
M&*1K)I"QKCESPO)B#BQ5)@L>'Q*Z(+T[GO,3\)P)&BFE][QSJ\;LP*,CWH$[
MG_=MQM5XWL\Y[X?C>?^D\W[_RSSO]_B\_Y94E52\^U8_:>"KZY9)^]YE>3:'
M_?+/),_=>O)#4GS0$QMOH2-J%3A\N/.!O3<>V,LXL.-YO<!Y??!EGM?[EW)>
M8[^>%>SAHYW/Z_WQO(X*]NH/[.'!_N'#__@2SNGAP9/'1X_O?9_"#P>/[\%!
M/03]9TQI.@,>6H <TN=(D/D:2YU?,W#IQ>SHW]K_S28_" I5/;GS=X1!_F_X
MSUUX'K% Z&'_1U*T2;665[,Q?;B_XV&G-=ARW)\5!?)@77FL\O#@W&"E:58\
M>L)?.9ZQ\\[8O</K3$BE7%I'446)^X00C[2+_E(A)>$*-M7+CV[>$KK&&X8O
MF/S2Z<RLKV*GW4OV#N_?2>YZ 8^!SLM_S8,T?@VS@]%^#BUE+S]*#^RS.6%$
M@KRY3_2ZS])RA>?6SL@[QJ[3N,V1ALS>)=4L*5R]]^8C&@+RJ*.#@Z/Q>)Q_
M/*XQK&J/Q]&YQ^-'3^0V'H_K.A[74;@Y(HG<")+(@Q%)Y)M!$OEVZY&W%/_>
MVUQ=?%[-\&54 E]3\<G1_N'_O1&-?G01@Q>5:D^_UY$Z.WQ,G$;/]V/%=GCO
MP<%N*O#)P</10KR$(,7A_JN?WUWYEGI%BFKROS^\?3UY52!8,#CJ+\IY2Z$%
M\L</GPK6GOPUU;^F)4Q,P>UH8*HHH,XKY;.!#?<"B<DI?#9S0K;>U/RV)CFN
MB2<!@UAI*IZW?T88EKYO+-G8OEW>/?_[M6Z7]\G'LBB7:Y OH']K"LPBCT/B
M]\^X8%L7[/FSUS>]8,^3?"X XA@T_###B/^X?#LMWXN7/][T\KUP"T(I&U?O
MPJOW^MD/-[UZKY.9R\>%N^#"_?+VY4TOW"](VU TH]B\^/I=?3W+<^*J^07)
M588MT3L,4-$P>J-=:G2/F).*_Q:R58=WKSM<]R7W6=_Z*,;.>UO&>[0[0L,N
MB>4O&B#A>N*FSZ6>,S-P,N0;9@@OS\<2?BR7&1WDX%WB;_$,"L&3TA_BR:Z9
MO&R]<@'IW:2_B10/><4\8RV1716++&4:J2[6RE5)A/&X[7[<=@FZ?4G'[3U%
M6J(][SMDCO8/D:X@SVEOS]PDQ;J.E*(T1P=/J7R!?CY\2DCXJ[9:E34S*,3!
MO,<:H;.9KJEGA#K+ZHB^DLB4 X4:WPP'J.:'3G'X,K+,#FQS*4A6$*0_0ODK
MV4$W"?>,:9*[HZ0"$T^&"6?Z?]JD@E.>KWO5(C;$?TG%(O^#!5IT2-LB1^94
M'-[;($,0_IFBL#DA8OO/YPLQ87-<XLCC):8I1EY/#775T6P%CH Q9?@MI P?
MCBG#FTT9WMH/N/D4YY4 ;WS6H;R-@%WO7OWMYV?O?WW[\MUUDG3=/IY.FR1D
M:_M?;58Y5G&:)#RO[J9CIB.E0]HB:7/2,L54AI2RI/KA-6!](%<P4HX5E&R:
M.3!,%LJD1::&7("FCFM1^]+S8(N?E!5\;;HCJ.+HH=\8[IF,\OZ#4"0P]/?#
M3ZL]N+_AJ9_PJ'M7,\ 'MZ8XXF(3==&"A\]ZM ^8!DZ.#:^Y-E3-=Z]>__/E
MVQ^>/?_OR?N_OWS[[)>7O[Y_]?S==/+JY^<#,)N?'D0FR1)/X);X\;5=?>.;
M]04X8W^9_)1HWP*3*'Y"K?HU[>&MC_YA_9<K?/KW]?>3UTE;)9-W)\G9*8+"
MC7ORFQ*@-_7H<=>-N^[Z'_W\)'.+@>X@S!V\$-;3R9V^)8\_^PCNA8WY#<_+
M&AC;?,"CVMS&9,V'N^.I&>V'6V __*,LD@9\^LDO6?+''\FX*T=9?BV/'O?=
MN.]NSH;HMU#>'K.A-[:-9L.U5#G=(F*:,0EZBS('CQ]M28+"0?Q^5J9K^.-)
ML\S_^O\!4$L#!!0    ( )N"K5*3YK9!" <  # :   1    9#$U-34W.61E
M>#,Q,2YH=&WM65%OVD@0?D?B/ZPX]91($$+25"="D @XC24:4G![[>-B+_$J
MMI=Z[5#NU]\WNW:@0)KDVJ8OEP>"U[.SL]\W\^W8="Z]=\-NY]+I#;K52L=S
MO:'3=3XUCEL'K4[37F*\61BPSOEH\)F=O^V/AJ/Q6>WO2]=S:EU6K<"H+Y),
MI-W.P/W()M[GH7-66\@@"]M_'9S(I,9X)&^2LUHD9EG-^+HNS6*>WLBDD:EY
M^W">G;+B>JJR3,5V:*:2K*'E/Z+=6EW/>"RC9=N3L=#L2BS86,4<*_6&[MNK
MLUHJ;T(LU3GO.E]#.949HVVQ3O.\VVE>T[YV1= Z^HDA^ 83$T/?&7ONA=OO
M>>[HBHTN6/_2=2Z8\\GI?_#<CPZ&<-<9L^L/X\F'WI7'O-%CL?Y,M-9"G3A]
M$^3QX1$%ZETZ;-(;G_>NG$EC]&GH?&:]OD=WC@YA\1)X=MTZ&_(\Y6P2\L6=
M2.O,%VDF9TN6A3QK,PI@=T;]G/5;!W\F4ST_W?YTJY60WPF6BCLI%B) 0%*S
M]SE/ 6>T9&,Q5VG&5,(N5!JSSL4(U);U$<I,-/2<^Z*=J$7*YUCIL/&^TR2K
M+D)*X4ZP+]8;$TF !=[QU _MXL>M.D@X:C$U8Q,9 9@I]V^9%PKX$GDF?5UG
M;N(?G+)?3M'1@Q!YBL5+=HL=1B*X$74+46J!"13<)"IC/IQSF3">+%F>9&DN
MF,YX)F(D)NV/(T* ('G$9MS'4,I4C*+.E+7;,DB$+[3F*7)$52LQOQ4&S'NG
M&O8!HL&:$4D%+4(&ODS]/(99@OD()0#R8,H/F<[I8S5_(5)1.*$=Q%)'@@<R
MN6$+F878H9X+WT1(?N>(3078)V@"C=/E.@XO0-#Q<P@2;"83($!HKG9<!SL!
M4[B=KMV7"1(5V$LDN4S\**<L!:IKVZN#$DGE, <H1"@1'47WC%4K!5AZ8VUD
M12#)<YW@S",8@"8%+,UZV@3D<QVR6:06NN0P%3=29RG'2IP&;> (L[Y&A2ZC
MV0KW!=AX_3 ;W\3_YQ^MUV].=0%ZH7J48FHVD[C<T_MF;R[CJ3 I!U3D-!)&
M/02XFT92AS2#S&*4&)4970=2^Y'2.>91\:4J,G!6*_-4^2+ N&9[@"\0X,-B
MY'SU0Y[<"-9#7H_S"!:/*]HQ;[1.]L1^*6L4Q^.S3@([:W]3#=>YA2=2W_;W
M^'KS %W%$#4D[=>OGDG?'M]G Z'1T@ 8HPL/H,E68-9)LWR>ZZ=/(>V8"C!0
MK&352.4I'"")[Z2FTJA68"82XXC.PY40KI=F*B)\ >^%'JWA**T6&@E(Z'ZN
M29],SFDC9J8^E!98)D,]TF;F.)2DGT><ZAK1&M<KG<,,JYKK:H]O4T&&J#S,
M%\%W*^W7,#?=9\X=CW*>F=,:6YK-H#SR3B0X+[85I*S )[!E+W=KBF$-$Z&/
MVBK75.49J'LH@J<D%+^W%B3,L\</&C;EE'_(!Y."PB*!@$YM7;XT&S[JR&YT
M&S%J!0J],7=VL2*I;4WL24$8,=KUV@%B7=G<1&4HW\]30F65L'3V;'J-E<XP
ME9IB^-(^')5-V-[N.&:@%V?^AG$1-@XH87H8:F^2_#ZL?1M4R/5]R:*6N,D&
M$1B],&APK1+H^!*-RJV(J*'9MJ\_!Z!J90="JPSXE:WTR4\_^$S_'91)5%]E
M.%7<&I/5RBK;B8TGITY]6S++Z'B.]D2EMC+)Q S 8XS>-!/B83F9*IZ:D@TD
MPC,^]L WBE>3.N _27<IJN)++A&\R<<\\4WOL_][CKT>^C8ZCB1HH,.#V@-?
M"F!6*.#]Z;,0_)843>BR$.Q!9GKWLH5[%A/%D8*3@ZIV1UGP #.UN*^*AVB;
MRDAF9@; 5RFRQLBJAJ;J/ 9& ,1LII"BG=WN;Y),'& ]*.,L1:[5@8@P%0),
MS4-( 7[=2HM,[A2>"TE?$GY3/$RE15&)>!ZII<#=1:AL&?%OJ 45#TMOM?)D
MV@XV565MPR0J&^\TMA"K=:U"&"_THJIW/G18WQD.)]>]OGOU]JQV6#/7U[W!
MH+S^VQUXEV>UUN'AJQH['XT'SMB,%S'8D49_-!SVKB=.N_SR7?@WN:)76=6*
MB6G<+;X,RI5?G[RJ=3M-;["Z\[%XW6+WMHJQ--QP\-C\79..?W31^ZCQ,5[;
M7PG<'(G4F*+\;AL2SQJ!:/,[)0/V3. V@@/YM>X V=MF[_C2\MTZMN\WUJ/<
M1*#,C&T+X_$'IIXOVS\P^\DO.%LT-(4&B70U])5I%0'3/P[-WX^]TVOJI@UV
MXQW:=7@P.*":6K']8DS_'DK_^]1-3'=#^3^,SX21WHR'4LR8\U7X.3T"L9'M
M[^Q[Y?\!?2Z@;G?O&H\VOISC!-Y"=;_3=+\1=_RCP]2X;@[<CQ@O?LFQLM^D
MGWPP:'XI^A=02P,$%     @ FX*M4BNS944!!P  *AH  !$   !D,34U-3<Y
M9&5X,S$R+FAT;>U977/:.A!]9X;_H*'33C(# 9*F<X<09@@XC>_0D!+Z]2C;
M(FAB6]2R0^FOOV<E.U @37+3IB_- \'R:K4Z9_=H;=IGXW>#3OO,Z?8[Y5)[
M[(X'3L?Y7#MH[NVWZ_82X_7<@+5/AOTO[.1M;S@8CHXKG\[<L5/IL'()1CT1
MIR+IM/ON1W8Y_C)PCBMS&:33UC][AS*N,![*J_BX$HI)6C&^+@JSB"=7,JZE
M:M9JS-(CEE][*DU59(<F*DYK6GX7K>;R>L(C&2Y:8QD)S<[%G(U4Q+%2=^"^
M/3^N)/)JBJ7:)QWGVU1Z,F6T+=:NGW3:]0O:U[8(FON_, 3?8&)BZ#FCL7OJ
M]KIC=WC.AJ=L?.:PWIGKG+)3][Q[WG.[ PS#PAFQBP^CRP_=\S$;#^^+]U<B
MMA+NI=,S@1XT]HM@+[NCD^ZY<UD;?AXX7UBW-Z8[^XW&\V#:<:OL7Q7S=,IC
M=B'Y]^^\RGR1I'*R8!A,6XQ"V)Y7OR:"YMZKV-.SH\U/MUR:\AO!$G$CQ5P$
M"$AJ]C[C"0 -%VPD9BI)F8K9J4HBUCX=@MRB2J8R%34]X[YHQ6J>\!E6:M3>
MM^MDU4%("=P)]M5Z8R(.L, [GOA3N_A!LPH:]IM,3=BE#&]$XG'_FHVG KY$
MEDI?5YD;^WM'[+>3M'\G1&/%H@6[Q@Y#$5R)JH4HL< $"FYBE3(?SKF,&8\7
M+(O3)!-,ISP5$5*3]L<1(4"0/&03[F,H82I"::?*VFT8Q,(76O,$.:+*I8A?
M"P/FK5,-^P#18,V0!(,6(0-?)GX6P2S&?(02 'DPY4^9SNAC.7\N$I$[H1U$
M4H>"!S*^8G.93K%#/1.^B9#\SA";"K!/T 0:O<4J#L] T,'/"$)^KG,DV$3&
M ($ 76ZZ"H("IG [6;DO8^0JX)?P(V,_S"A1 >S*#JM@15)%S( +<4I<AR$Q
MD[.6XZ77UD9B!)(\5\DB"V$ IA3@-.MI$Y#/]91-0C77!8V)N)(Z33A6XC1H
M T>8U14V=!'-1KC/0,CKNPGY(?Y7+YJOWQSI'/1<^"C+U&0B<;FC=\W>7,83
M85 $*M(+A1$0 >Z\4.HIS2"S"%5&E4;7@=1^J'2&>51_B0H-G.72+%&^"#"N
MV0[@"P3XL!@YWWSH\)5@7:3V* MA<;^H'?!:\W!'[!;*1G'</^LPL+-VUP5Q
ME5MX(@%N_8RO-W?0E0]19])Z_?*1].WP7=87&KT-@#'2< >:; EFE63+YYE^
M^!22#T^ @7PE*T@J2^  27PC-95&N00S$1M'="0NM7"U-!,1X@MXSR5I!4=I
MY=!(0$SW,TT297).&STS]:&TP#(IZI$V,\.Y)/TLY%37B-:X7DH=9ECA7!5\
M?/,$&:+R,%\$/ZVTW\.<M\N<&QYF/#4'-K8TF4!YY(V(<61L*DA1@0]@RUYN
MUQ3#&B9"'[55+D]E*:B[*X*')!2_M18DS)/[SQKF<<H_Y(-)06&10$!'MBZ?
MFPT?=60WNHD8=0.YWI@[VUB1U+O&]J0@C!CM>N4 L:YL;J(RE.]G":&R3-AR
M:=-KI'2*J=09PY?VX:CHPW:VQS$!O3CVUXSSL'% "=/&4(<39[=A[=J@IES?
MEBQJB9ML$('1"X,&U^B /=P*Y;4(J:?9M*\^!J!R:0M"RPSXG=WTX2\_^$P+
M'A1)5%UF.%7<"I/ETC+;B8T'ITYU4S*+Z'B&]D0EMC+)Q S 8X3V-!7B;CGQ
M%$],R082X1D?.^ ;Q:M)'?"?I+L05?$UDPC>Y&,6^Z;WV?TSQUXW1$N(XTB"
M!CH\J#WPI0!FN0+>GCYSP:])T80N"L$>9*9]+UJX1S&1'RDX.:AJMY0%#S!3
MB]NJN(LV3X8R-3, ODJ0-496-3159Q$P B!F,[D4;>UV_Y!DX@#K0ADG"7*M
M"D2$J1!@:IY#<O"K5EID?*/P:$CZ$O.K_'DJR8M*1+-0+03NSJ?*EA'_@5I0
M<;?TEDL/IFUO7556-DRBLO9B8P.Q2L<JA/%";ZRZ)P.']9S!X/*BVW//WQY7
M&A5S?='M]XOK3VY_?'9<:38:+ROL9#CJ.R,SGL=@1VJ]X6#0O;AT6L67G\*_
MSA6]TRJ73$RC3OZE7ZS\^O!EI=.NC_O+.Q_S=RYV;\L8"\,U!_?-WS;IX*F+
MWD:-C]'*_@K@9DBDFH?RNZY)/&L$HL5OE S8(X%;"P[D5SI]9&^+O>,+RW?S
MP+[B6(UR'8$B,S8MC,<G3#U9M)XP^\%O.ILTY$&#1+(<^L:T"H'IBX;Y>]J+
MO;JNK[]#HTI:<OQL_/X9(O__U'4D-U#\B^ C$:1WXE,I)NST]I@8VH;.ODW^
M"^AC 74[.Q=XEO'E#%ANH+K;KKL_J#G^T>EI7-?[[D>,Y[_A6)VOTX\]&#2_
M$?T'4$L#!!0    ( )N"K5+XVT)_TP4  !L9   1    9#$U-34W.61E>#,R
M,2YH=&WM65MOVDH0?D?B/XQ<M4HD;B:7IH18,M@)/J*!@GM[7.PU7M78[GH=
M0G_]F?4E$$B;YM+V)5&$\'IV]IMO9G=VAN[ ?C_4N@-3-[1JI6M;]M#4S"_U
M@W9#[3;S1QQO%@+0[8V,K]"[Z(^&H\F9\GE@V::B0;6"0GT:"LJUKF%]@JG]
M=6B>*4OF"K]STCABH0(D8//P3 FH)Y1,U[@46Q ^9V%=1'&G%8M3*)YGD1#1
M(A_RHE#4$_:#=M3ULT<6+%AU;+:@"5S2)4RB!<&5]*%U<7FF<#;W<:EN3S.O
M?39C J19T&WVM&YS+.VZ"X':?D8(3L9)AJ%O3FSKW.KKMC6ZA/''R?2C?FF#
M/;H/T'-2LH%'/8&/C6FCWX"IV<\PJ0='K=H_0J-/03=&8]LT<FHF_Y2;DI%W
MK6,8G8,],&&J3WKZI3FMC[X,S:^@]VWYIMUJM1\=4()>BSH+75RW<_CZ8: U
M*P0G"D/J"!:%L&3"!^%3^) 2CE8$*YC0..("\.5YQ!?0/1\AH^6^])F@]20F
M#NV$T9*36-'45OU#MRFE-(@\F++@BO(9<;Z![5.4H*E@3E(#*W0:L(=K52MO
M7JF';T_[T2(FX4H^G)SN(VJ>(8DI9Y$+%.USX3WACO\FG"7QZ8%:0]K:^"DB
M0"".!,X2Z%,NF,<<DAF$ T0(XOC4K0%)P&,!JKDQ<TJ=E#/!D!,2NF!>.SX)
MYQ00RX(EB=2 _U+2)8("&D#1)HD:<M Y.P7F&E!<25HM!5)$S!,\JW#!R$-$
M^%2^*VRM5E#C; 5.CIDB+7'*DY2$0EJUL;5R_^26Y_L+C2%N% O4OCGGEJ2,
MNV+%*4$GA#2ICZX#N@+=$?*-C#LDT"?97)1C'+ZA)Y&D.>W +Z+Q^"?!6 S)
MT_GAP:@V<MR[GQ@[921Z:8!AZ2"#@?3;C2\Y_9XR3A>X#3*>MSC;(_N (:4>
M[;G[-Z2LW7_C^IR9:D5]=W!XFD6%9.'N+/-'2&C_D@06XL98Y,&-&U<0)N.+
MY4%:,D28W+DQIXDDHR9?DR! 6+BE&0F0JB1&=I):-LMC(0D='*]64*/+,MW2
M<!1+@YS,"+=AMNAV"#>VZ=FP51Y86X?L#EF*EMN6:9%7![TW-*%O#H?3L=ZW
M+B_.E):2/8]UPRB?/UN&/3A3U%;KM0*]T<0P)]EX@2$?J>/M8JB/IV:G_/)+
MYK?=)"\7>+V0F"9:\<4H5SX\>HTG?-,VUF\^%>=_;ML:8RFXI>"^^7=-.GCJ
MHC>H\6.R85])7$SFM#[CE'S#A)(PEW;(5<1<>"!Q6^#0^8IF8/!U\ !?E1LR
M/[XW46XS4$;&KD2F\0E3>ZO.$V;_]I53E4.SB&,B6 ]=0Q(%R.FK5O;WM$M&
M,VGF8(<DY02F/EEBNJW!V&\8#;FGUM[^:Y[^-RY]_-1M3N^F\H7&!](H:Q6?
M40]3*Z99P:XHC/)K4'[1?2'TH81:VMZ8,TS5,>;P'5;WNTWKI[1N\+-!S\"T
M+@8VIHOCVS@WQ@%S)V9BA-%^9IF_Z_R7]/.'T@_\%X4$*X@0QHS\^$%>DLZC
M-O<.BR\,/C;?G)?US$N^><9\L\/J5KZ1[=VL>/O)^?1;[:MW#RV694F,!3&=
M1RR<EWV4=>]G1N6PE_*0)3[6R7CT4:R,103$<?("=K-POKOY\N:5>OSVM%HI
M^BY8&*/F,!*E]JRE)-M5.#V.$GI']^'D_HX#R(9#WM999,VN6TLAH)DL_IT(
ME\!*'%><K;! ]RBGH2/?2)O0&D0C0=TNTFNP]"D^<^3?I:A)4B:[(<1#3V_W
MMVJH=TZX&] DR5HA4N^<AI2C\]<0),4!&I#B#I(=AB1U_&+Y!NA0=KXX0X?C
MQ P16K-$\P5%<8$KRF9-V;C)+-II7_E$>A'E8QY=,=D#S!M5I6D924L6!)(?
M3HM^R&RU([,.@D+!_;V_:@4I8B*16#T/TA@MEF!I(AIE;ZQI6)]P Q0_6N3U
M=%/^NH&#V8\B_P-02P,$%     @ FX*M4G)T,\^([ $ "GL" !$   !G,34U
M-3<Y9S(U=#,T+FIP9^R\!UB33=,H?(<.4D1 FO0F*KUW 6DBTHM4(00(A 12
MJ **!4$!104!$16D"R+2!2P4D2:]@XCTWFO(GX#M>=_G_=KYONN<\Q]7DWMV
M=F9V=G:VW)FYP/7@1HX):?E!70# P  X 0  !4 !.@(0XR$0_A\ 8@-(]V$
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M]L*@]W\YQQ<C%-K4"8& [5/HP=$0"!SC^0/>_\D=AB34Z?9Y3:%^! H-*)K
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M%[Y-29;/M' 9/[\58P^_NCR)U%Y'Y7+F+/WLO '@M3$X70DM!;0N7C>V"8)
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M1T6GMH-V.G_$T)FG$/<T=Q TU6"8\"->ZF9EF6_Z7'4(4]P\ISP#SZ)P^ W
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M3[LH?FC=*=(.L,\.#[._DCG'S'0]:%OK]%(!W3+XC%#IR@ZA4O7%BV YS/2
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MA/.\U3_1TH[Y<(<W55H(Y$7W5NP(1*^IJOG35?JJUA>;(W0$JCDC4 *S@@-
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M%V!M52O8</29=6%-V(9,@<(PI;TB43SKH)COG'EQ>G6.8G1H1]0JB-?3VO2
M%CKJB$(A V=@1CS+XG3A:S!(*$IYO<7WP-GS4HH4M6+XLM@K<@;UJD ABEA
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M6&)8G.$L]/85@<'S7YS\G^=*9Z0^; 3/5,V_!&H+^&[F#@%3; " _>J?  "
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M8".JMF\ \R:!UWN-H'_;R 8B;:\LT-$=_[3U'[+5TJ7GZ5!Z.#I[G<7AQJK
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MZ?A/X)_ _S]@&937/G4;D<!-+J3RL5VGA'_'7P_RCS> ^I3RJQN *]#DNN)
MP.2ZJ_D5JZ)%U>G-'&S$Y"(]*^,&8)?=<@-849X\@/F5_ >_E?B_V:"_QB*)
MW%D;L;X!X-?LW*9CG=QEU[?M5A+_WN%M")TZMN4,U>!-FUI+M\-[ SCW<"*\
M'E7UB F^ 90X_SG9/#0Y*2B9]-K/^H<G$3'< $A7<J[+CTPPP9)MS3_6S&X
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MZ6D2UR!N.RC+A2C;I;_#LW<')R)Z%3^\"/R244:.*/)I==];-'"R\%SS(-4
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MC0IT#7L8+-%^N$TD7V[5!9$?; 36DA%L%"IJE.Q"4IC\S@7GE>] 8I268$Q
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MG=$9#.#+IE:^:^58!\YNQ+]C0S3J9Y\[.HJ0!9#2$:[AE;G!G9,G&G'9_.Y
M)_:[O:W&5CGW6U'6XO-X;> _>"V7.G15,,C)=(K"GX 96O32@'@RS:S".^>H
MPBHY[EX4N=QCTG$=0,V=#!71N[Q^,=][=Y]RY[E,/BL&(N6V ^FM_$% 7D8G
M/P;R)TI(U-JW+E>1G1 H%*XW,'<CH*J35_>]>0"U;!0:7:GA-5"I_2*9V*AY
MLIOV),ZZ9W+1HC1'V%+?1"Z,ZT->ZP/<ADXCZPQ="@8YR:;<V@_RB$3O#?R
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M# W1\$-S5%&Y[Q;=P^?L<\^2]\5+1?8.7-&@@$)VF26DAGO ]%":VYZ!Y&0
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MJR+,O3;5QMIJ8M$@++$L$3@@;UP[E)$>=]<;G&&);F8^969\1[XA1<<,_83
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M[MY#-)DKO?W[<Z6RGADD:+FVD]"V'+$I*8^J,$AR4=B\2T7J'WQ<V8;YGI0
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MQXFS9T-\3U@VK!%\UY*?/ @$.\]@M17412(D&DM6146FOYEUJ/P8&HF,MOG
M<X#RJ8&A\_GC8L@";W7A-F2R41-^!>ZKA1\FJT:E?_3GFM^MMU1.03$]J[])
MSJ_689 3MX8./YEZQTQ"54'/3[/,Q$2I_FQ/F3CWV._2W>W4L+M .:LN"'1
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MD81FK<&]X0#'8*]\B[A/:*[SV7[9!WQM.10SA.FAN?)+2<Q1[II)];XRW7#
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M^__@G6E_F:9PH:OZ0B?LUS=FTSAE3W]4]"I_2WA5+JGV,S IQ!J+!=JY^CV
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M<$'D)\7/X6.328^KWG5#.QQ>B2%.O>O147;Z/2$ZP\L] ;W-UNWFK,9_QPI
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MB^Z\ _ABX=W=/5,Y3^\G5';O>+[H(G7F>Q^Y1&&JG#K42!EC0I\MC4NW7Q7
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M+%XC=Q'MEQ8&N9&=J'12-OX'#S6Y+M<!IE']S=>[6T7^$63]P##!P;LAU83
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M E7#HKD42D? U_+**(7XPD^#0V9.O*"7&YLIJ#+.D.]Y/UN>SS ^JL^LU9<
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MV>;6-*%J)6)'B6Z6PF[G!F7$*64\7B$ EK5O?-N?)M%E;98V* L4XZM#LQ2
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M[F*E/Q;+QOPO?0_4]^I7B*^ONM+'[X/6 BY,;C0C\OH?G\6@G:@\)S=.()4
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M6ZPY*/1O<H2Q#F7*\?54]\M/:/::BTWSH2 H.SH"*VH3J['7)RAXTX!)/,3
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M_.SV<5L*H=P[X0%53^;:0;UJAQES9?$?$1&SW!/%FY7:E05(='F<\B69&Q(
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MBBFF1NUY2>M$2>3<XHJ-)ME0[8J-U"\^QD0S/T((^?7\UN%R\0D,/)7^"4S
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ML:F/C4<9SN3= ^O^IK4U([+#,9P%L?X?[BJE_*T&PLH=#NO=:@'1VXY+]R@
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M:$)FQPZ3<7V+KS"D(E Y__U3U2[X;T[HZFVOHPZOR]^G',G8]-F3*5/J]^J
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M5@42ST/Z-PX,G^I^$4T8=+)BA/Q0^.4-ZH^LZ:OP_Z;OR/V=F/=1?16Y":@
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M*5+%F\:G:A/X+RQF0:."J+_3),]?E[NR.?Q,X _J+LX\][B+URY0)$?07:M
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MT'&_)_8'= SOG(3 0VI=9/;VJ2D%+C5DJ@JMA.RZ@>04A%O[\IO!RXD\6-,
M=[)H8/0_L"4UF'L]\?BS9.-35QX8GSJ7U'4\UNKZ?'R;4M*G%X8J/_SL%\JB
MUXU0D:OIX$SP182TU#A22M>S>S(2MR;[/D3GUWI/.!-\QK60/?HJ\[%7*R^R
MJ&>A3M>5%M_UT^O*V\7>[WL@=X(] L;J"^[<[L]>"?F6X=0^H7E7[H:*D2"]
MT&\H\];@)24?M<;;[27O63;V?+ GTB,TEFX6(P3$&<@*AM@5XD9<@+\>E/JJ
M^]=M9L*?>W'],@N:73(4 BPO(+^(\V5)XCQ!"(!6L4V%@&<H92$ KQ IFIF4
MOC^;8&1/!5M"5.[?TI[B/M?%R4LR%59A51U1 T/G%'BW*Y',@@XA@'[0@*K
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M DUTR/C7#M=KCQ=SP)C2D9\_W3%J!K_U796-:@2_A'^#C_%_M\3C7[5<UQ<
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MAMI?A".[J /LP: "_DOAC "5X+_H</Y+OG^/?$=!_:Q2G%S".G@&W#7_;>7
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ML'T@U(D6/[ 2D8$/?SG%>U2[_7,!-,QW:HNS,"M/H@]\@&4\HA;Q38?MJ-O
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MC3==SB3'GSV>:BHIC'B!]R 3&^K+$5U48/2HG&&5#M2=9L:VG1X;O;3I6%+
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M?@;$S'46F@;&5[P?AIZE I"8IW\)ST*.K'3SPD,?/'&_,_+S0NA,=:'F;!X
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M(3[!V*62_-5Z.@:7#6DGH;8QYL<R&I(GW">MG:(BAQ1978K,<>Y/B]10T^&
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MG06'UA"6[\=L!" EPH=-VE^Z-[.9])3*/#D+^G5&H^-XW!9LC&%[LV'!E[)
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M=4FE/[^<,>GRA:0Y0#(IVFN1? .CT@-HPBM=2+<+'6T1[HZ'Q7C023X3J9S
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MB*9=^?N'Y0N#\=%!3WZ5G_I'X1NT" ][A_W@CW[_6/[[\:<_@W\&;_X-0Z5
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MIF@ =)MGN)*R0,Z5L=5P5TG=$H@J===@XC;EL%9"D)<UY14Q0")S4L[(U<J
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M9:_\]V<YKF4^&3=F5VBQW;V!&1P5S- :0<*5=UZ ;U2C:%F.<@UH@:SE%ZW
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M_D[S*)AQ)*96J&_;J7X/Y5GPXQ;>:L;$I_46TP6 P@=J+TS@5C6$P%5-HQQ
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MEF@?(,/B=#WOM^L;7!08VUEI@[[.T:'F1 *8;(UX+[\L['B.X'%O@*AA53"
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M!QAJ;A1EM7H8\:8LED;N:JP(0H?"2_TV2GNXI.X&AAR!?N&HJ&-L5NB'/"N
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M'?4EZ-?E9SUC!G%V#6#)F[ JL_[H, !JC8#X$(B/ 7IIX &;[JX8QN"U>_$
M!E:SZPAWLSG7KIY_\NPEB!/JX+W-\K>[<I?C%KT_$#-7&ED1BV'<VA$;_B23
MT@R!R!B(#]*9$L3'@;<F/C#KV*98XW? JL" U\*N.)S7>:W+P9Y=!>2_5Y]Q
M'L;$41KOI.C'@?)3##C46WTV"&I&\=== >06S&LQQ;#2<7$*X%&^R_)3NYB1
M*;9;6@#Y.4NHWV1K6B2]P0R*C!N)]'<MZ=_?W:%V7Z],AR5?'\?P!6<DE!A4
MFX;E 3C.(,P(1*!K"7:071UKWQADC9&T=WBV)Z-8"&AA]PW-#80O"6.4 N^?
MLBFE[1 DV6:3I8R*BV ;ET'" ?T!TTJJ.&J\[^NBV-%:VBH V8_E$EPC.!4C
MJ>@8''8K5 V#*A-0#\2*A5>[C7JLV9>@%YP_9OK'IG,PS7*MPKR5G8-\83.X
M5FX&00W(6&44C,M8371XU;EC47;O@OP77-Z1@7&>XSHN(,8%(_X>Y^1'W66H
M[4@NKTNMN10NHO@(B ^!FC'089!5M0[R<7RX=QTWM\+-[+B)]1+##W&9Z&]G
MQP[H)Z*[/$\&]@JQ ;VXCYTV\Q. /C#M#F,5& GGVG#Z7CN7T0$]"@5G@)O(
M<Z"S@=G(=!I[,#3K0M# T)1/..;Z@".,-]1?8^"G=2#R(B;_O$U9W%_T<4L4
M)DYP468IUIQZC1S,U2'86%[[J#F,4]G-PTCH-N7QDA':;:G1;4:#/"5SR_A'
M0\:=':--PGCG5 T>X$:';*! G^<4KLC+UGI)_M5?*\FO_LH2-5)IW(<X#?(X
MD^Q@%&U=V!X%I6+8+_\SX.9"*]A&(W1277CRJR]^3(LM#N-UC".IWZ]I[PH$
M"HKE0 #TPHW$W(&#3L8.WT'CS3;+@WQ?73*&88ZIS7S(J%7;;.G//])Z1@K_
MVF(,E^^E+3@3L]14?:LCN15JNM.ZBX<!$!L!QFN?PJ",G9<A=IP^_+;%H_ 8
MW!:,$W8%]7'E[;K:;QP\@8LL?<%Y27V PPZ:.@=OL_PB*)YE>X-)0[K:(4SC
M6\@J7(W&;M#JG69^\*G"PY"TQ%IU+%,P3XL>GH=D6(#=@O]"<+9SF$$/.OL'
M7Y3 :!?A'P[FBNWIF5)&.:6/>"NMA*CL-P4SJ;<IY[@@XKI=M[A_GY5X<,>Q
MR&?<93B<6SXZ/Z3:7_*/=+,'\U\6W"%!&<V847^*)?!JX89]#237XM+RFJ(]
M;'\>=H36;IX."<UAZL=%5+&7.])?/31,/GG$^@CU6)Q=Q',&[O(XI%7HV.]4
M]RGR/JY?7DHHEP1=\,8KQ)K3>>*Q,D"7+A;TWW5M%>$@R!%9[:N2.1QC4GZ<
MOPQ5X6GP>:<*3.YTX2[/0HRCXBWAZN#529TXA898C^10;^RY%-'(1T!T^E%[
MS6U;M=8-.AT'1LD\8=:E!HY$<5\O1T(8/%-!PCY)?THC%M0:KV/^B^OT;9P2
M-N(@:<[CB[/'HLR#4%6)<.X/P6<G&"^CP87UY)%^ 55/[]L9_%9UI:B(Y<JI
M@O_B?]!%F-?G0S_7H_N8T& BF Q3&4Q$$D1FH:O--LGV&)--U@M9LW6,W:X_
MX#![2NG,<_?X(BM*BYQ$LWX/))O1O!);0 ]]2I>T +SDB986P);+$HAAML&-
M<;BI+8DZ1EG9RVEI1!7U8OE!VAHUS5'=WH,88X-Y$$L3:B<!'$?:$&%-/W@L
M24,'%&CR(*+7:#X,$0456T"?=Q"VGXE;<XE?<))M*5752J2-VC7J[1!?9MR(
ML6&\%UMW6_WJ!1DX\G<&IJ(64UC#E$L-LD!?7X\LH.=.FW[ *<Z#A-!T%FWB
M-*:; )H,W52?#/L[U"A3COKPJ_KQ=/&=GIYHU1R,!5W&?-(L*R3V=<L*ANZT
M:YY-P(W!N_;9O^108^>7T@(;V1L_GM\OA*B^/BT$)X>O%CEM.!HFO5???4"A
M3 =P^2K1E*>Q\(=9UT:SQ=[L\[O+BKFPU:]>W$!?4%JA4'@Q:05!D%3PH[/H
M6B2.G_H-F#3SDR6C3$K?4NCV^&VM+FC2^D'-9XD@O#J9G0E'BK3W\X (_![R
M0+",7A-G<8[!X>\;[62A6A-E*J31($]<POF@8ITDW1@G1Z XM^P11]%*S_Q^
MITL!,/^WCD&M%)*:7<M6J/K:JITX>X7X%V=W6+=L\W)?!GFI<UN=B:] ][O'
MO^&PI*^JJLY=89SCISA-:93H8Y LDHF+R^4JC8Y(*E<\Q[I$)$=AH74V:3:#
MK3-(QV._>8*SZY0?0_R09\4BGI#J:T=DPX>EM:05K[+,QVD5T4Y_0[X*&"WM
M1GQZ>\4&PQ%4%D6'LD#G(I2XO:&;VUHX$GD<D^%6&*.Y3;?"$AV/\?X1%V3&
MS]*(GFV%Y,>'C/[*I4]N3L(1F7D+N2YI^SD9[(ZE)H1:0_IKE^Z] S=VJL!U
MJT4ERB_)R;75_;D-J*WB'X]5;;'P$XZ?GBF;Q"D(GG!=QH$]D7)ST*&FX(AL
MJKE4G1V*U'2@BI"F3 =_F_B%G)982KMN?B*1RI=Z?#*[F+Z<I<;2("YXRF)B
M#3U::*2W9(.;D*46FSFI\&G!F56Z8Q8=]96Q\A#']=(SS_'.HA+76]1C..&8
M7^7G*\4\6M^/R*36](-;54M"CLFPVLIX4=O:$//EF]>I<C?P6>LZA4=M8T?9
M@-G-["@#X)&EG7S^ W1X,I4PGRSQTG/@Q^DUS#F,%\?:,UOP_Y3GW!!G$O,8
M&<?6_E'/[Z/U&<P'3-\UD]]?9"G+B+(+D@><;U[K3+QK:ES;=>?2ACLW;ZA"
M+;(0I0O0TP:7OVBLA^5T$Z\Q^OHO.,B+;\ M-8R-&#3/, ;B>&RR]1HDX_UT
M05,])Y%'9,%GG1M/O?0OS>HO.F=C%H/5?^$D'?.B,+^1FGNMF-]"'<\A3HO)
M:\)+G!9QJ"LTM. WC^CH124Y9XYX\^6%*B#!!*QHY7GV])3CIZ#$?0%\J;$I
M4R3RY9P$:8W5@H$GPY;J> R]<!G!DD$XL_EFGS\B\V\HSR57@L&+SZ57!"?/
MA$8*5V4$C^)><T8=GML4VBCP\5A%O>O?8,J9J9Q TQ'9SRF2]^,X1&IMCM/F
MSCDA"D-<R??+<4HGFQ#W-Y,:^W$$!^!O@SAG-)\5Q6Y3KU 5NTL=:!M\]!@.
MJ$UDMX"%I9^M2F2U/KPZ6-DC/#<>(\K#JD(:H*^)Z[X_WHL_8SV<[<S66 F/
MP E5\?)CEI!ADKC<?R"&>@EWT^;KQ^!86DD3PL =B$"4BB-S$R>)MY'!2],2
MW-ZYT=C9O#M[=3U2"_@A+GYYFV/JG&*B!J5+^S?\[6.U?A)).K1]E )$24 U
M#5^*Z3.4+6UVLJ8"B&L!Y ,".%KCIU+614V?2E./U/#5UOPR?HDCG$80CE_W
MV\=J^"22A'#Z:A*^%+MG*-J&_ZCF?Q_CY#AO7VQUU8G+-Z2H#JM%I&4<Q<F.
MEHRYQ^$NC\L8$]K"9!?AB!8KIJSN2L;I[?HJR&E(1E$7%3_?#P^@J9>XZ%==
MUJ585'K"87RK,3JTEE1K=&.2?): TWH7R^N14"1C>26"MD/O@PW6ELS4=P6W
M"!T^#$&]0K27M'@FI'HOP Z\KHI8,U,X$6@F6E,\EI^I+IR^>E-I OW-7S^F
M+^S2CVCN)DOO:8$?:2%"70<'J-?2W ='W1;QQHBU!JHNN##Q+A!MAID:QPX!
M$V7ACGJ_;.V95?8AESVK??5M6^:>U39\GU44LPU P8*LVG^G9>+>9^5?<'DH
M(,=$4%W^*Q8\1]_WK0[B#!*U+@_7?+,;7K1"]&/DKR7:XQ(=OE=73819K;]X
M,7I7;W(N+1]5A7(N%?\"+">/9'V;Y=6O:#M5Z)!K0KX$6RJ3\71K(+4"_)-H
MG>6H]=$OS+AZ*]<OPMHJ+8,SLZLT"T=PR\43P%?5)(NS7?F<Y92O)6ZUY-\Z
MAELLA:06N+4ZU([AWT.'#Q[9%96W<CN*FRV=?LYVDZ533N@38^/C;[[!6.Z.
MJAX?_.S97B*FMR[UR(@"&;7&IGI5CTY]#:YDL'OC_ZS",:R!MI1X[K*2F(XX
M2)(]:L14,./AWQ7 2.,Q\\5<UW(<P1N>SG.E^E5I$_*P?$JJH4\>P_L=O=P<
MO(]LO3@_A$ =V>L=>T&VHKT./N"7DJ))KH++)%R2Z]\1[&Q-0K.J]HN4T[7[
M_C'L@"TE"AK+6=-Q9)OE.40\5(I6%-!?</P%!WOV%=MIP&=?JX_ 6)J4G6%_
MO Q*W,A@";,YEI)C,*"CI>RV>KF0190U090H/US)_R_[8[3;TVS,LL7%C0V,
M.UM^20A[">A1PW5:E#F+NJ)/JC01^.IN#JVDAOZ^6AV:HT-[#^*_3::ACTV3
M.8  4IT,]X%\4AM]K>X& J1!^A5 JMM[$9QL,@UR(,GGP*%W>0@QDL8N*]JZ
M]- &*!7>O_U]1_,\\%9 D<HV]/*@Y(I<'J$ &J*L186P8LL@X0[!'W!"%G7B
M#N3E_H&L\071*.H,G._;?]&LL#:#.,2\%6_"(WC>!+$V'JRZ]A/51YO]+,'
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M?(-SR7^3&@;=1FF _J7[LC/UOUIT7_H@.IA)[(57*@_PC_LFOBH$U0(\[K8
M_T<>L(RP: 'WFP;Q;92&1:,'\Z:I_]6B.^FVZ![Y+CF5!B,KV6T6!_ ]V&0:
M 2C.VGO=%!_LF:]BKH>!L' 3OH 'Q<*N/2145P$6/G5?C%8@%*+LJ-VD./X
M!E!*&D]$-()R(=15@=/N05]$:0"A$&5'K2R%Q7BQ?_#T2+-(=8+8+ 9H>S#Z
ME!U7B*FCIA6^!H@8UH?%["F)%#):*P,X>[#*5?=:(9V.VE"62G;Q&DZ#>$(T
MILJJHH#Z<_=EI>V\0F0=M:# 5'Y)(W*3SYX(TRY;;\4 ;0].W<J.*\3445,)
MP'@,7J_&G!CIY"IZ;B$S11W@H0<W.'8H%-+LJ/5DN14.$\;W3N#.(4)8S\05
M-%N<)6/]#8^V)G#2 XN*"Q:%?#MJ7 %DH_&8@<^^^.>:QF1?*]6*\A+_Y]Z<
M"'0(%!+LJ(U%A>? 48('@+\'^T\S L6M>:?-+ 60,_[C+7M,?L0V\GLK#=A[
M<+PS]5\ANT[;50HT<DVX97<L>:&0R<<HP(TJP$(/SA56(!2B[*A=90W279)F
M0?0_Z=RXPZFJ  STX(+= H)"B!VUNH@)9<1(H!%;N0B@[,'AL++3"M%TU.0B
M,I1%=],DUI_?-XL!VAX<_Y0=5XBI\V86=L:G]4G"] YA:R4EYJ/>N/!5]UTA
MKT[;6QYF012])7+2R&NM)&#NS:FMNN\*>77:HG(Q(VQ"X\FO+/F1386[?Q#K
MQUEE#>"@-V<V/0:%'#MM.;EX?;OK!T\;O1"WBG/T1\?'O1F!&@ *\77:;/(P
M)5%D,_K*!4%A>W/4KNRZPDN]TQ:24D05! ??YIG(F2LN(_4^#)J*P$AO3MQ6
M4!3";61"^;@98M9&V%E5NETGS5HJUG.0/DDP>?IA$@1ST"X29>GR-YMJ5OSZ
MCU6"SMOG2QKS;E"^J4]@PM.$JKE4%W(ZV3]V'37-L16Y4,PHU@O*_AXB#9%:
MQ*Z/'@,J3_%O&6$IN:XS'?H2;.'E9"W?C?) "-)MG$%&.H&J8'@*G<.4JR+A
M4W86,+;@,[X,IM?(V:J^) PK[,Y.E-7B=T/G*2X/4QWN&)D'=)D;B4._S:9\
M[U"F3J,,%K6!+*3#2!-5<,'F*=:O,_.][3P/!" =6YH(MQJ%I^B_+,F""&T\
M)W/"LH7([)MQI16SV%SL<6Z(?B"KJXG3^-Y!)T:PY2)NA<93L"#FF%W/T7B3
MQ*%Q^*JJ "V=&,F60C8B\112B"G@]6QX]W0RY6>5;WPU$D1II*RM!P0AW237
M$K4='$\1B/B+L''UE9 /^S0C;_3;4\0AYD);ROU:^6Z,Q9'9M@F@K?_&$F>\
MOD(;,8=T";2],45=";A!GKR=!6G4!Q5*7Q&1J),Z9.-.B]RK%D>LR@K ";(M
MS4)DB@5 C\E7N"2RG$6:Z6V*]**NKB.9^8247,"'M VP? 5>HD[M21 O%?HQ
M.0WB[V:!*^L ,TAN%XT%;H;E*Y:S.\>Q)5D+L]3U%8$CY/U=;=%;8O,5&-JM
MO9S3'@ZX0/(,;C[$U7A\19-BGN<4:FQE5#/6!::0'(X][]KMP?H*2^W(D+<;
MZQ+]Y^YLW#P=T%:P?,6B8HYU[=N,ZIMO=2U@!]EZ[DGH-C!]A;-BCNQ:)CL]
MJ_M[R"X/GE3  J6O<%ADWX?2Z]\FQY>*TL &\EQO(2RE@X,2D*^(651/IS>_
M5J-3TT91X 'Y@J6V8)5H? 7/HEK95L^$W 5T?!6?!7.:!579L PU@!5D@TMM
M&9M ^0JQQ75OR (:D_'RL9)1&.:S7#Z'M'H$7>/H8*H,7*%?J]54  =\OF)Z
MN[5;<]JE 1?(UV:U9:W!XRL0N,M7Z0VNT(&G[IC</)W&]5A]!1MOZ016P,Z=
MI'E*,AIR0(.,WCG:7Z6,0#L!<9IOF>SO6.X;EX^#61^*5 T /N2K:R=!V)R8
MC&@'$ 6TCAC" T=Y-DT8_?-M5!L58[,B4(1L#_>N$$J4 P@;JD(JWLUU5@*H
M)*G!2NK1L@)L(!Q&D- 62GV@M&5-( G=SM**&E3!'$"<4,FX5&._8%$;R$*^
M2_&@$RY0?04>=4,O'+8)FEI #KIYQJ<>*"$.(!9I"Z9Q=Z"H :2@FVK\RWT#
MW@#"DQRSI]A4D_0<]W]C:(6QK8BE7=II5EREM\^%:U 2@^? C']R*EYY?R'B
M3?-=&VY$;O496?7/PE:CJ"'D=;!_N/OQM7*U*H+0;?*L*.L "N1]E8GAZL%D
MQC0 4\L]%P@G4Z2?."<O)$IDQ'*!6'O1I:DG"<)Z1MY>?*HK+AMD S"N_$IB
MSE#$<8[&,QK+)\#%&W%FX1MJ DG(Y^NZXK?%-@ #RQ9%+A,\$(%\QU57R&HT
MOFPE7? IAV5/;H(L!/M6&LA MI,W7+,KT S W"%?\B1I!N@*Y=7G6%%5D;1@
M1_/7$[(1T@ ,&QR.U?!=*P<$]'*S78W#E[4"<39>>DHMK:^G04I#L;>D49YI
M+56&FD 2LJ6RGK!MD0T@M\KO1.2-(>/1"U^8)L6#"K?/$G;).&.O%?4:!$J1
M=VOUE*4A8%])7[IB[;HG8T)F,IM!$O,J&>4_KM\$5OII+7U7\?R8:H:^6-27
MPOYRLOO1O>K=HQ"(#0Q94/;W&#V"PX79ZK&I@.7)+A9A.?T6H,ZB($T+=D:O
M5+<-4]8!3KKB:[ N)H-,E5 &8/LJ8SM/9@&M>J1071BH0(_B, E*<4FDAC,
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MAHF@=KM ,/;II,X$T1RR+V_!) NB+J2E79FR=%D]1]FJ[F:"3QP;E6LN4EZ
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MPP"V6+8<_(,$[/%'XD&KBI: 1.3M-H(R;<(?Q+[.#KH'Y0':D#?U"%JSPCV
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MQ1"JVY16848O?&,FIN35GJT$XU?.HN8YTSK- "7(6WT<I7'GJ*TP*Y_SS$7
M_[UX)2RDG*OZ4XVI'2 %^58 >[:Q)@GUJ0!;S4GG<Y$/5^S]^7^ZZDME;2
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M.UD6,+[%Z9R$])F2L?(TH"T/'"!M]LV2J9"D$0E62*<ONU?!1]F>:=C)*>L
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M_2V003>MXW54R;.N&FGS9.F:@]]2%K ,\WZ_ 46PB[N*89?\*TO25N9:]==
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M2P$"% ,4    " ";@JU2X!3IF.,O @!>$14 #P              @ $
M9#$U-34W.60Q,'$N:'1M4$L! A0#%     @ FX*M4I/FMD$(!P  ,!H  !$
M             ( !$# " &0Q-34U-SED97@S,3$N:'1M4$L! A0#%     @
MFX*M4BNS944!!P  *AH  !$              ( !1S<" &0Q-34U-SED97@S
M,3(N:'1M4$L! A0#%     @ FX*M4OC;0G_3!0  &QD  !$
M ( !=SX" &0Q-34U-SED97@S,C$N:'1M4$L! A0#%     @ FX*M4G)T,\^(
M[ $ "GL" !$              ( !>40" &<Q-34U-SEG,C5T,S0N:G!G4$L!
M A0#%     @ FX*M4IB3E-B*#0  X7T  !$              ( !,#$$ '-B
M='@M,C R,3 S,S$N>'-D4$L! A0#%     @ FX*M4A:S;VP]"   7F4  !4
M             ( !Z3X$ '-B='@M,C R,3 S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( )N"K5+$P)W#PAP  #K" 0 5              "  5E'! !S8G1X+3(P
M,C$P,S,Q7V1E9BYX;6Q02P$"% ,4    " ";@JU2T# _9IA$  !9# 0 %0
M            @ %.9 0 <V)T>"TR,#(Q,#,S,5]L86(N>&UL4$L! A0#%
M  @ FX*M4M79[I+A,@  KDH# !4              ( !&:D$ '-B='@M,C R
C,3 S,S%?<')E+GAM;%!+!08     "@ * (0"   MW 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
